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The Ubiquitin-proteasome system (UPS) is involved in the degradation of many
proteins, including the short-lived regulatory proteins.  Thus, UPS plays an important
role in many biological processes, such as controlling the cell cycle, cell
differentiation and cell death.  UPS has another important role in the cell — it is able
to degrade misfolded or unfolded proteins, thus protecting the cell against the
accumulation of protein aggregates.  Dysfunction of the proteasome is believed to be
the main cause of neurodegenerative disease, since the presence of ubiquitinated
protein aggregates is commonly found in diseased neurons.  However, proteasome-
inhibition-mediated apoptosis is still not well understood.
Exposure of the proteasome inhibitor lactacystin to mouse primary cortical neurons
induced neuronal apoptosis.  Upon the activation of cell death, the tumor suppressor
PTEN (phosphatase tensin homolog deleted from chromosome 10) was cleaved and
accumulated in the detergent-insoluble fraction of the plasma membrane, suggesting
the translocation of PTEN to its membrane-bound substrate phosphatidylinositol-
(3,4,5)-triphosphate during cell death.  PTEN’s tumor suppressor function is
attributed to its phospholipid phosphatase activity, that specifically dephosphorylates
the plasma membrane phospholipid secondary messenger phosphatidylinositol-
(3,4,5)-triphosphate (PtdIns(3,4,5)P3).  The recruitment of PTEN, which is commonly
localized in the cytosol, into the plasma membrane where PtdIns(3,4,5)P3 accumulates
is believed to be necessary during apoptosis.  In this study, translocation of PTEN to
the plasma membrane microdomain is demonstrated for the first time in primary
cortical neurons treated with the proteasome inhibitor lactacystin.  In addition,
xvi
proteolysis of PTEN to a shorter 50 kDa form that is preferentially targeted to the
plasma membrane was observed.  This truncated species of PTEN might play an
important role in suppressing cell growth and promotes apoptosis by antagonizing the
PI3-kinase/Akt signaling pathway.
Microarray analysis of neurons exposed to lactacystin reveals the early up-regulation
of genes in response to unfolded proteins, such as those encoding proteasome
subunits, heat shock proteins (HSPs), and endoplasmic reticulum (ER) stress.  A
mechanism of apoptotic cell death through the abnormal accumulation of protein and
ER stress is suggested.  ER stress can also cause the disruption of calcium
homeostasis and oxidative stress in cells.  The up-regulation of genes which encode
calcium-binding proteins and enzymes involved in oxidative defense are likely to be
regulated by the downstream effects of ER stress.
The lipid profile of the neural membrane reveals the accumulation of ceramides and
N-acyl phosphatidylethanolamines (NAPEs) during lactacystin-induced apoptosis.
Ceramide has been known to be involved in the apoptotic cell death pathway, but the
role of NAPE is so far unclear.  NAPE accumulation has been associated with
excitotoxic or necrotic cell death, but the accumulation of NAPE in the apoptotic cell
death pathway has not been reported.
(-)-Epigallocatechin-3-gallate (EGCG) from green tea extract is a naturally occurring
proteasome inhibitor.  Although high concentrations of EGCG were able to induce
neuronal cell death through the activation of caspase-3, microarray analysis reveals
that low concentrations of EGCG caused the up-regulation of genes encoding
xvii




1.1 The ubiquitin-proteasome system
The ubiquitin-proteasome system (UPS) and the lysosomal pathway constitute the
major mechanisms of protein degradation in eukaryotic cells.  Lysosomal degradation
is responsible for the degradation of membrane-associated proteins and extracellular
proteins taken up by endocytosis.  On the other hand, UPS is an ATP-dependent
protein degradation system which is responsible for the degradation of soluble
proteins in the cytosol.  UPS degrades proteins selectively — only proteins that have
been tagged for degradation by a process called ubiquitination (or ubiquinylation) will
be degraded.  Many short-lived regulatory proteins are degraded by UPS; this
selective degradation of regulatory proteins by UPS underlies the regulation of many
cellular processes, including regulation of the cell cycle, modulation of cell surface
receptors and ion channels, and antigen presentation (Ciechanover and Schowartz,
2002).  In the central nervous system (CNS), UPS plays a role, among others, in
neuronal signaling, synapse formation and function (review by Hegde, 2004), and in
the prevention of abnormal protein accumulation.  UPS is particularly important in the
mechanism that controls the quality of newly synthesized proteins in the endoplasmic
reticulum (ER), degrading any protein that fails to be folded properly in a process
called ER-associated degradation (ERAD) (Travers et al, 2000; Hampton, 2002; Sitia
and Braakman, 2003).  It is becoming increasingly evident that the dysfunction or
altered activity of UPS is involved in pathogenesis of neurodegenerative diseases such
as Alzheimer’s disease (Lam et al, 2000; Layfield, 2000; Lopez Salon et al, 2000;
Hope et al, 2003; Song and Jung, 2004), Parkinson’s disease (Shimura et al, 2000;
2Snyder et al, 2003; Cookson, 2005; McNaugh and Olanow, 2005), Huntington’s
disease, Amyotrophic Lateral Sclerosis, prion diseases and spinocerebellar ataxia
(Alves-Rodrigues et al, 1998; Sherman and Goldberg, 2001; Layfield et al, 2003).
The molecular mechanisms that underlie these processes are presently being
unraveled.
The UPS consists of different components: a multi-component protease, ubiquitin,
ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and ubiquitin
protein ligase (E3) (Fig. 1.1).  The structures and functions of these components are
described below.
1.1.1 Structure and function of proteasome
The proteasome is a multi-component protease (review by DeMartino and Slaughter,
1999).  The fully assembled proteasome (26S) is a large 1500–2000 kDa protein
complex.  It is formed by the association of one core 20S proteasome (catalytic
complex) with one or two 19S regulatory subunits (also known as PA700) at each end
of the barrel-shaped 20S (Fig. 1.1).  The eukaryotic 20S consists of two outer and two
inner rings that are stacked to form a barrel structure.  Each outer ring has seven α-
subunits (α1 to α7) while each inner ring contains seven β-subunits (β1 to β7) (Groll
and Clausen, 2003).  The three main proteolytic activities of the 20S proteasome
complex are: chymotrypsin-like (mediated by the β5-subunit), trypsin-like (mediated
by the β2-subunit) and peptidyl-glutamyl peptide hydrolyzing or caspase-like
(mediated by β1-subunit) (DeMartino and Slaughter, 1999).  The chymotrypsin-like
activity of the 20S proteasome is believed to be the rate-limiting step in the protein
d e g r a d a t i o n  p a t h w a y .   T w o  a d d i t i o n a l
3Figure 1.1. The ubiquitin-proteasome system.  An E3 enzyme recognizes the substrate
and mediates the transfer of ubiquitin from an E2.  The latter receives its
ubiquitin by transfer from an E1.  Poly-ubiquitinated proteins are targeted for
degradation by the 26S proteasome.  The 26S proteasome is made up of the core
20S catalytic complex and the 19S regulator complexes.  It releases free
ubiquitin and degrades the substrate into short peptides.  Poly-ubiquitinated
proteins can be deubiquitinated by the action of numerous deubiquitinating
enzymes (DUBs)
4activities, called branched chain amino acid-preferring and small neutral amino acid-
preferring activities have been recently described.  Several evidences suggest that the
peptidyl-glutamyl peptide hydrolyzing activity and the branched amino acid-
preferring activity are expressed by the same active site, enabling the 20S proteasome
alone to degrade a wide variety of protein substrates, such as poorly-folded or
unfolded proteins, and oxidized proteins characterized by an increase of surface
hydrophobicity (Amici et al, 2003).
Situated at both ends of the 20S catalytic complex, the 19S acts in an ATP-dependent
fashion to unfold proteins for degradation and feed them into the catalytic barrel of
the 20S proteasome for degradation (DeMartino and Slaughter, 1999).  In addition to
that, an ubiquitin recognition function is present in the 19S to selectively degrade
proteins that are ubiquitinated.  The functions of 19S are coupled to its ATPase
activity, making it highly susceptible to ATP depletion, such as during ischemia.
1.1.2 Structure and function of ubiquitin
Ubiquitin is a small protein with 76 amino acids.  It is present in all studied eukaryotic
cells and tissues.  Ubiquitin is encoded by the ubiquitin B (Ubb) gene and is one of
the most conserved proteins known; the yeast’s ubiquitin protein sequence differs
from that of the human’s in only 3 out of the 76 amino acids (Hershko and
Ciechanover, 1998).  Ubiquitin can be covalently attached to another protein, or to
another ubiquitin, by a tightly controlled ATP-dependent process known as
ubiquitination, involving an ubiquitin-activating enzyme (E1 or Uba), an ubiquitin-
conjugating enzyme (E2, also known as Ubc) and an ubiquitin protein ligase (E3).
The process of ubiquitination is as follows: first, an E1 activates the free ubiquitin in
5an ATP-dependent manner.  Next, the activated ubiquitin is transferred to an E2.
Finally, an E3 brings together the target protein and the conjugating enzyme,
facilitating the transfer of the activated ubiquitin to the targeted protein.  The
attachment of ubiquitin to the targeted protein is through the N-terminal of a lysine
residue of the target.  Subsequent rounds through the E1 ubiquitin-activating enzyme,
E2 ubiquitin-conjugating enzyme and E3 ubiquitin ligase lead to the formation of a
poly-ubiquitinated target protein, ready to be recognized and degraded by the 26S
proteasome (DeMartino and Slaughter, 1999; Wójcik, 2002).  The ubiquitination
cascade leading to the degradation of the substrate by the 26S proteasome is depicted
in Fig. 1.1.  In some instances, the proteasome can degrade proteins through
alternative regulatory mechanisms, which include the binding of adaptor proteins or
covalent modification by ubiquitin-like proteins (eg. Nedd8).  The UPS degradation
pathway is further complicated by the existence of numerous deubiquitinating
enzymes (DUBs).  DUBs can cleave not only the free poly-ubiquitin chains released
from tagged substrates which have already been degraded by the proteasome, but also
the poly-ubiquitin chains bound to undegraded substrates.  In the latter case, DUBs
can perform a rescue function, releasing the tagged substrate from the fate of
degradation (Wójcik, 2002).
1.2 Ubiquitin-proteasome system and neurodegeneration
The accumulation of unfolded proteins in the cell is a threat to its function and
viability (Sherman and Goldberg, 2001; Schröder and Kaufman, 2005).  Intra- or
extra-cellular accumulation of often cross-linked and misfolded proteins is a
characteristic feature of many neurodegenerative diseases, including Amyotrophic
Lateral Sclerosis, Alzheimer’s disease and Parkinson’s disease (Sherman and
6Goldberg, 2001; Shen et al, 2004; Grune et al, 2004).  The protein aggregates found in
diseased brains do not have a common terminology; the terms ‘protein aggregates’,
‘plaques’, ‘inclusion bodies’ or ‘aggresomes’ are commonly used (Wójcik and
DeMartino, 2003).  Johnston et al, defines an aggresome as a “peri-centriolar,
membrane-free, cytoplasmic inclusion containing misfolded, ubiquitinated proteins
ensheeted in a cage of intermediate filaments formed specifically at the microtubuli
organization centre (MTOC)” (Johnston et al, 1998).  On the other hand, the term
‘protein aggregate’ appears to have a rather wide specificity, requiring mainly the
existence of aggregations of misfolded protein.  For extracellular protein aggregates,
the term ‘plaque’ is more common.  The terms lipofuscin and ceroid are used in
general to describe protein material that accumulates during the aging process (Grune
et al, 2004).
Aggregation-prone proteins linked to neurodegenerative diseases have been shown to
disrupt the function of the UPS (reviewed in Song and Jung, 2004). The majority of
neurodegenerative disease cases are sporadic.  However, the identification of a
number of genes responsible for rare familial forms of neurodegenerative disease has
provided insights into the underlying mechanisms of the disease’s formation (Bossy-
Wetzel et al, 2004; Moore et al, 2005).  For example, loss-of-function mutation in the
gene encoding the E3 ubiquitin ligase, Parkin, is linked to autosomal recessive
juvenile parkinsonism (ARJP) (Shimura et al, 2000; Mizuno et al, 2001; Bossy-
Wetzel et al, 2004).  On the other hand, over-expression of Parkin could counter
unfolded protein stress-induced cell death (Imai et al, 2000).  Recent studies also
found that a frame-shift mutation of the ubiquitin B gene produces a variant form of
ubiquitin, UBB+1, which is found in intracellular protein inclusions in Alzheimer’s
7diseases and progressive supranuclear palsy (de Vrij et al, 2001).  This mutation
abolishes the C-terminal G76 of ubiquitin, preventing the ligation of UBB+1 to target-
protein substrates, or poly-ubiquitin chains.  Instead, UBB+1 is readily poly-
ubiquitinated and acts as a potent competitive inhibitor of the 26S proteasome (Lam et
al, 2000; Hope et al, 2003; Song and Jung, 2004).
1.3 Ubiquitin-proteasome system in aging
Familial types of neurodegenerative diseases are linked to loss-of-function mutations
of ubiquitin protein ligase, such as in the case of Parkinson’s disease.  However,
sporadic forms of neurodegeneration are often associated with aging.  Proteins, once
synthesized, will be folded into their functioning conformation (Schröder and
Kaufman, 2005).  In the cell however, the properly folded proteins are subject to a
highly reactive environment, and can undergo post-synthetic damage and
modification through oxidation, isomerization or glycation (Goldberg, 2003).  The
rate of such damage inflicted will increase markedly upon the exposure of cells to
stresses such as an increase of temperature, or reactive oxygen species (Sherman and
Goldberg, 2001).  Eukaryotic cells have two main strategies to counteract these
stresses and avoid the accumulation of protein aggregates.  These include the (i)
induction of heat shock proteins (HSPs) and molecular chaperones that are involved
in the protein refolding systems and (ii) targeted degradation of damaged and
unfolded proteins by the UPS (Taylor et al, 2005).  In an aging cell, the capacity to
handle the building up of unfolded or damaged proteins becomes insufficient to
prevent their accumulation and toxic consequences (Keller et al, 2002).  Recent
studies report that the expression of neuroprotective antioxidants and molecular
chaperones decrease in aging cells (Keller et al, 2004).  The decrease in
8neuroprotective antioxidants exposes proteins to oxidative stress and enhances the
building up of protein aggregates.  This building up of protein aggregates contributes
to the overloading and inhibition of the UPS, causing it to be less effective (Keller et
al, 2004).  Much remains to be discovered about the inducibility and functioning of
heat shock proteins, molecular chaperones and the UPS in mammalian cells.  Such
studies appear very important to undertake, since genetic polymorphism in these
protective systems, and in their expression with aging may play critical roles in the
accumulation of abnormal proteins and pathogenesis of neurodegenerative diseases.
Moreover, pharmacological induction or activation of these protein repair-and-
degradative systems could present an attractive new approach to treatment or delaying
the neurodegenerative process (Sherman and Goldberg, 2001).
1.4 Proteasome-inhibition-induced neuronal cell death
The use of proteasome inhibitors to inhibit proteasome activities in cells is sufficient
to induce both the formation of protein aggregates and neuronal apoptosis (Sawada et
al, 2004).  Therefore, research on the prevention of neurodegenerative diseases has to
be focused on the mechanisms of protein aggregation and the resultant neuronal cell
death that is caused by the inhibition of proteasome activities.  The mechanism of cell
death through the inhibition of the proteasome is, however, unclear.  Proteasome
inhibition has been found to mediate several cell death signaling pathways, including
the activation of the cysteine-dependent aspartate-directed (caspase) protease family,
the c-jun N-terminal kinase (JNK) pathway, and its upstream kinase and apoptosis-
signal regulating kinase 1 (ASK) pathway.  Recently, studies have also proposed the
ER stress-mediated cell death pathway to be involved in the toxicity of proteasome
inhibition (Nakagawa et al, 2000; Rao et al, 2005).  Caspase-12 is an ER-localized
9caspase, which is activated by ER stress and can possibly lead to the cleavage of
caspase-3 (Rutkowski and Kaufman, 2004).  It is worth noting that caspase-12 was
identified in the mouse, but its presence in human tissues is controversial (Rao et al,
2005).  Nevertheless, pro-apoptotic signals resulting from ER stress can also be sent
through the induction of the pro-apoptotic transcription factor C/EBP-homologous
protein (CHOP).  CHOP is normally undetectable, but is expressed at high levels in
cells exposed to conditions that perturb protein folding in the ER, and induces ER
stress-mediated apoptosis (Wang et al, 1996).  The increase in CHOP protein
expression is believed to suppress the anti-apoptotic Bcl-2 expression in cells, which
makes them more susceptible to apoptosis induction (McCullough et al, 2001; Rao et
al, 2004).  Furthermore, ER stress can also cause the disruption of calcium
homeostasis in cells, which in turn activates the calcium-regulated protease calpain
and subsequently induces cell death (Rutkowski and Kaufman, 2004).
1.5 Proteasome inhibitors
Proteasome inhibitors can be divided into 5 classes: (1) peptide aldehydes, (2) peptide
vinyl sulfones, (3) peptide boronates, (4) peptide epoxyketones (epoxomycine and
eponomycin), and (5) β-lactones (lactacystin and its derivatives), based on the
pharmacophore that reacts with the threonine residue in the active site of the
proteasome (reviewed by Adam, 2003).  In addition to being useful research tools for
dissecting the roles of the proteasome, these inhibitors elicit appreciable interest
because of their potential applications in biotechnology and medicine.  For example,
through their ability to block the activation of NFκB, proteasome inhibitors can
dramatically reduce in vitro and in vivo production of inflammatory mediators, as
well as that of various leukocyte adhesion molecules, which play crucial roles in
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many diseases (Lee and Goldberg, 1998; Di Napoli and Papa, 2003; Wójcik and Di
Napoli, 2004).  Also of appreciable promise is the potential use of these proteasome
inhibitors in cancer therapy (Rajkumar et al, 2005).  The proteasome inhibitor PS-341
(generic name bortezomib) has become the first proteasome inhibitor to be used in
clinical practice to treat relapse cases of multiple myeloma (Adams, 2003; Rajkumar
et al, 2005; Elliott and Ross, 2001).  The other potential proteasome inhibitor is MLN-
519, a small-molecular-weight lactacystin analog developed by Millennium
(Leukosite) for the potential treatment of inflammatory disease and stroke (Wojcik
and De Napoli, 2004).  However, of all the inhibitors mentioned above, only two
currently exhibit properties that are suitable for clinical development.  Reasons to
reject a proteasome inhibitor for future clinical development include metabolic
instability (Adams et al, 2003), lack of enzyme specificity, and irreversible binding to
the proteasome, such as in the case of β-lactone.  Nonetheless, proteasome inhibitors
such as peptide aldehydes and lactacystin have been useful in the study of UPS in
cancer cell lines or in neurons (Adam, 2003).
1.5.1 Many effects of proteasome inhibitors
Although the inhibition of proteasomes by proteasome inhibitors leads to cell death
and is related to neurodegenerative disease, other studies have also shown that
proteasome inhibition can cause the induction of various HSPs, which increase cell
tolerance to stressful conditions (Bush et al, 1997).  For example, Meriin et al
reported that proteasome inhibition using peptidyl aldehyde MG-132 was able to
trigger both pro-apoptotic and anti-apoptotic responses in U937 lymphoid and 293
kidney human tumor cells (Meriin et al, 1998).  In their study, the prolonged
incubation of cells with MG132 activates the apoptotic program through the c-Jun N-
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terminal kinase (JNK) pathway.  However, a short incubation of cells with MG-132,
followed by its withdrawal caused the accumulation of the heat shock protein 72
(Hsp72) and thus suppressed the JNK-dependent apoptosis caused by heat-shock or
ethanol treatment (Meriin et al, 1998).  In another study using cultured rat cerebellar
granule neurons, prolonged incubation with MG132 increased the expression and
phosphorylation of c-Jun and the pro-apoptotic protein Bim, and triggered neuronal
apoptosis.  Short-term incubation, on the other hand, exerted a neuroprotective effect
by stabilizing the MEF2 transcription factor (Butts et al, 2005).  Drug exposure time
is not the only factor that determines the fate of cells.  In a separate report, Suh et al
observed that a lower concentration of MG-132 (0.1 µM) induced neuronal apoptosis
in mouse cortical neuronal cultures, while a higher concentration (10 µM) attenuated
apoptosis (Suh et al, 2005).  The authors concluded that the complete inhibition of
proteasome activity might have prevented neuronal cell death through the regulation
of mitochondrial-mediated apoptotic pathways.  Therefore, both the concentrations
and the times of exposure to the proteasome inhibitor might define the fate of cells.
1.5.2 Lactacystin
Lactacystin, a proteasome inhibitor, was first isolated from the soil bacteria
Streptomyces sp. OM-6519 because of its ability to promote differentiation in mouse
neuroblastoma cell line (Neuro 2a) and rat Oligodendroglial cells (Nakagawa, 1994;
Pasquini et al, 2003).  Lactacystin was found to induce apoptosis in actively dividing
cancerous cell lines (Imajoh-Ohmi et al, 1995), and more recently, in cultured cortical
neurons (Qiu et al, 2000).  Lactacystin is specific, non-reversible and potent as a
proteasome inhibitor.  It can inhibit the chymotrypsin-like and trypsin-like activities
of 20S proteasome; many studies suggest that chymotrypsin-like activity is the rate-
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limiting step in protein degradation (Lee and Goldberg, 1998).  Lactacystin does not
react with the proteasome; rather, it undergoes a spontaneous conversion
(lactanization) to the active proteasome inhibitor, clasto-lactacystin β-lactone (or β-
lactone in short).  When β-lactone is added to mammalian cells in culture, it rapidly
enters the cells, where it can react with the sulfhydryl of glutathione (GSH) to form a
thioester adduct that is both structurally and functionally analogous to lactacystin
(called lactathione).  Like lactacystin, lactathione does not react with the proteasome,
but can undergo lactanization to yield back the active β-lactone (Dick et al, 1996).  In
cells, β-lactone binds specifically to the β5 subunit of 20S and inhibits its
chymotrypsin-like activities (Dick et al, 1996).  Fig. 1.2 illustrates the mechanism of
proteasome inhibition by lactacystin in cells.
1.6 The aims of this study
Aberration of the UPS has been implicated in the pathogenesis of many
neurodegenerative disorders.  The mechanism of proteasome inhibition-induced
neuronal apoptosis is still not well understood.  Therefore, the aim of this study is to
address the mechanism of proteasome dysfunction-mediated neuronal apoptosis,
using the proteasome inhibitor lactacystin.  Understanding the underlying mechanism
involved in this cell death system is important for the development of novel,
mechanism-based drugs for the treatment of neurodegeneration.
I started out my research by studying the role of the tumor suppressor PTEN
(phosphatase and tensin homolog deleted from chromosome 10) in lactacystin-
induced neuronal apoptosis.  PTEN is a novel phospholipid and protein phosphatase.
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Figure 1.2. Mechanism of proteasome inhibition by lactacystin in cells.  The detailed
information of proteasome inhibition by lactacystin is described in the text.  This
diagram is according to the report of Dick et al, 1997.
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Mutation of the PTEN gene is associated with many cancer types such as gliomas and
endometrial cancers (Leslie and Downes, 2002; Waite and Eng, 2002), mammalian
cells transfected with the PTEN gene are more sensitive to the induction of apoptosis
(Wang et al, 1999; Gary and Mattson, 2002), suggesting that its interplay with PI3-
kinase is an important regulatory step in the cellular cascades related to apoptosis.  It
has been suggested that PTEN needs to be translocated to the plasma membrane
during apoptosis to dephosphorylate the phospholipid secondary messenger
phosphatidylinositol-(3,4,5)-triphosphate (PtdIns(3,4,5)P3), a product of PI3-kinase.
It is tempting to speculate that PTEN regulates neuronal cell death and is involved in
the pathogenesis of neurodegeneration.  The initial aim of this study was therefore to
demonstrate that translocation of PTEN occurred during proteasome inhibition-
induced neuronal cell death.  Using mouse primary cortical neurons as a cell death
model, it was tedious but not difficult to prove that PTEN was recruited into the
detergent-insoluble fraction or lipid raft of the plasma membrane during neuronal cell
death.  The tough part however, would have been to demonstrate that this
translocation could actually result in the dephosphorylation of the PtdIns(3,4,5)P3 on
the neural membrane.  Furthermore, recent studies have shown that PTEN has a
complex role in the central nervous system, and is involved in the differentiation and
maturation of neurons.  This led to a decision to switch the research interest to focus
on the study of the mechanisms of proteasome inhibition-induced neuronal apoptosis
using microarray GeneChip® technology.
Gene expression studies lie at the heart of a wide variety of medical and biological
research projects, including classifying diseases, understanding basic biological
processes, and identifying new drug targets.  Until recently, comparing expression
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levels across different tissues or cells was limited to tracking one or a few genes at a
time. Using GeneChip® arrays, it is possible to simultaneously monitor the activities
of thousands of genes.  Global views of gene expression are often essential for
obtaining comprehensive pictures of complex biological processes.  For example,
microarray technology has been applied to study neuroprotective gene expression in
ischemic preconditioned in vitro and in vivo models (Stenzel-Poore et al, 2003).  In
this study, Affymetrix GeneChip® was used to study the global gene expression of
cultured cortical neurons exposed to lactacystin.
The breakdown of the neuronal membrane is a characteristic feature of neuronal
degeneration (Klein, 2000).  Changes in plasma membrane phospholipid
compositions might increase the susceptibility of neurons to pro-apoptotic signals
(Farooqui et al, 2004).  Furthermore, neural plasma membrane is also a rich source of
lipid messengers, which are known to regulate cell death and survival.  Differential
lipid profiling (analogous to differential protein expression profiling) between healthy
and dying cells will provide insight into the changes of lipid compositions in
apoptotic cells.  Information on alterations in lipid metabolites in dying cells may
facilitate subsequent studies to examine the kinetics of lipid metabolism and the
interactions of lipids with cellular proteins, and provide new insight into the function
of cellular networks.  Lipid profiling can thus be integrated with genomics and
proteomics to provide a multidimensional perspective of the biological system.  In
this study, lipid profiling was carried out to complement the results obtained from the
microarray analysis.
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(-)-Epigallocatechin-3-gallate (EGCG) is the major flavonoid (or polyphenol) in green
tea (Camelliea sinensis) leaf extract.  Most of the experimental and epidemiological
studies with green tea extract have been targeted at its possible cardiovascular,
anticarcinogenic and anti-inflammatory activities, which are thought to rely on the
antioxidant and iron-chelating actions of its polyphenol constituents, and on
modulation of endogenous metabolizing and antioxidant enzymes (Mandel and
Youdim, 2004).  However, it has been found that EGCG can selectively inhibit the
chymotrypsin-like activity of proteasomes by binding to the active site of the β5-
subunit of 20S proteasome (Wan et al, 2004).  Furthermore, Nam et al shows that
EGCG can potently inhibit proteasome activity in vitro and in vivo (Nam et al, 2001).
Recent studies suggest that the neuroprotective effect of EGCG is due to its ability to
inhibit proteasomes (Mandel and Youdim, 2004; Shay and Banz, 2005).  EGCG was
therefore chosen as a comparative proteasome inhibitor to lactacystin in the
microarray study.
This thesis therefore contains the following topics of interest:
1) PTEN accumulation in the detergent-insoluble fraction during lactacystin-induced
neuronal apoptosis
2) Microarray GeneChip® study of gene expression during lactacystin-induced
neuronal apoptosis
3) Lipid profile of neural membrane during lactacystin-induced neuronal apoptosis
4) Microarray GeneChip® study of gene expression of cultured cortical neurons
during exposure to (-)-epigallocatechin-3-gallate
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CHAPTER 2
2 MATERIALS AND METHODS
2.1 Primary cortical neurons
Cultures of mouse neocortical neurons (gestational days 15–16) were prepared from
cortices microdissected from the brains of fetuses and subjected to trypsin digestion
and mechanical trituration (Cheung et al, 1998).  The dissociated cells were harvested
by centrifugation and resuspended in Neurobasal™ (NB) medium with 2.5% B-27
supplement, 0.25% GlutaMAX™-I supplement (all of the above are from GIBCO™),
10% fetal calf serum and 1% penicillin and streptomycin.  Cells were seeded to a
density of 2×105 cells per cm2 culture area previously coated with 100 µg/ml poly-D-
lysine.  The cultures were maintained in a humidified 5% CO2 incubator at 37°C.
After 24 h in vitro, the culture medium was replaced with serum-free NB medium
with 2.5% B-27 supplement, 0.25% GlutaMAX-I supplement and 1% penicillin and
streptomycin and cultured for 5 days in vitro before treatment.  Immunocytochemical
staining of the cultures for microtubule-associated protein 2 (MAP-2) and glia
fibrillary acidic protein (GFAP) indicated >95% of the cells were neurons with
minimal contamination by glia (Fig. 2.1).
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Figure 2.1. Immunocytochemical staining of the mouse cortical neurons for
microtubule-associated protein-2 (Map-2) and glia fibrillary acidic protein




2.2.1 Lactacystin stock solution preparation
The synthetic lactacystin (cat# 426100, CALBIOCHEM®, Lajolla, CA, USA) was
dissolved and maintained as a 10 mM stock solution [200 µg in 53 µl Dimethyl
sulfoxide (DMSO)].  The 10 mM stock solution was stored at -20° for not more than
6 months.  The stock solution was further diluted to 2 mM in DMSO and added into
NB medium to obtain the final concentrations of drug in the range of 0.1 to 5 µM for
cell culture treatment.  The same volume of DMSO was used in the control treatment
as the drug vehicle.
2.2.2 (-)-Epigallocatechin-3-gallate from green tea
EGCG from green tea (≥95%, cat# E-4143, Sigma-Aldrich, USA) was dissolved in
water to make a 10 mM stock solution.  The stock solution was further diluted to
concentrations (0.1–10 µM) in NB before treatment.  Fresh stock solution was
prepared from the powder for each set of experiments.
2.2.3 Caspase and calpain inhibitors
The irreversible, cell-permeable, broad-spectrum caspase inhibitor z-VAD-FMK (cat#
P-416, BIOMOL®, PA, USA), caspase-3 inhibitor IV (cat# 235421,
CALBIOCHEM®, Lajolla, CA, USA) and calpain inhibitor calpeptin (cat#03-34-
0051, CALBIOCHEM®, Lajolla, CA, USA) were prepared as 50 mM stock solutions
in DMSO.  All stock solutions were kept at -20°C for not more than two months.  For
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treatment with cultured neurons, the stock solutions were diluted to 50–100 µM
concentrations using NB medium before treatment.
2.3 Immunocytochemistry
Fixed cells were quenched in 1% H2O2 and non-specific binding was subsequently
blocked with 10% normal goat serum and 0.1% Triton X-100 in Tris buffered saline
(TBS) for 1 h at 4°C.  Cells were incubated with polyclonal antibody to PTEN
(1:2000) overnight at 4°C and then secondary antibody for 3 h in solution with 2%
normal goat serum and 0.1% Triton X-100 in TBS.  Detection of immunoreactive
cells was carried out using 3,4-diaminobenzidine (DAB) substrate solution (0.5
mg/ml DAB and 0.01% H2O2 in TBS).  Immunoreactive cells were visualized under
bright-field microscopy.
2.4 Immunofluorescence and confocal microscopy
Cells were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS).
Fixed cells were treated with 100 mM NH4Cl and with 0.2% Triton X-100 and then
blocked with 10% goat serum in PBS, immuno-labeled with primary antibodies and
with Alexa Fluor 488 goat anti-rabbit IgG or Alexa Fluor 594 goat anti-mouse
IgG (Molecular Probes).  Images were obtained using laser scanning confocal
microscope (Carl Zeiss LSM510).
2.5 Transmission electron microscopy
Cells were fixed in 3% glutaraldehyde and 2% paraformaldehyde.  After osmication
in 2% osmium tetroxide, samples were dehydrated in an ascending series of ethanol
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and embedded in araldite.  Ultra-thin sections (70 nm) were cut and mounted on
formvar-coated copper grids.  Grids were stained with uranyl acetate and lead citrate
before viewing in a Philips BioTwin CM 120 transmission electron microscope.
2.6 Preparation of plasma membrane sheet and gold labeling for transmission
electron microscopy
Plasma membrane rip-off and gold labeling was done according to Wilson et al
(Wilson et al, 2004).  In brief, coverslips with cultured cortical neurons on it were
rapidly chilled by immersion in ice-cold HEPES buffer (25 mM HEPES, pH 7, 25
mM KCl, 2.5 mM Mg acetate) and inverted onto nickel electron microscopy grids that
had been coated with Formvar and carbon and, on the day of the experiment, glow
discharged and floated on poly-L-lysine (0.8 mg/ml for 30 min, followed by 10 s
distilled water rinse and air drying.  Pressure was applied to the coverslip for 20 s by
bearing down with a cork.  The coverslips were lifted, leaving sections of the upper
cell surface adherent to the poly-L-lysine-coated grid. Membranes were then fixed in
2% paraformaldehyde for 10 min at 4°C immediately after cell membrane sheet
preparation.  PTEN were labeled from the inside by incubating sequentially with
primary antibodies and gold-conjugated secondary reagents, by inverting the grids
onto the droplets.  Samples were then post-fixed in 2% glutaraldehyde in phosphate-
buffered saline.  The samples were then incubated with antibodies specific for PTEN
(10 nm gold) and Flottilin-1 (15 nm gold) at the dilution of (1:100).  Next, samples
were stained for 10 min with 1% OsO4 prepared in 0.1 M cacodylate buffer, then
washed for 5 min with cacodylate buffer and then twice for 5 min in H2O.  Samples
were then processed for 10 min in 1% aqueous tannic acid, followed by two 5-min
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rinses with H2O, 10 min with 1% aqueous uranyl acetate, and two 1-min rinses with
H2O.  Grids were air-dried and examined using a TEM.
2.7 MTT cell viability assay
3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was dissolved
in RPMI medium 1640 (GIBCO) at a stock concentration of 5 mg/ml.  MTT
solution (30 µl) was added to each well of the 24-well plate containing cells in 300 µl
culture medium and the plate was incubated at 37°C for 30 min.  The culture medium
was then removed by aspiration.  An aliquot of 200 µl DMSO was added to dissolve
the formazan formed in each well and the absorbance of the solution at the
wavelength of 570 nm was read using a TECAN plate reader.  MTT assay measures
the loss of mitochondrial Krebs cycle activity.
2.8 Western blotting
For whole cell lysate preparation, neurons were lysed in 5× sample buffer (0.5 M Tris
(pH 6.8), 10% SDS, 20% glycerol, 0.05% bromophenol blue, 20% β -
mercaptoethanol).  When RIPA buffer (10 mM Tris HCl (pH 7.4), 1 mM EDTA, 150
mM NaCl, 1% Nonidet P-40, 0.5% Deoxycholate, 0.1% SDS) was used for
extraction, cells were lysed in RIPA buffer and the insoluble materials were pelleted
by centrifugation at 14,000 rpm for 10 min.  Pellets were re-dissolved in 5× sample
buffer.  Equal volumes of the whole cell lysate and the pellet obtained from extraction
using RIPA buffer were loaded onto SDS-PAGE gels.  An aliquot of the supernatant
containing an equal amount of proteins was used for Western blot analysis.  After
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SDS-PAGE, proteins were electro-transferred to PVDF membranes and probed with
antibodies.
2.9 Antibodies
A PTEN polyclonal antibody was raised by immunizing rabbits with 5 synthetic
peptides from different regions of PTEN.  The peptides were
K352ANRYFSDNFKVKLYF367,  T2AIIKEIVSRNKRRYQED19,
T232RREDKFMYFEF243,  E388NEPFDEDQHTQITKV403 a n d
K260QNKMLKKDKMF271.  Two other PTEN antibodies, one of which recognizes the
N-terminal of PTEN [anti-PTEN (N-19), sc-6818] from Santa Cruz Inc. (CA, USA)
and the other of which recognizes the C-terminal of PTEN [anti-PTEN (26H9),
cat#9556] from Cell Signaling Technology (Beverly, MA, USA) were obtained
commercially.  Anti-β-tubulin (ATN01) was purchased from Cytoskeleton Inc.
(Denver, CO, USA).  Anti-β-actin (clone AC-74, cat#A-5316) and anti-MAP-2 (clone
AP-20, cat# M 1406) were obtained from Sigma, USA.  Anti-active caspase-3 (cat#
557035) was obtained from BD Biosciences PharMingen (San Diego, CA, USA).
Anti-PARP (AB-2) (Clone C-2-10, cat# AM30) was obtained from Oncogene
Research Products (San Diego, CA, USA).  Anti-p35 (cat# sc-820) was obtained from
Santa Cruz Inc. CA, USA.
2.10 Caspase activities measurement
Caspase activities were measured using 9 types of fluorogenic substrates from
BioVision, California, USA according to the manufacturer protocol.  The substrates
used were Ac-YVAD-AFC (caspase-1), Ac-VDVAD-AFC (caspase-2), Ac-DEVD-
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AFC (caspase-3), Ac-LEVD-AFC (caspase-4), Ac-WEHD-AFC (caspase-5), Ac-
VEID-AFC (caspase-6), Ac-IETD-AFC (caspase-8), Ac-LEHD-AFC (caspase-9) and
Ac-AEVD-AFC (caspase-10).  In brief, 2.25×106 cells were lysed in 150 µl chilled
cell lysis buffer (Cat# 1201-1).  The protein concentrations were determined using
BCA protein assay kit (Pierce, USA).  In a black 96-well plate, 10 µg of total proteins
were added into each well, containing 50 µl of 2× reaction buffer (Cat# 1068-20) with
10 mM DTT (freshly added).  25 µM of AFC conjugated substrates were added into
each well last, and incubated at 37ºC for one hour.  The samples were read in the
TECAN ULTRA 384 plate reader (Tecan, Austria) using 400 nm excitation filter and
505 nm emission filters.  The fold-increase in caspase activity was determined by
comparing the fluorescence of the treated sample with that of the non-induced control.
2.11 Proteasome activity measurement using fluorogenic substrates
The fluorogenic peptide substrates: substrate II (Z-Leu-Leu-Glu-AMC), substrate III
(Suc-Leu-Leu-Val-Tyr-AMC) and substrate VI (Z-Ala-Arg-Arg-AMC) were used
respectively to assay for the postglutamate, chymotrypsin-like and trypsin-like
peptidase activities of the neuronal cell proteasomes.  Cells were lysed in ice-cold
homogenization buffer (10 mM Tris, pH 7.5, 5 mM EDTA, 1 mM DTT, 5 mM ATP,
20% glycerol, 0.04% Nonidet P-40).  The protein concentration was determined, and
an equal amount of protein (5 µg) was incubated with 50 µM of substrate II, substrate
III, or substrate VI in assay buffer (50 mM Tris and 0.5 mM DTT) prior to protease
activity measurement using a TECAN plate reader with excitation wavelength of 360
nm and emission wavelength of 465 nm.  All fluorogenic substrates were purchased
from Calbiochem®, San Diego, CA, USA.
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2.12 Plasma membrane isolation using Percoll gradient
All steps were carried out at 4°C.  Each well was washed once with 3 ml of buffer A
(0.32 M sucrose, 1 mM EDTA, 20 mM Tris, pH 7.8) containing a protease inhibitor
cocktail (Complete mini, Roche, Switzerland) and phosphatase inhibitors (25 mM
sodium fluoride, 2 mM sodium orthovanadate and 10 mM sodium pyrophosphate),
and the cells were scraped off and collected in 3 ml of buffer A.  The cells were
pelleted by centrifugation for 5 min at 1,000 g.  Cells were resuspended in 0.5 ml
buffer A, placed in a Dounce homogenizer and homogenized using a tight-fitted
plunger for 20 strokes.  The suspension was transferred to a 1.5-ml Eppendorf tube
and centrifuged at 1,000 g for 10 min.  The post nuclear supernatant (PNS) were
stored on ice and the pellet from each tube was resuspended in 0.5 ml buffer A,
homogenized and centrifuged again.  The PNS were combined and layered on top of
30% Percoll in buffer A and centrifuged at 84,000 g for 30 min in a Beckman SW 41
Ti rotor.  This method was modified from Smart et al, 1995.  Plasma membrane
fractions were determined using anti-flotillin-1 (BD Transduction Laboratories,
610820) and anti-caveolin-1 (Santa Cruz, sc-894).  Cytosolic fractions were
determined by measuring lactate dehydrogenase (LDH) using the CytoTox 96®Non-
Radioactive Cytotoxicity Assay (Promega).  Protein concentrations of fractions were
determined using BCA protein assay kit (Pierce, USA).
2.13 Microarray GeneChip®
2.13.1 Experimental design for lactacystin treatment
A total of 15 murine genome U74Av2 GeneChips® (Affymetrix, Santa Clara, CA,
USA) were used in this experiment.  U74Av2 was selected for the experiment
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because it contains all the known genes of mouse and some ESTs.  The following
treatments were used: 24 h control (n=4), 4.5 h 1 µM lactacystin treatment (n=2), 7.5
h 1 µM lactacystin treatment (n=3), 24 h 1 µM lactacystin treatment (n=3) and 48 h 1
µM lactacystin treatment (n=3).
2.13.2 Experimental design for (-)-epigallocatechin-3-gallate treatment
A total of 7 murine genome U74Av4 GeneChips® were used in this experiment.  The
following treatments were used: control 24 h (n=2), 1 µM 24 h EGCG treatment
(n=2), 25 µM 24 h EGCG treatment (n=3).
2.13.3 Total RNA isolation
Total RNA was extracted from cultured cortical neurons using RNeasy mini Kit
(Qiagen, Valencia, CA) according to manufacturer protocol.  Total RNA from a 6-
well plate was pooled by adding 350 µl of RLT buffer into each well and scrapping
with a cell scraper.  The cell lysate collected was passed through a 20-gauge needle
10 times, after which 350 µl of 70% ethanol was added to the homogenized lysate.
The mixture was then applied into an RNeasy mini column and subjected to
centrifugation.  The flow-through was discarded.  The column was washed with 700
µl RW1 and after that twice with 500 µl RPE buffer.  The column was spun dry and
the total RNA eluted using 30 µl RNase-free water.  The quality and the yield of the
total RNA extracted were determined by spectrophotometer (A260 and A280) and by
running a 1% agarose formaldehyde denaturing gel to check the integrity of the 28S
and 18S ribosomal RNA bands.
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2.13.4 One-cycle cDNA synthesis
One Cycle Kit (Affymetrix, Santa Clara, CA, USA) was used to synthesize
biotinylated cRNA according to manufacturer protocol.  10 µg of total RNA was used
for the cDNA synthesis.  For details of microarray GeneChip® protocol, reagents and
suppliers, please refer to the technical manual (expression_print_manual.pdf) which
can be obtained from the Affymetrix website (www.affymetrix.com).  This section of
the thesis documents the conditions under which the microarray experiments were
conducted.
2.13.4.1 First-strand cDNA synthesis
The RNA sample, diluted poly-A RNA controls and T7-Oligo(dT) primer were mixed
as in Table 2.1.
Table 2.1.  Preparation of RNA/T7-Oligo(dT) Primer Mix
Component Volume/µl
Sample RNA 10 µg (variable volume)
Diluted poly-A RNA controls 2
T7-Oligo(dT) primer, 50 µM 2
RNAse-free water Variable
Total volume 11
The above mixture was subjected to incubations in a thermal cycler with the
following program:
70°C 10 min
4°C Hold for the addition of First-Strand Master Mix




The First-strand Master Mix is assembled as in Table 2.2:
Table 2.2.  Preparation of First-Strand Master Mix
Component Volume/µl
5× 1st Strand Reaction Mix 4
DTT, 0.1 M 2
DNTP, 10 mM 1
Total volume 7
SuperScript II (2 µl) was added after 2 min of incubation at 42°C.  After incubation
for 1 h at 42°C, the sample was cooled for at least 2 min at 4°C before the second-
strand cDNA synthesis.
The following program was used to perform the second-strand cDNA synthesis in a
thermal cycler:
16°C 2 h
4°C Hold for the addition of T4 DNA Polymerase
16°C 5 min
4°C Hold
A Second-Strand Master Mix was prepared according to Table 2.3.
Table 2.3.  Preparation of Second-Strand Master Mix
Component Volume/µl
RNase-free water 91
5×2nd Strand Reaction Mix 30
dNTP, 10 mM 3
E. coli DNA ligase 1
E. coli DNA polymerase I 4
RNase H 1
Total volume 130
The Second-Strand Master Mix (130 µl) was added to each first-strand synthesis
sample for a total volume of 150 µl.  The mixtures were incubated for 2 h at 16°C.
T4 DNA polymerase (2 µl) was added to each sample and incubated for another 5
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min at 16°C.  After that, 10 µl of 0.5 M EDTA was added into each sample before the
cleanup of double-strand cDNA.
2.13.4.2 Cleanup of double-stranded cDNA for one-cycle target labeling assay
cDNA Bidding Buffer (600 µl) was added to the double-stranded cDNA synthesis
preparation.  This mixture was applied into the cDNA Cleanup Spin Column,
centrifuged and the flow-through was discarded.  The spin column was then washed
with 750 µl cDNA Wash Buffer, dried and the cDNA was eluted from the column
with 14 µl cDNA Elution Buffer.  The average volume of eluate was 12 µl from 14 µl
Elution Buffer.
2.13.4.3 Synthesis of biotin-labeled cRNA for one-cycle target labeling assay
The template cDNA (6 µl) was transferred to RNAse-free microfuge tubes and the
following reaction components were added in the order indicated in Table 2.4.




10× IVT Labeling NTP Mix 4
IVT Labeling NTP Mix 12
IVT Labeling enzyme Mix 4
Total volume 40
The mixtures were incubated at 37°C for 16 h.  To prevent condensation, incubation
was carried out in a thermal cycler with a heated lid.
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2.13.4.4 Cleanup and quantification of biotin-labeled cRNA
RNase-free H2O (60 µl) was added into the IVT reaction and mixed for 3 s.  After that
350 µl of IVT cRNA Binding Buffer was added, followed by 750 µl 96–100%
ethanol.  The samples were applied to the IVT Cleanup Spin Column sitting on a 2 ml
collection tube.  The column was centrifuged and the flow-through was discarded.
The column was then washed with 500 µl IVT cRNA Wash Buffer, followed by 500
µl 80% (v/v) ethanol.  The column was spun dry and the cRNA was eluted by 11 µl
RNase-free water.  A second elution using 10 µl was performed to maximize the
yield.  The cRNA was diluted 1:100 fold for quantification.
The yield of cRNA was determined by: 1 absorbance unit at 260 nm equals 40 µg/ml
RNA.  The purity of the cRNA was checked by calculating the A260/A280 ratio.
Ratios between 1.9 and 2.0 were considered acceptable.
For quantification of cRNA using total RNA as starting material, an adjusted cRNA
yield must be calculated to reflect carryover of unlabeled total RNA.  The following
formula was used to determine adjusted cRNA yield:
Adjusted cRNA yield = RNAm-(total RNAi) (y)
Where,
RNAm = amount of cRNA measured after IVT (µg)
Total RNAi = starting amount of total RNA (µg)
y = fraction of cDNA reaction used in IVT
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2.13.4.5 Fragmenting the cRNA for target preparation
Fragmentation of cRNA target before hybridization onto GeneChip probe arrays has
been shown to be critical in obtaining optimal assay sensitivity.  The reaction mix was
set up as in Table 2.5.
Table 2.5.  Sample fragmentation reaction
Component For 49 (standard)/64 array format
cRNA 20 µg
5× Fragmentation Buffer 8 µg
RNase-free water Top up to 40 µl final volume
The reaction was incubated at 94°C for 35 min and cooled down on ice following
incubation.  The fragmented sample cRNA can be stored at -20°C (or -70°C for
longer-term storage) until ready to perform the hybridization.  An aliquot of the
fragmented cRNA was run on 1% agarose gel to check the quality of the
fragmentation.  The standard fragmentation procedure should produce a distribution
of RNA fragment sizes from approximately 35 to 200 bases.
2.13.4.6 Eukaryotic target hybridization
Table 2.6 shows the components in the hybridization cocktail for a single probe array.
Table 2.6.  Hybridization cocktail for a single 49 format (standard)/64 format array
Component Volume/µl
Fragmented cRNA 15 µg (variable volume)
Control oligonucleotide B2 (3 nM) 5
20X Eukaryotic Hybridization Control 15
Herring Sperm DNA (10 mg/ml) 3
Acetylated BSA (50 mg/ml) 3
2× hybridization buffer 150
DMSO 30
Water Top up to final volume of 300 µl
The frozen stock of 20× GeneChip® Eukaryotic Hybridization Control cocktail was
heated to 65°C for 5 min to completely resuspend the cRNA before aliquoting.  It
contains bioB, bioC, bioD and cre prokaryotic enzymes.  bioB, bioC and bioD are
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genes of the biotin synthesis pathway from the bacteria E. coli.  c r e  is the
recombinase gene from P1 bacteriophage.  These genes can be labeled and serve as
hybridization controls when mixed with labeled eukaryotic cRNA samples.  The
probe array was equilibrated to room temperature immediately before use.  The array
was wetted by filling it through the lower septa with 100 µl of 1×hybridization buffer
while the array was held in a vertical position.  The probe array was incubated at
45°C for 10 min in an incubator with rotation.  The hybridization cocktail was heated
to 99°C for 5 min in a heat block, cooled down to 45°C for 5 min and centrifuged for
5 min at maximum speed to spin down any insoluble material from the hybridization
mixture.  After incubation, the 1× hybridization buffer was aspirated out and the
hybridization cocktail was added into the probe array.  Test chips were used before
the actually probe arrays (U74Av2) to ensure the quality of the targets and reagents.
Tapes were stuck over the septa to prevent leakage.  The probe array was placed into
the hybridization oven at 45°C, rotated at 60 rpm and hybridized for 16 h.
2.13.4.7 Washing, staining and scanning of the probe array
After 16 h of hybridization, the hybridization cocktail was removed from the probe
array and kept in a centrifuge tube.  The probe array was filled with 200 µl of non-
stringent wash buffer.  For staining, Streptavidin phycoerythrin (SAPE) staining
reagent was prepared before use as in Table 2.7.  For each probe array to be stained,
the following components were combined in a microfuge tube:
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Table 2.7.  SAPE solution mix
Component Volume/µl
2× MES stain buffer 600
50 mg/ml acetylated BSA 48
1 mg/ml SAPE 12
Milli-Q water 540
Total volume 1,200
The SAPE solution was mixed well and divided into 2 aliquots of 600 µl each to be
used for the first and third staining respectively.  An antibody mixture was prepared
with the following reagents as in Table 2.8.
Table 2.8.  Antibody solution mix
Component Volume/µl
2×MES stain buffer 300.0
50 mg/ml acetylated BSA 24.0
10 mg/ml normal goat IgG 6.0
0.5 mg/ml biotinylated antibody 3.6
Milli-Q water 266.4
Total volume 600.0
The staining and washing of probe arrays were performed in GeneChip® Fluidics
Station 450.  The fluidic protocol (Micro_1v1, Appendix B) was used for the test
chip. For the U74Av2 probe array, the EukGE-WS2v5 Fluidics Scripts (Appendix B)
were used.  At the end of the wash protocol, the probe array was scanned using
Affymetrix® GeneChip® Scanner 3000.  The data obtained was saved.  The probe id,
signal, detection and detection p value from the absolute analysis results file were
extracted and saved as .txt file for analysis using GeneSpring® (Silicon Genetics,
Redwood City, CA, USA; www.silicongenetics.com).
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2.13.5 Microarray data analysis
The microarray analysis was conducted with GeneSpring 7 Software (Silicon
Genetics, Redwood City, CA).  The raw data from the treatments were normalized to
the median of the control values.  GeneSpring 7 calculates the median expression for
each gene in the control samples, then uses that value to normalize all the samples.
The data is represented as fold change, relative to the median of all four control
samples.  All genes demonstrating smaller than 2-fold change were eliminated from
further consideration.  Furthermore, the genes that showed absence in all the
treatments were removed from the differentially expressed gene list.  To determine
whether the difference in gene expression in response to the treatments was
significant, a one-way ANOVA test was performed and genes with values of p<0.05
were considered to be significant.  To further test the integrity of the gene list,
Bonferroni Correction, a very stringent statistical analysis (Jung et al, 2005) was
performed.  The gene list with comprehensive functional annotations (molecular
and/or biological) was exported to Microsoft Excel for further analysis.  Genes were
then clustered according to their biological function in Excel spreadsheet with
reference to Gene Ontology Mining Tool from Affymetrix® NetAffx™ Analysis
Center (www.affymetrix.com/analysis/). Follow-up experiments were done to address
the biological relevance of the findings.
2.14 RNA gel electrophoresis
Denaturing agarose-formaldehyde gel electrophoresis was used for the size
fractionation of RNA.  A 1% (w/v) agarose-formaldehyde was prepared by melting
0.5 g of agarose in 43.5 ml of milli-Q water and cooled to 60%.  5 ml of 10× MOPS
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and 1 ml of 37% formaldehyde were added and casting of the gel was carried out in
the fume hood.  The RNA samples were prepared as follows:
RNA (1 µg) 4.5 µl
10× MOPS buffer 2.0 µl
Formaldehyde (pH>4, 37%) 3.5 µl
Deionized formamide 10 µl
RNA loading buffer 3.5 µl
The sample was mixed and heated to 60°C for 10 min prior to loading and
electrophoresis was carried out in 1× MOPS buffer.  RNA bands were visualized
under UV-light after electrophoresis.  The image was recorded using Chemi Genius
gel documentation system (Syngene, Cambridge, UK).
2.15 Quantitative real-time PCR
Total RNA was extracted using the High Pure RNA Isolation Kit (Roche Applied
Science, Indianapolis, IN, USA) with on-column DNase treatment according to
manufacturer’s specifications.  The RNA was then reverse transcribed using
TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster City, CA).
The final reverse transcription reaction includes 200 ng of RNA, 1×RT Buffer, 5.5
mM MgCl2, 0.5 µM per dNTP mixture, 2.5 µM Random Hexamers, 4 U RNase
Inhibitor and 12.5 U MultiScribe™ Reverse Transcriptase.  Reaction conditions were
25°C for 10 min, 37°C for 60 min and 95°C for 5 min.  The reaction was carried out
using a thermocycler (PTC-100™ Peltier Thermal Cycler, MJ Research).  A
Multiplex real-time PCR amplification was then carried out in the TagMan 7000
Sequence Detection System (Applied Biosystems) using TagMan Universal PCR
Master Mix (Applied Biosystems) and the specific primers and probes according to
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the manufacturer’s protocol.  The probes were labeled with 6-carboxyfluorescein as
the reported fluorescent dye at their 5’ ends while the 3’ ends were labeled with 6-
carboxy-tetramethyl-rhodamine as the quencher.  18S ribosomal RNA was used as the
internal control and its probe was labeled with reporter dye VIC at the 5’ end instead.
All primers and probes were synthesized by Applied Biosystems and details of
sequences are available upon request.
The PCR conditions were: an initial incubation of 50°C for 2 min and 95°C for 10
min followed by 40 cycles of 94°C for 15 s and 60°C for 1 min.  All reactions were
carried out in triplicates.  The threshold cycle, CT, which correlates inversely with the
levels of target mRNA, was measured as the cycle number at which the reporter
fluorescence emission exceeded a preset threshold level.  The amplified transcripts
were quantified using the comparative CT methods as described previously (Livak
and Schmittgen, 2001), with the formula for relative fold change = 2-ΔΔCT, where
ΔΔCT = [ΔCT gene of interest (treated sample)-ΔCT 18S rRNA (treated sample)]-
[ΔCT gene of interest (control sample)-ΔCT 18 rRNA (control sample)].  ΔC T
represents the mean CT value of each sample.  Data were obtained by carrying out at
least three independent experiments.
2.16 Cellular ATP and GSH measurement
Cells were washed twice in ice-cold PBS.  A volume of 250 µl of ice-cold
tricholroacetic acid (TCA) 6.5% (w/v) was added and the plate was left on ice for 10
min.  The TCA extract was removed and either stored at -80ºC or used immediately
for analysis.  NaOH (200 µl of 1 M solution) was then added to solubilize cellular
protein.  Protein concentration then was measured using BioRad protein assay.
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Cellular ATP concentration was assessed by using firefly lantern extract (Sigma,
FLE-50).  Each sample (3 µl) was incubated with 200 µL of sodium arsenite buffer
(comprising 26.67 mM MsSO4.7H2O/3.33 mM KH2PO4/33.33 mM Na2HASO4.7H2O,
pH 7.4).  After the addition of 25 µL of firefly lantern extract per sample, light
emission was measured for 3 s per sample by using TECAN ULTRA 384.  The
concentrations of ATP were determined by comparing the values obtained with a
freshly prepared standard curve of ATP.
For cellular GSH measurement, 7.5 µl of TCA extract was added to a 96-well black
plate followed by the addition of 227.5 µl of 100 mM KH2PO4-KOH buffer, pH 10
and 15 µl of o-phthaldialdehyde (10 mg/ml freshly prepared in methanol).  Samples
were stored in the dark at room temperature for 25 min and measured by fluorescence
(excitation=350 nm; emission=420 nm) using TECAN ULTRA 384.  Concentrations
of GSH were then determined by comparing the values obtained with a freshly
prepared standard curve of GSH.  The GSH concentrations were normalized with the
protein concentrations to get the final value.
2.17 Cholesterol measurement using gas chromatography mass spectrometry
Cells were washed twice with PBS.  The internal standard, consisting of a cholesterol
control containing heavy isotopes was added into each well before the extraction.
Cholesterol was extracted by adding 200 µl methanol, followed by 200 µl of KOH (1
M).  Cells from each well were scraped, collected into glass vials and hydrolyzed at
RT for 2 h in the dark.  Twenty-five µl of HCl (5 M) were added into each glass vial
to neutralize the KOH.  The samples were dried under a stream of N2 for 15 min in a
fume hood.  One hundred microliters of 200 mM formic acid (pH 4.5) were added
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into each vial followed by 1 ml of ethyl ether / Hexane (30:70) and mixed by
vortexing.  The aqueous phase was removed from the bottom of the glass vial and the
solvent was dried under a stream of N2.  The samples were then subjected to
derivatisation with acetonitrile (20ul) and BSTFA + 1% TMCS (20ul, Pierce, USA)
for 1 h in the dark, and then injected into gas chromatography mass spectrometer
(GC-MS).
Derivatised samples were analyzed by a Hewlett-Packard 5973 mass selective
detector interfaced with a Hewlett- Packard 6890 gas chromatograph and equipped
with an automatic sampler and a computer workstation.  The injection port, MS
source and GC-MS interface were kept at 280°C, 180°C and 290°C, respectively.
Separations were carried out on a fused silica capillary column (12m x 0.2mm i.d.)
coated with cross-linked 5% phenylmethylsiloxane (film thickness 0.33µm), (Agilent,
J and W). Helium was the carrier gas with a flow rate of 0.8 ml/min (average velocity
= 55cm/sec).  Derivatised samples (1 µl) were injected with a 10:1 split into the GC
injection port (280°C). Column temperature was increased from 240°C to 300°C at
25°C/min after 1 min at 240°C, then held at 300°C for 4 min.  Selected-ion
monitoring was performed using the EI mode at 70eV with the ion source maintained
at 230°C and the quadrapole at 150°C.  Selected-ion monitoring was performed to
monitor one target ion and two qualifier ions selected from each compound mass
spectrum to optimize sensitivity and specificity. Quantitation of cholesterol was
achieved by relating the peak area of the cholesterol with its corresponding internal
standard 5a-cholestane peak and comparison with a standard calibration curve.
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2.18 Lipid profiling using Electro-Ionization Mass Spectrometry
2.18.1 Lipid extraction from cultured neurons
All buffers and reagents were kept chilled in an icebox.  Control and treated cells
were washed with 3 ml of PBS twice.  Once all trace amounts of PBS was removed,
0.3 ml of 50% Methanol/HCl was added into each well of a 6-well culture plate.
Cells were scraped immediately and transferred to a microfuge tube (cells from two
wells were combined into one tube).  Internal standards were spiked into the sample
prior to lipid extraction.  Tubes were vortexed and stored on ice until all the cells had
been collected.  Prechilled chloroform (0.6 ml) was added into each tube and the
mixtures were subjected to vigorous vortexing for 30 s.  This was repeated twice.
Tubes were then centrifuged for 2 min at 9,000 rpm in a microcentrifuge.  The
organic layer (bottom layer) was transferred to clean microfuge tubes, pooling organic
layers from two tubes into one.  The organic layers were dried in a speed vac.  The
lipid film was later resuspended in 0.5 ml choloroform:methanol (1:1).
2.18.2 Electrospray-Ionization mass spectrometry
Electrospray-Ionisation Mass Spectrometry (ESI-MS) was performed using a Waters
Micromass Q-Tof micro (Waters Corp., Milford, MA) mass spectrometer. Typically,
2 µl of sample were injected for mass spectrometry analysis. The capillary voltage
and sample cone voltage were maintained at 3.0 kV and 50 V respectively. The
source temperature was 80°C and the nano-flow gas pressure was 0.7 bar. The mass
spectrum was acquired from m/z 400–1200 in the negative ion mode with an
acquisition time of ten minutes [mrw], and the scan duration was 1 sec. The HPLC
system, consisting of a Waters CapLC Autosampler and a Waters CapLC Pump, was
40
used to provide the mobile phase and to inject samples. Chloroform-methanol 1:1
(v/v) at a flow rate of 3 µl/min was used as the mobile phase. Individual molecular
species were identified using tandem mass spectrometry and in general, the collision
energy used ranged from 25–80 eV.
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CHAPTER 3
3 PTEN accumulation in detergent-insoluble fraction during lactacystin-
induced neuronal apoptosis
3.1 Introduction
3.1.1 PTEN and cell death
PTEN (phosphatase and tensin homolog deleted from chromosome 10) is a novel
phospholipid and protein phosphatase.  Its tumor suppressor function is attributed to
its phospholipid phosphatase activity that specifically dephosphorylates the plasma
membrane phospholipid secondary messenger phosphatidylinositol-(3,4,5)-
triphosphate (PtdIns(3,4,5)P3), a product of phosphoinositide-3 kinase (PI3-kinase)
(Fig. 3.1).  Mutation of the PTEN gene is associated with many cancer types such as
gliomas and endometrial cancer (Leslie and Downes, 2002; Waite and Eng, 2002).
Furthermore, mammalian cells transfected with the PTEN gene are more sensitive to
the induction of apoptosis (Wang et al, 1999; Gary and Mattson, 2002), suggesting
that its interplay with PI3-kinase is an important regulatory step in the cellular
cascades related to apoptosis.
3.1.2 The role of PTEN in central nervous system
In the central nervous system (CNS), PTEN is a regulatory molecule with multiple
functions at multiple subcellular sites (Review by Ross et al, 2001).  PTEN plays a
very important role in brain development.  Recent in vivo studies have revealed a
novel role for PTEN in the size control of neurons; dysregulation of cell growth
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Figure 3.1. PTEN translocation and the PI3-kinase/Akt cell survival pathway.  Figure
shows the hypothetical model for pro-apoptotic PTEN translocation during
neuronal cell death.
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control by PTEN is associated with the neurological disorder Lhermitte-Duclos
disease, a rare CNS manifestation of Cowden’s disease caused by a hamartomatous
overgrowth of the cerebellum (Backman et al, 2002).  In addition, PTEN also
regulates migration of precursor cells in the subventricular zone to the olfactory bulb
(Li et al, 2003).  Recently, Perandones et al reported an observation that PTEN might
be involved in synaptogenesis during brain development (Perandones et al, 2004).
Furthermore, the lost and altered distribution of PTEN in Alzheimer’s diseased
neurons suggests the important role of PTEN in the pathogenesis of
neurodegenerative diseases (Griffin et al, 2005).
3.1.3 The structure of PTEN
The PTEN structure can be divided into a phosphatase domain in the N-terminal
portion, a C2 domain and a C-terminal tail (Fig. 3.2).  The phosphatase domain
contains the active site responsible for catalyzing the dephosphorylation reaction.
Mutations abolishing PTEN phosphatase activity are frequently found in cancer.
Both phosphatase- and C2- domains contain phospholipid-binding motifs that are
essential for targeting PTEN to the plasma membrane and activation of PTEN (Waite
and Eng, 2002; Das et al, 2003).  The 50-residue C-terminal tail contains the
physiological phosphorylation sites Ser-380, Thr-382 and Thr-383 and the ITKV-
motif at the C-terminus that mediates binding of PTEN to PDZ domain-containing
cellular proteins (Georgescu et al, 1999; Leslie and Downes, 2002).  In most
mammalian cells, PTEN is mainly localized in the cytosol, with little or no
association with the plasma membrane (Leslie et al, 2001).  In the PC12 cell line, a
significant portion of PTEN is also localized in the nucleus (Lachyanker et al, 2000;
Ross et al, 2001; Lian and Di Cristofano, 2005).  Since PtdIns(3,4,5)P3 is located on
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Figure 3.2. A cartoon drawing of the structure of PTEN.  PTEN protein contains 3
main parts, the phosphatase at the N-terminal, the C2 domain and the C-terminal
tail with the PDZ sequence.  The C-terminal tail contains 3 main phosphorylation
sites at Ser-380, Thr-382 and Thr-383.
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the plasma membrane, PTEN needs to translocate from the cytosol and/or the nucleus
to the plasma membrane before it can dephosphorylate the phospholipid substrate.
However, the mechanism of recruitment of PTEN to the plasma membrane is still
poorly understood. Data presented in a recent report by Das et al. suggests
dephosphorylation of Ser-380, Thr-382 and Thr-383 in the C-terminal tail enhances
PTEN targeting to the plasma membrane and nucleus (Das et al, 2003).  In spite of
this, physiological and pathological conditions that induce PTEN targeting to the
plasma membrane have not been identified.
3.1.4 The possible role of PTEN in proteasome inhibition-induced neuronal
apoptosis
Inhibition of the proteasome has been postulated to be responsible for the
pathogenesis of neurodegenerative diseases such as Alzheimer’s and Parkinson’s
diseases (Keller et al, 2000; Naujokat and Hoffmann, 2002; Halliwell, 2002; Song and
Jung, 2004; Bossy-Wetzel et al, 2004).  Inhibition of proteasome function by
lactacystin treatment induces apoptosis of cultured cortical neurons and cerebellar
granule cells via stimulation of mitochondrial cytochrome c release and activation of
a caspase-3-like protease activity (Qiu et al, 2000; Pasquini et al, 2000).  Herein, this
study reports that neuronal apoptosis and activation of caspase-3 induced by
lactacystin treatment is associated with conversion of PTEN to a truncated form that
lacks parts of the C-terminal tail, and accumulation of both PTEN and its truncated
fragment to the detergent-insoluble membrane fraction.  This data suggests the
association of PTEN with the plasma membrane in a pathological condition.
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3.2 Results and discussions
3.2.1 Lactacystin-induced neuronal apoptosis
Lactacystin treatment suppresses proteasome activity and induces apoptosis of
cultured cortical neurons.  The morphological and biochemical changes of cultured
cortical neurons induced by treatment with the proteasome inhibitor lactacystin were
examined.  As shown in Fig. 3.3, treatment of cultured neuronal cells with 1 µM
lactacystin for 48 h induced apoptosis-associated phenotypic changes such as cell
shrinkage, DNA condensation and chromatin fragmentation.  The MTT assay
confirmed that the viability of the treated cells decreased in a dose- and time-
dependent manner (Fig. 3.4A).  Decrease in cell viability was concomitant with the
dose-dependent decrease in proteasome activities — the postglutamyl peptidase
(caspase-like) activity, chymotrypsin-like peptidase activity and the trypsin-like
peptidase activity of the proteasome in the treated cells (1 µM for 48 h) were
decreased to 54.3 ± 1.2 %, 40.6 ± 2.4 % and 42.8 ± 2.7 %, respectively, of the level in
untreated cells (Fig. 3.4B).  To ascertain if the caspase-3 signaling pathway is
involved in lactacystin-induced neuronal cell death, the level of the active caspase-3
generated from proteolysis of procaspase-3, and the caspase-3 activity level in
cultured neurons treated with different doses of lactacystin were measured.  As shown
in Fig. 3.5, Western blotting of the whole cell lysate extracted from lactacystin-treated
neurons reveals the presence of a cleaved form of caspase-3.  The appearance of the
cleaved form of caspase-3 is accompanied with a dose-dependent activation of
caspase-3 activity in the lactacystin-treated neurons.  Taken together, the results
demonstrate that treatment with lactacystin at 1 µM for 48 h could efficiently inhibit
proteasome activity, activate caspase-3 activity and induce apoptosis of cultured
neuronal cells.
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Figure 3.3. Morphological changes of cultured cortical neuronal cells induced by
lactacystin treatment.  (A) Staining of apoptotic nuclei using Hoechst 33258.
Control and treated (1 µM lactacystin for 48 h) cells were stained and viewed
under the fluorescence microscope (Carl Zeiss LSM510).  White arrow indicates
the apoptotic nuclei in treated cells.  (B) Transmission electron micrographs of
cultured cortical neurons.  Control and lactacystin-treated (1 µM lactacystin for
48 h) cells showing the normal (a) and condensed nuclei (b).
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Figure 3.4. The effects of lactacystin treatment on viability and proteasome activity of
cultured cortical neurons.  (A) Cell viability of lactacystin-treated (1 µM
lactacystin for 48 h) cultured cortical neurons was determined using the MTT
assay (as described in materials and methods).  Cell injury was found to be
concentration- and time-dependent.  Values are mean ± standard error of at least
3 independent samples and *p<0.05 (ANOVA with Tukey’s test) compared with
the corresponding control.  (B) Proteasome activity measurement of cultured
cortical neurons treated with lactacystin (0, 0.05, 0.1, 0.25, 1 and 2 µM for 48 h)
using fluorogenic peptide substrate.  Five micrograms of total protein were
incubated with substrate II, substrate III or substrate VI for the measurements of
postglutamyl, chymotrypsin-like or the trypsin-like peptidase activities
respectively and the fluorescent products were detected using a TECAN plate
reader.  Values are mean ± standard error of at least 3 independent samples and
*p<0.05 (ANOVA with Tukey’s test) compared with the corresponding control.
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Figure 3.5. Detection of active caspase-3 in cultured cortical neurons treated with
lactacystin.  Western blot showing the presence of a cleaved form of caspase-3
and the increase in caspase-3 activity in lactacystin-treated (0, 1 and 2 µM for 48
h) cells.  Statistically significant (*p < 0.01) over control cells determined by
one-way ANOVA with Tukey’s test.
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3.2.2 Changes of PTEN level in cultured neuronal cells during development
PTEN has been implicated in enhancing the apoptosis of neurons induced by several
pathological conditions (Gary and Mattson, 2002).  Since the regulatory properties of
PTEN are not fully understood, the exact role played by PTEN in enhancing neuronal
apoptosis is not known.  As a part of the ongoing study of the molecular mechanism
of lactacystin-induced neuronal cell death, this study examined if lactacystin
treatment induced biochemical changes of PTEN.  As a background study, the time-
dependent changes in PTEN expression levels in cultured primary cortical neurons
were examined.  Fig. 3.6 shows that PTEN expression could be detected from as early
as day 2 in the in vitro culture, and the expression level increased in a time-dependent
fashion until it reached the maximum level on day 6–9 in culture.  This observation is
reminiscent of the report by Luukko et al. of the high level of PTEN expression in
embryonic mouse brain (Luukko et al, 1999).  Since the PTEN expression level of
cultured neurons was relatively high at day 5, reaching a maximum level at day 7 in
culture, and neuronal cells required treatment with lactacystin for 48 h before they
exhibited prominent apoptotic phenotypes (Fig. 3.3), neurons at day 5 to day 7 in
culture were used for this investigation into the effect of lactacystin on PTEN
expression level and subcellular localization.
3.2.3 Lactacystin treatment enhances the conversion of PTEN to a 50kDa
truncated fragment and accumulation of both forms of PTEN in the
detergent-insoluble membrane fraction
Western blot analysis of the whole cell lysate of neurons in treated and untreated cells
revealed two forms of PTEN — a 55 kDa form
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Figure 3.6. Western blot analysis of PTEN expression in cultured mouse primary
cortical neurons.  (A) PTEN expression in cultured mouse cortical neurons from
day 1 to day 9 in vitro.  Equal amount of proteins (5 µg) were loaded and run on
a SDS-PAGE, transferred to PVDF membrane and immuno-labeled with anti-
PTEN and anti-actin.  Since the expression of actin increased from day 1 to 6
before reaching a plateau, it was used as an internal control for cultures from day
6 onwards only.  (B) Graph represents the densitometric intensities of the bands
in (A).
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and a 50 kDa truncated form (Fig. 3.7).  PTEN in untreated cells exists predominantly
as the 55 kDa form.  Treatment with increasing concentrations of lactacystin
decreased the total expression level of PTEN (Fig. 3.7).  Intriguingly, the treatment
also caused the conversion of a significant amount of the 55 kDa species to the
truncated 50 kDa species.  After lysis of the neuronal cells with RIPA buffer, PTEN
levels in the soluble and the insoluble fractions were determined by Western blotting.
As shown in Fig. 3.8A, only the 55 kDa species appeared in the soluble fraction while
both the 55 kDa and the 50 kDa species were present in the insoluble fraction (Fig.
3.8B).  Since RIPA buffer contains detergents (NP40, deoxycholate and SDS), the
soluble portion represents the cytosolic fraction and the detergent-soluble membrane
fraction of the neuronal cells, while the insoluble portion represents the detergent-
resistant plasma membrane.  To establish the identity of the 50 kDa species, the blots
were re-probed with two other PTEN antibodies, the PTEN-N-19 and PTEN 26H9,
that target the N-terminal segment and the C-terminal segment, respectively. The
PTEN 26H9 antibody failed to recognize the 50 kDa truncated PTEN (Fig. 3.8B),
indicating that the latter lacks part of the C-terminal tail. Taken together, the data in
Fig. 3.8 demonstrate that lactacystin treatment of neuronal cells induced proteolysis of
PTEN to the truncated 50 kDa form of PTEN, which is preferentially targeted to the
detergent-resistant fraction.
Recently, Torres et al. reported that PTEN is cleaved by caspase-3 at several target
sites located in unstructured regions within the C-terminus of the molecule (Torres et
al, 2003) (Fig. 3.9).  In this study, caspase-3 was activated upon treatment with
lactacystin (Fig. 3.5).  This makes caspase-3 the most likely candidate that cleaved
PTEN to its 50 kDa truncated form during lactacystin-induced apoptosis.
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Figure 3.7. Western blots and graphic representation of the relative amounts of 55
kDa and 50 kDa PTEN species found in the whole cell lysate of cortical neurons
treated with increasing concentrations of lactacystin.  Mouse cortical neurons
were treated with increasing concentrations of lactacystin (0, 0.25, 0.5 and 1 µM)
for 48 h and proteins were harvested using 5× sample loading buffer.  Proteins
were resolved in a 10% gel SDS-PAGE and electro-transferred to PVDF
membrane.  The blot was later immuno-labeled with PTEN polyclonal antibody
raised from 5 peptides chemically synthesized according to 5 regions of the
PTEN protein.  β-tubulin is the internal control for equal loading of protein.  The
graph represents the densitometric intensities of the 50 and 55 kDa PTEN
species found in different concentrations of lactacystin treatments.
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Figure 3.8. Distribution of the 55 kDa PTEN and the 50 kDa PTEN species in the
soluble and insoluble fractions of cortical neurons treated with lactacystin.  (A)
The 55 kDa PTEN species in the detergent-soluble fraction of the lactacystin-
treated cells.  (B) The 55 kDa and 50 kDa species of PTEN in the detergent-
insoluble fraction of the lactacystin-treated (1 µM for 48 h) cells.  Relative
amounts of the 55 kDa and 50 kDa species of PTEN were quantitated by
densitometric scan of the immunoreactive bands in the Western blots and were
expressed in densitometry units.
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Figure 3.9. PTEN protein sequence and potential caspase-3 cut sites.  Arrows
indicates potential caspase-3 cleavage sites.  The underlined protein sequences
are the sequences of peptides generated for poly-clonal anti-PTEN antibody, as
described in Materials and Methods sections.
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3.2.4 Lactacystin treatment enhances accumulation of PTEN in the detergent-
insoluble fraction that has been co-purified with plasma membrane protein
markers
As PtdIns(3,4,5)P3 is localized on the plasma membrane, it is likely that the detergent-
insoluble fraction in which PTEN and its truncated form accumulate upon lactacystin
treatment are part of the plasma membrane.  To examine this notion,
immunocytochemistry was performed to investigate how lactacystin treatment
affected localization of PTEN in cultured cortical neurons.  Fig. 3.10A shows that
PTEN in the untreated neurons was localized predominantly in the cytosol and
nucleus.  The image, however, could not reveal if PTEN was associated with the
plasma membrane.  Since flotillin-1 is expressed exclusively in specific micro-
domains of the plasma membrane such as the lipid-raft, its localization was therefore
compared with that of PTEN.  As shown in Fig. 3.10B, the localization of flotillin-1
had little, if any, overlap with that of PTEN in the untreated cells.  In contrast, the
significant overlap of the confocal images of PTEN and flotillin-1 in the lactacystin-
treated neurons suggests that PTEN was co-localized with flotillin-1 in the
lactacystin-treated cells.
To further investigate the subcellular distribution of PTEN in lactacystin-treated and
untreated neuronal cells, the post-nuclear supernatants of cell lysates from both the
treated and untreated cells were subjected to Percoll gradient centrifugation. Analysis
of the centrifugation fractions with various protein markers revealed: (i) the plasma
membrane lipid-raft markers caveolin-1 and flotillin-1 resided predominantly in
fractions 4-6 (Fig. 3.11A), corresponding to the low-density membrane fraction; (ii)
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Figure 3.10. Effects of lactacystin treatment on PTEN subcellular localization in
cultured neuronal cells.  (A) Immunocytochemistry showing PTEN localized at
the plasma membrane during neuronal apoptosis (arrow).  (B)
Immunofluorescence showing PTEN co-localized with flotillin-1 during
neuronal apoptosis.  Cortical neurons were treated with 1 µM lactacystin for 48 h
for the induction of neuronal apoptosis.
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Figure 3.11. Lactacystin-induced changes in PTEN distribution in the various
subcellular compartments of neuronal cells separated by Percoll gradient
centrifugation.  (A) The plasma membranes of cortical neurons treated and
untreated with 1 µM lactacystin for 48 h were isolated with Percoll gradient
centrifugation.  Fractions (from top to bottom of the gradient) were collected and
immunoblotted for PTEN, flotillin-1 and caveolin-1 (plasma membrane lipid-raft
markers).  (B) LDH enzyme activity measurement of fractions from cells treated
with 1 µM lactacystin for 48 h.  Graph shows the majority of LDH was in
fraction 2, which corresponds to the cytosolic fraction.
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besides residing in fractions 4-6, the plasma membrane-bound protein tyrosine kinase
c-Src was also present in fractions 21-22, which correspond to the high-density
membrane fraction; and (iii) the catalytic activity of the cytosolic protein marker
lactate dehydrogenase (LDH) peaked at fraction 2 (Fig. 3.11B), suggesting that
fractions 1-3 were derived from the cytosolic compartment of the neuronal cells.  In
the untreated cells, PTEN was present in the cytosol (fractions 1-3), the low-density
membrane fraction (fractions 4-6) and the high-density membrane fraction (fractions
21-22).  However, in the lactacystin-treated cells, PTEN and its truncated fragment
were almost absent in the cytosol and accumulated in both the low-density and high-
density membrane fractions.  In summary, the data shown in Fig. 3.10 and 3.11 lend
further support to the conclusion drawn from the biochemical data (Fig. 3.8) that
lactacystin treatment induced accumulation of PTEN and its truncated fragment to the
membrane fraction.
Co-localization of anti-PTEN and anti-flotillin-1 immunoreactivities in the
lactacystin-treated cells (Fig. 3.10) and co-migration of PTEN and its truncated
fragment with the plasma membrane markers in Percoll density gradient
centrifugation (Fig. 3.11), suggest that the detergent-insoluble fraction at which both
forms of PTEN accumulate (Fig. 3.8) are parts of the plasma membrane.  However,
unequivocal proof that both forms of PTEN are targeted to the plasma membrane such
as the lipid-raft upon lactacystin treatment entails demonstration of a correlative
decrease in plasma membrane PtdIns(3,4,5)P3 level and/or binding of PTEN and its
fragments to protein complexes that are found exclusively in the plasma membrane.
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3.2.5 Implications of the appearance of the 50kDa truncated PTEN in neuronal
cells induced by lactacystin treatment
Previously, Das et al. 2003 demonstrated that deletion of the segment corresponding
to residues 354 to 403, or prevention of PTEN C-terminal tail phosphorylation by
replacing Ser-380, Thr-382 and Thr-383 with alanine, targets the “phosphatase-dead”
[C124A] PTEN mutant to the plasma membrane.  Their results suggest that the C-
terminal tail, upon phosphorylation, prevents PTEN from targeting to the plasma
membrane.  This notion is reminiscent of this study’s finding that the C-terminally
truncated 50 kDa PTEN species preferentially accumulated to the detergent-insoluble
membrane fraction in the lactacystin-treated neuronal cells. It is possible that the
truncated PTEN species is an activated form of PTEN, which upon dephosphorylation
of PtdIns(3,4,5)P3 in the plasma membrane, suppresses cell growth and promotes
apoptosis by antagonizing the PI-3 kinase/PKB signaling pathway.  A model of PTEN
phosphorylation or truncation corresponding to its tumor suppressor activity or pro-
apoptotic role is therefore proposed (Fig. 3.12).  Since PTEN phosphorylation and
dephosphorylation are reversible processes, the regulation of PTEN through
phosphorylation might play a role in PTEN tumor suppressor activity.  On the other
hand, the deletion of the C-terminal tail during apoptosis is most likely to be
associated with cell death since this process is not reversible.  Cells undergoing
apoptosis probably activate proteases such as caspase-3 to cleave PTEN, causing the
latter to translocate to the plasma membrane to suppress the PI3-kinase/Akt survival
pathway.
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Figure 3.12. Hypothetical model of PTEN regulation associated with its tumor
suppressor activity and cell death.
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In spite of these findings, the exact mechanism of PTEN in mediating apoptotic
effects during lactacystin treatment is still not known.  Future investigation should
focus on (i) identifying the proteases responsible for converting the full length PTEN
to the truncated PTEN, (ii) defining the segments deleted from PTEN to generate the
50 kDa truncated form in neurons, (iii) ascertaining how the deletion facilitates
targeting of PTEN to the plasma membrane and (iv) ascertaining if the truncated
PTEN is enzymatically active.
3.3 Follow-up work
3.3.1 Identification of the protease responsible for converting the full length
PTEN to the truncated PTEN
Western blot analysis of α-fodrin, a caspase-3 substrate, showed a clear 120 kDa band
associated with caspase-3 cleavage 24 h after lactacystin treatment.  Interestingly, a
very faint doublet (145 and 150 kDa), which is associated with calpain cleavage, was
observed too (Fig. 3.13A). Calpain is known to cleave p35, the neuronal-specific
activator of cyclin-dependent kinase 5 (Cdk5) to produce the truncated form called
p25.  p25 has been reported to accumulate in the brains of patients with Alzheimer’s
disease (Patrick et al, 1999; Lee et al, 2000).  Unlike p35, p25 is not readily degraded,
and the binding of p25 to cdk5 constitutively activates cdk5 and hyper-phosphorylates
tau to disrupt the cytoskeleton and promote neuronal death (Patrick et al, 1999; Lee et
al, 2000).  Incidentally, p35 was found to have been cleaved into its truncated form of
p25 24 h after lactacystin treatment (Fig. 3.13A).  The cleavage of p35 into p25 in
lactacystin-treated neurons strongly supports the involvement of calpain in
lactacystin-induced neuronal cell death.  To further confirm this observation, caspase
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Figure 3.13. PTEN is cleaved by caspase-3 during lactacystin-induced neuronal
apoptosis.  (A) Western blot analysis of the cleavage of caspase-3 and α-fodrin
in protein samples obtained from cultured cortical neurons treated with 1 µM
lactacystin alone (Lact), or with 100 µM z-VAD-FMK caspase inhibitor
(Lact+VAD), or with 100 µM caspase-3 inhibitor IV (Lact+C3), or with 10 µM
calpeptin (Lact+CP), or with both 100 µM z-VAD-FMK and 10 µM calpeptin
(Lact+VAD+CP) for 24 h.  The 120 kDa α-fodrin fragment corresponds to
caspase-3 cleavage and the 145/150 doublet corresponds to calpain cleavage.
(B) In vitro digestion of recombinant PTEN by calpains and caspase-3.
Recombinant PTEN (1 µg) was incubated with calpain 1, calpain 2 and caspase-
3 for 3 h and the products were analyzed using Western blot.  Both calpain 1 and
calpain 2 produced truncated TPEN with molecular size <50 kDa.  Caspase-3-
digested recombinant PTEN produced 50 kDa truncated PTEN, similar to those
observed in the detergent-insoluble pellets of lactacystin-treated cultured cortical
neurons.  The control soluble proteins were extracted from untreated cultured
cortical neurons using RIPA buffer.
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and calpain inhibitors were used in the following experiments.  As expected, Western
blot showed a more intense caspase-3-cleavage-associated 120 kDa α-fodrin fragment
compared to the 145/150 kDa calpain-cleavage-associated doublet (Fig. 3.13A) in
protein samples extracted from cultured neurons exposed to lactacystin (1 µM) alone.
When caspase pan-specific inhibitor z-VAD-FMK (100 µM) or caspase-3 inhibitor IV
(100 µM) were used together with lactacystin (1 µM), Western blot analysis of α-
fodrin cleavage showed a more intense calpain-cleavage-associated 145/150 kDa
doublet but a faint  120 kDa caspase-3-cleavage-associated band, indicating that
calpain activity was dominant when caspase-3 activity was blocked (Fig. 3.13A).  On
the other hand, when the calpain inhibitor calpeptin (10 µM) was used together with
lactacystin (1 µM), the absence  of the 145 kDa calpain-cleavage-associated band and
the presence of a more prominent caspase-3-cleavage associated 120 kDa band in the
western blot of α-fodrin suggest an increase in caspase-3 activity (Fig. 3.13A).  This
western blot result indicates that the inhibition of caspase-3 activity using inhibitors
could affect the activity of calpain or vice versa.  This observation suggests that a
cross-talk between caspase-3 and calpain exists in lactacystin-induced neuronal
apoptosis.
To confirm if caspase-3 was the protease that cleaved PTEN to generate the truncated
form of 50 kDa during lactacystin-induced neuronal apoptosis, in vitro enzymatic
digestion was performed on recombinant PTEN obtained from an insect cell line (a
gift from Heung-Chin Cheng, Department of Biochemistry and Molecular Biology,
Melbourne University) using recombinant caspase-3 enzyme (recombinant protein
expressed in E. coli, cat#14-264, Upstate Biotechnology, Lake Placid, NY, USA).
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Figure 3.14. The effects of caspase and calpain inhibitors on the cleavage of PTEN
and cell viability.  (A) Both caspase-3 inhibitor IV and z-VAD-FMK can
effectively inhibit the cleavage of PTEN.  (B) Caspase-3 inhibitor IV, z-VAD-
FMK and calpeptin when co-treated with lactacystin cannot protect the cultured
neuron against cell death.
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The Western blotting result shows that the recombinant PTEN was cleaved to exactly
the same truncated form as the lactacystin-treated control (Fig. 3.13B).  This
observation supports the hypothesis that caspase-3 was the protease responsible for
the cleavage of PTEN to the 50 kDa-truncated form.  Both calpain-1 and -2 generated
a smaller (<50 kDa) truncated PTEN fragment (Fig. 3.13B), indicating a different cut
site.  Furthermore, both z-VAD-FMK and caspase-3 inhibitor IV could effectively
inhibit the cleavage of PTEN during lactacystin-induced neuronal apoptosis (Fig.
3.14A).
Cell viability assay was performed on cultured cortical neurons treated with
lactacystin (1 µM), caspase-3 and calpain inhibitors to investigate whether these
inhibitors could effective attenuate cell death.  MTT assay shows that they were
ineffective in protecting neurons from lactacystin-induced apoptosis (Fig. 3.14B). The
result shows that inhibition of caspase-3 and calpain activity could not block
lactacystin-induced neuronal apoptosis in cultured cortical neurons.
Caspase-3 was identified as the protease responsible for the cleavage of PTEN to the
truncated 50 kDa form during lactacystin-induced neuronal apoptosis.  Calpain was
found to be activated, although not as much as caspase-3, and was found to cleave
p35 into p25.  In vitro digestion study using recombinant PTEN showed that PTEN
could be cleaved by calpain, but the cleavage generates a smaller PTEN fragment
compared to those generated by caspase-3.  In lactacystin-treated cultured cortical
neurons, this <50 kDa PTEN fragment was not observed and probably served no
physiological role in the cell death.
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3.3.2 Recruitment of PTEN onto the plasma membrane during lactacystin-
induced neuronal apoptosis
In this study, an attempt was made to demonstrate the recruitment of PTEN onto the
plasma membrane of cultured cortical neurons treated with lactacystin using
immunogold TEM.  Under the TEM, the plasma membrane sheets contained dark
(electron-dense) patches (Fig. 3.15).  These patches were caused by the accumulation
of Osmium, which is a stain for lipids with double bonds; therefore the dark patches
indicated areas rich in lipids or cholesterol, such as the lipid raft or the detergent-
insoluble plasma membrane microdomain (Wilson et al, 2004).  In this experiment,
the immuno-reactivity of anti-flotillin-1 against the antigens on the membrane sheets
was not as good as that of anti-PTEN antibody.  Nevertheless, both treated and
untreated neurons showed small clusters of flotillin-1 (2–5 size 15-nm gold particles)
on the inner surface of the membrane sheets (Fig. 3.15A).  In contrast, lactacystin-
treated neurons showed a marked increased of the 10-nm gold particles corresponding
to PTEN on the inner membrane sheets, compared to the untreated neurons (Fig.
3.15B).  A closer examination revealed the localization of gold particles in the
electron-dense patches (Fig 3.15B, inset), confirming that PTEN accumulated in the
lipid-rich membrane microdomain or lipid-raft.
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Figure 3.15. Accumulation of PTEN at the plasma membrane of mouse cortical
neurons treated with lactacystin.  (A) Control membrane sheet showing some
immunogold labeling of PTEN (10 nm) and flotillin-1 (15 nm).  (B) Membrane
sheet from lactacystin-treated neurons showing marked increased in PTEN
immunogold labeling.
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Lipid rafts are plasma membrane microdomains that contain high concentrations of
cholesterol and glycosphingolipids (Pike, 2003).  Lipid rafts exist as liquid-ordered
regions of membrane that are resistant to extraction with nonionic detergents such as
Triton X-100 (Schroeder et al, 1998).  A variety of proteins, especially those involved
in cell signaling have been shown to partition into lipid rafts (Pike, 2003).  PTEN
accumulation into the detergent-insoluble fraction during lactacystin-induced
neuronal apoptosis was previously reported.  In this study, the localization of PTEN in
the electron-dense and lipid-rich microdomains was shown using immuno-gold TEM
on the plasma membrane sheets.
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CHAPTER 4
4 Microarray GeneChip® analysis of gene expression during lactacystin-
induced neuronal apoptosis
4.1 Introduction
Global views of gene expression are often essential for obtaining comprehensive
pictures of cell function.  Understanding the critical relative changes among all the
genes would be impossible without the use of whole-genome analysis. Whole-genome
analyses also provide an efficient tool to sort through the activities of thousands of
genes, and to recognize the key players.  Global analyses frequently provide insights
into multiple facets of a biological process and may also reveal clues about the basic
biology of disorders, and suggest novel drug targets.
The GeneChip® probe array, with its sensitivity, specificity, and reproducibility, is an
excellent tool for the study of global gene expression.  Taking advantage of these
capabilities, many researchers have used GeneChip® probe arrays to study the
regulation of gene expression associated with a wide variety of basic biological
functions and disease conditions (Stenzel-Poore et al, 2003; Fribley et al, 2004).
Microarray GeneChip® technology has also been used to study the global response of
proteasome inhibition in Saccharomyces cerevisiae (Flemming et al, 2002) and in
human breast carcinoma cells, demonstrating the up-regulation of members of various
transcription factor families (Zimmermann et al, 2000).  Recently, the chronic effect
of proteasome inhibitors was tested on SH-5Y5Y neural cell lines (Ding et al, 2004).
However, a similar analysis of the effects of proteasome inhibition upon primary
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neurons has not been reported.  Because proteasome inhibition is likely to contribute
to neurodegeneration and is also able to generate initial neuroprotective proteins, the
identification of genes that are differentially expressed upon proteasome inhibition in
a primary neuronal culture model might enable us to have a clearer idea of the
possible pro-apoptotic and neuroprotective pathways activated in this process.  The
fundamental objective in any neurodegeneration and neuroprotection research is to
determine which of these factors constitutes the primary event, the sequence in which
these events occur, and whether they act in concurrence in the pathogenic process
(Mandel and Youdim, 2004).  In this study, Affymetrix U74Av2 microarray was used
to analyze the changes in gene expression upon lactacystin treatment of mouse
primary cortical neurons at different time points.  The microarray result showed that
lactacystin-induced proteasome inhibition caused differential expression of genes
involved in the UPS, heat shock protein (HSP), ER stress, oxidative stress and
cholesterol biosynthesis among others.
4.2 Results
4.2.1 Time course of lactacystin-induced proteasome inhibition and neuronal
apoptosis
Proteasomal chymotrypsin-like activity was assayed using flurogenic substrate on the
cell lysate extracted from cultured cortical neurons treated with 1 µM lactacystin.
The chymotrypsin-like activity was inhibited considerably (94% decrease in activity
compared to the control) at the earliest time point (4.5 h) measured (Fig. 4.1A).  The
slight recovery of chymotrypsin-like activity was observed at 24 h after lactacystin
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Figure 4.1. Effects of lactacystin (Lact) on proteasome activities and cell viability of
mouse cultured cortical neurons.  (A) Proteasomal chymotrypsin-like activity
was measured using fluorogenic substrate III.  Activity was presented as percent
relative fluorescence unit (RFU) compared to the control.  * denotes significant
difference compared to the control according to the one-sample t test, p<0.05.
(B) MTT cell viability assay showing cell viability of cultured cortical neurons
treated with 1 µM lactacystin at 4.5 h, 7.5 h and 24 h time points.  * indicates
significant difference according to ANOVA with post hoc Tukey’s test, p<0.05.
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treatment; this was probably due to the degradation of fluorogenic substrates by other
proteases during apoptosis. The calpain inhibitor calpeptin (10 µM) effectively
suppressed the increase of chymotrypsin-like activity at 24 h, suggesting that calpain
could be involved in the interference of chymotrypsin-like activity measurement.
MTT cell viability assay showed a time-dependent decrease of neuronal cell viability
after treatment by 1 µM of lactacystin; a more significant decrease was observed at
the 24 h time point (Fig. 4.1B).
Western blot analyses were performed to investigate when caspase-3 was activated
during lactacystin-induced neuronal apoptosis.  Pro-caspase-3 (32 kDa) was cleaved
to its active form (17 kDa) at 15 h after lactacystin treatment (Fig. 4.2A).  Similarly,
the caspase-3 substrates (α-fodrin and poly (ADP-ribose) polymerase or PARP) were
cleaved at the same time point as when caspase-3 was activated (Fig. 4.2A).
Likewise, measurement of caspase activity in the cell lysate of cultured cortical
neurons treated with 1 µM lactacystin showed a maximum increase (1,200% caspase-
3 activity compared to the untreated control) at the 15 h time point (Fig. 4.2B).  Other
caspases activated during lactacystin-induced neuronal apoptosis include: caspase-2
(700% at 15 h), caspase-10 (600% at 15 h), caspase-4 (400% at 15 h), caspase-6
(250% at 15 h), caspase-8 (160% at 15 h) and caspase-9 (200% at 15 h).  Caspase-1,
caspase-4 and caspase-5 are caspases involved in inflammation (Salvesen and Dixit,
1997; Nicholson, 1999) but among them, only caspase-4 was activated (400%
increase) at the 15 h time point.  Taken together, the data above suggest that
apoptosis, as determined by the activation of caspase-3, was initiated at 15 h after
lactacystin treatment.
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Figure 4.2. Time-course study of caspase-3 activation and substrate cleavage during
lactacystin-induced neuronal apoptosis.  (A) Western blots show the cleavage of
pro-caspase-3 to active caspase-3, and the cleavage of caspase-3 substrates
PARP and α-fodrin.  (B) The measurement of caspase activities using caspase-
family fluorogenic substrates detected a maximum increase (12-fold) of caspase-
3 activities 15 h after 1 µM lactacystin treatment.
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To investigate whether there were any apoptotic cells in the neuronal cultures 7.5 h
after exposure to 1 µM lactacystin, the fixed cells were stained with DNA-staining
dye (Hoechst 33258) at 7.5 h and 24 h after lactacystin exposure and observed under
the microscope.  As expected, no chromatin fragmentation was observed at the 7.5 h
time point, confirming the absence of apoptotic cells at this time point (Fig. 4.3A).
On the other hand, nuclear condensation and chromatin fragmentation were observed
in the neuronal cultures 24 h after treatment with lactacystin (Fig. 4.3).  Apoptotic
cells can also be detected using annexin V-FITC dye. The change in the apoptotic cell
plasma membrane exposes phosphatidylserine to the outer cell surface without
compromising membrane integrity; annexin V-FITC binds to the exposed
phosphatidylserine on the surface of the apoptotic cell, giving out green fluorescence
under FITC excitation/emission wavelengths (485/530 nm).  According to the annexin
V-FITC staining assay, only neuronal cultures subjected to 24 h lactacystin treatment
contained apoptotic cells (Fig. 4.3B).
4.2.2 RNA isolation from lactacystin-treated cultured cortical neurons
The quality of RNA extracted from cells needs to be evaluated before microarray
analysis.  Fig. 4.4 shows gel photos of total RNA extracted from cultured cortical
neurons, taken from RNA samples used in both microarray analysis and verification
real-time PCR analysis.  Using the Qiagen RNeasy Mini Kit for RNA extraction, the
yield of total RNA obtained was in the range of 40–80 µg with a purity of 1.4–1.8
(A260/A280 ratio) from each 6-well culture plate.  A yield of 2.1–5.9 µg of total
RNA with a purity of 1.3–1.6 (A260/A280 ratio) could be obtained from a single well
of cultured neurons in a 6-well plate using High Pure Isolation Kit (Roche, Penzberg,
Germany).
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Figure 4.3.  Apoptotic cell death of cultured cortical neurons exposed to lactacystin.
(A) Hoechst staining showing the presence of chromatin fragmentation in
cultures treated with lactacystin (1 µM) for 24 h.  (B) Annexin V-FITC staining
showing apoptotic cells (round and green) in cultures treated with lactacystin (1
µM) for 24 h.  During the late stage of apoptosis, the nuclei of dead cells are
stained red with propedium iodide, indicating that the plasma membranes have
been disrupted.
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Figure 4.4. Total RNA extracted from cultured cortical neurons.  (A) Total RNA
extracted from cultured cortical neurons treated with 1 µM lactacystin for 7.5 h
using RNeasy Mini Kit (Qiagen) for microarray analysis and (B) total RNA
extracted from untreated and treated (1 µM lactacystin) cultured cortical neurons
in time-course real-time PCR study.
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4.2.3 Microarray analysis
Microarray analyses revealed that a large number of genes were differentially
expressed in cultured cortical neurons which underwent neuronal apoptosis after
treatment with 1 µM lactacystin; out of a total of 12,488 genes and Expressed
Sequence Tags (ESTs) in the murine genome GeneChip® U74Av2, 1,168 genes were
differentially expressed by more than two-fold according to the one-way ANOVA,
p<0.01.  To reduce the number of genes to a manageable size, a more stringent
condition was applied; genes that were differentially expressed by more than three-
fold at least once in any of the time points (4.5 h, 7.5 h, 24 h and 48 h) tested were
selected for analysis.  Under this condition, the number of genes was reduced to 342.
These genes were then arranged according to their biological functions and listed in
Tables 4.1–4.13.  Bonferroni correction, a very stringent statistical analysis was
performed to check the integrity of the gene list.  Genes that passed the Bonferroni
correction were indicated by an asterisk (*).  More than one-third of genes (123
genes) passed the Bonferroni test, indicating a highly significant set of data.
For an overview of the changes in global gene expression across the time points,
selected genes from Tables 4.1–4.13 are shown in Fig. 4.5 as gene clusters with their
expression profile indicated by colors: red for up-regulation and blue for down-
regulation (Fig 4.5).  Most genes were up-regulated during earlier time points
compared to later time points, as shown in Figure 4.5.
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Table 4.1.  Differentially expressed genes after lactacystin treatment: Ubiquitin-
proteasome system.  Gene expression is indicated as fold change±Standard
Error.  Only genes differentially expressed >3-fold and significantly expressed
according to one-way ANOVA, p<0.05 are included in this list.  * indicates
genes that passed the Bonferroni Correction.
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
Ubiquitin-proteasome system
95600_at Arih2* ariadne homolog 2 (Drosophila) 2.61 ± 0.14 4.11 ± 0.14 1.24 ± 0.15 -1.05 ± 0.19 AJ130975
96892_at Psma1* proteasome subunit, alpha type 1 2.79 ± 0.09 3.37 ± 0.10 2.49 ± 0.20 -1.06 ± 0.14 AI836804
93988_at Psma7* proteasome subunit, alpha type 7 2.60 ± 0.08 3.53 ± 0.07 2.35 ± 0.13 -1.09 ± 0.19 AI836676
94025_at Psmb3 proteasome subunit, beta type 3 2.78 ± 0.06 4.50 ± 0.20 3.22 ± 0.21 1.10 ± 0.24 AW045339
160152_at Psmc1* proteasome 26S subunit, ATPase
1
2.28 ± 0.12 3.79 ± 0.09 2.29 ± 0.16 -1.06 ± 0.13 U39302
93734_i_at Psmc3* proteasome 26S subunit, ATPase
3
2.71 ± 0.07 3.13 ± 0.11 2.27 ± 0.12 -1.05 ± 0.13 D49686
160305_at Psmd11 proteasome 26S subunit, non-
ATPase, 11
5.34 ± 0.07 5.03 ± 0.27 2.75 ± 0.17 1.02 ± 0.12 AW121693
93971_f_at Psmd12 proteasome 26S subunit, non-
ATPase, 12
3.34 ± 0.06 3.62 ± 0.20 2.56 ± 0.31 -1.09 ± 0.17 AI838669
94302_at Psmd4 proteasome 26S subunit, non-
ATPase, 4
2.85 ± 0.07 5.29 ± 0.12 3.07 ± 0.35 -1.05 ± 0.21 AF013099
103350_at Psmd7 proteasome 26S subunit, non-
ATPase, 7
2.38 ± 0.08 3.03 ± 0.08 1.88 ± 0.30 -1.31 ± 0.15 M64641
95124_i_at Rbx1 ring-box 1 3.18 ± 0.11 2.00 ± 0.19 1.13 ± 0.15 -1.21 ± 0.17 AW122337
97906_at Siah2 seven in absentia 2 1.54 ± 0.12 2.90 ± 0.08 -1.06 ± 0.26 -1.51 ± 0.19 Z19581
101255_at Ubb* ubiquitin B 3.10 ± 0.07 3.62 ± 0.06 1.08 ± 0.15 -1.19 ± 0.14 X51703
95215_f_at Ubc* ubiquitin C 4.04 ± 0.09 4.79 ± 0.07 1.39 ± 0.16 -1.25 ± 0.12 D50527
101581_at Ube3a* ubiquitin protein ligase E3A 3.65 ± 0.08 1.93 ± 0.09 1.24 ± 0.11 -1.20 ± 0.10 U82122
93303_at Ufd1l* ubiquitin fusion degradation 1
like
2.49 ± 0.07 4.45 ± 0.07 2.05 ± 0.34 -1.43 ± 0.16 U64445
161870_at Usp15 ubiquitin specific protease 15 -3.77 ± 0.09 -3.28 ± 0.12 -1.57 ± 0.12 1.50 ± 0.24 AV359471
101069_g_at Mkrn1* makorin, ring finger protein, 1 1.96 ± 0.09 3.10 ± 0.08 -1.25 ± 0.12 -1.32 ± 0.12 AA656621
161814_f_at Rnf19* ring finger protein (C3HC4 type)
19
4.51 ± 0.12 2.67 ± 0.18 -1.03 ± 0.10 -1.48 ± 0.10 AV355427
102131_f_at Rnf20* ring finger protein 20 -3.05 ± 0.08 -2.93 ± 0.06 1.01 ± 0.13 1.08 ± 0.13 AU014874
101966_s_at Rnf13* ring finger protein 13 2.09 ± 0.09 3.13 ± 0.12 1.00 ± 0.10 1.13 ± 0.12 AF037206
93164_at Rnf2* ring finger protein 2 1.79 ± 0.10 3.25 ± 0.17 -1.57 ± 0.10 -1.12 ± 0.14 Y12783
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Table 4.2.  Differentially expressed genes after lactacystin treatment (continued): ER
stress; heat shock proteins and molecular chaperones; apoptosis. Gene
expression is indicated as fold change±Standard Error.  Only genes differentially
expressed >3-fold and significantly expressed according to one-way ANOVA,
p<0.05 are included in this list.  * indicates genes that passed the Bonferroni
Correction.
Time points (h) GenbankProbe id Symbol Gene Title




3.77 ± 0.13 11.13 ± 0.38 6.68 ± 1.76 2.06 ± 0.27 U19118
100599_at Atf4 activating
transcription factor 4




-1.13 ± 0.18 4.26 ± 0.14 3.44 ± 0.34 1.32 ± 0.13 M61007
101429_at Ddit3 DNA-damage
inducible transcript 3








1.93 ± 0.08 3.18 ± 0.16 1.17 ± 0.22 -1.32 ± 0.11 AI846938




2.45 ± 0.11 3.46 ± 0.11 1.38 ± 0.11 1.28 ± 0.18 AW125408
Heat shock proteins and molecular chaperones
96254_at Dnajb1 DnaJ (Hsp40)
homolog, subfamily
B, member 1
2.11 ± 0.20 3.52 ± 0.15 1.42 ± 0.26 -1.12 ± 0.12 AB028272
93875_at Hspa1a heat shock protein 1A
(HSP70)
-1.27 ± 0.13 4.70 ± 0.53 13.82 ± 6.14 1.78 ± 0.53 M12571
97914_at Hspa9a heat shock protein, A 1.68 ± 0.07 3.68 ± 0.07 2.18 ± 0.27 1.07 ± 0.16 D17666
160139_at Hspb8* heat shock 27kDa
protein 8
-1.37 ± 0.12 1.67 ± 0.16 8.08 ± 0.47 2.22 ± 0.48 AI848798
94817_at Serpinh1* serine (or cysteine)
proteinase inhibitor,
clade H, member 1
(HSP47)




1.37 ± 0.29 1.97 ± 0.24 6.36 ± 1.02 3.41 ± 0.70 AV373612
97724_at Cry2 cryptochrome 2
(photolyase-like)
1.85 ± 0.26 3.47 ± 0.09 -1.75 ± 0.17 -1.29 ± 0.22 AB003433
95545_at Igf1 insulin-like growth
factor 1
-4.23 ± 0.08 -2.11 ± 0.07 -1.49 ± 0.11 -1.45 ± 0.14 X04480




2.07 ± 0.08 3.06 ± 0.07 1.55 ± 0.37 -1.25 ± 0.17 AI848853
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Table 4.3.  Differentially expressed genes after lactacystin treatment (continued):
proteolysis; inflammatory response; glutathione synthesis; metal ion
homeostasis. Gene expression is indicated as fold change±Standard Error.  Only
genes differentially expressed >3-fold and significantly expressed according to
one-way ANOVA, p<0.05 are included in this list.  * indicates genes that passed
the Bonferroni Correction.
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
Proteolysis




2.43 ± 0.10 3.38 ± 0.10 1.75 ± 0.18 -1.15 ± 0.19 AJ005253
92256_at Ctsb* cathepsin B 2.85 ± 0.27 3.18 ± 0.16 2.20 ± 0.12 1.82 ± 0.20 AI853714
101019_at Ctsc cathepsin C 1.79 ± 0.45 3.27 ± 0.26 6.64 ± 1.10 3.65 ± 0.87 U74683
161358_r_at Dpep3 dipeptidase 3 -1.64 ± 0.13 -3.89 ± 0.09 -1.48 ± 0.11 -1.13 ± 0.11 AV209030
98287_at Dpp6 dipeptidylpeptidase 6 -3.44 ± 0.07 -2.61 ± 0.06 -1.41 ± 0.11 -1.26 ± 0.14 AF092507
160290_at Ide* insulin degrading
enzyme





-1.24 ± 0.11 -2.06 ± 0.09 1.65 ± 0.23 3.29 ± 0.21 AW228316
Inflammatory response
98088_at Cd14* CD14 antigen -2.35 ± 0.13 -3.62 ± 0.07 -1.13 ± 0.11 1.33 ± 0.13 X13333
101341_at H2-M9 histocompatibility 2,
M region locus 9
-5.34 ± 0.14 -5.30 ± 0.06 -1.52 ± 0.10 -1.01 ± 0.13 AF016308





2.97 ± 0.10 2.63 ± 0.14 3.25 ± 0.48 1.51 ± 0.25 U95053
96085_at Gsta4* glutathione S-
transferase, alpha 4
1.17 ± 0.10 1.03 ± 0.08 5.07 ± 0.12 4.56 ± 1.18 L06047
97681_f_at Gstm3 glutathione S-
transferase, mu 3




1.63 ± 0.14 1.07 ± 0.12 4.13 ± 0.61 2.97 ± 0.36 AW124337
Metal ion homeostasis
93573_at Mt1 metallothionein 1 -1.24 ± 0.07 -2.35 ± 0.06 2.98 ± 0.10 4.14 ± 1.04 V00835
95340_at Mt3 metallothionein 3 -4.44 ± 0.06 -3.65 ± 0.06 1.15 ± 0.11 1.85 ± 0.27 M93310
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Table 4.4.  Differentially expressed genes after lactacystin treatment (continued):
calcium homeostasis and calcium binding; cell adhesion.  Gene expression is
indicated as fold change±Standard Error.  Only genes differentially expressed
>3-fold and significantly expressed according to one-way ANOVA, p<0.05 are
included in this list.  * indicates genes that passed the Bonferroni Correction.
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
Calcium homeostasis and calcium binding
102815_at Anxa11 annexin A11 -6.37 ± 0.18 -6.68 ± 0.13 1.41 ± 0.16 1.85 ± 0.11 U65986
100569_at Anxa2* annexin A2 1.45 ± 0.09 1.80 ± 0.08 4.56 ± 0.25 2.84 ± 0.43 M14044
101393_at Anxa3* annexin A3 -1.81 ± 0.18 -2.57 ± 0.24 12.33 ± 3.14 9.26 ± 0.80 AJ001633
104006_at Eps15 epidermal growth factor
receptor pathway substrate
15
1.78 ± 0.09 3.26 ± 0.38 1.02 ± 0.10 1.16 ± 0.11 L21768
98475_at Matn2 matrilin 2 -5.18 ± 0.36 -1.81 ± 0.11 -1.06 ± 0.15 1.34 ± 0.13 U69262
92539_at S100a10* S100 calcium binding
protein A10 (calpactin)
-1.80 ± 0.10 -1.23 ± 0.06 4.77 ± 0.55 2.54 ± 0.22 M16465
98600_at S100a11* S100 calcium binding
protein A11 (calizzarin)
-3.12 ± 0.08 -3.10 ± 0.06 5.31 ± 0.85 8.03 ± 0.50 U41341
100959_at S100a13 S100 calcium binding
protein A13
-3.02 ± 0.08 -3.37 ± 0.13 -1.23 ± 0.12 1.52 ± 0.11 X99921
162428_I_at S100a14* S100 calcium binding
protein A14
-3.78 ± 0.06 -3.92 ± 0.06 -1.46 ± 0.10 -1.28 ± 0.12 AV293396
101051_at S100a3 S100 calcium binding
protein A3
-5.37 ± 0.13 -2.44 ± 0.16 -1.20 ± 0.10 1.00 ± 0.10 AF004941
Cell adhesion
94886_at Canx* calnexin -3.08 ± 0.08 -3.06 ± 0.06 -1.14 ± 0.15 -1.16 ± 0.11 L18888
94305_at Col1a1 procollagen, type I, alpha 1 -1.71 ± 0.38 -8.55 ± 0.07 -1.14 ± 0.22 1.38 ± 0.22 U03419
99800_at L1cam L1 cell adhesion molecule 1.39 ± 0.11 2.49 ± 0.10 -3.41 ± 0.13 -3.06 ± 0.27 X12875
99669_at Lgals1* lectin, galactose binding,
soluble 1
-1.06 ± 0.07 -1.03 ± 0.06 4.01 ± 0.36 5.89 ± 0.72 X15986
95706_at Lgals3 lectin, galactose binding,
soluble 3
2.70 ± 0.29 1.91 ± 0.24 8.66 ± 2.94 7.08 ± 1.46 X16834
161708_f_at Mpdz multiple PDZ domain
protein
-1.01 ± 0.39 -3.97 ± 0.16 1.48 ± 0.14 1.29 ± 0.17 AV244715
160469_at Thbs1* thrombospondin 1 -2.17 ± 0.07 -3.20 ± 0.06 2.16 ± 0.39 2.91 ± 0.31 M62470
103088_at Chl1* cell adhesion molecule
with homology to L1CAM
3.83 ± 0.08 1.93 ± 0.11 -1.83 ± 0.11 -1.79 ± 0.12 X94310
103492_at Cpxm1* carboxypeptidase X 1
(M14 family)
1.16 ± 0.35 3.05 ± 0.22 3.44 ± 0.21 1.38 ± 0.18 AF077738
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Table 4.5.  Differentially expressed genes after lactacystin treatment (continued): lipid
and cholesterol. Gene expression is indicated as fold change±Standard Error.
Only genes differentially expressed >3-fold and significantly expressed
according to one-way ANOVA, p<0.05 are included in this list.  * indicates
genes that passed the Bonferroni Correction.
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
Lipid and Cholesterol
95425_at Acadl acetyl-Coenzyme A dehydrogenase,
long-chain
1.99 ± 0.39 1.35 ± 0.28 3.85 ± 0.22 4.33 ± 0.70 U21489
101006_at Acat2* acetyl-Coenzyme A acetyltransferase 2 1.10 ± 0.07 -2.20 ± 0.06 -3.50 ± 0.09 -2.90 ± 0.10 M35797
93320_at Cpt1a* carnitine palmitoyltransferase 1a, liver 1.03 ± 0.08 1.05 ± 0.06 2.79 ± 0.13 3.23 ± 0.49 AF017175
94916_at Cyp51 cytochrome P450, 51 -1.41 ± 0.06 -1.47 ± 0.10 -3.21 ± 0.10 -3.12 ± 0.10 AW122260
98989_at Dhcr7 7-dehydrocholesterol reductase -1.64 ± 0.07 -2.25 ± 0.06 -3.65 ± 0.11 -3.52 ± 0.10 AF057368
97518_at Fdft1 farnesyl diphosphate farnesyl
transferase 1
1.25 ± 0.08 1.71 ± 0.10 -3.17 ± 0.10 -3.22 ± 0.10 D29016
99098_at Fdps farnesyl diphosphate synthetase 1.22 ± 0.06 1.21 ± 0.06 -4.21 ± 0.10 -4.63 ± 0.09 AW045533
161682_f_at Gpaa1 GPI anchor attachment protein 1 -3.57 ± 0.07 -2.88 ± 0.07 -1.90 ± 0.13 -1.08 ± 0.15 AV161234
104285_at Hmgcr* 3-hydroxy-3-methylglutaryl-Coenzyme
A reductase
-1.77 ± 0.06 -1.53 ± 0.06 -2.43 ± 0.10 -3.38 ± 0.09 M62766
96269_at Idi1* isopentenyl-diphosphate delta
isomerase
-1.53 ± 0.06 -2.39 ± 0.06 -5.82 ± 0.09 -4.78 ± 0.09 AA716963
160737_at Lss lanosterol synthase -1.23 ± 0.12 -1.11 ± 0.13 -2.65 ± 0.11 -3.17 ± 0.11 AW060927
160770_at Mvd mevalonate (diphospho) decarboxylase -3.06 ± 0.07 -2.61 ± 0.06 -6.96 ± 0.08 -4.98 ± 0.09 AW049778
95632_f_at Mvk* mevalonate kinase 1.51 ± 0.15 1.17 ± 0.09 -8.26 ± 0.09 -7.52 ± 0.09 AW122653
98631_g_at Nsdhl* NAD(P) dependent steroid
dehydrogenase-like
1.51 ± 0.06 -1.28 ± 0.06 -4.73 ± 0.09 -3.41 ± 0.11 AW106745
100927_at Pltp* phospholipid transfer protein -3.48 ± 0.09 -3.43 ± 0.09 1.45 ± 0.27 3.04 ± 0.12 U28960
160388_at Sc4mol* sterol-C4-methyl oxidase-like -1.12 ± 0.07 -1.59 ± 0.06 -2.95 ± 0.10 -3.66 ± 0.09 AI848668
94056_at Scd1* stearoyl-Coenzyme A desaturase 1 -2.08 ± 0.06 -2.02 ± 0.07 -5.64 ± 0.09 -7.42 ± 0.09 M21285
160865_at Vldlr* very low density lipoprotein receptor 3.68 ± 0.16 1.83 ± 0.15 -1.68 ± 0.12 -1.46 ± 0.16 L33417
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Table 4.6.  Differentially expressed genes after lactacystin treatment (continued):
protein biosynthesis; protein modification. Gene expression is indicated as fold
change±Standard Error.  Only genes differentially expressed >3-fold and
significantly expressed according to one-way ANOVA, p<0.05 are included in
this list.  * indicates genes that passed the Bonferroni Correction.
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
Protein biosynthesis
104048_at Cars cysteinyl-tRNA synthetase 2.11 ± 0.07 3.77 ± 0.11 1.23 ± 0.34 -1.32 ± 0.13 AI848732
100636_at Eif4ebp1 eukaryotic translation initiation
factor 4E binding protein 1
3.25 ± 0.25 3.89 ± 0.31 3.17 ± 0.33 1.55 ± 0.21 U28656
98141_at Eif5b* eukaryotic translation initiation
factor 5B
3.76 ± 0.11 1.78 ± 0.13 1.52 ± 0.14 -1.30 ± 0.11 AA647048
103891_i_at Ell2 elongation factor RNA
polymerase II 2
1.69 ± 0.14 1.72 ± 0.16 3.50 ± 0.41 1.49 ± 0.15 AI197161
161683_r_at Gtpbp1* GTP binding protein 1 -2.94 ± 0.07 -3.60 ± 0.06 -1.31 ± 0.09 -1.16 ± 0.10 AV239949
93752_at Iars isoleucine-tRNA synthetase 2.12 ± 0.07 3.22 ± 0.07 1.17 ± 0.26 -1.32 ± 0.14 AI848393
103630_at Lars leucyl-tRNA synthetase 1.85 ± 0.06 2.97 ± 0.08 1.42 ± 0.29 -1.30 ± 0.14 AI844089
96693_at Rars arginyl-tRNA synthetase 2.10 ± 0.10 3.57 ± 0.26 2.54 ± 0.37 -1.16 ± 0.16 AI849453
Protein modification
93219_at Acp1 acid phosphatase 1, soluble 1.94 ± 0.12 3.74 ± 0.13 1.13 ± 0.19 -1.10 ± 0.12 Y17343
92383_at Dyrk1a dual-specificity tyrosine-(Y)-
phosphorylation regulated
kinase 1a
1.01 ± 0.17 2.91 ± 0.24 -1.03 ± 0.10 -1.23 ± 0.12 U58497
98771_at Ephb2 Eph receptor B2 2.86 ± 0.08 2.67 ± 0.13 -2.00 ± 0.17 -1.42 ± 0.17 L25890
161492_i_at Mgat1* mannoside
acetylglucosaminyltransferase 1
-2.72 ± 0.07 -3.21 ± 0.06 -1.02 ± 0.13 -1.03 ± 0.11 AV089873
102047_at Nmt1* N-myristoyltransferase 1 2.84 ± 0.12 3.45 ± 0.11 2.46 ± 0.20 1.23 ± 0.15 AF043326
95079_at Pdgfra platelet derived growth factor
receptor, alpha polypeptide
-3.86 ± 0.08 -3.31 ± 0.07 -1.75 ± 0.19 -1.10 ± 0.15 M57683
97096_at Prkar2a protein kinase, cAMP dependent
regulatory, type II alpha
3.58 ± 0.17 3.63 ± 0.09 -2.13 ± 0.23 -1.76 ± 0.23 J02935
161964_r_at Prkcz protein kinase C, zeta -2.07 ± 0.12 -3.14 ± 0.08 -1.38 ± 0.12 -1.10 ± 0.12 AV367375
161270_i_at Prkwnk1 protein kinase, lysine deficient 1 1.22 ± 0.13 -5.24 ± 0.07 1.55 ± 0.14 -1.07 ± 0.25 AV319920
92380_r_at Ptprz1 protein tyrosine phosphatase,
receptor type Z, polypeptide 1
1.45 ± 0.17 -3.42 ± 0.07 -1.81 ± 0.12 1.26 ± 0.12 AJ133130
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Table 4.7.  Differentially expressed genes after lactacystin treatment (continued):
transport. Gene expression is indicated as fold change±Standard Error.  Only
genes differentially expressed >3-fold and significantly expressed according to
one-way ANOVA, p<0.05 are included in this list.  * indicates genes that passed
the Bonferroni Correction.
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
Transport
100074_at 2400003B06Rik* RIKEN cDNA
2400003B06 gene
-6.99 ± 0.06 1.31 ± 0.20 1.59 ± 0.14 -1.34 ± 0.13 AW046723
104453_at 2310079P12Rik RIKEN cDNA
2310079P12 gene
2.78 ± 0.12 3.44 ± 0.06 1.89 ± 0.34 -1.02 ± 0.21 AW046336
92288_at Ap1g1 adaptor protein
complex AP-1, gamma
1 subunit
2.53 ± 0.10 3.99 ± 0.22 -1.48 ± 0.16 -1.50 ± 0.30 X54424
100492_at Ap2a2* adaptor protein
complex AP-2, alpha 2
subunit
-3.73 ± 0.07 1.17 ± 0.08 -1.18 ± 0.11 -1.29 ± 0.11 AW122807
102704_at Aqp4 aquaporin 4 -1.59 ± 0.08 -6.24 ± 0.09 -6.17 ± 0.10 1.22 ± 0.16 U88623




(subunit 9), isoform 1
-3.88 ± 0.08 -2.23 ± 0.07 -1.69 ± 0.10 -1.34 ± 0.11 L19737
102854_s_at Atp7a* ATPase, Cu++
transporting, alpha
polypeptide
3.21 ± 0.13 2.24 ± 0.16 1.23 ± 0.13 1.04 ± 0.12 U03434
95654_at Clic1* chloride intracellular
channel 1
1.45 ± 0.11 1.76 ± 0.09 3.64 ± 0.18 3.20 ± 0.45 AF109905
97248_at Dbi* diazepam binding
inhibitor
-1.52 ± 0.06 -3.44 ± 0.06 -1.91 ± 0.09 1.19 ± 0.14 X61431
94376_s_at Mre11a* meiotic recombination
11 homolog A (S.
cerevisiae)




3.63 ± 0.15 2.19 ± 0.09 -1.18 ± 0.13 -1.91 ± 0.14 X61455
93466_at Sec8l1 SEC8-like 1 (S.
cerevisiae)
3.02 ± 0.08 2.60 ± 0.09 -1.16 ± 0.21 -1.10 ± 0.34 AF022962
98457_at Slc4a4 solute carrier family 4
(anion exchanger),
member 4
-1.30 ± 0.13 -3.96 ± 0.11 -1.48 ± 0.13 1.46 ± 0.15 AF020195




-3.75 ± 0.07 -2.01 ± 0.07 -1.12 ± 0.10 1.02 ± 0.16 AV278013
102319_at Snx12 sorting nexin 12 1.55 ± 0.08 3.10 ± 0.13 1.31 ± 0.12 -1.22 ± 0.13 AF062484
96019_at Sypl synaptophysin-like
protein
2.22 ± 0.18 3.17 ± 0.22 1.51 ± 0.11 -1.01 ± 0.18 AI843476
98339_at Syt11 synaptotagmin 11 2.85 ± 0.07 3.38 ± 0.11 -1.59 ± 0.17 -1.61 ± 0.19 AB026808
160190_at Syt4* synaptotagmin 4 3.50 ± 0.20 1.10 ± 0.06 -1.45 ± 0.10 -1.40 ± 0.10 U10355
101420_at Viaat vesicular inhibitory
amino acid transporter
-2.76 ± 0.07 -3.23 ± 0.06 -1.45 ± 0.12 -2.57 ± 0.14 AJ001598
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Table 4.8.  Differentially expressed genes after lactacystin treatment (continued):
electron transport; cytoskeleton.  Gene expression is indicated as fold
change±Standard Error.  Only genes differentially expressed >3-fold and
significantly expressed according to one-way ANOVA, p<0.05 are included in
this list.  * indicates genes that passed the Bonferroni Correction.
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
Electron transport
101991_at Fmo1* flavin containing
monooxygenase 1
-2.32 ± 0.08 -4.02 ± 0.07 -2.35 ± 0.12 -1.45 ± 0.11 D16215
98984_f_at Gpd2* glycerol phosphate
dehydrogenase 2,
mitochondrial
3.92 ± 0.22 2.12 ± 0.14 1.19 ± 0.12 -1.54 ± 0.10 D50430
98918_at Txndc5 thioredoxin domain
containing 5
-3.23 ± 0.12 -1.25 ± 0.06 1.18 ± 0.15 1.10 ± 0.17 AI841920
94209_g_at Txndc7* thioredoxin domain
containing 7
2.11 ± 0.14 3.17 ± 0.17 1.04 ± 0.10 -1.26 ± 0.10 AW045202
102000_f_at Uqcrc2* ubiquinol cytochrome
c reductase core
protein 2
3.40 ± 0.10 2.28 ± 0.11 1.19 ± 0.10 -1.03 ± 0.12 AI842835
103922_f_at 1500005G05Rik RIKEN cDNA
1500005G05 gene
-1.38 ± 0.08 1.73 ± 0.10 4.87 ± 0.97 1.32 ± 0.34 AI839690
Cytoskeleton
93100_at Acta2* actin, alpha 2, smooth
muscle, aorta
-2.11 ± 0.07 -4.06 ± 0.08 1.68 ± 0.37 3.89 ± 0.49 X13297
95705_s_at Actb actin, beta,
cytoplasmic
-10.94 ± 0.06 -6.82 ± 0.05 1.45 ± 0.22 -1.67 ± 0.26 J04181
94863_r_at Dncl2a dynein, cytoplasmic,
light chain 2A
3.05 ± 0.16 1.88 ± 0.17 1.27 ± 0.17 -1.16 ± 0.19 AI850000
101698_f_at Krt2-17 keratin complex 2,
basic, gene 17
-3.27 ± 0.15 -1.89 ± 0.07 -1.17 ± 0.13 1.07 ± 0.13 AI852429
98059_s_at Lmna* lamin A 1.26 ± 0.07 2.82 ± 0.19 3.54 ± 0.18 1.34 ± 0.18 D49733
102742_g_at Mapt* microtubule-associated
protein tau
3.07 ± 0.07 2.10 ± 0.06 -1.16 ± 0.12 -1.51 ± 0.11 M18775
160308_at Msn* moesin -2.05 ± 0.07 -1.19 ± 0.08 5.12 ± 0.35 2.80 ± 0.61 AI839417
102108_f_at Myh9 myosin heavy chain IX 1.69 ± 0.31 1.30 ± 0.07 3.20 ± 0.24 1.82 ± 0.16 AI505453
93541_at Tagln transgelin -1.63 ± 0.09 -2.06 ± 0.07 2.53 ± 0.49 4.16 ± 0.53 Z68618
93413_at Terf2 telomeric repeat
binding factor 2
2.95 ± 0.17 1.97 ± 0.10 1.05 ± 0.16 -1.09 ± 0.18 AF003000
101543_f_at Tuba6* tubulin, alpha 6 2.41 ± 0.06 3.07 ± 0.06 1.06 ± 0.12 -1.19 ± 0.14 M13441
162379_r_at Vim* vimentin -8.34 ± 0.07 -7.48 ± 0.08 -1.49 ± 0.10 -1.01 ± 0.12 AV245272
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Table 4.9.  Differentially expressed genes after lactacystin treatment (continued): cell
cycle; signalosome complex; carbohydrate metabolism. Gene expression is
indicated as fold change±Standard Error.  Only genes differentially expressed >
3-fold change and significantly expressed according to one-way ANOVA,
p<0.05 are included in this list.  * indicates genes that passed the Bonferroni
Correction.
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
Cell cycle
96146_at Btg3 B-cell translocation gene 3 1.65 ± 0.08 2.12 ± 0.14 4.15 ± 0.43 1.62 ± 0.35 D83745
96236_at Cdc16 CDC16 cell division cycle 16
homolog (S. cerevisiae)
3.04 ± 0.23 2.92 ± 0.11 1.81 ± 0.21 -1.34 ± 0.18 AW122965
98067_at Cdkn1a cyclin-dependent kinase
inhibitor 1A (P21)
1.27 ± 0.09 1.25 ± 0.08 3.14 ± 0.33 1.19 ± 0.17 U09507
97411_at Ect2 ect2 oncogene 2.94 ± 0.09 2.13 ± 0.16 1.10 ± 0.19 2.20 ± 0.23 L11316
160901_at Fos* FBJ osteosarcoma oncogene 1.84 ± 0.20 2.05 ± 0.13 3.11 ± 0.30 2.66 ± 0.21 V00727
100130_at Jun Jun oncogene 4.76 ± 0.45 8.30 ± 0.13 1.91 ± 0.42 -1.45 ± 0.14 X12761
161931_r_at Mki67 antigen identified by
monoclonal antibody Ki 67
-4.08 ± 0.18 -1.83 ± 0.13 -1.29 ± 0.10 1.22 ± 0.13 AV309347
103418_at Rfc4 replication factor C (activator
1) 4
3.54 ± 0.17 2.36 ± 0.10 1.34 ± 0.11 1.21 ± 0.26 AW122092
103520_at Vegfa vascular endothelial growth
factor A
2.88 ± 0.43 4.89 ± 0.21 -1.07 ± 0.22 -1.38 ± 0.14 M95200
102292_at Gadd45a* growth arrest and DNA-
damage-inducible 45 alpha
2.49 ± 0.12 4.20 ± 0.16 4.73 ± 0.62 1.98 ± 0.26 U00937
101979_at Gadd45g* growth arrest and DNA-
damage-inducible 45 gamma
2.45 ± 0.12 3.10 ± 0.07 1.78 ± 0.20 2.57 ± 0.18 AF055638
Signalosome complex




3.73 ± 0.20 3.08 ± 0.09 1.37 ± 0.17 -1.12 ± 0.18 AF071313




2.90 ± 0.07 3.30 ± 0.08 1.55 ± 0.18 -1.07 ± 0.12 U70736
Carbohydrate metabolism
96803_at Gbe1 glucan (1,4-alpha-),
branching enzyme 1
2.78 ± 0.32 1.57 ± 0.42 2.95 ± 0.22 2.33 ± 0.49 AW210370
103637_at Naga N-acetyl galactosaminidase,
alpha
-3.61 ± 0.27 1.23 ± 0.07 -1.17 ± 0.14 1.52 ± 0.11 AJ223966
100573_f_at Gpi1 glucose phosphate isomerase
1
1.93 ± 0.07 2.49 ± 0.13 3.13 ± 0.16 1.28 ± 0.21 M14220
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Table 4.10.  Differentially expressed genes after lactacystin treatment (continued):
cell signaling. Gene expression is indicated as fold change±Standard Error.  Only
genes differentially expressed >3-fold and significantly expressed according to
one-way ANOVA, p<0.05 are included in this list.  * indicates genes that passed
the Bonferroni Correction.
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
Cell signaling
95022_at Akap12* A kinase (PRKA) anchor
protein (gravin) 12
1.19 ± 0.09 -1.03 ± 0.08 3.13 ± 0.30 1.02 ± 0.10 AB020886
99481_at Atp1a2 ATPase, Na+/K+ transporting,
alpha 2 polypeptide
1.02 ± 0.08 -1.64 ± 0.07 -3.57 ± 0.09 -1.03 ± 0.26 AI839697
94006_at Azi2* 5-azacytidine induced gene 2 3.29 ± 0.28 2.49 ± 0.15 -1.19 ± 0.13 -1.21 ± 0.11 AB007141
102773_at Car8 carbonic anhydrase 8 -1.54 ± 0.37 -3.26 ± 0.14 -1.69 ± 0.13 -1.63 ± 0.11 X61397
102896_at Dok1* downstream of tyrosine kinase
1
3.28 ± 1.07 6.24 ± 0.31 3.79 ± 0.14 1.17 ± 0.17 U78818
97740_at Dusp16 dual specificity phosphatase 16 2.35 ± 0.26 3.35 ± 0.11 2.67 ± 0.51 1.02 ± 0.20 AI642662
103550_at Ednrb endothelin receptor type B 1.63 ± 0.09 -3.50 ± 0.07 -1.62 ± 0.10 1.98 ± 0.17 U32329
98446_s_at Ephb4* Eph receptor B4 2.48 ± 0.09 3.16 ± 0.09 1.53 ± 0.11 -1.11 ± 0.12 U06834
101096_s_at Hs1bp1 HS1 binding protein 2.20 ± 0.09 2.88 ± 0.06 1.42 ± 0.14 -1.07 ± 0.13 AF023482
99491_at Il10rb* interleukin 10 receptor, beta -2.07 ± 0.16 -3.73 ± 0.07 -1.01 ± 0.11 1.25 ± 0.13 U53696
161796_r_at Kcnq1* potassium voltage-gated
channel, subfamily Q, member
1
-2.37 ± 0.07 -4.41 ± 0.07 -1.56 ± 0.10 -1.19 ± 0.12 AV367240
103235_at Npy* neuropeptide Y 1.09 ± 0.08 -1.19 ± 0.06 -3.07 ± 0.09 -3.12 ± 0.10 AI848386
93007_at Npy1r neuropeptide Y receptor Y1 1.92 ± 0.10 1.15 ± 0.15 -4.01 ± 0.15 -2.59 ± 0.14 Z18280
102255_at Osmr oncostatin M receptor -1.83 ± 0.41 -1.59 ± 0.25 3.84 ± 0.17 2.70 ± 0.21 AB015978
102049_at Pdk4 pyruvate dehydrogenase kinase,
isoenzyme 4
-1.74 ± 0.18 -4.52 ± 0.19 1.25 ± 0.16 1.81 ± 0.16 AJ001418
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Table 4.11.  Differentially expressed genes after lactacystin treatment (continued):
growth and development. Gene expression is indicated as fold change±Standard
Error.  Only genes differentially expressed >3-fold and significantly expressed
according to one-way ANOVA, p<0.05 are included in this list.  * indicates
genes that passed the Bonferroni Correction.
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
Growth and development
101475_at Bmi1 B lymphoma Mo-MLV insertion
region 1
3.02 ± 0.14 2.88 ± 0.07 1.13 ± 0.12 -1.14 ± 0.16 M64068
100022_at Cish* cytokine inducible SH2-
containing protein
2.16 ± 0.40 3.02 ± 0.14 -1.34 ± 0.10 -1.12 ± 0.10 D89613
93294_at Ctgf connective tissue growth factor 2.94 ± 0.70 2.11 ± 0.28 14.63 ± 0.63 7.93 ± 1.62 M70642
97426_at Emp1* epithelial membrane protein 1 1.18 ± 0.15 1.04 ± 0.08 4.98 ± 0.45 4.06 ± 0.14 X98471
100277_at Inhba inhibin beta-A -2.15 ± 0.09 -3.25 ± 0.06 -1.77 ± 0.12 -1.59 ± 0.10 X69619
160463_at Myd116 myeloid differentiation primary
response gene 116
1.93 ± 0.09 4.30 ± 0.09 2.71 ± 0.47 1.12 ± 0.15 X51829
97474_r_at Ptn* pleiotrophin -1.04 ± 0.08 -3.79 ± 0.07 1.04 ± 0.10 1.46 ± 0.13 D90225
95387_f_at Sema4b sema domain, immunoglobulin
domain (Ig), transmembrane
domain (TM) and short
cytoplasmic domain,
(semaphorin) 4B
8.87 ± 0.47 3.89 ± 0.12 1.07 ± 0.20 -1.36 ± 0.17 AA266467
99911_at Sema6b sema domain, transmembrane
domain (TM), and cytoplasmic
domain, (semaphorin) 6B
-4.00 ± 0.07 -2.12 ± 0.06 -1.66 ± 0.10 -1.82 ± 0.12 AF036585
103302_r_at Sox3* SRY-box containing gene 3 -3.45 ± 0.07 -2.25 ± 0.06 -1.12 ± 0.11 1.29 ± 0.11 AA866668
95436_at Sst somatostatin 1.35 ± 0.11 1.64 ± 0.08 -1.19 ± 0.19 -4.06 ± 0.10 X51468
161258_at Wt1* Wilms tumor homolog -3.34 ± 0.10 -3.99 ± 0.07 -1.23 ± 0.10 -1.20 ± 0.10 AV322247
99549_at Ogn osteoglycin 1.03 ± 0.31 -6.87 ± 0.19 1.62 ± 0.49 4.77 ± 0.64 D31951
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Table 4.12.  Differentially expressed genes after lactacystin treatment (continued):
other processes. Gene expression is indicated as fold change±Standard Error.
Only genes differentially expressed >3-fold and significantly expressed
according to one-way ANOVA, p<0.05 are included in this list.  * indicates
genes that passed the Bonferroni Correction.
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
Other processes
97689_at F3* coagulation factor III -1.16 ± 0.11 1.42 ± 0.14 3.29 ± 0.17 2.14 ± 0.17 M26071
98372_at Aldh1a3 aldehyde dehydrogenase
family 1, subfamily A3
1.43 ± 0.29 -1.94 ± 0.29 3.25 ± 0.21 -1.31 ± 0.13 AW050387
95133_at Asns asparagine synthetase 1.74 ± 0.07 3.13 ± 0.13 1.11 ± 0.24 -1.50 ± 0.17 U38940
96775_at Cbx1 chromobox homolog 1
(Drosophila HP1 beta)
4.97 ± 0.10 1.47 ± 0.13 -1.36 ± 0.14 1.16 ± 0.12 X56690
160711_at Decr1 2,4-dienoyl CoA reductase 1,
mitochondrial
-1.97 ± 0.17 -4.46 ± 0.21 1.31 ± 0.37 2.94 ± 0.34 AI844846
160101_at Hmox1 heme oxygenase (decycling) 1 1.11 ± 0.14 2.34 ± 0.11 5.39 ± 0.82 2.23 ± 0.49 X56824
162387_f_at Mfn1 mitofusin 1 -4.95 ± 0.09 -2.55 ± 0.21 -1.31 ± 0.10 1.20 ± 0.11 AV255723
94485_at Peci* peroxisomal delta3, delta2-
enoyl-Coenzyme A isomerase
2.00 ± 0.10 2.23 ± 0.09 3.11 ± 0.12 2.42 ± 0.38 AI840013
93542_at Pter phosphotriesterase related 1.33 ± 0.15 1.02 ± 0.12 1.56 ± 0.11 3.54 ± 0.51 U28016
162317_r_at Rps12 ribosomal protein S12 -5.09 ± 0.18 1.30 ± 0.19 1.13 ± 0.22 -1.23 ± 0.16 AV064697
95049_at Snrpd2 small nuclear
ribonucleoprotein D2
3.17 ± 0.12 2.52 ± 0.18 1.21 ± 0.12 -1.10 ± 0.19 AI837853
94564_at Sult4a1 sulfotransferase family 4A,
member 1
1.40 ± 0.13 3.05 ± 0.07 -2.26 ± 0.16 -2.37 ± 0.19 AF059257
93794_at Appbp1 amyloid beta precursor protein
binding protein 1
3.45 ± 0.16 1.85 ± 0.13 1.13 ± 0.13 -1.21 ± 0.14 AI846393
102780_at Npn3 neoplastic progression 3 4.13 ± 0.19 8.60 ± 0.52 18.46 ± 0.98 2.64 ± 1.18 Z31362
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Table 4.13.  Differentially expressed genes after lactacystin treatment (continued):
unknown biological functions. Gene expression is indicated as fold
change±Standard Error.  Only genes differentially expressed >3-fold and
significantly expressed according to one-way ANOVA, p<0.05 are included in
this list.  * indicates genes that passed the Bonferroni Correction.
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
Unknown biological processes
97012_f_at 0610033H09Rik RIKEN cDNA 0610033H09
gene
3.00 ± 0.23 2.44 ± 0.27 1.73 ± 0.14 1.08 ± 0.18 AI838702
104400_at 0610042I15Rik RIKEN cDNA 0610042I15
gene
2.11 ± 0.10 2.97 ± 0.10 -1.80 ± 0.21 -1.98 ± 0.17 AF076956
95732_at 1110005L13Rik RIKEN cDNA 1110005L13
gene
3.23 ± 0.12 2.17 ± 0.09 1.20 ± 0.10 -1.11 ± 0.16 AW047746
103773_at 1110020K19Rik RIKEN cDNA 1110020K19
gene
1.66 ± 0.09 3.01 ± 0.46 1.06 ± 0.15 -1.30 ± 0.13 AW047874
104314_r_at 1110032A03Rik RIKEN cDNA 1110032A03
gene
3.12 ± 0.95 4.51 ± 0.25 -1.08 ± 0.16 -1.03 ± 0.19 AI851206
96068_at 1500034J20Rik RIKEN cDNA 1500034J20
gene
3.48 ± 0.19 1.97 ± 0.12 1.31 ± 0.16 1.10 ± 0.26 AI848821
95561_at 1700013H19Rik RIKEN cDNA 1700013H19
gene
3.10 ± 0.27 1.53 ± 0.17 -1.05 ± 0.25 1.27 ± 0.12 AW120867
161004_at 1700097N02Rik* RIKEN cDNA 1700097N02
gene
-2.14 ± 0.12 -3.37 ± 0.06 -1.03 ± 0.11 -1.01 ± 0.10 AA250414
98942_r_at 2310032D16Rik RIKEN cDNA 2310032D16
gene
-2.99 ± 0.10 -4.97 ± 0.06 1.03 ± 0.19 1.14 ± 0.30 AW125284
92703_at 2310032M22Rik RIKEN cDNA 2310032M22
gene
3.33 ± 0.15 1.95 ± 0.08 -1.05 ± 0.14 -1.37 ± 0.13 AI325791
104100_at 2310075E07Rik* RIKEN cDNA 2310075E07
gene
-3.46 ± 0.10 -2.52 ± 0.07 1.31 ± 0.14 1.65 ± 0.11 AI845915
95449_at 2310075G12Rik RIKEN cDNA 2310075G12
gene
-3.12 ± 0.11 -1.83 ± 0.06 -1.10 ± 0.11 1.16 ± 0.12 AW049793
161906_f_at 2410022L05Rik* RIKEN cDNA 2410022L05
gene
-3.11 ± 0.09 -3.26 ± 0.06 -1.28 ± 0.10 -1.61 ± 0.12 AV113045
97864_at 2510049I19Rik RIKEN cDNA 2510049I19
gene
3.66 ± 0.36 2.42 ± 0.13 1.15 ± 0.17 1.26 ± 0.17 AW258842
93802_at 2610103J23Rik RIKEN cDNA 2610103J23
gene
5.92 ± 0.55 3.46 ± 0.62 1.56 ± 0.19 1.12 ± 0.21 AA815890
98973_at 2610318G08Rik* RIKEN cDNA 2610318G08
gene
3.15 ± 0.22 4.09 ± 0.35 1.39 ± 0.18 1.10 ± 0.11 AA982595
100306_at 2700007P21Rik RIKEN cDNA 2700007P21
gene
2.70 ± 0.22 6.66 ± 0.34 1.29 ± 0.18 -1.13 ± 0.15 AI510297
92268_at 2700007P21Rik RIKEN cDNA 2700007P21
gene
2.60 ± 0.10 4.08 ± 0.22 1.49 ± 0.21 1.06 ± 0.14 AI854851
104470_at 2700066J21Rik RIKEN cDNA 2700066J21
gene
2.61 ± 0.67 4.61 ± 0.13 1.77 ± 0.22 1.20 ± 0.18 AI957346
160752_at 2810002D13Rik RIKEN cDNA 2810002D13
gene
-4.05 ± 0.17 -1.20 ± 0.14 -1.13 ± 0.10 1.00 ± 0.13 AA667021
104089_at 2810026P18Rik* RIKEN cDNA 2810026P18
gene
3.53 ± 0.23 5.50 ± 0.23 1.35 ± 0.11 1.05 ± 0.10 AW045664
103071_at 2810429C13Rik* RIKEN cDNA 2810429C13
gene
3.33 ± 0.10 2.52 ± 0.09 1.22 ± 0.11 1.35 ± 0.13 AI843655
92840_at 3110079L04Rik* RIKEN cDNA 3110079L04
gene
4.91 ± 0.58 6.87 ± 0.17 1.54 ± 0.32 1.04 ± 0.12 AA683712
104356_at 4921516M08Rik RIKEN cDNA 4921516M08
gene
3.39 ± 0.22 1.75 ± 0.25 1.10 ± 0.13 1.13 ± 0.11 AI465543
104639_i_at 4930553M18Rik RIKEN cDNA 4930553M18
gene
3.05 ± 0.35 5.24 ± 0.18 1.13 ± 0.24 1.12 ± 0.28 AI464596
92992_i_at 5730497N03Rik* RIKEN cDNA 5730497N03
gene
4.26 ± 0.39 3.11 ± 0.32 -1.20 ± 0.12 1.12 ± 0.15 AI324972
94426_at 6330575P11Rik RIKEN cDNA 6330575P11
gene
2.72 ± 0.11 2.86 ± 0.08 -1.04 ± 0.26 -2.08 ± 0.18 AI851052
161104_at 9430099J10Rik RIKEN cDNA 9430099J10
gene
3.82 ± 0.25 1.91 ± 0.22 1.10 ± 0.17 1.79 ± 0.13 AI846811
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160713_at AA407930 expressed sequence
AA407930
2.08 ± 0.07 3.61 ± 0.21 2.74 ± 0.52 1.01 ± 0.15 AI841579
93464_at Akap9 A kinase (PRKA) anchor
protein (yotiao) 9
1.54 ± 0.08 -3.17 ± 0.07 -1.27 ± 0.10 -1.35 ± 0.14 AI561567
93900_at Bat2 HLA-B associated transcript
2
1.42 ± 0.21 3.01 ± 0.12 -1.67 ± 0.13 -1.69 ± 0.18 AW050268
100946_at Bat9 HLA-B-associated transcript
9
-1.21 ± 0.07 1.92 ± 0.07 5.47 ± 2.18 -1.07 ± 0.20 AF109906
103485_at BC030046 cDNA sequence BC030046 -2.20 ± 0.07 -4.47 ± 0.07 -1.32 ± 0.26 1.07 ± 0.16 AA795415
100410_at C330027G06Rik RIKEN cDNA C330027G06
gene
3.24 ± 0.31 1.82 ± 0.15 1.14 ± 0.15 -1.04 ± 0.16 AW122781
103016_s_at Cd68* CD68 antigen -1.39 ± 0.11 1.01 ± 0.09 3.10 ± 0.23 2.79 ± 0.51 X68273
162251_f_at Centg2 centaurin, gamma 2 -1.51 ± 0.08 -3.15 ± 0.09 -1.38 ± 0.10 -1.22 ± 0.12 AV335015




1.66 ± 0.07 3.00 ± 0.07 1.56 ± 0.20 -1.24 ± 0.10 AW122453
97352_f_at Coxvib2 cytochrome c oxidase
subunit VIb, testes-specific
-1.93 ± 0.08 -3.61 ± 0.08 1.00 ± 0.27 2.66 ± 0.11 AW123567
95432_f_at D16Wsu109e* DNA segment, Chr 16,
Wayne State University 109,
expressed
3.00 ± 0.07 2.78 ± 0.10 -1.04 ± 0.11 -1.57 ± 0.10 AI844034
103861_s_at D7Wsu128e* DNA segment, Chr 7,
Wayne State University 128,
expressed
1.62 ± 0.07 3.86 ± 0.10 1.88 ± 0.13 -1.14 ± 0.11 AA388099
103862_r_at D7Wsu128e* DNA segment, Chr 7,
Wayne State University 128,
expressed
1.96 ± 0.08 3.01 ± 0.11 1.51 ± 0.11 -1.05 ± 0.10 AA388099
103460_at Ddit4 DNA-damage-inducible
transcript 4
2.36 ± 0.11 3.79 ± 0.19 1.11 ± 0.17 -1.03 ± 0.19 AI849939
100037_at Ddx18 DEAD (Asp-Glu-Ala-Asp)
box polypeptide 18
1.82 ± 0.23 2.98 ± 0.16 1.01 ± 0.12 -1.12 ± 0.21 AW213225
99096_at Ddx24 DEAD (Asp-Glu-Ala-Asp)
box polypeptide 24
1.82 ± 0.10 3.05 ± 0.07 1.35 ± 0.16 -1.30 ± 0.13 U46690
99366_at E030024M05Rik* RIKEN cDNA E030024M05
gene
-1.32 ± 0.13 1.01 ± 0.10 3.48 ± 0.21 3.24 ± 0.34 AI553536
98525_f_at Erdr1 erythroid differentiation
regulator 1
1.64 ± 0.12 3.02 ± 0.07 1.51 ± 0.24 -1.12 ± 0.18 AJ007909
92553_at Es10 esterase 10 1.78 ± 0.09 1.67 ± 0.08 4.08 ± 0.11 2.21 ± 0.50 AB025408
96569_at Fignl1* fidgetin-like 1 -2.61 ± 0.07 -3.11 ± 0.06 -1.17 ± 0.10 1.13 ± 0.11 AA266298
93443_at Fndc1 fibronectin type III domain
containing 1
-3.37 ± 0.11 -1.90 ± 0.09 -1.38 ± 0.10 1.08 ± 0.16 AW212271
98531_g_at Gas5* growth arrest specific 5 2.25 ± 0.07 3.20 ± 0.08 2.08 ± 0.20 1.30 ± 0.14 AI849615
94805_f_at Hist1h2ac histone 1, H2ac 4.05 ± 0.10 3.04 ± 0.10 1.03 ± 0.14 1.03 ± 0.21 M33988
98090_at Hrb2* HIV-1 Rev binding protein 2 4.04 ± 0.21 3.24 ± 0.24 1.75 ± 0.11 -1.10 ± 0.13 AW210014
99109_at Ier2 immediate early response 2 1.77 ± 0.08 3.53 ± 0.07 1.72 ± 0.14 1.24 ± 0.18 M59821
94384_at Ier3* immediate early response 3 4.75 ± 0.30 7.40 ± 0.48 7.33 ± 0.22 1.29 ± 0.28 X67644
102152_f_at Igh-VS107* immunoglobulin heavy chain
(S107 family)
-3.88 ± 0.07 -3.28 ± 0.08 -1.36 ± 0.10 -1.12 ± 0.10 M16724
162006_r_at Immt* inner membrane protein,
mitochondrial
-1.34 ± 0.07 -3.01 ± 0.07 -1.32 ± 0.10 -1.07 ± 0.10 AV334115
101501_r_at Impact imprinted and ancient 1.86 ± 0.26 1.29 ± 0.11 3.21 ± 0.56 1.19 ± 0.14 D87973
103523_at Leng8 leukocyte receptor cluster
(LRC) member 8
-5.32 ± 0.11 -1.12 ± 0.13 1.43 ± 0.24 1.10 ± 0.10 AI851703
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101214_f_at LOC14433 similar to glyceraldehyde-3-
phosphate dehydrogenase
2.78 ± 0.07 3.07 ± 0.11 1.51 ± 0.17 -1.07 ± 0.16 M32599
92564_at Lrrfip1 leucine rich repeat (in FLII)
interacting protein 1
2.84 ± 0.35 1.22 ± 0.26 3.92 ± 0.30 2.37 ± 0.22 AI891475
98440_at Ltb4dh* leukotriene B4 12-
hydroxydehydrogenase
1.13 ± 0.22 1.33 ± 0.16 10.74 ± 1.04 6.95 ± 1.90 AA596710
96151_at Mocos* molybdenum cofactor
sulfurase
2.25 ± 0.28 2.16 ± 0.29 3.26 ± 0.13 1.08 ± 0.13 AA839813
96285_at Myadm myeloid-associated
differentiation marker
-2.24 ± 0.10 -3.54 ± 0.07 -1.10 ± 0.12 1.03 ± 0.10 AJ001616
101366_f_at Nvl* nuclear VCP-like 3.47 ± 0.26 2.60 ± 0.20 1.26 ± 0.11 -1.26 ± 0.11 AA250299
100626_at Odf2 outer dense fiber of sperm
tails 2
1.64 ± 0.19 3.04 ± 0.31 1.08 ± 0.10 -1.16 ± 0.16 AF034105
103388_at P42pop Myb protein P42POP -3.59 ± 0.06 -3.12 ± 0.07 -1.25 ± 0.13 -1.10 ± 0.12 AW047050
99926_at Pigr* polymeric immunoglobulin
receptor
-4.91 ± 0.11 -3.78 ± 0.06 -1.42 ± 0.09 -1.11 ± 0.10 AB001489
96145_at Pigt phosphatidylinositol glycan,
class T
-3.12 ± 0.08 -1.78 ± 0.07 -1.28 ± 0.16 1.03 ± 0.16 AW211407
95631_at Ppp4c* protein phosphatase 4,
catalytic subunit
1.52 ± 0.10 3.06 ± 0.09 1.11 ± 0.11 1.02 ± 0.11 AF088911
97496_f_at Prkcdbp* protein kinase C, delta
binding protein
1.17 ± 0.23 1.23 ± 0.18 5.96 ± 0.65 3.36 ± 0.17 AW048944
161006_at R75096 expressed sequence R75096 -2.93 ± 0.10 -3.07 ± 0.07 -1.36 ± 0.10 -1.38 ± 0.11 AI853978
102724_at Rabep1* rabaptin, RAB GTPase
binding effector protein 1
5.36 ± 0.50 3.28 ± 0.26 -1.14 ± 0.10 -1.43 ± 0.10 AI608324
95077_at Rabggtb* RAB geranylgeranyl
transferase, b subunit
2.60 ± 0.09 3.77 ± 0.07 1.51 ± 0.26 -1.04 ± 0.10 U12922
97838_at Rnu22* RNA, U22 small nucleolar 3.38 ± 0.13 4.31 ± 0.22 2.16 ± 0.19 1.14 ± 0.12 AA684508
95664_at Sec14l1* SEC14-like 1 (S. cerevisiae) 2.21 ± 0.08 3.43 ± 0.09 -1.43 ± 0.11 -1.44 ± 0.13 AW048159
97160_at Sparc secreted acidic cysteine rich
glycoprotein
1.28 ± 0.07 -1.84 ± 0.10 3.00 ± 0.17 3.64 ± 0.59 X04017
94387_at Spata5 spermatogenesis associated 5 1.94 ± 0.11 2.87 ± 0.19 1.36 ± 0.26 -1.47 ± 0.19 AF016544
101995_at Sqstm1* sequestosome 1 3.11 ± 0.06 5.59 ± 0.09 3.58 ± 0.34 1.17 ± 0.27 U40930
104283_at Tbc1d15* TBC1 domain family,
member 15
3.18 ± 0.11 3.82 ± 0.22 1.98 ± 0.14 1.39 ± 0.12 AI037493
99144_s_at Tgoln1 trans-golgi network protein 1.74 ± 0.18 3.11 ± 0.10 1.25 ± 0.16 1.14 ± 0.20 D50031
92437_at Tm7sf2 transmembrane 7
superfamily member 2
-1.29 ± 0.11 -1.09 ± 0.07 -4.50 ± 0.10 -2.69 ± 0.10 AW047445
100039_at Tmem4 transmembrane protein 4 2.86 ± 0.24 2.93 ± 0.13 1.34 ± 0.10 1.25 ± 0.17 AW125880
162362_f_at Tnc tenascin C 3.27 ± 0.24 2.00 ± 0.16 2.46 ± 0.39 1.03 ± 0.33 AV230686
162463_at Tpd52 tumor protein D52 -3.26 ± 0.25 -2.46 ± 0.09 -1.07 ± 0.10 -1.07 ± 0.15 AV059497
100717_at U90926* cDNA sequence U90926 -2.99 ± 0.07 -3.01 ± 0.06 -1.38 ± 0.10 1.02 ± 0.10 U90926
103753_at Zzz3* zinc finger, ZZ domain
containing 3
3.06 ± 0.10 2.43 ± 0.18 1.29 ± 0.15 1.05 ± 0.11 AI159572
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2.55 ± 0.08 3.74 ± 0.11 1.22 ± 0.18 -1.30 ± 0.13 AI849678
161535_at --- -2.76 ± 0.07 -3.37 ± 0.06 -1.31 ± 0.11 -1.23 ± 0.11 AV234882
162311_f_at --- -2.22 ± 0.07 -3.54 ± 0.08 -1.11 ± 0.10 -1.20 ± 0.10 AV050648
161528_r_at --- -1.14 ± 0.11 -3.51 ± 0.11 -1.99 ± 0.10 -1.06 ± 0.14 AV227261
161737_at --- -5.94 ± 0.08 -2.93 ± 0.17 1.13 ± 0.12 -1.05 ± 0.13 AV312560
96963_s_at Anti-PC rearranged Ig kappa
chain V-J region mRNA,
hybridoma 31-23-1, partial
cds.
-5.41 ± 0.19 -3.10 ± 0.19 -1.41 ± 0.11 1.00 ± 0.11 L14553
101863_at --- -5.45 ± 0.18 -1.42 ± 0.22 -1.18 ± 0.13 1.00 ± 0.16 C78246
161655_at --- -1.78 ± 0.18 -8.10 ± 0.20 -1.02 ± 0.11 1.02 ± 0.13 AV099898
101217_at --- -11.95 ± 0.15 -3.15 ± 0.11 -1.30 ± 0.10 1.06 ± 0.12 D18865
95891_at Hypothetical LOC328660
(LOC328660), mRNA
-3.83 ± 0.10 -2.60 ± 0.09 -1.48 ± 0.10 1.10 ± 0.13 AI591977
102348_at --- -2.41 ± 0.07 -4.37 ± 0.06 1.66 ± 0.25 1.17 ± 0.19 AI551087
96316_at Transcribed sequences 3.01 ± 0.23 1.82 ± 0.15 -1.08 ± 0.12 1.21 ± 0.15 AI839289
103709_at  --- -5.41 ± 0.12 -3.78 ± 0.07 -1.27 ± 0.10 1.24 ± 0.18 AA763466
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Figure 4.5.  The gene expression profile of lactacystin-treated cultured cortical
neurons.  Total RNAs were isolated from lactacystin-treated cultured cortical
neurons at different time points: Control (n=4), 4.5 h (n=2), 7.5 h (n=3), 24 h
(n=3) and 48 h (n=3). Expression of each gene was determined using Affymetrix
GeneChip U74Av2.  The data analysis was carried out using GeneSpring 7.  The
differentially expressed genes were grouped according to their biological
processes: a)  UPS, b) stress, c) cholesterol, d) lipid, e) calcium, f) transcription,
g) protein synthesis, h) proteolysis, I) transport, j) electron transport, k) cell
cycle, l) apoptosis, m) signaling and n) inflammation.  The color bar=scale bar
denotes changes in expression in fold-change, red indicates up-regulation and
blue indicates down-regulation of genes.
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4.2.3.1 Genes differentially expressed during the early phase of lactacystin-induced
neuronal apoptosis
Ubiquitin-proteasome system
Almost all genes in cluster a) UPS were up-regulated in the early time points, as
shown in red (Fig. 4.5).  Genes that encode the proteasome subunits (Psma1, Psmd12
and Psmd7), ubiquitins (Ubb), E2 ubiquitin conjugating enzyme (Ubc), ubiquitin
protein ligase E3A (Ube3a) and ubiquitin fusion degradation 1-like (Ufd1l) were up-
regulated as early as 4.5 h after lactacystin treatment.  Most of the genes encoding the
proteasome subunits were up-regulated persistently (until 24 h after lactacystin
treatment), while others like Ubb and Ubc lasted only until 7.5 h after treatment
(Table 4.1).
Heat shock proteins and molecular chaperones
The genes encoding heat shock proteins (HSPs) such as DnaJ (Hsp40) homolog
subfamily B (Dnajb1), HSP A (Hspa9a), HSP70 (Hspala), HSP27 (Hspb8) and
HSP47 (Serpinh1) were up-regulated later (at 7.5 h) compared with genes that encode
proteasome subunits and ubiquitin.  There was hardly any HSP gene expression
detected at the 4.5 h time point (Table 4.2).
Endoplasmic reticulum stress
The group of genes that encodes protein response to ER stress consisted of the earliest
pro-apoptotic genes to be up-regulated at early time points (Table 4.2).  Genes
encoding the transcription factor DNA-damage inducible transcript 3 (Ddit3), also
known as C/EBP-homologous protein (CHOP), as well as its interaction partner
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CCAAT/enhancer binding protein (C/EBP) beta (Cebpb), are involved in the
induction of apoptosis mediated by ER stress (Rutkowski and Kaufman, 2004).
Inflammation
Genes associated with in inflammatory response, such as CD14 antigen (Cd14), histo-
compatibility 2, M region locus 9 (H2-M9) and interleukin 16 (Il16), were down-
regulated at early time points (Table 4.3).
4.2.3.2 Genes differentially expressed during the late phase of lactacystin-induced
neuronal apoptosis
Antioxidant
Microarray data shows late up-regulation of genes involved in glutathione (GSH)
biosynthesis, such as the glutamate-cysteine ligase, modifier subunit (Gclm),
glutathione S-transferase, alpha 4 (Gsta4) and microsomal glutathione S-transferase 1
(Mgst1).  Similarly, the gene encoding metallothionein 1 (Mt1) was also up-regulated
at a later time point (Table 4.3).
Calcium homeostasis and binding
Genes encoding calcium-binding proteins such as Annexin A2 (Anxa2), Annexin A11
(Anxa11), S100 calcium-binding protein A10 (S100a10) and S100 calcium-binding
protein A11 (S100a11) were also up-regulated at a later time point (24 h) (Table 4.4).
Cholesterol biosynthesis
Interestingly, most of the genes involved in the biosynthetic pathway of cholesterol
were down-regulated after lactacystin treatment (Table 4.5).  Genes encoding
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enzymes involved in determining the rate of cholesterol biosynthesis, such as 3-
hydroxy-3-methylglutaryl-Coenzyme A reductase (Hmgcr), as well as others such as
cytochrome P450, 51 (Cyp51) 7-dehydrocholesterol reductase (Dhcr7), lanosterol
synthase (Lss ), mevalonate kinase (Mvk) and NAD(P)-dependent steroid
dehydrogenase-like (Nsdhl) were all down-regulated during lactacystin-induced
neuronal apoptosis.
4.2.4 Validation of differentially expressed genes identified by microarray
analysis
4.2.4.1 Endoplasmic reticulum stress
Western blot analysis of proteins extracted from cultured cortical neurons treated with
lactacystin (1 µM) for 7.5 h and 24 h detected CHOP protein expression (Fig. 4.6A).
Similarly, the stress-associated activating transcription factor 3 (Atf3) protein was
detected in protein samples from these two time points (Fig. 4.6A).  Since ER stress-
mediated cell death is associated with the disruption of calcium homeostasis and the
activation of calpain, a calcium-regulated protease (Rutkowski and Kaufman, 2004),
Western blot analysis was performed on the cell lysate of cultured cortical neurons
treated with lactacystin, to check whether the calpain substrate p35 was cleaved into
its truncated form of p25.  Fig. 4.6A shows the presence of p25, the product of calpain
cleavage, in the cell lysate 24 h after lactacystin treatment.  Fig. 4.6B shows that the
intracellular calcium chelator BAPTA-AM (2.5 µM), when co-applied with
lactacystin (1 µM), could mildly improve the cell viability of cultured cortical
neurons.  This observation suggests that calcium homeostasis disruption might be
involved in lactacystin-induced neuronal apoptosis (Fig. 4.6B).
100
Figure 4.6. Lactacystin-induced ER stress-associated cell death events.  (A) Western
blotting showing the induction of Atf3 and Ddit3/CHOP proteins at 7.5 h and 24
h after lactacystin treatment.  p35 was cleaved to p25 24 h after the cultured
cortical neurons were exposed to 1 µM lactacystin.  Since p35 is degraded by the
UPS (Patrick et al, 1999), the increased p35 expression at the 7.5 h time point
could have been due to the inhibition of proteasome degradation by 1 µM
lactacystin.  (B) MTT cell viability assay demonstrates a mild neuroprotective
effect of 2.5 µM BAPTA-AM on lactacystin-induced neuronal apoptosis.  *
denotes significant difference compared to the treatment with 1 µM lactacystin
(Lact), according to ANOVA with post hoc Tukey’s test, p<0.05.
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ER stress can also lead to the production of reactive oxygen species (ROS) (Pahl,
1999).  ROS production can lead to the reduction of cellular GSH and ATP.  The
level of cellular GSH in lactacystin-treated cortical neurons decreased to 60% at 7.5 h,
but rebounded to 80% at 24 h after lactacystin treatment (Fig 4.7).  This could be due
to the up-regulation of the GSH biosynthesis genes (Table 4.3).
4.2.4.2 The down-regulation of cholesterol biosynthesis
Real-time quantitative PCR reveals the down-regulation of mRNA expression of both
acetyl-Coenzyme A acetyltransferase 2 (Acat2) and mevalonate (diphospho)
decarboxylase (Mvd), confirming the microarray data (Fig 4.8A, Table 4.5).
Corresponding to that, the total cholesterol levels in the lactacystin treated neurons
were found to be significantly decreased compared to the untreated control (Fig
4.8B).
4.3 Discussion
Most microarray analyses are done at a single time point.  This approach provides
only a snapshot of molecular events.  However, by performing a time course
microarray study, we can determine the sequence in which these events occur, and
whether they act in concurrence in a process like apoptosis.  The time course
microarray analysis revealed that a large number of genes were differentially
expressed during lactacystin-induced neuronal apoptosis.  Some of these genes were
potentially neuroprotective while others were potentially pro-apoptotic.  When these
differentially expressed genes were grouped according to their biological functions, it
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Figure 4.7. GSH and ATP levels in lactacystin-treated cultured cortical neurons.  (A)
Cellular ATP of cultured cortical neurons treated with 1 µM lactacystin
decreased significantly  24 h after treatment.  (B) Cellular GSH of cultured
cortical neurons treated with 1 µM lactacystin decreased 7.5 h and 24 h after
treatment.  * denotes significant difference compared to the control according to
ANOVA with post hoc Tukey’s test, p<0.05.
103
became obvious that some groups of genes were differentially expressed at early time
points while others were expressed at later time points.  The following section
discusses, in detail, the different groups of genes that might play important roles
during lactacystin-induced neuronal apoptosis.
4.3.1 Ubiquitin-proteasome system
It is now evident that UPS plays an important role in the degradation of misfolded and
unfolded proteins in neurons (Sherman and Goldberg, 2001; Schroder and Kaufman,
2005).  The abnormal accumulation of proteins in neurons might be the main cause of
neurodegeneration (Halliwell, 2002).  Consistent with this hypothesis, alterations in
proteasome function have been found in many biological processes, including aging
(review in Gaczynska et al, 2001) and neurodegenerative diseases (Mandel et al,
2005).  A recent study showed that genes encoding proteasome subunits were down-
regulated in the Parkinson’s diseased substantia nigra pars compacta, suggesting that
a robust transcription of proteasome subunits might play an important role in the
survival of cells under stress conditions (Mandel et al, 2005).  In another study,
pretreatment of cultured neocortical neurons with sub-lethal concentrations of
proteasome inhibitors (for example with 10–100 nM MG-132, 0.1–3 nM epoxomicin
or 10–30 nM clasto-lactacystin β-lactone) could increase proteasomal activity and
promote resistance to oxidative injury (Lee et al, 2004).  Recently, Chondrogianni et
al demonstrated that stable over-expression of the proteasome β5 subunit alone was
able to increase the amount of assembled proteasomes and confer protection against
oxidative stress in primary IMR90 human fibroblasts (Chondrogianni et al, 2005).
All these observations imply that enhancement of proteasomal activity is
neuroprotective.
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Figure 4.8. Exposure to lactacystin caused the down-regulation of genes associated
with cholesterol biosynthesis.  (A) Real-time quantitative PCR performed on
total RNA extracted from cultured cortical neurons treated with 1 µM lactacystin
at different time points show the down-regulation of Mvd and Acat2 gene
expression after treatment.  (B) Total cholesterol of cells treated with 1 µM
lactacystin was significantly lower compared to the control according to one
sample t test (p<0.05), 24 h after treatment.  * denotes significant difference
compared to the control according to ANOVA with post hoc Tukey’s test,
p<0.05.
105
In this study, the microarray results revealed that genes encoding various proteasome
subunits were up-regulated after lactacystin treatment (Table 4.1).  This result is
consistent with a similar study using primary cultures of rat vascular smooth muscle
cells (Meiners et al, 2003).  In the yeast Saccharomyces cerevisiae, genes encoding
proteasomal subunits are preceded by a common upstream activating cis-element
called the proteasome-associated control element.  This proteasome-associated control
element serves as a target sequence for the transcription factor Rpn4 that activates
proteasomal gene expression in a concerted manner (Mannhaupt et al, 1999).
Interestingly, Rpn4 is also a substrate of the 26S proteasome:  the same protein that
controls the induction of proteasome formation is also destroyed by the proteasome;
such a combination, or regulatory mechanism, yields a negative feedback circuit in
yeast.  More recently, Rnp4 was found to be responsible for the elevation of
proteasome subunit mRNA levels in response to various stress conditions such as the
abnormal accumulation of proteins, suggesting that Rpn4 is indeed a master regulator
responsible for the ability of the cell to compensate for proteasome inhibition
(London et al, 2004; Glickman and Raveh, 2005).
Knowledge of the mechanisms by which mammalian proteasome formation is
regulated is still very limited.  Meiners et al showed that not only was there a transient
and concerted up-regulation of the genes encoding the 26S proteasome subunit
mRNA during proteasome inhibition, the inhibitor-induced proteasome gene
activation resulted in enhanced de novo protein synthesis of all subunits, increasing
the de novo formation of proteasomes.  Their experiments present the first evidence
that the amount of proteasomes in mammalian cells is regulated at the transcriptional
level, and that there exists an autoregulatory feedback mechanism that compensates
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for reduced proteasomal activity (Meiners et al, 2003; Goldbaum and Richter-
Landsberg, 2004).
Besides that of proteasome subunits, the genes encoding ubiquitin (Ubb), ubiquitin-
conjugating enzyme E2 (Ubc) and ubiquitin protein ligase E3A (Ube3a) were also
significantly up-regulated, according to the microarray data (Table 4.1).  The up-
regulation of these genes might be neuroprotective, since they encode proteins that are
essential for the UPS.  Both Ubb and Ubc genes were reported to be up-regulated
following ischemic injury in animal models, and therefore might play a role in the
degradation of the denatured proteins resulting from oxidative stress during the injury
(Noga and Hayashi, 1996).  A recent report revealed that the presence of wild type or
mutant ubiquitin transgenes resulted in a small but significant delay in the onset of
clinical symptoms, and mild acceleration, respectively, of familial amyotrophic lateral
sclerosis in animal models, although the neuroprotective mechanism at present is still
not clear (Gilchrist et al, 2005).
The other group of genes that shows an early up-regulation during proteasomal
inhibition is that of the ring finger protein.  The ring finger proteins are proteins with
the consensus sequence CX2CX(9-39)CX(1-3)HX(2-3_C/HX2CX(4-48)CX2C, with
the Cys and His representing zinc-binding residues (Joazeiro and Weissman, 2000).
Recent studies demonstrated that many ring finger-containing proteins are E3s that
catalyze autoubiquitination and/or ubiquitination of their substrates (Joazeiro and
Weissman, 2000; Yang and Yu, 2003).  Ring finger-containing E3s play pivotal roles
in diverse cellular processes and have been implicated in contributing to disease, such
as in the case of the Parkin gene mutation and juvenile parkinsonism (Joazeiro and
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Weissman, 2000).  Ring finger E3 also plays key roles in the quality control of protein
synthesis.  For example, Hrd1p is a yeast ER membrane ring finger protein that
regulates the degradation of abnormal ER protein via the UPS (Shen et al, 2004).
Therefore, the up-regulation of these ring finger proteins might have a
neuroprotective role against the accumulation of abnormal unfolded protein in
neurons.
4.3.2 Heat shock proteins and molecular chaperones
Heat shock proteins (HSPs) with chaperoning function work together with the UPS to
prevent the accumulation of misfolded, potentially toxic proteins, as well as to control
catabolism of the bulk of cytoplasmic, cellular protein.  The levels of these proteins
are often increased in response to stress and they have been shown to enhance cell
resistance to various insults (Bush et al, 1997; Ding and Keller, 2001).  HSPs and
molecular chaperones facilitate the refolding of misfolded proteins to prevent them
from aggregating in the cell (Meriin and Sherman, 2005).  Mammalian cells possess a
number of HSPs, which are induced in response to stresses and display protective
chaperone activity (Ohtsuka and Suzuki, 2000).
HSPs can act via two mechanisms to confer cellular protection.  First, as molecular
chaperones, where HSPs are active in the formation and maintenance of the native
conformation of cytosolic proteins and the stabilization of actin filaments which make
up the cytoskeleton of the cell.  Second, both Hsp70 and Hsp27 can inhibit the release
of cytochrome c by suppressing Bid, a pro-apoptotic member of the Bcl-2 family
(review by Franklin et al, 2005).
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Hsp70 proteins and their associated co-chaperones CHIP (carboxyl terminus of
Hsp70-interacting protein)and Hsp40 are the best characterized among these proteins.
Functionally, Hsp70 are ATPases that can bind newly exposed hydrophobic
sequences on denatured proteins.  The co-chaperones from the Hsp40 (Dnaj) family
play essential roles in this process by stimulating the ATPase activity of Hsp70.
When correct refolding is not possible, Hsp70/Hsp40 target bound substrates to
proteasomal degradation in collaboration with other Hsp70-interacting proteins such
as CHIP, and ubiquitin E3 ligase (McDonough and Patterson, 2003).  Hsp70 can
suppress both necrosis and apoptosis induced by various injuries in vivo and in vitro
(Mosser et al, 2000; Sun et al, 2005; Lai et al, 2005).  Although the majority of
studies on the protective effect of individual HSPs have concentrated on the major
inducible Hsp70, a variety of evidence suggests that the small Hsp27 may have a
more potent protective effect in the nervous system (Latchman, 2005).
Another group of HSPs, called the small HSPs (sHSPs), consists of 10 members in
humans and mice (Hspb1–10), of which Hsp27 (Hspb1) and Hsp22 (Hspb8) are the
best-known representatives (Carra et al, 2005).  Unlike Hsp70, sHSPs have no
ATPase activity and binding to substrates appears to be modulated by the de-
oligomerization of the sHSPs, a process itself modulated by mechanisms such as
phosphorylation or temperature change (Giese and Vierling, 2002).
According to the microarray analysis, genes encoding both HSPs and sHSPs were up-
regulated (Table 4.2).  Recent findings have demonstrated that mutation of either
Hsp27 or the related protein Hsp22 can be observed in specific families with
hereditary motor neuropathy caused by premature axonal loss, possibly due to
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neuronal death and subsequent degeneration.  Therefore, Hsp27 appears to be a potent
protective factor for neuronal cells whose mutation results in neuronal cell death and
disease, whilst enhanced expression of the wild type protein may be a therapeutic
option for human diseases involving excessive neuronal cell death (Latchman, 2005).
A recent report demonstrated that Hsp27 expression is regulated by members of the
cAMP response element binding protein (CREB)/ATF families, such as  Atf3 and c-
Jun.  Atf3 is considered to be a nerve injury marker because it is not normally found
in neuronal cells but is highly expressed in response to nerve injury (Takeda et al,
2000; Tsujino et al, 2000).  Atf3 is also known as a stress-inducible gene (Liang et al,
1996; Hai et al, 1999).  Recently, the expression of Atf3 is linked to proteasome
inhibition (Zimmermann et al, 2000) and ER stress (Jiang et al, 2004).  The Atf3
homodimer is known to function as a repressor, whereas the heterodimer, for instance
in combination with c-Jun, functions as an activator for Hsp27, conferring
neuroprotection against nerve injury (Nakagomi et al, 2003).  Consistent with this
observation, the microarray results (Table 4.2) show that up-regulation of the genes
encoding both Atf3 and c-Jun preceded the up-regulation of the Hsp27 gene.
Much of the research to date has focused on the actions of Hsp27 and Hsp70
individually, whereas the full therapeutic benefit of these molecules may be
dependent on a better understanding of their combined neuroprotective action.
4.3.3 Endoplasmic reticulum stress
The ER is the site of protein synthesis in eukaryotic cells.  The UPS regulates the
removal of misfolded proteins in cells.  Proteasome inhibitors can, however, disrupt
this process and cause ER stress. Genes encoding these ER stress-associated
110
transcription factors, such as DNA-damaged inducible transcript 3 (Ddit3), also
known as C/EBP-homologous protein (CHOP), CCAAT/enhancer binding protein
(C/EBP) beta (Cebpb), and activating transcription factor 4 (Atf4), have been reported
to be up-regulated during proteasomal inhibition and ER stress (Reimertz et al, 2003;
Yew et al, 2005).
Ddit3/CHOP is a small nuclear protein transcription factor of the C/EBP family that is
normally undetectable, but expressed at high levels in cells exposed to conditions that
perturb protein folding in the ER and induce the ER stress response (Wang et al,
1996).  The expression of Ddit3/CHOP in stressed cells is linked to the development
of programmed cell death (Wang et al, 1998; Zimmermann et al, 2000, Fribley et al,
2004, Rao et al, 2004).  The increase in Ddit3/CHOP protein expression is believed to
lead to the suppression of Bcl-2 expression in cells, making them more susceptible to
apoptosis (McCullough et al, 2001; Rao et al, 2004).
Besides being a principal site for protein synthesis and folding, the ER also acts as a
site for calcium storage and calcium signaling (Rao et al, 2004).  The pro-apoptotic
response of ER stress can also be due to the disruption of calcium homeostasis in the
cells.  Thus, ER stress may result in the activation of calpain and subsequently trigger
apoptosis through the activation of caspase-3 (Rutkowski and Kaufman, 2004).  The
calcium-regulated calpain is known to cleave p35, the neuronal-specific activator of
cyclin-dependent kinase 5 (Cdk5), to produce p25, which is known to accumulate in
the brains of patients with Alzheimer’s disease (Lee et al, 2000).  p25 could hyper-
phosphorylate tau to disrupt the cytoskeleton and promote neuronal death (Lee et al,
2000; Kusakawa et al, 2000).
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4.3.4 Inflammation
Neuroinflammation plays a key role in the pathophysiology of cerebral ischemia.
Proteasomal inhibition is able to attenuate the inflammatory cascade in cerebral
ischemia and reduce ischemic damage (Wojcik and Di Napoli, 2004).  The
mechanism of this neuroprotection involves the deactivation of NF-κB by stabilizing
the inhibitor IκB, and preventing the translocation of NF-κB to the nucleus where it
can bind to the promoter regions of pro-inflammatory genes.  The effect of
proteasome inhibitors on animal models has been recently evaluated.  Intravenous
infusion of PS-519 (analog of clasto-lactacystin β-lactone) effectively attenuated the
expression of cell adhesion proteins, reducing the invasion of leukocytes and hence
limiting brain tissue damage (Phillips et al, 2000).  The microarray analysis shows
that proteasomal inhibition by lactacystin caused an early down-regulation of genes
associated with the inflammatory response (Table 4.3).  This is so far consistent with
the anti-inflammatory effect of proteasome inhibitors.
Other studies, however, reported that proteasome inhibition induced cyclooxygenase-
2 (COX-2) activation in neuronal culture (Rockwell et al, 2000; Yew et al, 2005).
Inflammatory pathways involving COX-2 enzymes and the subsequent generation of
prostaglandins are potential causes of neurodegeneration such as amyotrophic lateral
sclerosis (Consilvio et al, 2004) and Alzheimer’s disease.  Several regulatory
elements on the murine COX-2 promoter, including a cyclic AMP response element,
two C/EBP sites and a single NFκB site, have been shown to be involved in COX-2
promoter activation (Cieslik et al, 2002).  The regulation of COX-2 expression during
proteasome inhibition is unlikely to be mediated by NF-κB (Rockwell et al, 2000).
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Instead, COX-2 may be activated by CCAAT/enhancer-binding protein-β (C/EBP-β)
binding to the promoter region of COX-2 (Cieslik et al, 2002).  Since C/EBP-β
expression is mediated by ER stress, ER stress may be the trigger for the activation of
COX-2 in neurons during proteasome inhibition.
Furthermore, the caspase activity assay reveals that both caspase-1 and caspase-5
were not activated in the course of lactacystin treatment; only caspase-4 activity was
detected (Fig. 4.2B).  Caspase-1, -4 and -5 are primarily involved in inflammatory
response (Salvesen and Dixit, 1997).   These caspases are needed in the maturation of
cytokines.  ER stress triggers apoptosis via an alternative intrinsic pathway that might
involve the activation of caspase-12 (Rao et al, 2004).  The involvement of caspase-
12 during ER stress-mediated apoptosis in humans is still unclear since human
counterparts of murine caspase-12 have not yet been identified.  Recently, caspase-4
has been suggested to be involved in ER stress-mediated cell death (reviewed in
Katayama et al, 2004).  This report is consistent with the results of the current study.
4.3.5 Antioxidants
Oxidative stress has been linked to ER stress. The release of calcium into the cytosol
could lead to the production of reactive oxygen species (ROS) (Pahl, 1999;
McCullough et al, 2001).  In our study, the groups of genes which are associated with
antioxidant response, such as glutathione S-transferase, alpha 4 (Gsta4), microsomal
glutathione S-transferase 1 (Mgst1) and metallothionein 1 (Mt1), were up-regulated at
the later time points (Table 4.3).  Besides their role in sequestration and distribution
of metal ions such as copper and zinc, metallothioneins are known to provide
cryoprotection from ROS.  The down-regulation of metallothioneins is implicated in
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redox status and increased susceptibility to oxidative stress and metal-induced
neurotoxicity (Aschner et al, 1997).  Cells also respond to oxidative stress by
increasing the expression of genes associated with the antioxidant GSH, such as
Gsta4, Mgst1 and Gclm (Coppedè et al, 2005; Maeda et al, 2005; Chen et al, 2005).
The Gsta4 gene was previously reported to be up-regulated at a later time point after
lactacystin treatment (Yew et al, 2005).  Gsta4 is known for its high catalytic
efficiency in the conjugation of 4-hydroxinonenal and other genotoxic products of
lipid peroxidation during oxidative stress (Hubatsch et al, 1998).  Mgst1, an ER-
bound enzyme known for its oxidative stress protection, was also up-regulated.
Cellular GSH is an important antioxidant in the cell.  A decrease in its level was
reported to be an early event in the pathogenesis of Parkinson’s disease (Owen et al,
1996).  In our study, the depletion of cellular ATP and GSH indicated that the neurons
were under oxidative stress after lactacystin treatment (Fig. 4.7A and 4.7B).  Since
Gclm is the rate-limiting enzyme in GSH biosynthesis, an increased Gclm expression
might have accounted for the ‘rebound synthesis’ of cellular GSH in the cultured
neurons treated with lactacystin at the 24 h time point (Fig. 4.7B).
4.3.6 Cholesterol biosynthesis
Cholesterol, an essential component of cellular membranes, is synthesized on the ER
surface (Chapman et al, 1998; Pahl, 1999).  The disruption of cholesterol homeostasis
in neurons has been associated with Alzheimer’s disease.  Furthermore, the down-
regulation of the rate-limiting enzyme 3-hydroxy-3-methylglutaryl-Coenzyme A
reductase (Hmgcr), encoded by the Hmgcr gene, causes cell death.  The microarray
data reveals that all genes involved in cholesterol biosynthesis were down-regulated
24 h after lactacystin treatment (Table 4.5).  This data is supported by the decrease of
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total cholesterol in neurons treated with lactacystin (Fig. 4.8B).  In cultured neurons,
the inhibition of Hmgcr using inhibitors such as pravastatin is sufficient to cause the
reduction of neurite growth and ultimately cell death (Schulz et al, 2004; Tanaka et al,
2000).  Not much is understood about the regulation of fatty acid and cholesterol
synthesis in neurons (Koudinova et al, 2003; Pfrieger 2003).  Cholesterol is a
multifaceted molecule that serves as an essential membrane component (lipid raft) as
well as a precursor for steroid hormone synthesis.  In neurons, cholesterol is important
for the stability of the synapse, in addition to maintaining synaptic plasticity (Pfrieger
2003).
How lactacystin treatment induces the down-regulation of lipid and cholesterol
biosynthesis genes is not clear, but it is not unexpected that the synthesis of lipid and
cholesterol will be affected during ER stress, since cholesterol is synthesized in the
ER.  A recent report suggests that cholesterol and fatty acid biosynthesis are
controlled by a common family of transcription factors, known as the sterol regulatory
element binding proteins (SREBPs) (Eberlé et al, 2004).  Upon activation (eg. when
the ER is deficient in lipid and sterol), the ER-anchored SREBP precursor transits to
the Golgi, where it undergoes a sequential two-step cleavage process to release the
NH2-terminal active domain, the designated nuclear form of SREBP, SREBP(N),
which is transported to the nucleus and promotes the expression of many genes
involved in cholesterol and fatty acid synthesis.  Similarly, activating transcription
factor 6 (ATF6), an ER membrane-bound transcription factor, can also undergo a
similar two-step cleavage process to form ATF6(N) during ER stress.  This
proteolytic cleavage can cause the nuclear translocation of ATF6(N) to direct the
transcriptional activation of chaperone molecules and enzymes essential for protein
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folding.  Zeng et al showed that over-expression of ATF6(N) in HepG2 (liver cell
line) could suppress the SREBP(N)-mediated transcription of HMGCR  and 3-
hydroxy-3-methylglytaryl-Coenzyme A synthase (HMGCS) (Zeng et al, 2004).  This
report suggests a direct link between ER stress and the down-regulation of lipid and
cholesterol biosynthesis.
Cholesterol biosynthesis is a complex synthetic pathway that requires dozens of
enzymes and large amounts of energy (Pfrieger 2003).  The down-regulation of
cholesterol synthesis genes might be a step taken by cells to conserve energy,
especially when cells are under stress.
4.3.7  Apoptosis
The microarray analysis picks up other genes that might be involved in the survival
and cell death action of lactacystin.  The gene encoding Bcl-2-associated athanogene
3 (Bag3) was found to be up-regulated strongly 24 h after lactacystin treatment (Table
4.2).  Bag3 can form a complex with more than one apoptosis-modulating factor such
as Hsp70 and Bcl-2 proteins, and thus can participate in apoptosis regulation (Antoku
et al, 2001). An earlier study showed that the down-regulation of Bag3 enhanced the
apoptotic response to chemotherapy in human primary B chronic lymphocytic
leukemia cells (Romano et al, 2003).  The role of Bag3 in neurons is, however, less
clear, but based on the microarray results, it might have an important role in
neuroprotection.
Insulin-like growth factor 1 (Igf1) is a 70-amino acid protein that is structurally
similar to insulin.  It acts as a major neurotrophic factor, promoting neuronal
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proliferation and differentiation during normal brain development.  Igf1 also acts as a
neuroprotective survival factor under pathological conditions such as stroke, brain
trauma, multiple sclerosis and Alzheimer’s disease (Trejo et al, 2003; Carro and
Torres-Aleman, 2004).  The biological functions of Igf1 are mediated by the Igf1
receptor.  Binding of Igf1 to the extracellular domain of the Igf1 receptor leads to the
phosphorylation of the insulin receptor substrates IRS-1 and IRS-2, which results in
the activation of two downstream signaling cascades for cell survival, namely the
mitogen-activated protein kinase (ERK) and PI3-kinase/Akt pathways (Mendez et al,
2005).  A recent study showed that direct administration of Igf1 into the intrathecal
space may have a therapeutic benefit for amyotrophic lateral sclerosis (Nagano et al,
2005).  In this microarray study, Igf1 gene expression was down-regulated as early as
4.5 h after lactacystin treatment.  This down-regulation of Igf1 might contribute to the
apoptosis of the neurons treated with lactacystin.
4.4 Conclusion
The UPS is involved in the regulation of many important biological processes in
neurons.  The study using microarray GeneChip® revealed that many potentially
neuroprotective and pro-apoptotic genes were differentially expressed during
proteasome inhibition by lactacystin.  The early up-regulation of some genes is
important in determining the fate of cells; genes encoding the proteasome subunits
and HSPs were up-regulated early, before the onset of apoptosis in the lactacystin-
treated cells.  These genes seemed to have responded to the abnormal build-up of
unfolded proteins in the cells caused by the inhibition of proteasome activity.  Since
lactacystin is an irreversible proteasome inhibitor, cells exposed to lactacystin can
undergo apoptosis.  The microarray data shows an early ER stress response after
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lactacystin treatment, in spite of the up-regulation of neuroprotective genes such as
those encoding proteasome subunits and HSPs.
The microarray data also reveals that some genes encoding neuroprotective
antioxidants were up-regulated later, after the onset of apoptosis.  This suggests the
neurons were under oxidative stress at the later stages of proteasome inhibition.  ER
stress has been reported to cause oxidative stress in many cell death models
(McCullough et al, 2001).  The fact that ER stress-associated genes were up-regulated
before the genes encoding antioxidants might suggest that ER stress is the main cause
of cell death in lactacystin-induced cultured cortical neurons.
118
CHAPTER 5
5 Lipid profile of the neural membrane during lactacystin-induced neuronal
apoptosis
5.1 Introduction
The microarray analysis of cultured cortical neurons subjected to proteasome
inhibition using lactacystin reveals a significant down-regulation of genes associated
with cholesterol and lipid biosynthesis, metabolism and homeostasis (Chapter 4,
Table 4.5).  The collective evidence from many studies suggests that neural
membrane phospholipid metabolism is disrupted in neural trauma neurodegenerative
diseases (review by Farooqui et al, 2004).  The neural membrane is very complicated
and diverse.  It contains three major categories of lipids, phospholipids, cholesterol
and sphingolipids, that form the membrane lipid bilayer.  The cytoplasmic leaflets of
membranes are enriched in the negatively-charged phospholipids that interact with
positively-charged protein surfaces.  Phosphoinositides play a particularly important
role in the regulation of protein binding, because the number and location of negative
charges on the inositol ring are controlled by a variety of kinases and phosphatases.
The non-cytoplasmic leaflet of the membrane contains a variety of glycolipids, that,
together with their interacting proteins, may contribute to the generation of lipid
microdomains (Wenk and De Camilli, 2004).  Phospholipids and sphingolipids not
only form the lipid bilayer of membranes, but also act as reservoirs for the precursors
of lipid signaling molecules or messengers such as acetylcholine, eicosanoids,
diacylglycerol and ceramides (Review by Araki and Wurtman, 1998; Ariga et al,
1998; Buccoliero and Futerman 2003; Colombaioni and Garcia-Gil, 2004; Bazan et
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al, 2005).  Specific lipid messengers can be released from this reservoir of lipids by a
class of proteins known as the phospholipases (Farooqui et al, 2004).  This can
happen in response to signals such as hormones, growth factors, cytokines, membrane
depolarization, ion channel activation and neurotransmitters such as glutamate (Bazan
et al, 2005).  These lipid messengers are known to play important roles in the
regulation of cell proliferation, differentiation and death.
The electrospray ionization mass spectrometry (ESI-MS) has been used successfully
to study the lipid profile in complex lipid mixtures from human fibroblasts and
cultured cortical neurons (Wenk et al, 2003).  ESI-MS was used in this study to
investigate the lipid profile of cultured cortical neurons during lactacystin-induced
neuronal apoptosis.  By comparing the lipid profile of apoptotic neurons with the
control cells, it was observed that two groups of lipids were prominently accumulated
in lactacystin-treated cultured neurons undergoing apoptosis. Ceramide, a second
messenger, can be generated in cells undergoing cell death (review by Goswami and
Dawson, 2000).  Ceramide accumulation in neurons has been reported in various
disorders associated with acute or chronic neurodegeneration.  For example, recent
studies have shown that ceramides accumulate in the normal aging brain and in the
diseased brains of Alzheimer’s disease patients (Goswami and Dawson, 2000).  More
interestingly, the lipid profile analysis also shows the accumulation of N-acyl
phosphatidylethanolamine (NAPE) during lactacystin-induced neuronal apoptosis.
NAPE is the precursor of anandamide (N-arachidonoylethanolamine) and other N-
acylethanolamines (NAEs).  Anandamide is an endogenous cannabinoid receptor
ligand and has been reported to have neuroprotective property in vivo (Veldhuis et al,
2003).  Therefore the accumulation of NAPE during lactacystin-induced neuronal
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apoptosis might be a neuroprotective response.  The significance of these results will
be discussed subsequently.
5.2 Results
5.2.1 Lipid profile of lactacystin-treated cultured neurons
Lipids were extracted from mouse cultured cortical neurons and analyzed using
negative-ion ESI-MS.  The differences in the lipid profiles between control and
lactacystin-treated cells (1 µM for 24 h) were computed using a chemometric method
in a semi-quantitative fashion (Fig. 5.1).  Among the most pronounced differences are
(i) an increase in levels of ions with m/z 536, 564 and 600, (ii) a drop in levels of ions
with m/z of 597, 714, 732, 760, 786, 965, and 967 and (iii) increased signals in m/z
980, 1004, and 1030. Some of these m/z correspond to small yet readily visible peaks
in the single mass spectrum (e.g. 564, 760), while others, such as 965, 980, 1004, and
1030, are minor ions (Fig 5.1).  Based on tandem mass spectrometry, the following
trends were observed: (i) an increase in m/z which corresponds to ceramides; (ii) a
drop in lysophosphatidylinositol, phosphatidylinositol phosphate (PIP),
phosphatidylethanolamine (PE) and phosphatidylserine (PS) and (iii) up-regulation of
levels of N-acyl phosphatidylethanolamines (NAPEs) (Fig. 5.2).  In order to better
characterize some of the ions which showed differential response, we used tandem
mass spectrometry to show the MSMS of ions at m/z (A) 744, (B) 812 and (C) 976,
which correspond to 34:1 PC or 36:1 PE, 38:3 PS and 54:2 NAPE (Fig. 5.3).  The up-
regulation of ceramide was confirmed by employing the precursor ion scan with the
use of an internal standard (C-19-ceramide).
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Figure 5.1. Differential analysis of lipid profile.  Negative ion mode ESI-MS of
control (A) and lactacystin-treated (B) cultured mouse cortical neuron lipids 24 h
after treatment.  Average spectra of independent experiments (n=4) for each
condition was aligned and the relative difference (Lactacystin/Control) in peak
intensity of negative molecular ions within the scan range of 400–1200 was
computed (C).
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Figure 5.2. Lactacystin-induced changes in lipid profile of neurons and identification
of lipid molecular species as revealed by ESI-MS and ESI-MSMS.  Relative
changes in lipid compositions 24 h after lactacystin exposure.
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Figure 5.3. MSMS of ions at m/z (A) 744, (B) 812 and (C) 976, corresponding to 34:1
PC or 36:1 PE, 38:3 PS and 54:2 NAPE.
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To check whether the changes of lipid profile changes in response to neuronal
apoptosis, ESI-MS was used to analyze lipids extracted from cultured cortical neurons
treated with 1 µM lactacystin for 7.5 h.  Under this condition, neurons have yet to
undergo apoptosis  (Fig. 4.3B).  The lipid profile obtained at this time point (Fig. 5.4)
is different from that of cultures 24 h after lactacystin treatment.  The changes in
lipids from the early time point (7.5 h) are primarily of the ethanolamine/choline-
containing lipids (note: ethanolamine and choline lipids can share the same mass and
a single stage scan MS cannot differentiate the two).  Other phospholipids (eg.
Phosphatidyl-inositol-serine) did not show an observable change (Fig. 5.4).  In
contrast to the lipid profile obtained from apoptotic neurons (24 h time point), there
were no elevations of NAPEs or ceramides at this time point.
5.3 Discussion
5.3.1 Lactacystin induces the accumulation of ceramide during neuronal
apoptosis
The role of ceramide in neuronal cell death is well documented (Ariga et al, 1998;
Goswami and Dawson, 2000; Buccoliero and Futerman, 2002).  Ceramides can be
generated in the cell either from de novo synthesis, by the action of
sphingomyelinases (SMase) or from breakdown of complex glycolipids (Goswami
and Dawson, 2000; Buccoliero and Futerman, 2003).  Experimental manipulations
that increase intracellular ceramide levels, for example, by treatment with bacterial
sphingomyelinase or exposure to synthetic preparations of ceramide, potently induce
apoptosis in mammalian cells (Ariga et al, 1998).  Numerous signaling systems are
associated with ceramide action, including activation of the mitogen-activated protein
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Figure 5.4. Lactacystin-induced changes in the lipid profile of neurons and
identification of lipid molecular species as revealed by ESI-MS and ESI-MSMS.
Relative changes in lipid compositions of mouse cultured cortical neurons 7.5 h
after lactacystin exposure.
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kinase (MAPK) cascade (Sotica et al, 2005) and death-associated protein kinase
(DAPK) cascade (Pelled et al, 2002).  Cutler et al recently reported that the
accumulation of long-chain ceramides and cholesterol in the brain of Alzheimer’s
disease patients suggests the involvement of ceramides in the pathogenesis of
Alzheimer’s disease (Cutler et al, 2004).  In spite of these, the role of ceramides in
neuronal apoptosis induction is still debatable, since some data suggests that the
formation of ceramides might be a post-apoptotic event (Sillence and Allan, 1998)
5.3.2 Lactacystin induces accumulation of NAPE during neuronal apoptosis
NAPE in which the free amino group of phosphatidylethanolamine is acylated by a
further fatty acid is a common constituent of cereal grains (eg. wheat, barley and
oats), and of some other seeds, but it may occur in other plant tissues too, especially
under conditions of physiological stress (Chapman, 2000; Holmback et al, 2001).
NAPE can be found in very small amounts in brain tissue.  NAPE is the precursor of
N-arachidonoylehtanolamine (anandamide) and N-acylethanolamines (NAEs).  In
animal tissues, anandamide and NAEs are principally biosynthesized through the
transacylation-phosphodiesterase pathway, which consists of two enzyme reactions.
The first reaction is the transfer of an acyl group from sn-1 position of
glycerophospholipid to the amino group of phophatidylethanolamine (PE) and this is
catalyzed by calcium-dependent N-acyltransferase.  The resultant NAPE is then
hydrolyzed to become NAE and phosphatidic acid by a phosphodiesterase of the
phospholipase D (PLD)-type, generally abbreviated to NAPE-PLD (Ueda et al, 2005).
The gene of NAPE-PLD has recently been cloned, and over-expression of NAPE-
PLD was able to cause significant decreases in the NAPE level in transfected cells
(Okamoto et al, 2005).
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Anandamide is an endocannabinoid (or endogenous ligand) of the brain cannabinoid
receptor (Maccarrone and Ainazzi-Agró, 2003).  Anandamide is involved in many
biological processes such as pain relief, regulation of cell growth, differentiation and
even apoptosis (Calignano et al, 1998; Maccarrone and Ainazzi-Agró, 2003).  The
levels of anandamide and its precursor NAPE were markedly increased upon post-
decapitative brain ischemia, experimental stroke and traumatic brain injury (Hansen et
al, 2001; Ueda et al, 2005).  The role of NAPE accumulation in cultured cortical
neurons undergoing neuronal apoptosis is not clear, but recent studies have shown
that anandamide was able to protect neurons against excitotoxicity and ischemic
injury (Shen and Thayer, 1998; Sinor et al, 2000).  Therefore, NAPE accumulation
might indirectly confer neuroprotective effect on cells under cellular insults (Hansen
et al, 2001).
So far, the accumulation of NAPE has been reported only in necrotic cell death
models such as decapitative brain ischemia, experimental stroke and traumatic brain
injury models (Hansen et al, 2001).  In this study, however, the accumulation of
NAPE was observed in an apoptotic cell death model.  The apoptotic nature of the
lactacystin-induced cell death model has been demonstrated in Chapter 3 of this
thesis.  One possible explanation for the accumulation of NAPE species during
lactacystin-induced neuronal apoptosis is the involvement of ER stress in this cell
death pathway.  In the previous chapter, the microarray and Western blot data show
that exposure of lactacystin (1 µM) to cultured cortical neurons can induce the up-
regulation of ER stress-associated genes and proteins.  Since ER is the main calcium
store in cells, ER stress can cause the elevation of cellular calcium levels in affected
128
cells (Verkhratsky and Toescu, 2003).  The elevation of cellular calcium could cause
the activation of N-acyltransferase, and this would lead to the accumulation of NAPE
species in neural membranes undergoing apoptosis.
The role of NAPE in neurons during neuronal apoptosis remains to be explored.
Currently, there are only a handful of laboratories working on NAPE-related projects.
With the recent successful cloning of the NAPE-PDL gene from mouse (Okamoto et
al, 2005), a step closer to understanding the role of NAPE in neurons has been taken.
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CHAPTER 6
6 Microarray analysis of gene expression during exposure to (-)-
epigallocatechin-3-gallate on cultured cortical neurons
6.1 Introduction
The leaves of green tea (Camellia sinensis) contain many constituents; among these
are the polyphenolic catechins, which are thought to confer beneficial biological
effects such as neuroprotective, anti-carcinogenic and anti-inflammatory activities.
Fresh tea leaves contain high amounts of polyphenolic catechins, which constitute
30–40% of the solid green tea extract (Wang et al, 1994).  Among the tea catechins, (-
)-epigallocatechin-3-gallate (EGCG) is the major constituent, accounting for more
than 10% of the extract dry weight (Mandel and Youdim, 2004).
Initially, the beneficial biological effects of these polyphenolic catechins were thought
to rely on the antioxidant and/or iron-chelating actions of its polyphenol constituents,
and on modulation of endogenous metabolizing and antioxidant enzymes (reviewed in
Mandel and Youdim, 2004).  However, several recent studies have begun to associate
the biological activity of the polyphenols present in green tea, especially EGCG, with
the inhibition of proteasome activity (Wan et al, 2004; Shay and Banz, 2005).  Like
lactacystin, EGCG is found to specifically inhibit the chymotrypsin-like activity of
the proteasome (Nam et al, 2001; Wan et al, 2004).  The experiments carried out by
Nam et al demonstrated that EGCG, at concentrations typically observed in the serum
of green tea drinkers (1–10 µM), can inhibit proteasome activity and cause growth
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arrest in the G1 phase of the cell cycle in several tumor and transformed cell lines
(Nam et al, 2001).
In addition to its role in reducing the risk of cancers, consumption of EGCG-
containing tea has also been shown to lessen the risk of atherosclerosis and to
improve blood lipid levels (Shay and Banz, 2005).  These clinically observed
improvements were probably due to the inhibitory effect of EGCG on proteasomes.
In this case, the target of proteasomal regulation may be the sterol regulatory element-
binding proteins (SREBPs).  SREBPs are a family of transcription factors that
regulate lipid homeostasis in cells.  Three isoforms of SREBPs have been known to
control the expression of more than 30 genes required for the biosynthesis of
cholesterol, fatty acids, triacylglycerols and phospholipids (Horton, 2002).  Two
SREBP genes encode three different isoforms; the isoform most directly related to
cholesterol regulation is SREBP-2.  Genes regulated by SREBP-2 include that of the
low-density lipoprotein (LDL) receptor, and genes encoding enzymes of the
cholesterol biosynthetic pathway, such as Hmgcr.  Thus, the activation of SREBP-2
can lead to an increase in the transcription and synthesis of receptors that promote the
uptake of cholesterol-containing lipoprotein from the serum into cells.  Concurrently,
intracellular cholesterol synthesis will also be promoted by the up-regulation of genes
encoding the cholesterol biosynthetic enzymes.  Since proteasome inhibition can
stabilize the active SREBP-2 and induce the expression of LDL receptors (Hirano et
al, 2001), the proteasomal inhibitory effect of EGCG might contribute to the
cholesterol lowering (in serum) and heart disease-preventive effects of green tea
(Kuhn et al, 2003).
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In Chapter 4, the differentially expressed genes during lactacystin-induced neuronal
apoptosis were analyzed using microarray GeneChip. In this chapter, microarray
analysis was carried out once again to study the genes that were differentially
expressed after the cultured cortical neurons were exposed to EGCG.  The special
focus for this study was to investigate whether EGCG could induce a gene expression
profile similar to that observed for cultured cortical neurons treated with lactacystin (1
µM).
6.2 Results
6.2.1 EGCG induced apoptosis in primary cortical neurons with caspase-3
activation and proteasome inhibition
The MTT assay results showed decreasing cell viability with increasing EGCG
concentrations, with about 67.46±2.08% and 31.64±1.61% residual cell viability with
treatment with 20 µM and 50 µM EGCG for 24 h respectively; treatment with 1 µM
EGCG for 24 h had little effect on cell viability (Fig. 6.1A).  The caspase activity
measurement using fluorogenic substrates indicated a 491% increase in caspase-3
activity (compared with the control) with treatment with 25 µM EGCG for 24 h.
Treatment with 1 µM EGCG for 24 h, however, did not activate the caspase-3 activity
(Fig. 6.1B).  Other caspases that were found to be activated 24 h after treatment with
25 µM EGCG were caspase-2 (238%), caspase-4 (207%), caspase-6 (184%) and
caspase-10 (248%) (Fig. 6.1B). The proteasomal activity (chymotrypsin-like) assay
reveals that chymotrypsin-like activity in the cell lysate decreased to 60±0.3% after
the cells were exposed to 25 µM EGCG for 24 h.  The decrease of chymotrypsin-like
activity was not detected in cells exposed to 25 µM EGCG for 7.5 h.  Cells exposed to
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Figure 6.1. The effects of EGCG treatment on cell viability and caspase-3 activity
activation of cultured cortical neurons.  (A) The viability of EGCG-treated
primary cortical neurons was quantified using the MTT assay.  Cell injury was
found to be concentration-dependent.  * indicates significant difference
according to ANOVA with post hoc Tukey’s test, p<0.05.  (B) Caspase activity
measurement reveals the activation of caspase-3, as well as other caspases
(caspase-2, caspase-4, caspase-6 and caspase-10) after treatment with 25 µM
EGCG for 24 h.
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Figure 6.2. The effect of EGCG treatment on the chymotrypsin-like proteasome
activity.  Chymotrypsin-like activity of the proteasome was measured at (A) 7.5
h and (B) 24 h after the cultured cortical neurons were exposed to EGCG.  *
indicates significant difference according to ANOVA with post hoc Tukey’s test.
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1 µM EGCG did not show any inhibition of chymotrypsin-like activity at both 7.5 h
and 24 h time points (Fig. 6.2).  Taken together, the results from the chymotrypsin-
like proteasomal activity assay and MTT assay show that exposure to a low dosage of
EGCG (1 µM) did not induce chymotrypsin-like activity inhibition and neuronal cell
death, but exposure to a high dosage of EGCG (25 µM) induced chymotrypsin-like
activity inhibition and neuronal apoptosis.
6.2.2 Microarray analysis
Two EGCG treatment conditions were chosen for the microarray analysis: a low
concentration (1 µM EGCG) that does not induce chymotrypsin-like proteasomal
activity inhibition and neuronal apoptosis, and a high concentration (25 µM EGCG)
that inhibits the chymotrypsin-like activity and induces neuronal apoptosis.  Out of
the 12,488 genes and ESTs from the Murine Genome U74Av2 GeneChip®, 387 were
differentially expressed based on the criteria of genes showing a change of two-fold
or more with a p-value of <0.01. These genes were identified and sorted according to
their biological functions (Table 6.1–6.9).
6.2.3 Effect of EGCG on the protein expression of CHOP, Atf3 and the cleavage
of p35
Western blot analysis shows that EGCG at high concentrations induced the expression
of Atf3, but not CHOP, in the cultured cortical neurons (Fig. 6.3).  This result is
consistent with the microarray data (Table 6.1).  There was no cleavage of p35 to p25
when the cultured cortical neurons were exposed to EGCG (25 µM), suggesting the
absence of calpain activation during EGCG-induced neuronal apoptosis.
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Table 6.1.  Differentially expressed genes after EGCG treatment: Ubiquitin-
proteasome system; heat shock proteins and molecular chaperones; response to
stress; apoptosis.  Gene expression is indicated as fold change ± Standard Error.
Only genes differentially expressed >2-fold and significantly expressed
according to one-way ANOVA, p<0.01 are included in the list.




96892_at Psma1 proteasome subunit, alpha type 1 1.81 ± 0.41 2.08 ± 0.35 AI836804
92544_f_at Psma3 proteasome subunit, alpha type 3 2.15 ± 0.41 2.14 ± 0.35 AF055983
93988_at Psma7 proteasome subunit, alpha type 7 1.97 ± 0.41 2.05 ± 0.35 AI836676
103319_at Psmd10 proteasome 26S subunit, non-ATPase,
10
1.80 ± 0.41 2.41 ± 0.35 AB022022
160305_at Psmd11 proteasome 26S subunit, non-ATPase,
11
2.14 ± 0.41 2.53 ± 0.35 AW121693
94302_at Psmd4 proteasome 26S subunit, non-ATPase,
4
1.94 ± 0.41 2.07 ± 0.35 AF013099
98522_at Psmd8 proteasome 26S subunit, non-ATPase,
8
1.92 ± 0.41 2.04 ± 0.35 AI839158
95124_I_at Rbx1 ring-box 1 2.36 ± 0.41 3.41 ± 0.35 AW122337
160205_f_at Rnf11 ring finger protein 11 2.07 ± 0.41 2.30 ± 0.35 AB024427
161814_f_at Rnf19 ring finger protein (C3HC4 type) 19 3.08 ± 0.41 2.63 ± 0.35 AV355427
101966_s_at Rnf13 ring finger protein 13 2.14 ± 0.41 2.16 ± 0.36 AF037206
101255_at Ubb ubiquitin B 3.00 ± 0.41 3.26 ± 0.35 X51703
95215_f_at Ubc ubiquitin C 2.71 ± 0.41 2.95 ± 0.35 D50527
93069_at Ube2d2 ubiquitin-conjugating enzyme E2D 2 2.04 ± 0.41 2.35 ± 0.35 U62483
101581_at Ube3a ubiquitin protein ligase E3A 3.15 ± 0.41 4.13 ± 0.78 U82122
94018_at Ubl3 ubiquitin-like 3 1.61 ± 0.41 2.07 ± 0.35 AW120725
93303_at Ufd1l ubiquitin fusion degradation 1 like 1.67 ± 0.41 2.05 ± 0.35 U64445
Heat shock proteins and molecular chaperones
93743_at Hsbp1 heat shock factor binding protein 1 2.20 ± 0.41 2.34 ± 0.35 AI838388
95699_f_at 2010009J04Rik DnaJ (Hsp40) homolog, subfamily C,
member 8
1.88 ± 0.41 2.08 ± 0.35 AI848094
97870_s_at Ero1l ERO1-like (S. cerevisiae) -2.40 ± 0.41 -1.93± 0.35 AA798624
101207_at Ppia peptidylprolyl isomerase A 2.51 ± 0.41 2.59 ± 0.35 X52803
Response to stress
95092_at Ppp3ca protein phosphatase 3, catalytic
subunit, alpha isoform
2.05 ± 0.41 1.98 ± 0.35 J05479
100606_at Prnp prion protein 2.05 ± 0.41 2.27 ± 0.35 M18070
96773_at Txndc4 thioredoxin domain containing 4
(endoplasmic reticulum)
1.97 ± 0.41 2.62 ± 0.35 AW125408
Apoptosis
102727_at Bdnf brain derived neurotrophic factor 1.46 ± 0.41 2.59 ± 0.35 X55573
160696_at Tia1 cytotoxic granule-associated RNA
binding protein 1
2.20 ± 0.42 2.07 ± 0.35 U00689
102599_at Tpt1 tumor protein, translationally-
controlled 1
2.08 ± 0.41 2.15 ± 0.35 X06407
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Table 6.2.  Differentially expressed genes after EGCG treatment (continued):
Transcription. Gene expression is indicated as fold change ± Standard Error.
Only genes differentially expressed >2-fold and significantly expressed
according to one-way ANOVA, p<0.01 are included in the list.




104155_f_at Atf3 activating transcription factor 3 -2.58 ± 0.41 1.64 ± 0.36 U19118
95674_r_at Basp1 brain abundant, membrane attached signal
protein 1
3.16 ± 0.41 3.52 ± 0.35 AI851985
94490_at Cnot8 CCR4-NOT transcription complex, subunit 8 1.63 ± 0.41 2.04 ± 0.35 AW122419
95460_at Cops5 COP9 (constitutive photomorphogenic)
homolog, subunit 5 (Arabidopsis thaliana)
2.46 ± 0.41 2.49 ± 0.35 U70736
160502_at Creg cellular repressor of E1A-stimulated genes 2.16 ± 0.42 2.80 ± 0.36 AF084524
97550_at Hdac7a histone deacetylase 7A -2.20 ± 0.41 -1.99 ± 0.35 AW047228
161051_at Hes5 hairy and enhancer of split 5 (Drosophila) -1.12 ± 0.41 -2.34 ± 0.35 D32132
99024_at Mad4 Max dimerization protein 4 2.15 ± 0.41 2.13 ± 0.35 U32395
104590_at Mef2c myocyte enhancer factor 2C 2.55 ± 0.41 2.30 ± 0.35 L13171
160138_at Mxi1 Max interacting protein 1 1.50 ± 0.41 2.16 ± 0.35 L38822
96497_s_at Myt1l myelin transcription factor 1-like 1.91 ± 0.41 2.78 ± 0.35 AI848062
92893_at Nfia nuclear factor I/A 2.09 ± 0.41 2.28 ± 0.35 D90173
93740_at Nsep1 nuclease sensitive element binding protein 1 3.48 ± 0.41 3.64 ± 0.35 U33196
99015_at Pml promyelocytic leukemia -2.24 ± 0.41 -2.07 ± 0.35 U33626
160146_r_at Polr2c polymerase (RNA) II (DNA directed)
polypeptide C
2.82 ± 0.41 2.65 ± 0.35 D83999
93325_at Polr2e polymerase (RNA) II (DNA directed)
polypeptide E
1.96 ± 0.41 2.09 ± 0.35 AI845735
95003_at Polr2k polymerase (RNA) II (DNA directed)
polypeptide K
6.43 ± 0.41 8.08 ± 0.35 AA880275
98085_f_at Rpo1-1 RNA polymerase 1-1 2.82 ± 0.41 3.01 ± 0.35 U11248
99665_at Satb1 special AT-rich sequence binding protein 1 2.12 ± 0.41 2.48 ± 0.35 U05252
160869_at Sirt3 sirtuin 3 (silent mating type information
regulation 2, homolog) 3 (S. cerevisiae)
2.21 ± 0.41 2.08 ± 0.35 AI849490
104158_at Skiip SKI interacting protein 4.23 ± 0.60 5.94 ± 0.35 AW046671
101684_r_at Srst simple repeat sequence-containing transcript 2.78 ± 0.41 3.86 ± 0.35 X67863
103504_at Ssbp2 single-stranded DNA binding protein 2 2.21 ± 0.41 2.40 ± 0.35 AI837107
93918_at Taf9 TAF9 RNA polymerase II, TATA box
binding protein (TBP)-associated factor
2.69 ± 0.41 2.78 ± 0.36 AA673500
94008_at Tceb1 transcription elongation factor B (SIII),
polypeptide 1
2.04 ± 0.41 1.95 ± 0.35 AW045358
100947_at Tcf20 transcription factor 20 3.38 ± 0.41 3.59 ± 0.35 AI847906
99603_g_at Tieg1 TGFB inducible early growth response 1 2.08 ± 0.41 2.20 ± 0.35 AF064088
92444_f_at Zfp1 zinc finger protein 1 1.94 ± 0.41 2.13 ± 0.35 X16493
94937_at Zfp277 zinc finger protein 277 2.14 ± 0.41 2.89 ± 0.36 AW121594
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Table 6.3.  Differentially expressed genes after EGCG treatment (continued): Protein
biosynthesis; protein modification. Gene expression is indicated as fold change ±
Standard Error.  Only genes differentially expressed >2-fold and significantly
expressed according to one-way ANOVA, p<0.01 are included in the list.




101213_at Arbp acidic ribosomal phosphoprotein P0 2.56 ± 0.41 2.60 ± 0.35 X15267
94766_at Eef1a1 eukaryotic translation elongation
factor 1 alpha 1
2.46 ± 0.41 2.60 ± 0.35 M17878
98141_at Eif5b eukaryotic translation initiation
factor 5B
2.27 ± 0.41 3.00 ± 0.36 AA647048
98120_at Mrpl27 mitochondrial ribosomal protein L27 1.86 ± 0.41 2.11 ± 0.35 AI844807
93859_at Mtif2 mitochondrial translational initiation
factor 2
2.39 ± 0.41 2.59 ± 0.35 AI875598
100720_at Pabpc1 poly A binding protein, cytoplasmic
1
2.29 ± 0.41 2.04 ± 0.35 X65553
99975_at Prkrir protein-kinase, interferon-inducible
double stranded RNA dependent
inhibitor, repressor of (P58
repressor)
2.15 ± 0.41 2.25 ± 0.35 AA879937
96693_at Rars arginyl-tRNA synthetase 2.47 ± 0.41 2.41 ± 0.35 AI849453
94767_at Rnu35b /// Rps11 RNA, U35b small nucleolar ///
ribosomal protein S11
2.55 ± 0.41 2.69 ± 0.35 U93864
96290_f_at Rpl21 ribosomal protein L21 2.20 ± 0.41 2.23 ± 0.35 U93863
100729_at Rpl26 ribosomal protein L26 2.43 ± 0.41 2.69 ± 0.35 X80699
100734_at Rpl3 ribosomal protein L3 2.34 ± 0.41 2.25 ± 0.35 Y00225
92577_f_at Rpl37 ribosomal protein L37 2.07 ± 0.41 2.26 ± 0.35 AW047116
101129_at Rpl5 ribosomal protein L5 1.86 ± 0.41 2.00 ± 0.35 X83590
97695_s_at Rpl7 ribosomal protein L7 2.02 ± 0.41 2.05 ± 0.35 M29015
100694_at Rplp1 ribosomal protein, large, P1 2.04 ± 0.41 2.05 ± 0.35 U29402
99590_at Rps17 ribosomal protein S17 2.13 ± 0.41 2.29 ± 0.35 D25213
100686_at Rps2 ribosomal protein S2 2.21 ± 0.41 2.10 ± 0.35 M20632
96300_f_at Rps27 ribosomal protein S27 2.15 ± 0.41 2.49 ± 0.35 AI854238
101664_at Rps3a ribosomal protein S3a 2.48 ± 0.41 2.58 ± 0.35 Z83368
101212_at Rps7 ribosomal protein S7 2.58 ± 0.41 2.57 ± 0.35 AF043285
Protein modification
93460_at Acvr1 activin A receptor, type 1 2.08 ± 0.42 2.20 ± 0.36 L15436
101936_at Clk4 CDC like kinase 4 -2.29± 0.41 -2.33 ± 0.35 AF033566
161171_at Dusp8 dual specificity phosphatase 8 1.52 ± 0.41 2.40 ± 0.35 AV226788
95298_at Epha3 Eph receptor A3 2.26 ± 0.41 1.51 ± 0.36 M68513
161119_at Epha5 Eph receptor A5 1.52 ± 0.41 2.07 ± 0.35 AI854630
92906_at Epha7 Eph receptor A7 2.65 ± 0.41 2.56 ± 0.35 X79083
98446_s_at Ephb4 Eph receptor B4 2.00 ± 0.41 1.99 ± 0.35 U06834
99511_at Prkcb protein kinase C, beta 2.07 ± 0.41 2.04 ± 0.35 X53532
97890_at Sgk serum/glucocorticoid regulated
kinase
1.91 ± 0.41 2.16 ± 0.35 AW046181
138
Table 6.4.  Differentially expressed genes after EGCG treatment (continued): Lipid
and cholesterol biosynthesis; grwoth and development; electron transport; metal
ion homeostasis. Gene expression is indicated as fold change ± Standard Error.
Only genes differentially expressed >2-fold and significantly expressed
according to one-way ANOVA, p<0.01 are included in the list.
EGCG (µM)Probe id Symbol Gene Title
1 25
Genbank
Lipid and cholesterol biosynthesis
94177_at Hsd17b7 hydroxysteroid (17-beta)
dehydrogenase 7
-1.47 ± 0.41 -2.43 ± 0.35 Y15733
95611_at Lpl lipoprotein lipase 1.62 ± 0.41 2.51 ± 0.35 AA726364
96909_at Ndufab1 NADH dehydrogenase (ubiquinone) 1,
alpha/beta subcomplex, 1
1.90 ± 0.41 2.21 ± 0.35 AI849803
98631_g_at Nsdhl NAD(P) dependent steroid
dehydrogenase-like
2.31 ± 0.41 1.59 ± 0.35 AW106745
98630_at Nsdhl NAD(P) dependent steroid
dehydrogenase-like
2.99 ± 0.41 1.85 ± 0.35 AW106745
94057_g_at Scd1 stearoyl-Coenzyme A desaturase 1 1.01 ± 0.41 -3.66 ± 0.35 M21285
103569_at Sh3glb1 SH3-domain GRB2-like B1
(endophilin)
2.70 ± 0.41 2.63 ± 0.35 AI842874
96534_at Vldlr very low density lipoprotein receptor 1.75 ± 0.42 2.58 ± 0.36 AA408956
Growth and development
101475_at Bmi1 B lymphoma Mo-MLV insertion region
1
3.35 ± 0.48 3.12 ± 0.35 M64068
160430_at Catnb catenin beta 1.86 ± 0.41 2.04 ± 0.35 M90364
100022_at Cish cytokine inducible SH2-containing
protein
2.51 ± 0.41 3.05 ± 0.35 D89613
104386_f_at Itgav integrin alpha V -1.63 ± 0.41 -2.05 ± 0.35 AI843901
93682_at Ldb2 LIM domain binding 2 2.78 ± 0.41 2.70 ± 0.35 U89489
103549_at Nes nestin -2.54 ± 0.41 -2.74 ± 0.35 AW061260
160668_at Ogfr opioid growth factor receptor 1.88 ± 0.41 2.10 ± 0.35 AI838195
95387_f_at Sema4b sema domain, immunoglobulin domain
(Ig), transmembrane domain (TM) and
short cytoplasmic domain, (semaphorin)
4B
7.13 ± 0.41 6.28 ± 0.40 AA266467
Electron transport
102124_f_at Cox4i1 cytochrome c oxidase subunit IV
isoform 1
2.04 ± 0.41 2.06 ± 0.35 AI836879
100550_f_at Cox6c cytochrome c oxidase, subunit VIc 2.65 ± 0.41 2.73 ± 0.35 AW060422
101580_at Cox7b cytochrome c oxidase subunit VIIb 3.83 ± 0.41 3.93 ± 0.35 AI851220
95072_at Cyc1 cytochrome c-1 2.58 ± 0.41 2.41 ± 0.35 AW121892
96112_at Etfa electron transferring flavoprotein, alpha
polypeptide
2.11 ± 0.41 1.77 ± 0.35 AI851178
160194_at Gcdh glutaryl-Coenzyme A dehydrogenase -2.28 ± 0.41 -2.28 ± 0.35 U18992
94208_at Txndc7 thioredoxin domain containing 7 3.07 ± 0.41 2.45 ± 0.35 AW045202
160115_at Txnl1 thioredoxin-like 1 2.40 ± 0.41 2.79 ± 0.35 AF052660
102000_f_at Uqcrc2 ubiquinol cytochrome c reductase core
protein 2
2.93 ± 0.41 3.31 ± 0.35 AI842835
Metal ion homeostasis
101561_at Mt2 metallothionein 2 -1.72 ± 0.41 -4.53 ± 0.35 K02236
95340_at Mt3 metallothionein 3 -2.71 ± 0.41 -5.56 ± 0.35 M93310
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Table 6.5.  Differentially expressed genes after EGCG treatment (continued):
Transmission of nerve impulse; transport. Gene expression is indicated as fold
change ± Standard Error.  Only genes differentially expressed >2-fold and
significantly expressed according to one-way ANOVA, p<0.01 are included in
the list.
EGCG (µM)Probe id Symbol Gene Title
1 25
Genbank
Transmission of nerve impulse
92946_f_at Gria2 glutamate receptor, ionotropic, AMPA2 (alpha
2)
2.00 ± 0.41 2.40 ± 0.35 L32372
92392_at Kcna3 potassium voltage-gated channel, shaker-
related subfamily, member 3
2.45 ± 0.42 2.40 ± 0.36 AI850484
98339_at Syt11 synaptotagmin 11 3.17 ± 0.41 3.29 ± 0.35 AB026808
160190_at Syt4 synaptotagmin 4 2.87 ± 0.41 3.63 ± 0.35 U10355
Transport
100032_at Aaas achalasia, adrenocortical insufficiency,
alacrimia
2.03 ± 0.41 2.17 ± 0.35 X60136
101016_at Arf1 ADP-ribosylation factor 1 2.34 ± 0.41 2.51 ± 0.35 D87898
102854_s_at Atp7a ATPase, Cu++ transporting, alpha polypeptide 2.09 ± 0.42 3.40 ± 0.36 U03434
94465_g_at Clcn3 chloride channel 3 2.10 ± 0.41 2.70 ± 0.35 AF029347
103642_at G3bp Ras-GTPase-activating protein SH3-domain
binding protein
-1.69 ± 0.41 -2.12 ± 0.35 AB001927
92749_at Gabrb1 gamma-aminobutyric acid (GABA-A) receptor,
subunit beta 1
2.42 ± 0.41 2.48 ± 0.35 U14418
161796_r_at Kcnq1 potassium voltage-gated channel, subfamily Q,
member 1
-2.72 ± 0.41 -2.94 ± 0.35 AV367240
101370_at Kpna1 karyopherin (importin) alpha 1 1.83 ± 0.41 2.02 ± 0.35 U20619
92952_f_at Napb N-ethylmaleimide sensitive fusion protein
attachment protein beta
3.26 ± 0.41 4.24 ± 0.35 X61455
102342_at Nsf N-ethylmaleimide sensitive fusion protein 2.14 ± 0.41 1.76 ± 0.35 U10120
101933_at Rab10 RAB10, member RAS oncogene family 2.31 ± 0.41 2.49 ± 0.35 AF035646
160868_at Rab3b RAB3B, member RAS oncogene family 2.30 ± 0.41 2.57 ± 0.35 AI835990
98927_at Rab6 RAB6, member RAS oncogene family 1.96 ± 0.41 2.53 ± 0.35 AI851048
104709_at Sec23a SEC23A (S. cerevisiae) 1.75 ± 0.41 2.00 ± 0.35 AI843665
93466_at Sec8l1 SEC8-like 1 (S. cerevisiae) 2.93 ± 0.41 3.36 ± 0.35 AF022962
92831_at Sfxn1 sideroflexin 1 2.22 ± 0.41 2.62 ± 0.35 AI846308
103918_at Slc15a2 solute carrier family 15 (H+/peptide
transporter), member 2
-1.01 ± 0.41 -8.64 ± 0.35 AI846682
93084_at Slc25a4 solute carrier family 25 (mitochondrial carrier,
adenine nucleotide translocator), member 4
2.32 ± 0.41 2.41 ± 0.35 U27315
104651_at Snx14 sorting nexin 14 2.06 ± 0.41 2.38 ± 0.35 AI839611
97477_at Timm8b translocase of inner mitochondrial membrane 8
homolog b (yeast)
2.02 ± 0.41 2.06 ± 0.35 AW124594
93215_at Tnfaip1 tumor necrosis factor, alpha-induced protein 1
(endothelial)
1.96 ± 0.41 2.04 ± 0.35 AF061346
101420_at Viaat vesicular inhibitory amino acid transporter -4.35 ± 0.41 -3.73 ± 0.35 AJ001598
97876_at Vps29 vacuolar protein sorting 29 (S. pombe) 2.34 ± 0.41 2.44 ± 0.35 AI842008
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Table 6.6.  Differentially expressed genes after EGCG treatment (continued):
Cytoskeleton; cell cycle; proteolysis; calcium homeostasis and binding. Gene
expression is indicated as fold change ± Standard Error.  Only genes
differentially expressed >2-fold and significantly expressed according to one-
way ANOVA, p<0.01 are included in the list.




95705_s_at Actb actin, beta, cytoplasmic -10.86± 0.41 -10.31 ± 0.35 J04181
96573_at Actg actin, gamma, cytoplasmic 2.65± 0.41 2.50 ± 0.35 M21495
93288_at Arpc2 actin related protein 2/3 complex,
subunit 2
2.30± 0.41 2.48 ± 0.35 AI835883
94863_r_at Dncl2a dynein, cytoplasmic, light chain 2A 2.47± 0.41 2.89 ± 0.35 AI850000
93674_at Fgd1 FYVE, RhoGEF and PH domain
containing 1
1.14± 0.41 2.29 ± 0.35 U22325
100398_at Kif3a kinesin family member 3A 2.14± 0.41 2.02 ± 0.35 D12645
94321_at Krt1-10 keratin complex 1, acidic, gene 10 1.92± 0.41 2.16 ± 0.35 V00830
102742_g_at Mapt microtubule-associated protein tau 3.15± 0.41 3.49 ± 0.35 M18775
97909_at Stmn1 stathmin 1 2.15± 0.41 2.26 ± 0.35 AI838080
96426_at Tmsb4x thymosin, beta 4, X chromosome 2.05± 0.41 2.13 ± 0.35 U38967
100342_i_at Tuba1 tubulin, alpha 1 2.87± 0.41 2.94 ± 0.35 M28729
98759_f_at Tuba2 tubulin, alpha 2 2.47± 0.41 2.39 ± 0.35 M28727
101543_f_at Tuba6 tubulin, alpha 6 2.87± 0.41 2.75 ± 0.35 M13441
94835_f_at Tubb2 tubulin, beta 2 2.23± 0.41 2.22 ± 0.35 M28739
94789_r_at Tubb5 tubulin, beta 5 2.11± 0.41 2.02 ± 0.35 X04663
Cell cycle
98478_at Ccng2 cyclin G2 1.61± 0.41 2.18 ± 0.35 U95826
96236_at Cdc16 CDC16 cell division cycle 16
homolog (S. cerevisiae)
2.27± 0.41 2.87 ± 0.35 AW122965
160901_at Fos FBJ osteosarcoma oncogene -1.18 ± 0.41 3.05 ± 0.46 V00727
100130_at Jun Jun oncogene 2.28± 0.41 5.48 ± 0.35 X12761
92502_at Plagl1 pleiomorphic adenoma gene-like 1 -2.20 ± 0.41 -2.87 ± 0.35 X95504
97506_at Rnf2 ring finger protein 2 2.38± 0.41 2.36 ± 0.35 AI043016
98905_at Sept7 septin 7 2.35± 0.41 2.39 ± 0.35 AJ223782
Proteolysis
101040_at Capn2 calpain 2 2.30± 0.41 2.70 ± 0.35 D38117
99642_i_at Cpe carboxypeptidase E 1.91± 0.41 2.08 ± 0.35 X61232
92256_at Ctsb cathepsin B 2.51± 0.43 2.15 ± 0.37 AI853714
101763_at Gpr50 G-protein-coupled receptor 50 -1.84 ± 0.41 -2.53 ± 0.35 AF065145
102296_at Pcsk2 proprotein convertase
subtilisin/kexin type 2
1.70± 0.41 2.31 ± 0.35 M55669
96730_at Tpp2 tripeptidyl peptidase II 2.34± 0.41 2.03 ± 0.36 X81323
Calcium homeostasis and binding
93293_at Calm2 calmodulin 2 2.07± 0.41 2.06 ± 0.35 M27844
102632_at Calmbp1 calmodulin binding protein 1 1.64± 0.43 -2.60 ± 0.36 AF062378
104529_at Caml calcium modulating ligand 1.88± 0.41 2.06 ± 0.35 U21960
102197_at Nucb2 nucleobindin 2 2.35± 0.41 2.09 ± 0.35 AJ222586
162428_i_at S100a14 S100 calcium binding protein A14 -2.87 ± 0.41 -2.95 ± 0.35 AV293396
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Table 6.7.  Differentially expressed genes after EGCG treatment (continued): Cell
signaling; cell adhesion; carbohydrate metabolism. Gene expression is indicated
as fold change ± Standard Error.  Only genes differentially expressed >2-fold
and significantly expressed according to one-way ANOVA, p<0.01 are included
in the list.




104135_at Arl3 ADP-ribosylation factor-like 3 1.94 ± 0.41 2.10 ± 0.35 AW045474
103611_at Cd47 CD47 antigen (Rh-related antigen,
integrin-associated signal transducer)
1.96 ± 0.41 2.66 ± 0.35 AB012693
98535_at Comt catechol-O-methyltransferase 2.16 ± 0.41 2.81 ± 0.35 AF076156
97740_at Dusp16 dual specificity phosphatase 16 1.13 ± 0.42 2.25 ± 0.36 AI642662
93667_at Fbxw7 F-box and WD-40 domain protein 7,
archipelago homolog (Drosophila)
2.16 ± 0.41 2.33 ± 0.35 AW120511
93271_s_at Gnas GNAS (guanine nucleotide binding
protein, alpha stimulating) complex
locus
2.15 ± 0.41 2.52 ± 0.35 AF107848
99175_at Gng10 guanine nucleotide binding protein (G
protein), gamma 10
2.12 ± 0.41 2.45 ± 0.35 AI843396
97004_at Olfr71 olfactory receptor 71 -1.71 ± 0.41 -2.24± 0.35 AJ133429
102759_at Pik3r2 phosphatidylinositol 3-kinase,
regulatory subunit, polypeptide 2 (p85
beta)
1.82 ± 0.41 2.13 ± 0.35 Y13569
93962_at Rap1a RAS-related protein-1a 2.49 ± 0.41 2.26 ± 0.35 AI848598
160747_at Rgs3 regulator of G-protein signaling 3 -1.71 ± 0.41 -2.14± 0.35 AI844739
162468_at Rhoc ras homolog gene family, member C -1.91 ± 0.41 -2.19± 0.35 AV064502
100213_f_at Rpl41 ribosomal protein L41 2.49 ± 0.41 2.61 ± 0.35 U93862
98564_f_at Rps26 ribosomal protein S26 2.38 ± 0.41 2.60 ± 0.35 U67770
97243_at Slc9a3r1 solute carrier family 9
(sodium/hydrogen exchanger),
isoform 3 regulator 1
-1.85 ± 0.41 -3.51± 0.35 U74079
95669_g_at Stmn2 stathmin-like 2 2.20 ± 0.41 2.23 ± 0.35 AI840972
160551_at Vdac3 voltage-dependent anion channel 3 1.92 ± 0.41 2.06 ± 0.35 U30839
Cell adhesion
104407_at Alcam activated leukocyte cell adhesion
molecule
2.11 ± 0.41 2.51 ± 0.35 L25274
95661_at Cd9 CD9 antigen 2.21 ± 0.41 1.34 ± 0.35 L08115
104743_at Cdh13 cadherin 13 2.49 ± 0.42 2.40 ± 0.35 AB022100
92936_at Cntn1 contactin 1 2.16 ± 0.41 2.67 ± 0.35 X14943
93606_s_at Igsf4a immunoglobulin superfamily, member
4A
2.24 ± 0.41 1.86 ± 0.35 AB021966
160610_at Pcdha4 protocadherin alpha 4 1.71 ± 0.41 2.08 ± 0.35 D86916
92558_at Vcam1 vascular cell adhesion molecule 1 1.32 ± 0.41 -2.29± 0.35 M84487
Carbohydrate metabolism
161889_f_at Aldo1 aldolase 1, A isoform -2.76 ± 0.41 -2.07± 0.35 AV102160
160546_at Aldo3 aldolase 3, C isoform 1.56 ± 0.41 -2.31± 0.35 AW121134
98984_f_at Gpd2 glycerol phosphate dehydrogenase 2,
mitochondrial
4.28 ± 0.41 5.49 ± 0.35 D50430
100573_f_at Gpi1 glucose phosphate isomerase 1 1.71 ± 0.41 2.02 ± 0.35 M14220
162262_f_at Gyg1 glycogenin 1 2.09 ± 0.41 2.15 ± 0.35 AV357306
104148_at H6pd hexose-6-phosphate dehydrogenase
(glucose 1-dehydrogenase)
-2.50 ± 0.41 -2.40± 0.35 AA939571
99335_at Hk1 hexokinase 1 2.10 ± 0.41 1.92 ± 0.35 J05277
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Table 6.8.  Differentially expressed genes after EGCG treatment (continued):
Nucleobase, nucleoside, nucleotide and nucleic acid metabolism; other
biological processes. Gene expression is indicated as fold change ± Standard
Error.  Only genes differentially expressed >2-fold and significantly expressed
according to one-way ANOVA, p<0.01 are included in the list.
EGCG (µM)Probe id Symbol Gene Title
1 25
Genbank
Nucleobase, nucleoside, nucleotide and nucleic acid metabolism
93833_s_at Hist1h2bc histone 1, H2bc 2.55 ± 0.41 2.89 ± 0.35 X05862
160107_at Hprt hypoxanthine guanine phosphoribosyl
transferase
1.86 ± 0.41 2.15 ± 0.35 K01515
102819_at Nap1l2 nucleosome assembly protein 1-like 2 1.72 ± 0.41 2.18 ± 0.35 X92352
93831_at Nono non-POU-domain-containing, octamer
binding protein
2.21 ± 0.41 2.21 ± 0.35 AI316087
97254_at Rbm8 RNA binding motif protein 8 2.25 ± 0.41 2.16 ± 0.35 AA690061
160192_at Rbmxrt RNA binding motif protein, X chromosome
retrogene
2.31 ± 0.41 2.38 ± 0.35 AF031568
103457_at Rev3l REV3-like, catalytic subunit of DNA
polymerase zeta RAD54 like (S. cerevisiae)
2.23 ± 0.41 2.67 ± 0.35 AF083464
92196_f_at Sf3a2 splicing factor 3a, subunit 2 -3.00± 0.41 -2.95 ± 0.35 X83733
97808_at Sf3b1 splicing factor 3b, subunit 1 2.17 ± 0.41 2.59 ± 0.35 AI844532
102062_at Smarcc1 SWI/SNF related, matrix associated, actin
dependent regulator of chromatin, subfamily
c, member 1
2.07 ± 0.41 2.83 ± 0.35 U85614
95049_at Snrpd2 small nuclear ribonucleoprotein D2 3.25 ± 0.41 3.39 ± 0.35 AI837853
97486_at U2af1 U2 small nuclear ribonucleoprotein
auxiliary factor (U2AF) 1
-1.74± 0.41 -2.11 ± 0.35 AA693246
Other biological processes
95745_g_at Atp6v1a1 ATPase, H+ transporting, V1 subunit A,
isoform 1
2.12 ± 0.41 2.79 ± 0.35 U13837
98066_r_at Brd2 bromodomain containing 2 2.20 ± 0.41 2.20 ± 0.35 AL009226
92642_at Car2 carbonic anhydrase 2 2.09 ± 0.42 -1.49 ± 0.35 M25944
103088_at Chl1 cell adhesion molecule with homology to
L1CAM
4.04 ± 0.41 5.22 ± 0.35 X94310
93582_at Coq7 demethyl-Q 7 1.83 ± 0.41 2.11 ± 0.35 AF080580
96298_f_at Dnclc1 dynein, cytoplasmic, light chain 1 2.29 ± 0.41 2.14 ± 0.35 AF020185
161682_f_atGpaa1 GPI anchor attachment protein 1 -2.82± 0.41 -3.04 ± 0.35 AV161234
161492_I_atMgat1 mannoside acetylglucosaminyltransferase 1 -3.37± 0.41 -2.32 ± 0.35 AV089873
96082_at Mrpl30 mitochondrial ribosomal protein L30 2.83 ± 0.41 2.67 ± 0.35 AI850644
162168_r_atPhgdh 3-phosphoglycerate dehydrogenase -2.33± 0.43 1.79 ± 0.37 AV361953
101061_at Ssr2 signal sequence receptor, beta 1.99 ± 0.41 2.04 ± 0.35 AI845293
162104_f_atTapbp TAP binding protein -2.88± 0.41 -2.10 ± 0.35 AV361189
93333_at Tbca tubulin cofactor a 1.83 ± 0.41 2.04 ± 0.35 U05333
160533_r_atTnp1 transition protein 1 2.51 ± 0.41 2.34 ± 0.35 X12521
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Table 6.9.  Differentially expressed genes after EGCG treatment (continued):
Unknown biological processes. Gene expression is indicated as fold change ±
Standard Error.  Only genes differentially expressed >2-fold and significantly
expressed according to one-way ANOVA, p<0.01 are included in the list.




102094_f_at --- --- -1.77 ± 0.41 -2.76 ± 0.35 AI841270
101685_f_at --- --- -1.84 ± 0.41 -2.56 ± 0.35 AI463421
92778_i_at --- --- -1.97 ± 0.41 -2.12 ± 0.35 Z22552
162311_f_at --- --- -2.13 ± 0.41 -2.03 ± 0.35 AV050648
161615_f_at --- --- -2.36 ± 0.41 -1.87 ± 0.35 AV352346
103710_at --- Transcribed sequence with weak
similarity to protein
ref:NP_115973.1 (H.sapiens) zinc
finger protein 347; zinc finger 1111
[Homo sapiens]
1.73 ± 0.41 2.14 ± 0.35 AI037032
96526_at --- 9 days embryo whole body cDNA,
RIKEN full-length enriched library,
clone:D030029J20 product:unknown
EST, full insert sequence
1.43 ± 0.41 2.16 ± 0.35 AW228840
95685_at --- Adult male testis cDNA, RIKEN
full-length enriched library,
clone:1700092M07
product:unknown EST, full insert
sequence
2.48 ± 0.41 2.28 ± 0.35 AI849678
101179_at --- --- 2.97 ± 0.41 2.35 ± 0.35 D50494
161083_at --- Transcribed sequence with strong
similarity to protein
ref:NP_057365.1 (H.sapiens)
STE20-like kinase; STE2-like kinase
[Homo sapiens]
1.94 ± 0.41 2.43 ± 0.35 AW121616
160740_at --- Hypothetical LOC228715
(LOC228715), mRNA
1.92 ± 0.42 2.55 ± 0.36 AA615984
98129_at --- M.musculus mRNA for testis-
specific thymosin beta-10
2.45 ± 0.41 2.62 ± 0.35 AI852553
100379_f_at --- --- 1.97 ± 0.41 3.16 ± 0.35 AI837905
96316_at --- Transcribed sequences 2.52 ± 0.43 3.43 ± 0.37 AI839289
95714_at 0610009D07Rik RIKEN cDNA 0610009D07 gene 2.21 ± 0.41 2.43 ± 0.35 AI226264
99143_at 0610039N19Rik RIKEN cDNA 0610039N19 gene 1.72 ± 0.41 2.08 ± 0.35 AA614914
95458_s_at 1110001C20Rik RIKEN cDNA 1110001C20 gene 1.66 ± 0.41 2.38 ± 0.35 AW121960
93805_at 1110003H09Rik RIKEN cDNA 1110003H09 gene 2.08 ± 0.41 1.93 ± 0.35 AW121164
98037_at 1110003H18Rik RIKEN cDNA 1110003H18 gene 1.94 ± 0.41 2.12 ± 0.35 AW122782
95732_at 1110005L13Rik RIKEN cDNA 1110005L13 gene 3.12 ± 0.41 3.35 ± 0.35 AW047746
104314_r_at 1110032A03Rik RIKEN cDNA 1110032A03 gene 3.56 ± 0.41 3.96 ± 0.70 AI851206
104077_at 1110049G11Rik RIKEN cDNA 1110049G11 gene 1.82 ± 0.41 2.11 ± 0.35 AW121992
104076_at 1190017O12Rik RIKEN cDNA 1190017O12 gene 2.12 ± 0.41 2.39 ± 0.35 AW122061
160184_at 1200007D18Rik RIKEN cDNA 1200007D18 gene -2.20 ± 0.41 -2.22 ± 0.35 AA815795
95568_at 1500011J06Rik RIKEN cDNA 1500011J06 gene 2.18 ± 0.41 2.41 ± 0.36 AI853412
96068_at 1500034J20Rik RIKEN cDNA 1500034J20 gene 3.69 ± 0.41 4.28 ± 0.54 AI848821
95561_at 1700013H19Rik RIKEN cDNA 1700013H19 gene 3.12 ± 0.42 3.65 ± 0.44 AW120867
97237_at 1810003N24Rik RIKEN cDNA 1810003N24 gene 2.10 ± 0.41 2.09 ± 0.35 AI837771
96686_i_at 2010100O12Rik RIKEN cDNA 2010100O12 gene 2.65 ± 0.41 2.55 ± 0.35 AI853864
95105_at 2010110M21Rik RIKEN cDNA 2010110M21 gene 1.96 ± 0.41 2.27 ± 0.35 AI847697
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104620_at 2010300G19Rik RIKEN cDNA 2010300G19 gene 2.05 ± 0.41 2.33 ± 0.35 AW123402
99187_f_at 2010315L10Rik RIKEN cDNA 2010315L10 gene 2.33 ± 0.41 2.78 ± 0.35 AI835662
103076_at 2210412K09Rik RIKEN cDNA 2210412K09 gene 1.81 ± 0.41 2.08 ± 0.35 AW046093
92703_at 2310032M22Rik RIKEN cDNA 2310032M22 gene 2.23 ± 0.41 2.81 ± 0.35 AI325791
160475_at 2310034L04Rik RIKEN cDNA 2310034L04 gene 1.87 ± 0.41 2.43 ± 0.35 AI839116
101404_at 2310061I09Rik RIKEN cDNA 2310061I09 gene 2.12 ± 0.41 2.85 ± 0.35 AI853654
95103_at 2310065K24Rik RIKEN cDNA 2310065K24 gene 2.10 ± 0.41 2.33 ± 0.35 AI839824
98039_at 2410015M20Rik RIKEN cDNA 2410015M20 gene 3.37 ± 0.41 3.04 ± 0.35 AI853819
96780_at 2410022L05Rik RIKEN cDNA 2410022L05 gene 2.23 ± 0.41 2.19 ± 0.35 AW208818
97864_at 2510049I19Rik RIKEN cDNA 2510049I19 gene 2.32 ± 0.42 2.71 ± 0.35 AW258842
95058_f_at 2610205H19Rik RIKEN cDNA 2610205H19 gene 2.78 ± 0.41 2.79 ± 0.35 AW121984
96688_at 2610318G18Rik RIKEN cDNA 2610318G18 gene 2.04 ± 0.41 2.22 ± 0.35 AI845463
93768_f_at 2700059D21Rik RIKEN cDNA 2700059D21 gene 2.33 ± 0.41 2.40 ± 0.35 AW124052
103071_at 2810429C13Rik RIKEN cDNA 2810429C13 gene 1.77 ± 0.41 2.29 ± 0.35 AI843655
99185_at 2810443J12Rik RIKEN cDNA 2810443J12 gene 3.35 ± 0.41 3.03 ± 0.35 AW047026
103664_r_at 2810452K22Rik RIKEN cDNA 2810452K22 gene 1.93 ± 0.41 2.08 ± 0.35 AA959648
95135_at 3110038L01Rik RIKEN cDNA 3110038L01 gene -1.17 ± 0.41 -2.18 ± 0.35 AI844396
92840_at 3110079L04Rik RIKEN cDNA 3110079L04 gene 2.26 ± 0.42 3.58 ± 0.36 AA683712
160183_f_at 3930401E15Rik RIKEN cDNA 3930401E15 gene 2.50 ± 0.41 2.60 ± 0.35 AI846109
97437_f_at 4631416I11Rik RIKEN cDNA 4631416I11 gene 2.83 ± 0.42 2.50 ± 0.36 AW122483
161756_at 4833420N02Rik RIKEN cDNA 4833420N02 gene 2.04 ± 0.42 2.90 ± 0.36 AV298145
161015_at 4933402J24Rik RIKEN cDNA 4933402J24 gene 2.00 ± 0.41 2.43 ± 0.36 AI845273
100587_f_at 5730403B10Rik RIKEN cDNA 5730403B10 gene 2.50 ± 0.41 2.18 ± 0.35 AI843959
103978_at 5730454B08Rik RIKEN cDNA 5730454B08 gene 1.44 ± 0.41 2.01 ± 0.35 AA666669
97916_at 5730494N06Rik RIKEN cDNA 5730494N06 gene 1.92 ± 0.41 2.26 ± 0.35 AI116222
92992_i_at 5730497N03Rik RIKEN cDNA 5730497N03 gene 3.60 ± 0.76 4.29 ± 0.38 AI324972
104059_at 5830451P18Rik RIKEN cDNA 5830451P18 gene 2.05 ± 0.41 2.50 ± 0.35 AI851751
102870_at 5930418K15Rik RIKEN cDNA 5930418K15 gene 2.38 ± 0.41 2.90 ± 0.35 AW125272
101929_at 6720463E02Rik RIKEN cDNA 6720463E02 gene -2.03 ± 0.41 -2.11 ± 0.35 AI836322
94895_at 9430020E02Rik RIKEN cDNA 9430020E02 gene 2.65 ± 0.41 2.60 ± 0.35 AW122948
161104_at 9430099J10Rik RIKEN cDNA 9430099J10 gene 3.78 ± 0.41 2.32 ± 0.35 AI846811
93427_at 9930104H07Rik RIKEN cDNA 9930104H07 gene 2.08 ± 0.43 1.67 ± 0.38 AW122310
94663_at AA407151 expressed sequence AA407151 -2.11 ± 0.41 -2.38 ± 0.35 AA407151
97918_at AA536743 expressed sequence AA536743 1.55 ± 0.41 2.01 ± 0.36 AA623587
93472_at AI413331 expressed sequence AI413331 -2.02 ± 0.41 -1.66 ± 0.35 AA796989
95503_at AI839562 expressed sequence AI839562 2.04 ± 0.41 2.22 ± 0.35 U95498
93627_at Ankrd28 ankyrin repeat domain 28 1.62 ± 0.41 2.21 ± 0.35 AI852287
96529_at Ap1gbp1 AP1 gamma subunit binding protein
1
1.90 ± 0.41 2.34 ± 0.35 AW122059
93794_at Appbp1 amyloid beta precursor protein
binding protein 1
3.24 ± 0.41 3.31 ± 0.35 AI846393
97554_at BC005624 cDNA sequence BC005624 1.95 ± 0.41 2.03 ± 0.35 AI838889
94823_at BC029892 cDNA sequence BC029892 2.10 ± 0.41 2.24 ± 0.35 AI835315
95061_at Bcas2 breast carcinoma amplified sequence
2
1.96 ± 0.41 2.11 ± 0.35 AI838996
100963_at Brp17 brain protein 17 2.91 ± 0.41 2.50 ± 0.36 AI854243
103695_f_at C330007P06Rik RIKEN cDNA C330007P06 gene 2.11 ± 0.41 2.21 ± 0.35 AW047329
160623_at Cdkl2 cyclin-dependent kinase-like 2
(CDC2-related kinase)
2.39 ± 0.41 2.68 ± 0.35 AI847045
92841_f_at Chgb chromogranin B 1.96 ± 0.41 2.88 ± 0.35 X51429
94030_at Commd2 COMM domain containing 2 2.54 ± 0.41 2.33 ± 0.35 AI853431
96881_at Commd6 COMM domain containing 6 2.08 ± 0.41 2.45 ± 0.35 AW049394
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101976_at Cops4 COP9 (constitutive
photomorphogenic) homolog,
subunit 4 (Arabidopsis thaliana)
1.97 ± 0.41 2.21 ± 0.35 AF071314
160522_at D0H4S114 DNA segment, human D4S114 1.85 ± 0.41 2.21 ± 0.35 D45203
94526_at D10Ertd214e DNA segment, Chr 10, ERATO Doi
214, expressed
2.23 ± 0.41 2.49 ± 0.35 AI848453
101960_at D10Wsu52e DNA segment, Chr 10, Wayne State
University 52, expressed
1.90 ± 0.41 2.17 ± 0.35 AI842208
103314_at D13Ertd275e DNA segment, Chr 13, ERATO Doi
275, expressed
1.81 ± 0.41 2.17 ± 0.35 AW046158
104714_at D14Wsu89e DNA segment, Chr 14, Wayne State
University 89, expressed
2.08 ± 0.41 2.14 ± 0.35 AW125299
95431_at D16Wsu109e DNA segment, Chr 16, Wayne State
University 109, expressed
2.53 ± 0.41 2.51 ± 0.35 AA623426
95432_f_at D16Wsu109e DNA segment, Chr 16, Wayne State
University 109, expressed
3.24 ± 0.41 3.39 ± 0.35 AI844034
93841_at D3Ertd194e DNA segment, Chr 3, ERATO Doi
194, expressed
2.35 ± 0.41 2.59 ± 0.35 AW060249
99779_at D6Bwg1452e DNA segment, Chr 6, Brigham &
Women's Genetics 1452 expressed
1.95 ± 0.41 2.12 ± 0.36 N28141
104418_at D6Ertd365e DNA segment, Chr 6, ERATO Doi
365, expressed
2.27 ± 0.41 2.08 ± 0.35 AA796868
93821_at D8Ertd594e DNA segment, Chr 8, ERATO Doi
594, expressed
2.61 ± 0.41 2.46 ± 0.36 AW046101
93534_at Dcn decorin 2.84 ± 0.41 3.15 ± 0.35 X53929
96636_at Dctn5 dynactin 5 2.08 ± 0.41 1.90 ± 0.35 AI852649
160327_at Dctn6 dynactin 6 2.10 ± 0.41 1.76 ± 0.35 AI848936
99096_at Ddx24 DEAD (Asp-Glu-Ala-Asp) box
polypeptide 24
1.82 ± 0.41 1.99 ± 0.35 U46690
101542_f_at Ddx3x DEAD/H (Asp-Glu-Ala-Asp/His)
box polypeptide 3, X-linked
2.14 ± 0.41 2.27 ± 0.35 L25126
95688_at Degs degenerative spermatocyte homolog
(Drosophila)
2.24 ± 0.41 2.25 ± 0.35 Y08460
103356_at Dock7 dedicator of cytokinesis 7 1.70 ± 0.42 2.36 ± 0.36 AI843267
94492_at Dstn destrin 2.16 ± 0.41 2.31 ± 0.35 AB025406
161176_r_at Epb7.2 erythrocyte protein band 7.2 -2.08 ± 0.41 -2.36 ± 0.35 AV230593
93309_at Fin14 fibroblast growth factor inducible 14 2.11 ± 0.41 1.85 ± 0.35 U42386
95756_at Ftsj3 FtsJ homolog 3 (E. coli) 2.16 ± 0.41 2.09 ± 0.36 AI839681
98048_at Fusip1 FUS interacting protein (serine-
arginine rich) 1
-2.01 ± 0.41 -2.23 ± 0.35 AF060490
96943_at Gps1 G protein pathway suppressor 1 2.48 ± 0.41 2.32 ± 0.35 AW125234
99944_at Hpca hippocalcin 1.98 ± 0.41 2.27 ± 0.35 AB015200
92371_at Hrc histidine rich calcium binding
protein
-1.48 ± 0.41 -2.68 ± 0.36 AI505355
102152_f_at Igh-VS107 immunoglobulin heavy chain (S107
family)
-4.67 ± 0.41 -2.43 ± 0.35 M16724
93511_at Itm2a integral membrane protein 2A 1.51 ± 0.41 2.12 ± 0.36 L38971
101123_at Itm2b integral membrane protein 2B 2.00 ± 0.41 2.03 ± 0.35 U76253
160517_at Lmnb1 lamin B1 -2.76 ± 0.41 -3.32 ± 0.35 M35153
93339_at Mdm4 transformed mouse 3T3 cell double
minute 4
-2.02 ± 0.41 -1.88 ± 0.35 AI846243
95417_at Mgat2 mannoside
acetylglucosaminyltransferase 2
2.32 ± 0.41 2.14 ± 0.35 AI117848
93787_f_at Mrpl18 mitochondrial ribosomal protein L18 2.25 ± 0.41 2.07 ± 0.35 AI837302
92826_at Mrps33 mitochondrial ribosomal protein S33 1.86 ± 0.41 2.02 ± 0.35 Y17852
160308_at Msn moesin -2.20 ± 0.41 -2.41 ± 0.35 AI839417
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104147_at Nans N-acetylneuraminic acid synthase
(sialic acid synthase)
1.77 ± 0.41 2.09 ± 0.35 AW122052
101484_at Nbr1 neighbor of Brca1 gene 1 1.44 ± 0.41 2.53 ± 0.35 U73039
93025_at Ndfip1 Nedd4 family interacting protein 1 2.19 ± 0.41 2.46 ± 0.35 AI835257
101634_at Npm1 nucleophosmin 1 2.08 ± 0.41 2.14 ± 0.35 M33212
101366_f_at Nvl nuclear VCP-like 3.65 ± 0.43 3.09 ± 0.42 AA250299
92848_at Oat ornithine aminotransferase 2.05 ± 0.41 1.71 ± 0.35 X64837
93600_at Obrgrp leptin receptor gene-related protein 2.40 ± 0.41 2.48 ± 0.35 AJ011565
94461_at Pbef1 pre-B-cell colony-enhancing factor 1 1.98 ± 0.41 2.35 ± 0.35 AI852144
160899_at Pcp4 Purkinje cell protein 4 1.76 ± 0.41 2.11 ± 0.35 X17320
101451_at Peg3 paternally expressed 3 1.84 ± 0.43 2.77 ± 0.35 AF038939
99926_at Pigr polymeric immunoglobulin receptor -2.30 ± 0.41 -2.68 ± 0.35 AB001489
96145_at Pigt phosphatidylinositol glycan, class T -1.72 ± 0.41 -2.05 ± 0.35 AW211407
94445_at Pls3 plastin 3 (T-isoform) 1.56 ± 0.41 2.25 ± 0.35 AW125273
95059_at Pnrc2 proline-rich nuclear receptor
coactivator 2
2.08 ± 0.41 1.99 ± 0.35 AW047399
102724_at Rabep1 rabaptin, RAB GTPase binding
effector protein 1
4.14 ± 0.53 4.07 ± 0.39 AI608324
98511_at Raly hnRNP-associated with lethal yellow 1.94 ± 0.41 2.04 ± 0.35 L17076
98602_at Rangap1 RAN GTPase activating protein 1 2.12 ± 0.41 2.09 ± 0.35 U08110
93020_at Rex3 reduced expression 3 2.30 ± 0.41 2.50 ± 0.35 AF051347
98119_at Rpl30 ribosomal protein L30 1.90 ± 0.41 2.02 ± 0.35 K02928
92981_at Scg2 secretogranin II 1.45 ± 0.41 2.20 ± 0.35 X68837
160360_at Sep15 selenoprotein 2.10 ± 0.41 1.92 ± 0.35 AI838205
93806_at Sh3bgrl SH3-binding domain glutamic acid-
rich protein like
2.21 ± 0.41 2.41 ± 0.35 AI848671
103813_at Sh3yl1 Sh3 domain YSC-like 1 2.00 ± 0.41 2.79 ± 0.36 D85926
104216_at Shoc2 soc-2 (suppressor of clear) homolog
(C. elegans)
2.36 ± 0.41 1.72 ± 0.35 AF068921
93273_at Snca synuclein, alpha 2.24 ± 0.41 2.72 ± 0.35 AF044672
94313_at Snrp1c U1 small nuclear ribonucleoprotein
1C
2.21 ± 0.41 2.13 ± 0.35 X96767
160319_at Sparcl1 SPARC-like 1 (mast9, hevin) 2.02 ± 0.41 1.60 ± 0.35 U66166
95430_f_at Spg21 spastic paraplegia 21 homolog
(human)
1.90 ± 0.41 2.00 ± 0.35 AI854154
101995_at Sqstm1 sequestosome 1 2.21 ± 0.41 2.72 ± 0.35 U40930
96724_r_at Ssx2ip synovial sarcoma, X breakpoint 2
interacting protein
2.40 ± 0.41 3.13 ± 0.35 AW122911
93365_s_at Sugt1 SGT1, suppressor of G2 allele of
SKP1 (S. cerevisiae)
2.50 ± 0.41 2.91 ± 0.35 AI838149
104283_at Tbc1d15 TBC1 domain family, member 15 1.99 ± 0.41 2.20 ± 0.35 AI037493
95101_at Tde2 tumor differentially expressed 2 2.00 ± 0.41 2.47 ± 0.35 AI834772
95120_at Tm4sf13 transmembrane 4 superfamily
member 13
1.95 ± 0.41 2.68 ± 0.35 AI837621
98555_at Ttc3 tetratricopeptide repeat domain 3 1.68 ± 0.41 2.00 ± 0.35 AB008516
97900_at Txndc9 thioredoxin domain containing 9 2.19 ± 0.41 2.25 ± 0.35 AI845714
97285_f_at Ubxd1 UBX domain containing 1 2.46 ± 0.41 2.88 ± 0.35 AW120609
160079_i_at Wac WW domain containing adaptor with
coiled-coil
2.07 ± 0.41 2.09 ± 0.35 AI845773
100523_r_at Wbp5 WW domain binding protein 5 2.36 ± 0.41 2.76 ± 0.35 U92454
160130_at Wdr26 WD repeat domain 26 2.22 ± 0.41 2.43 ± 0.35 AA795284
101883_s_at Xlr3a X-linked lymphocyte-regulated 3a 2.17 ± 0.41 2.10 ± 0.36 L22977
94780_at Zfp288 zinc finger protein 288 1.74 ± 0.41 2.21 ± 0.35 AI987985
147
104437_at Zfp30 zinc finger protein 30 1.90 ± 0.42 2.32 ± 0.35 Z30174
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Figure 6.3. Effects of EGCG on the protein expression of CHOP, Atf3 and the
cleavage of p35.  Western blot analysis shows EGCG treatment induced the
concentration-dependent increase of Atf3 but not CHOP expression.  p35 was
not cleaved to p25 during EGCG treatment.  β-tubulin was the internal control
for equal loading of proteins.
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6.3 Discussion
6.3.1 ER stress is not involved in EGCG-induced neuronal apoptosis
The exposure of cultured cortical neurons to high concentrations of EGCG could
induce neuronal apoptosis (Mandel et al, 2004).  In this study, it was found that
EGCG at a concentration of 25 µM could effectively inhibit chymotrypsin-like
proteasomal activity and activate the apoptotic-signaling pathway through the
activation of caspase-3 (Fig. 6.1).  In contrast to lactacystin-induced cell death, no up-
regulation of ER stress-associated genes such as the Ddit3/CHOP and Atf4 was
detected from the microarray data (Table 6.1).  Furthermore, Western blot analysis
demonstrated that the pro-apoptotic transcription factor Ddit3/CHOP protein was not
expressed in cultured cortical neurons treated with a lethal dosage of EGCG,
indicating the absence of ER stress in EGCG-induced neuronal cell death.  Calpain
activation has been associated with ER stress-mediated cell death (Rutkowski and
Kaufman, 2004).  The absence of p35 cleavage in the Western blot analysis of
proteins extracted from cultured cortical neurons exposed to EGCG also suggests
absence of calpain activation in the cell death system. Taken together, the results
suggest the absence of ER stress during EGCG-induced neuronal apoptosis.
6.3.2 EGCG treatment and the up-regulation of genes encoding ubiquitin-
proteasome system components
At both lethal and non-lethal concentrations, EGCG was able to induce the up-
regulation of genes encoding UPS components such as proteasome subunits, ubiquitin
and ubiquitin protein ligases (Table 6.1).  Higher expression levels of these genes
corresponded to higher concentrations of EGCG.  This observation is supported by
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the fact that higher concentrations of EGCG could inhibit chymotrypsin-like
proteasomal activity (Fig. 6.2).  Nevertheless, a non-lethal concentration of EGCG (1
µM) was also effective in up-regulating some of the genes encoding proteasome
subunits such as proteasome subunit alpha type 3 (Psma3) and proteasome 26S
subunit, non-ATPase, 11 (Psmd11), and also genes encoding ubiquitin b (Ubb),
ubiquitin c (Ubc), ubiquitin-conjugating enzyme E2D2 (Ube2d2) and Ubiquitin
protein ligase E3A (Ube3a) (Table 6.1).  These results suggest that EGCG at a low
concentration (1 µM) has the potential to protect neurons against the insult of
accumulated unfolded proteins, since the up-regulation of UPS components has been
reported to be neuroprotective by other studies (Meiners et al, 2003; Goldbaum and
Richter-Landsberg, 2004)
6.3.3 The effect of EGCG on the induction of genes encoding heat shock proteins
Unlike the case in lactacystin treatment (Chapter 4), not many genes encoding HSPs
were up-regulated by EGCG treatment (Table 6.1).  Atf3 and c-Jun have been
reported to play a major role in the transcriptional regulation of Hsp27 (Nakagomi et
al, 2003).  Although both Atf3 and c-Jun genes were up-regulated by EGCG (25 µM)
treatment, the low expression levels of the Atf3 gene and protein (Table 6.1 and Fig.
6.3) might have contributed to the absence of Hsp27 up-regulation in EGCG-treated
cultured neurons.
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6.3.4 The effect of EGCG on the regulation of lipid and cholesterol biosynthesis
genes
EGCG has been reported to regulate lipid metabolism by controlling SREBP-
regulated gene expression through the inhibition of proteasomes (Shay and Banz,
2005).  Kuhn et al reported that the exposure of the HepG2 cell line to EGCG caused
an increase in the low-density lipoprotein receptor (LDLR) protein expression (Kuhn
et al, 2003).  This effect of EGCG is believed to be responsible for the plasma
cholesterol-lowering and heart disease-preventative effect of green tea (Kuhn et al,
2003).  In this study, EGCG treatment was observed to up-regulate the expression of
the very low density lipoprotein receptor gene (Vldlr) (Table 6.4).  Vldlr is a member
of the LDLR family (Goudriaan et al, 2001).  The role of Vldlr in lipoprotein
metabolism has been suggested by in vitro experiments showing Vldlr binding and
internalizing particles that are rich in apolipoprotein E, such as very low density
lipoprotein (Goudriaan et al, 2001).
Unlike with lactacystin treatment, genes involved in the synthesis of cholesterol were
not down-regulated during EGCG-induced neuronal apoptosis (Table 6.4).  One
possible reason for this is that cultured neurons exposed to EGCG did not undergo ER
stress (Fig. 6.3).  A recent study demonstrated that ER stress in cells can lead to the
suppression of SREBP(N)-mediated transcription of cholesterol biosynthesis genes
(Zeng et al, 2004).  Therefore, the absence of ER stress during EGCG-induced
neuronal apoptosis might be the reason why no down-regulation of cholesterol
biosynthesis genes was observed in the microarray analysis (Table 6.4).
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The microarray data also shows that the gene encoding stearoyl-CoA desaturase-1
(Scd1) was down-regulated in neurons treated with EGCG.  Scd1 is the rate-limiting
enzyme in the synthesis of monosaturated fatty acids (Klaus et al, 2005).  Scd1 has
been reported to be down-regulated in liver cells exposed to EGCG (Klaus et al,
2005), but its role is not fully understood.  A recent study proposed that Scd1 might
play a major role in the process of cell regeneration (Breuer et al, 2004).  Thus, the




Proteasomal inhibition or dysfunction is likely to contribute to neuronal cell death and
neurodegeneration.  The study of the effects of lactacystin on cultured cortical
neurons shows that proteasome inhibition can lead to neuronal apoptosis.  The tumor
suppressor PTEN is one possible player in neuronal apoptosis.  The translocation of
PTEN to the plasma membrane during neuronal cell death is of significant interest
because PTEN can specifically dephosphorylate the phospholipid second messenger
PtdIns(3,4,5)P3 and act as an antagonist to the PI3-kinase/Akt survival signaling
pathway.  In this study, PTEN was found to be cleaved at the C-terminal end, forming
a shorter or truncated 50 kDa form during lactacystin-induced neuronal apoptosis.
The protease caspase-3 was found to be responsible for the cleavage of PTEN during
neuronal apoptosis.  Whether the cleavage of PTEN facilitates its translocation and
activation is still not clear.  Since the mutant PTEN without the C-terminal tail is
found to have a higher phosphatase activity compared to the wild-type PTEN
(personal correspondence with Heung-Chin Cheng), it is tempting to speculate that
PTEN can be activated by caspase-3 cleavage during cell death.
The study of the neural membrane lipid profile initially attempted to measure the
changes of PtdIns(4,5)P2 during lactacystin-induced neuronal apoptosis, in order to
complement the study of the role of PTEN in neuronal apoptosis.  However, the level
of PtdIns(4,5)P2 in the cultured neurons was too minute to be detected using ESI-MS.
Instead, the study of the neural lipid profile revealed the accumulation of ceramides
and NAPE in the cultured cortical neurons during lactacystin-induced neuronal
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apoptosis.  The accumulation of ceramides in neural membranes is known to be
involved in the activation of caspase-3 during apoptosis.  However, the accumulation
of NAPE in neural membranes during neuronal apoptosis has not been reported, since
NAPE accumulation has been associated with excitotoxic or necrotic, rather than
apoptotic cell death in both in vitro and in vivo systems (Hansen et al, 2001).
Incidentally, NAPE is a precursor of anandamide, an endogenous cannabinoid
receptor ligand.  The accumulation of NAPE during neuronal injury may suggest a
neuroprotective role of NAPE.
The use of microarray GeneChip® in this study has been beneficial in the
understanding of the mechanisms of lactacystin-induced apoptosis.  Microarray
analysis of the differentially expressed genes at different time points reveals the
sequence of events that leads to apoptosis. Genes that encode proteasome subunits,
ubiquitin, HSPs and molecular chaperones were up-regulated at early time points, as a
response to the abnormal accumulation of proteins during proteasome inhibition.
Incidentally, cultured cortical neurons exposed to a lethal dose of lactacystin (1 µM)
could also up-regulate the genes associated with ER stress, such asAtf4 and
Ddit3/CHOP.  The early detection of the pro-apoptotic transcription factor CHOP in
cultured neurons exposed to lactacystin suggests that ER stress was likely to be the
main cause of lactacystin-induced neuronal apoptosis.  ER stress is known to initiate
other secondary pro-apoptotic responses such as the disruption of calcium
homeostasis and oxidative stress in neurons.  ER stress can also cause the down-
regulation of genes associated with cholesterol biosynthesis, probably through a direct
binding of the ER stress-activated Atf6 to SREBP, which interferes with the
activation of cholesterol biosynthesis genes.  The down-regulation of cholesterol
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Figure 7.1.  The mechanism of lactacystin-induced neuronal apoptosis. The inhibition
of proteasomes by lactacystin induces the abnormal accumulation of proteins in
neurons.  To deal with this stress, the neurons activate the early neuroprotective
responses through the up-regulation of UPS and HSPs. Exposure to lactacystin
can also trigger ER stress responses, which lead to the activation of other pro-
apoptotic responses such as 1) oxidative stress, 2) up-regulation of ER stress-
associated pro-apoptotic transcription factor CHOP, 3) calcium disruption, 4)
decrease in cholesterol biosynthesis and 5) activation of the inflammatory
responses at the late phase of lactacystin treatment.
156
synthesis might play a role in energy conservation during apoptosis, since cholesterol
biosynthesis requires a large amount of energy.  Furthermore, we would expect
cholesterol biosynthesis to be disrupted during ER stress, since the ER is the site of
cholesterol biosynthesis.  Fig. 7.1 summarizes the possible mechanism of lactacystin-
induced neuronal apoptosis based on the microarray study.
Lastly, the effect of EGCG from green tea extract on cultured cortical neurons was
studied as a comparison to the effect of lactacystin.  EGCG is known for its
neuroprotective properties, and recent studies suggest that some of the biological
effect of EGCG is due to its proteasome inhibitory property.  A lethal dosage of
EGCG (25 µM) could activate caspase-3 and induce neuronal apoptosis.  Unlike
lactacystin, however, the lethal dosage of EGCG did not up-regulate the ER stress-
associated pro-apoptotic transcription factor CHOP (based on the microarray and
Western blot data).  At a non-lethal concentration (1 µM), EGCG could induce the
up-regulation of genes encoding UPS components, but was not so effective in the
induction of HSP gene expression.  Since EGCG can induce the up-regulation of
genes encoding proteasome subunits and ubiquitin, it might be effective in protecting
neurons against the accumulation of abnormal proteins under pathological conditions.
Future work should study the effectiveness of EGCG in protecting neurons against the
abnormal accumulation of proteins.
The microarray studies of lactacystin-induced neuronal apoptosis have revealed both
potentially neuroprotective, as well as pro-apoptotic genes in the cultured cortical
neurons during proteasomal inhibition.  Since the dysfunction or decrease in UPS
activity might play a role in the pathogenesis of neurodegenerative diseases, it is
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therefore important to study the transcriptional regulation of genes associated with the
UPS and HSPs as a therapeutic approach for neurodegenerative diseases.
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I9 APPENDIX A: Reagents and Buffers
9.1 Western blot
5X SDS/Glycine electrophoresis running buffer: 15.1 g/L Tris base, 72 g Glycine, 5 g
SDS (NUMI)
30% acrylamide, Bis solution, 37.5:1 (BioRad #161-0158)
TEMED (Fluka #87689)
Ammonium Persulfate (BioRad #161-0700)
SuperSignal® West Femto (Pierce # 34095)
SuperSignal® West Pico (Perice #34080)
SuperSignal® West Dura (Pierce #34075)
Western Blocking Reagent (Roche #1921681/1921673), or 5% Non-fat milk
(Anlene™ Gold), 4% non-fat milk+1% BSA (Albumin, bovine serum Fraction V
Sigma A-4503)
Complete Mini protease inhibitor tablets (Roche # 1836153)
Precision Plus Protein Standard (BioRad #161-0374)
Mild Ab stripping buffer (Chemicon #2502)
Strong Ab stripping buffer (Chemicon #2504)
Kodak BioMax film (Research Instruments)
PVDF membrane (Research Instruments)
Secondary antibodies, HRP conjugated (Pierce, BioRad, Sigma)
Beta-mercaptoethanol (Sigma #?)
Percision Plus protein™ standards (Dua Color) (#161-0374)
10_ Tris/Glycine buffer: 30.3 g/L Tris base, 144.13 g/L
Tris/Glycine transfer buffer: 1_Tris/Glycine buffer, 20% (v/v) methanol
RC DC Protein Assay (BioRad #500-0120)




PBS  [80 g/L NaCl, 2 g/L KCl, 14.4 g/L Na2HPO4, 2.4 KH2PO4] NUMI
Triton X-100 (Merck)
Goat Serum (Sigma #)
Alexa Fluor® 488 goat anti-mouse IgG (H+L), cat# A-11029,  Molecular Probes,
storage 4C in secondary antibody box
Alexa Fluor® 488 goat anti-rabbit IgG (H+L), cat# A-11034, Molecular Probes,
storage at 4C in secondary antibody box
Alexa Fluor® 594 goat anti-mouse IgG (H+L), cat# A-11032, Molecular Probes,
storage at 4C in secondary antibody box
Alexa Fluor® 594 goat anti-rabbit IgG (H+L), cat# A-11037, Molecular Probes,
storage at 4C in secondary antibody box
FluorSave™ Reagent, cat# 345789, Calbiochem®, Storage RT
II
9.3 Composition of Neurobasal Medium (Brewer et al, 1993)
Components Mg/liter µM
Inorganic salts
CaCl2 (Anhydrous) 200 1800
Fe(NO3)3.9H2O 0.1 0.2
Kcl 400 5360






Phenol red 8.1 23
HEPES 2600 10000






















D-Ca pantothenate 4 8
Choline chloride 2 28






Vitamin B12 0.34 0.2
III
9.4 Composition of B27 Medium Supplement for Neurons (Brewer et al, 1993).
Biotin Selenium
L-carnitine T3 (triodo-1-thyronine)
Corticosterone DL-α-tocopherol (vitamin E)
Ethanolamine DL-α-tocopherol acetate
D(+)-galactose Proteins:






Brewer GJ, Torricelli JR, Evege EK and Price PJ (1993).  Optimized Survival of
Hippocampal Neurons in B27-Supplemented Neurobasal, a New Serum-free
Medium Combination.  Journal of Neuroscience Research, 35: 567 – 576.
9.5 Microarray: Eukaryotic Target Hybridization
9.5.1 Materials needed
Bovine Serum Albumin (BSA) solution (50 mg/mL), Invitrogen Life Technologies,
P/N 15561-020
Herring Sperm DNA, Promega Corporation, P/N D1811
GeneChip Eukaryotic Hybridization Control Kit, Affymetrix, P/N 900454 (30
reactions) or
P/N 900457 (150 reactions), contains Control cRNA and Control Oligo B2
Control Oligo B2, 3 nM, Affymetrix, P/N 900301 (can be ordered separately)
5M NaCl, RNase-free, DNase-free, Ambion, P/N 9760G
MES hydrate SigmaUltra, Sigma-Aldrich, P/N M5287
MES Sodium Salt, Sigma-Aldrich, P/N M5057
EDTA Disodium Salt, 0.5M solution (100 mL), Sigma-Aldrich, P/N E7889
DMSO, Sigma-Aldrich, P/N D5879
Surfact-Amps 20 (Tween-20), 10%, Pierce Chemical, P/N 28320
9.5.2 Reagent Preparation
12X MES Stock Buffer (1.22M MES, 0.89M [Na+]) for 1,000 mL:
64.61g of MES hydrate
193.3g of MES Sodium Salt
800 mL of Molecular Biology Grade water
Mix and adjust volume to 1,000 mL.
The pH should be between 6.5 and 6.7. Filter through a 0.2 _m filter.
2X Hybridization Buffer (Final 1X concentration is 100 mM MES, 1M [Na+], 20
mM EDTA, 0.01% Tween-20) for 50 mL:
8.3 mL of 12X MES Stock Buffer
IV
17.7 mL of 5M NaCl
4.0 mL of 0.5M EDTA
0.1 mL of 10% Tween-20
19.9 mL of water
Store at 2°C to 8°C, and shield from light
Do not autoclave. Store at 2°C to 8°C, and shield from light.
Discard solution if yellow.
Eukaryotic Arrays: Washing, Staining, and Scanning
Reagents and Materials Required
R-Phycoerythrin Streptavidin, Molecular Probes, P/N S-866
20X SSPE (3M NaCl, 0.2M NaH2PO4, 0.02M EDTA), BioWhittaker Molecular
Applications / Cambrex, P/N 51214
Goat IgG, Reagent Grade, Sigma-Aldrich, P/N I 5256
Anti-streptavidin antibody (goat), biotinylated, Vector Laboratories, P/N BA-0500
Reagent Preparation
Wash Buffer A: Non-Stringent Wash Buffer (6X SSPE, 0.01% Tween-20) for
1,000 mL:
300 mL of 20X SSPE
1.0 mL of 10% Tween-20
699 mL of water
Filter through a 0.2 _m filter
Wash Buffer B: Stringent Wash Buffer(100 mM MES, 0.1M [Na+], 0.01%
Tween-20) for 1,000 mL:
83.3 mL of 12X MES Stock Buffer (see Section 2, Chapter 2 for reagent preparation)
5.2 mL of 5M NaCl
1.0 mL of 10% Tween-20
910.5 mL of water
Filter through a 0.2 _m filter
Store at 2°C to 8°C and shield from light
2X Stain Buffer (Final 1X concentration: 100 mM MES, 1M [Na+], 0.05%
Tween-20) for 250 mL:
41.7 mL of 12X MES Stock Buffer (see Section 2, Chapter 2 for reagent preparation)
92.5 mL of 5M NaCl
2.5 mL of 10% Tween-20
113.3 mL of water
Filter through a 0.2 _m filter
Store at 2°C to 8°C and shield from light
10 mg/mL Goat IgG Stock
Resuspend 50 mg in 5 mL of 150 mM NaCl
Store at 4°C
V10 APPENDIX B: The gene list of microarray analysis (lactacystin treatment):
>2FC, one-way ANOVA, p<0.01
Table 10.1.  Ubiquitin-proteasome System
Time points (h)
Probe id Symbol Gene Title
4.5 7.5 24 48
Genbank
100955_at 2700084L22Rik RIKEN cDNA
2700084L22 gene
2.24 ± 0.26 1.53 ± 0.11 1.06 ± 0.11 1.38 ± 0.16 AA989957
95600_at Arih2 ariadne homolog 2
(Drosophila)
2.61 ± 0.14 4.11 ± 0.14 1.24 ± 0.15 -1.05 ± 0.19 AJ130975
96892_at Psma1 proteasome subunit,
alpha type 1
2.79 ± 0.09 3.37 ± 0.10 2.49 ± 0.20 -1.06 ± 0.14 AI836804
92544_f_at Psma3 proteasome subunit,
alpha type 3
2.45 ± 0.09 2.83 ± 0.06 1.74 ± 0.14 -1.04 ± 0.15 AF055983
94841_at Psma5 proteasome subunit,
alpha type 5
2.16 ± 0.08 2.69 ± 0.10 2.48 ± 0.30 1.01 ± 0.21 AW048997
93988_at Psma7 proteasome subunit,
alpha type 7
2.60 ± 0.08 3.53 ± 0.07 2.35 ± 0.13 -1.09 ± 0.19 AI836676
98113_at Psmb1 proteasome subunit,
beta type 1
1.52 ± 0.07 1.80 ± 0.06 2.00 ± 0.10 1.04 ± 0.17 U60824
94219_at Psmb2 proteasome subunit,
beta type 2
-1.57 ± 0.06 2.28 ± 0.09 2.63 ± 0.39 -1.20 ± 0.22 AI853269
94025_at Psmb3 proteasome subunit,
beta type 3
2.78 ± 0.06 4.50 ± 0.20 3.22 ± 0.21 1.10 ± 0.24 AW045339
98557_f_at Psmb4 proteasome subunit,
beta type 4
2.21 ± 0.06 2.26 ± 0.07 1.95 ± 0.11 1.03 ± 0.19 U65636
101992_at Psmb6 proteasome subunit,
beta type 6
1.99 ± 0.10 2.60 ± 0.07 2.40 ± 0.16 -1.11 ± 0.18 U13393
160152_at Psmc1 proteasome 26S subunit,
ATPase 1
2.28 ± 0.12 3.79 ± 0.09 2.29 ± 0.16 -1.06 ± 0.13 U39302
95448_at Psmc2 proteasome 26S subunit,
ATPase 2
2.58 ± 0.09 2.53 ± 0.07 2.49 ± 0.26 -1.16 ± 0.13 AI839371
93734_i_at Psmc3 proteasome 26S subunit,
ATPase 3
2.71 ± 0.07 3.13 ± 0.11 2.27 ± 0.12 -1.05 ± 0.13 D49686
103319_at Psmd10 proteasome 26S subunit,
non-ATPase, 10
2.21 ± 0.10 1.19 ± 0.10 -1.21 ± 0.10 1.49 ± 0.18 AB022022
160305_at Psmd11 proteasome 26S subunit,
non-ATPase, 11
5.34 ± 0.07 5.03 ± 0.27 2.75 ± 0.17 1.02 ± 0.12 AW121693
VI
93971_f_at Psmd12 proteasome 26S subunit,
non-ATPase, 12
3.34 ± 0.06 3.62 ± 0.20 2.56 ± 0.31 -1.09 ± 0.17 AI838669
95742_at Psmd13 proteasome 26S subunit,
non-ATPase, 13
1.59 ± 0.07 2.30 ± 0.07 1.92 ± 0.11 1.02 ± 0.15 AW045451
97274_at Psmd14 proteasome 26S subunit,
non-ATPase, 14
2.26 ± 0.06 2.72 ± 0.09 2.22 ± 0.18 -1.18 ± 0.14 Y13071
92769_at Psmd3 proteasome 26S subunit,
non-ATPase, 3
1.12 ± 0.07 2.95 ± 0.07 1.95 ± 0.12 -1.12 ± 0.11 M25149
94302_at Psmd4 proteasome 26S subunit,
non-ATPase, 4
2.85 ± 0.07 5.29 ± 0.12 3.07 ± 0.35 -1.05 ± 0.21 AF013099
96698_at Psmd5 proteasome 26S subunit,
non-ATPase, 5
1.94 ± 0.07 2.79 ± 0.13 1.46 ± 0.19 -1.06 ± 0.14 AI835520
103350_at Psmd7 proteasome 26S subunit,
non-ATPase, 7
2.38 ± 0.08 3.03 ± 0.08 1.88 ± 0.30 -1.31 ± 0.15 M64641
98522_at Psmd8 proteasome 26S subunit,
non-ATPase, 8
2.30 ± 0.13 2.38 ± 0.10 1.38 ± 0.10 -1.11 ± 0.15 AI839158
95124_i_at Rbx1 ring-box 1 3.18 ± 0.11 2.00 ± 0.19 1.13 ± 0.15 -1.21 ± 0.17 AW122337
160205_f_at Rnf11 ring finger protein 11 2.04 ± 0.06 1.74 ± 0.09 1.01 ± 0.11 -1.29 ± 0.11 AB024427
101966_s_at Rnf13 ring finger protein 13 2.09 ± 0.09 3.13 ± 0.12 1.00 ± 0.10 1.13 ± 0.12 AF037206
93164_at Rnf2 ring finger protein 2 1.79 ± 0.10 3.25 ± 0.17 -1.57 ± 0.10 -1.12 ± 0.14 Y12783
96961_at Rnf110 ring finger protein 110 3.08 ± 0.15 1.55 ± 0.15 -1.08 ± 0.17 1.14 ± 0.17 AI503821
101069_g_at Mkrn1 makorin, ring finger
protein, 1
1.96 ± 0.09 3.10 ± 0.08 -1.25 ± 0.12 -1.32 ± 0.12 AA656621
100985_at Siah1a seven in absentia 1A 1.86 ± 0.07 2.33 ± 0.09 1.16 ± 0.11 -1.40 ± 0.12 Z19579
101255_at Ubb ubiquitin B 3.10 ± 0.07 3.62 ± 0.06 1.08 ± 0.15 -1.19 ± 0.14 X51703




1.82 ± 0.11 2.30 ± 0.06 1.66 ± 0.14 1.06 ± 0.13 AW210346
93069_at Ube2d2 ubiquitin-conjugating
enzyme E2D 2
2.46 ± 0.10 2.13 ± 0.12 1.08 ± 0.14 -1.30 ± 0.13 U62483
VII
101581_at Ube3a ubiquitin protein ligase
E3A
3.65 ± 0.08 1.93 ± 0.09 1.24 ± 0.11 -1.20 ± 0.10 U82122
94018_at Ubl3 ubiquitin-like 3 2.17 ± 0.06 1.57 ± 0.07 1.41 ± 0.13 1.13 ± 0.15 AW120725
95601_at Ubqln1 ubiquilin 1 1.31 ± 0.06 2.30 ± 0.10 1.08 ± 0.10 -1.29 ± 0.17 AW125420
93303_at Ufd1l ubiquitin fusion
degradation 1 like
2.49 ± 0.07 4.45 ± 0.07 2.05 ± 0.34 -1.43 ± 0.16 U64445
161870_at Usp15 ubiquitin specific
protease 15
-3.77 ± 0.09 -3.28 ± 0.12 -1.57 ± 0.12 1.50 ± 0.24 AV359471
99085_at Usp3 ubiquitin specific
protease 3
1.42 ± 0.14 2.55 ± 0.07 1.26 ± 0.12 1.03 ± 0.13 AI021421
99086_g_at Usp3 ubiquitin specific
protease 3
1.73 ± 0.10 2.74 ± 0.11 1.14 ± 0.12 -1.23 ± 0.15 AI021421
160724_at Usp49 ubiquitin specific
protease 49
2.06 ± 0.24 2.51 ± 0.08 -1.06 ± 0.10 -1.06 ± 0.11 AJ245617
Table 10.2.  Heat shock proteins and molecular chaperone
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
104589_at C80913 expressed sequence C80913 2.04 ± 0.10 -1.11 ± 0.06 1.38 ± 0.12 1.16 ± 0.11 AF091096
98153_at Cct3 chaperonin subunit 3 (gamma) 2.24 ± 0.10 2.54 ± 0.08 1.79 ± 0.22 -1.17 ± 0.14 L20509
160562_at Cct7 chaperonin subunit 7 (eta) 2.00 ± 0.10 2.09 ± 0.06 1.53 ± 0.25 -1.34 ± 0.12 Z31399
96254_at Dnajb1 DnaJ (Hsp40) homolog,
subfamily B, member 1
2.11 ± 0.20 3.52 ± 0.15 1.42 ± 0.26 -1.12 ± 0.12 AB028272
98572_at Dnajb11 DnaJ (Hsp40) homolog,
subfamily B, member 11
1.84 ± 0.10 2.21 ± 0.08 1.41 ± 0.13 -1.12 ± 0.12 AW122551
93853_at Dnajb4 DnaJ (Hsp40) homolog,
subfamily B, member 4
2.19 ± 0.16 2.69 ± 0.13 1.46 ± 0.21 -1.24 ± 0.12 AA763918
104625_at Dnajb6 DnaJ (Hsp40) homolog,
subfamily B, member 6
1.61 ± 0.21 2.16 ± 0.15 -1.30 ± 0.15 -1.03 ± 0.11 AA874130
103344_at Dnajc1 DnaJ (Hsp40) homolog,
subfamily C, member 1
2.31 ± 0.30 1.86 ± 0.09 1.42 ± 0.10 1.32 ± 0.11 L16953
94422_at Dnajc13 DnaJ (Hsp40) homolog,
subfamily C, member 13
2.12 ± 0.08 1.37 ± 0.08 1.07 ± 0.15 -1.17 ± 0.11 AI842938
102414_i_at Dnajc3 DnaJ (Hsp40) homolog,
subfamily C, member 3
2.05 ± 0.14 2.25 ± 0.15 1.31 ± 0.10 1.42 ± 0.12 U28423
93211_at Dnajc5 DnaJ (Hsp40) homolog,
subfamily C, member 5
1.41 ± 0.10 3.16 ± 0.17 -1.48 ± 0.17 -1.56 ± 0.16 AF032115
102761_at Grpel2 GrpE-like 2, mitochondrial 2.03 ± 0.12 2.07 ± 0.17 1.15 ± 0.13 -1.20 ± 0.10 AF041060
98111_at Hsp105 heat shock protein 105 1.57 ± 0.09 2.38 ± 0.08 2.54 ± 0.53 -1.20 ± 0.13 L40406
93875_at Hspa1a heat shock protein 1A -1.27 ± 0.13 4.70 ± 0.53 13.82 ± 6.14 1.78 ± 0.53 M12571
VIII
101955_at Hspa5 heat shock 70kD protein 5
(glucose-regulated protein)
2.20 ± 0.07 2.39 ± 0.06 1.87 ± 0.17 -1.13 ± 0.11 AJ002387
96564_at Hspa8 heat shock protein 8 2.05 ± 0.08 1.96 ± 0.10 1.14 ± 0.14 -1.18 ± 0.10 X54401
97914_at Hspa9a heat shock protein, A 1.68 ± 0.07 3.68 ± 0.07 2.18 ± 0.27 1.07 ± 0.16 D17666
160139_at Hspb8 heat shock 27kDa protein 8 -1.37 ± 0.12 1.67 ± 0.16 8.08 ± 0.47 2.22 ± 0.48 AI848798
95359_at Hspcb heat shock protein 1, beta 2.06 ± 0.06 2.82 ± 0.11 1.46 ± 0.20 -1.08 ± 0.17 M18186
92829_at Hspe1 heat shock protein 1
(chaperonin 10)
1.60 ± 0.07 1.38 ± 0.06 2.34 ± 0.15 1.17 ± 0.15 U09659
101207_at Ppia peptidylprolyl isomerase A 2.43 ± 0.07 1.98 ± 0.06 -1.08 ± 0.10 -1.18 ± 0.13 X52803
100089_at Ppic peptidylprolyl isomerase C 1.20 ± 0.11 -1.27 ± 0.07 1.77 ± 0.16 2.10 ± 0.16 M74227
99350_at Sec63 SEC63-like (S. cerevisiae) 1.70 ± 0.36 2.32 ± 0.12 1.28 ± 0.10 -1.06 ± 0.13 C76102
94817_at Serpinh1 serine (or cysteine) proteinase
inhibitor, clade H, member 1
1.14 ± 0.08 3.10 ± 0.06 6.16 ± 0.15 3.30 ± 0.43 X60676
Table 10.3.  Stress
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
ER stress
104155_f_at Atf3 activating transcription factor 3 3.77 ± 0.13 11.13 ± 0.38 6.68 ± 1.76 2.06 ± 0.27 U19118
100599_at Atf4 activating transcription factor 4 3.52 ± 0.06 3.73 ± 0.09 -1.03 ± 0.25 -2.13 ± 0.12 M94087
101429_at Ddit3 DNA-damage inducible
transcript 3





1.93 ± 0.08 3.18 ± 0.16 1.17 ± 0.22 -1.32 ± 0.11 AI846938
94821_at Xbp1 X-box binding protein 1 1.99 ± 0.08 2.30 ± 0.09 -1.21 ± 0.12 -1.74 ± 0.10 AW123880
92925_at Cebpb CCAAT/enhancer binding
protein (C/EBP), beta
-1.13 ± 0.18 4.26 ± 0.14 3.44 ± 0.34 1.32 ± 0.13 M61007
Oxidative stress
94132_at Gpx1 glutathione peroxidase 1 -2.11 ± 0.07 -2.43 ± 0.06 -1.10 ± 0.10 -1.02 ± 0.10 X03920
97681_f_at Gstm3 glutathione S-transferase, mu 3 -5.19 ± 0.15 -3.77 ± 0.07 -1.11 ± 0.11 1.06 ± 0.11 J03953
93026_at Mgst1 microsomal glutathione S-
transferase 1
1.63 ± 0.14 1.07 ± 0.12 4.13 ± 0.61 2.97 ± 0.36 AW124337
93573_at Mt1 metallothionein 1 -1.24 ± 0.07 -2.35 ± 0.06 2.98 ± 0.10 4.14 ± 1.04 V00835
101561_at Mt2 metallothionein 2 -1.51 ± 0.06 -2.20 ± 0.06 2.22 ± 0.11 2.77 ± 0.45 K02236
95340_at Mt3 metallothionein 3 -4.44 ± 0.06 -3.65 ± 0.06 1.15 ± 0.11 1.85 ± 0.27 M93310
100606_at Prnp prion protein 1.46 ± 0.08 2.09 ± 0.07 1.43 ± 0.12 -1.02 ± 0.12 M18070
100538_at Sod1 superoxide dismutase 1, soluble -3.26 ± 0.06 -1.50 ± 0.07 2.19 ± 0.43 1.05 ± 0.33 M35725
Other
100081_at Stip1 stress-induced phosphoprotein 1 1.67 ± 0.10 2.46 ± 0.10 1.25 ± 0.12 1.04 ± 0.11 U27830
IX
Table 10.4.  Inflammatory responses
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
98088_at Cd14 CD14 antigen -2.35 ± 0.13 -3.62 ± 0.07 -1.13 ± 0.11 1.33 ± 0.13 X13333
160511_at Cxcl12 chemokine (C-X-C motif) ligand
12
2.37 ± 0.17 1.77 ± 0.22 -1.32 ± 0.17 -1.51 ± 0.14 L12029
103202_at Gbp3 guanylate nucleotide binding
protein 3
1.14 ± 0.18 -1.19 ± 0.15 2.87 ± 0.18 2.67 ± 0.21 AW047476
101341_at H2-M9 histocompatibility 2, M region
locus 9
-5.34 ± 0.14 -5.30 ± 0.06 -1.52 ± 0.10 -1.01 ± 0.13 AF016308
102250_at Il27ra interleukin 27 receptor, alpha -2.61 ± 0.08 -2.23 ± 0.07 -1.23 ± 0.12 -1.16 ± 0.15 AF053005
93077_s_at Ly6c lymphocyte antigen 6 complex,
locus C
-2.71 ± 0.07 -2.44 ± 0.08 -1.20 ± 0.10 -1.09 ± 0.13 D86232
96939_at Myl9 myosin, light polypeptide 9,
regulatory
1.01 ± 0.17 -1.09 ± 0.11 1.62 ± 0.16 2.18 ± 0.25 AI842649
101923_at Pla2g7 phospholipase A2, group VII
(platelet-activating factor
acetylhydrolase, plasma)
-1.20 ± 0.07 -1.66 ± 0.06 -1.61 ± 0.15 2.14 ± 0.18 U34277
97944_f_at Tcra T-cell receptor alpha chain -2.45 ± 0.07 -1.71 ± 0.07 -1.14 ± 0.13 1.06 ± 0.13 AF099808
Table 10.5.  Cholesterol biosynthesis
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
94325_at Hmgcs1 3-hydroxy-3-methylglutaryl-Coenzyme
A synthase 1
1.39 ± 0.07 -1.22 ± 0.06 -2.85 ± 0.09 -2.07 ± 0.10 AW124932
94916_at Cyp51 cytochrome P450, 51 -1.41 ± 0.06 -1.47 ± 0.10 -3.21 ± 0.10 -3.12 ± 0.10 AW122260
160770_at Mvd mevalonate (diphospho) decarboxylase -3.06 ± 0.07 -2.61 ± 0.06 -6.96 ± 0.08 -4.98 ± 0.09 AW049778
95632_f_at Mvk mevalonate kinase 1.51 ± 0.15 1.17 ± 0.09 -8.26 ± 0.09 -7.52 ± 0.09 AW122653
98970_at Ggps1 geranylgeranyl diphosphate synthase 1 2.67 ± 0.13 2.79 ± 0.18 1.06 ± 0.13 -1.30 ± 0.11 AB016044
98630_at Nsdhl NAD(P) dependent steroid
dehydrogenase-like
1.62 ± 0.09 1.01 ± 0.06 -3.50 ± 0.09 -2.91 ± 0.10 AW106745
96269_at Idi1 isopentenyl-diphosphate delta
isomerase
-1.53 ± 0.06 -2.39 ± 0.06 -5.82 ± 0.09 -4.78 ± 0.09 AA716963
104285_at Hmgcr 3-hydroxy-3-methylglutaryl-Coenzyme
A reductase
-1.77 ± 0.06 -1.53 ± 0.06 -2.43 ± 0.10 -3.38 ± 0.09 M62766
160737_at Lss lanosterol synthase -1.23 ± 0.12 -1.11 ± 0.13 -2.65 ± 0.11 -3.17 ± 0.11 AW060927
100418_at Gng2 guanine nucleotide binding protein (G
protein), gamma 2 subunit
1.39 ± 0.07 2.36 ± 0.13 -1.96 ± 0.11 -2.00 ± 0.11 AW123750
XTable 10.6.  Lipid
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
102381_at Acsl4 acyl-CoA synthetase
long-chain family
member 4






-3.47 ± 0.08 -1.30 ±0.06 -1.44 ± 0.11 -1.28 ± 0.11 AB005623
98372_at Aldh1a3 aldehyde dehydrogenase
family 1, subfamily A3




1.03 ± 0.08 1.05 ±0.06 2.79 ± 0.13 3.23 ± 0.49 AF017175
103581_at Cte1 cytosolic acyl-CoA
thioesterase 1
1.09 ± 0.07 -1.14 ±0.07 1.59 ± 0.10 2.38 ± 0.37 Y14004
103924_at D8Ertd3
19e
DNA segment, Chr 8,
ERATO Doi 319,
expressed
-2.72 ± 0.06 -1.70 ±0.06 -1.09 ± 0.14 -1.24 ± 0.13 AW048884




-2.49 ± 0.06 -2.84 ±0.06 -1.45 ± 0.10 -1.40 ± 0.10 AI317360
94418_at Elovl6 ELOVL family member
6, elongation of long
chain fatty acids (yeast)
1.26 ± 0.07 -1.12 ±0.09 -2.30 ± 0.10 -2.13 ± 0.10 AI839004
98575_at Fasn fatty acid synthase -1.01 ± 0.07 -1.26 ±0.06 -2.29 ± 0.09 -2.22 ± 0.10 X13135
97518_at Fdft1 farnesyl diphosphate
farnesyl transferase 1












2.17 ± 0.16 2.91 ±0.23 1.38 ± 0.31 -1.49 ± 0.14 Y17851
94854_g_at Gnb1 guanine nucleotide
binding protein, beta 1
1.20 ± 0.07 2.26 ±0.07 -1.59 ± 0.10 -1.81 ± 0.12 U29055
96909_at Ndufab1 NADH dehydrogenase
(ubiquinone) 1,
alpha/beta subcomplex, 1
2.14 ± 0.06 1.76 ±0.10 1.34 ± 0.10 1.06 ± 0.17 AI849803
104342_i_a
t
Pla2g12a phospholipase A2, group
XIIA
2.08 ± 0.12 1.10 ±0.08 -1.02 ± 0.11 1.18 ± 0.13 AI845798
92466_at Plcb1 phospholipase C, beta 1 -2.04 ± 0.07 -2.03 ±0.06 -1.24 ± 0.10 -1.07 ± 0.11 U85714
92465_at Plcb1 phospholipase C, beta 1 2.07 ± 0.13 2.02 ±0.09 -1.67 ± 0.10 -1.57 ± 0.17 U85713
92474_at Pld1 phospholipase D1 -1.70 ± 0.12 -2.08 ±0.09 -1.03 ± 0.10 1.66 ± 0.19 AF083497
XI
100927_at Pltp phospholipid transfer
protein
-3.48 ± 0.09 -3.43 ±0.09 1.45 ± 0.27 3.04 ± 0.12 U28960
100622_at Prdx6 peroxiredoxin 6 1.29 ± 0.06 -1.10 ±0.06 1.66 ± 0.23 2.26 ± 0.21 AF093857
160808_at Prkab1 protein kinase, AMP-
activated, beta 1 non-
catalytic subunit





-1.56 ± 0.13 -2.27 ±0.08 1.19 ± 0.12 -1.18 ± 0.11 AV068306
103386_at Pte1 peroxisomal acyl-CoA
thioesterase 1
-1.08 ± 0.10 2.40 ±0.10 -1.39 ± 0.13 -1.65 ± 0.13 AW046123
160388_at Sc4mol sterol-C4-methyl
oxidase-like
-1.12 ± 0.07 -1.59 ±0.06 -2.95 ± 0.10 -3.66 ± 0.09 AI848668
94056_at Scd1 stearoyl-Coenzyme A
desaturase 1
-2.08 ± 0.06 -2.02 ±0.07 -5.64 ± 0.09 -7.42 ± 0.09 M21285
103569_at Sh3glb1 SH3-domain GRB2-like
B1 (endophilin)
2.71 ± 0.08 1.80 ±0.11 -1.30 ± 0.11 -1.24 ± 0.16 AI842874
160865_at Vldlr very low density
lipoprotein receptor
3.68 ± 0.16 1.83 ±0.15 -1.68 ± 0.12 -1.46 ± 0.16 L33417
Table 10.7.  Apoptosis
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
161980_f_at Bag3 Bcl2-associated athanogene 3 1.37 ± 0.29 1.97 ± 0.24 6.36 ± 1.02 3.41 ± 0.70 AV373612
94448_at Bcl10 B-cell leukemia/lymphoma
10
1.37 ± 0.14 2.06 ± 0.07 1.30 ± 0.10 1.11 ± 0.13 AJ006289
99018_at Bclaf1 BCL2-associated
transcription factor 1
1.21 ± 0.12 1.81 ± 0.09 -1.59 ± 0.12 1.33 ± 0.27 AA874446
102727_at Bdnf brain derived neurotrophic
factor
2.28 ± 0.19 1.23 ± 0.10 1.56 ± 0.12 -1.17 ± 0.13 X55573
95093_at Ccar1 cell division cycle and
apoptosis regulator 1
2.63 ± 0.09 1.58 ± 0.16 -1.02 ± 0.11 -1.27 ± 0.13 AI035334
95545_at Igf1 insulin-like growth factor 1 -4.23 ± 0.08 -2.11 ± 0.07 -1.49 ± 0.11 -1.45 ± 0.14 X04480
160309_at Map3k7ip2 mitogen-activated protein
kinase kinase kinase 7
interacting protein 2
2.00 ± 0.11 1.94 ± 0.11 1.29 ± 0.12 1.07 ± 0.15 AW259500
98110_at Mdm2 transformed mouse 3T3 cell
double minute 2
1.17 ± 0.07 1.18 ± 0.07 2.77 ± 0.41 1.26 ± 0.14 AI853375
93439_f_at Pawr PRKC, apoptosis, WT1,
regulator
-1.10 ± 0.17 1.06 ± 0.18 1.87 ± 0.27 2.70 ± 0.34 AA260005
160696_at Tia1 cytotoxic granule-associated
RNA binding protein 1
2.41 ± 0.08 1.95 ± 0.08 1.05 ± 0.10 1.03 ± 0.11 U00689
102599_at Tpt1 tumor protein,
translationally-controlled 1
2.10 ± 0.07 2.05 ± 0.06 1.10 ± 0.11 -1.10 ± 0.13 X06407
104275_g_at Trp53 transformation related
protein 53
-1.29 ± 0.08 2.01 ± 0.14 1.36 ± 0.15 1.16 ± 0.11 AB021961
160115_at Txnl1 thioredoxin-like 1 2.53 ± 0.09 1.79 ± 0.09 1.75 ± 0.11 1.13 ± 0.12 AF052660
XII
Table 10.8.  Proteolysis
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
94238_at 2310046G15Rik RIKEN cDNA
2310046G15 gene
-1.24 ± 0.11 -2.06 ± 0.09 1.65 ± 0.23 3.29 ± 0.21 AW228316
101040_at Capn2 calpain 2 2.23 ± 0.09 2.63 ± 0.12 1.57 ± 0.10 1.05 ± 0.14 D38117




2.43 ± 0.10 3.38 ± 0.10 1.75 ± 0.18 -1.15 ± 0.19 AJ005253
160349_at Cndp2 CNDP dipeptidase 2
(metallopeptidase M20
family)
1.56 ± 0.13 2.77 ± 0.13 1.88 ± 0.12 -1.13 ± 0.17 AI854839
92256_at Ctsb cathepsin B 2.85 ± 0.27 3.18 ± 0.16 2.20 ± 0.12 1.82 ± 0.20 AI853714
93810_at Ctsd cathepsin D 1.01 ± 0.06 1.69 ± 0.07 2.15 ± 0.13 1.91 ± 0.21 X68378
97336_at Ctsf cathepsin F -2.52 ± 0.07 1.11 ± 0.08 1.09 ± 0.10 1.14 ± 0.11 AJ131851
96270_at D11Bwg0434e DNA segment, Chr 11,
Brigham & Women's
Genetics 0434 expressed
-1.66 ± 0.06 -2.15 ± 0.06 -1.18 ± 0.10 -1.09 ± 0.10 AI847092
161358_r_at Dpep3 dipeptidase 3 -1.64 ± 0.13 -3.89 ± 0.09 -1.48 ± 0.11 -1.13 ± 0.11 AV209030
98287_at Dpp6 dipeptidylpeptidase 6 -3.44 ± 0.07 -2.61 ± 0.06 -1.41 ± 0.11 -1.26 ± 0.14 AF092507
94380_at Ide insulin degrading
enzyme
1.71 ± 0.07 3.48 ± 0.08 2.34 ± 0.53 -1.10 ± 0.13 AI852581
160290_at Ide insulin degrading
enzyme
3.17 ± 0.07 3.03 ± 0.08 2.78 ± 0.43 -1.04 ± 0.10 AI574278
92607_at Mest mesoderm specific
transcript
1.39 ± 0.07 -1.15 ± 0.08 2.56 ± 0.19 2.22 ± 0.19 AF017994
104015_at Metap1 methionyl
aminopeptidase 1
1.75 ± 0.10 2.27 ± 0.11 1.12 ± 0.19 -1.41 ± 0.12 AW047992
93981_at Plat plasminogen activator,
tissue
1.18 ± 0.14 1.05 ± 0.10 2.66 ± 0.13 2.11 ± 0.20 J03520
161446_r_at Prss25 protease, serine, 25 -2.11 ± 0.06 -2.26 ± 0.06 -1.32 ± 0.10 -1.06 ± 0.10 AV353694
104025_at Thop1 thimet oligopeptidase 1 -1.49 ± 0.07 1.96 ± 0.06 -1.02 ± 0.13 -1.15 ± 0.11 AW047185
96730_at Tpp2 tripeptidyl peptidase II 2.22 ± 0.14 2.98 ± 0.32 1.24 ± 0.10 -1.16 ± 0.13 X81323
Table 10.9.  Growth and development
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
100584_at Anxa4 annexin A4 -1.48 ± 0.18 -1.49± 0.22 2.69 ± 0.25 2.27 ± 0.21 U72941
93083_at Anxa5 annexin A5 -1.32 ± 0.11 -1.01± 0.07 1.75 ± 0.11 2.51 ± 0.13 D63423
101475_at Bmi1 B lymphoma Mo-
MLV insertion
region 1
3.02 ± 0.14 2.88 ± 0.07 1.13 ± 0.12 -1.14± 0.16 M64068
98066_r_at Brd2 bromodomain
containing 2
2.19 ± 0.07 2.18 ± 0.08 1.06 ± 0.20 -1.49± 0.11 AL009226
160430_at Catnb catenin beta 2.13 ± 0.07 1.84 ± 0.06 1.10 ± 0.11 -1.02± 0.10 M90364




3.83 ± 0.08 1.93 ± 0.11 -1.83 ± 0.11 -1.79± 0.12 X94310
100022_at Cish cytokine inducible
SH2-containing
protein
2.16 ± 0.40 3.02 ± 0.14 -1.34 ± 0.10 -1.12± 0.10 D89613
XIII





3.73 ± 0.20 3.08 ± 0.09 1.37 ± 0.17 -1.12± 0.18 AF071313
160098_s_at Cryab crystallin, alpha B 1.38 ± 0.07 2.67 ± 0.10 1.15 ± 0.12 -1.21± 0.11 AI842724
101450_at Csf1 colony stimulating
factor 1
(macrophage)
-1.41 ± 0.08 -1.32± 0.07 2.88 ± 0.24 2.02 ± 0.12 M21952
93294_at Ctgf connective tissue
growth factor
2.94 ± 0.70 2.11 ± 0.28 14.63 ± 0.63 7.93 ± 1.62 M70642
92777_at Cyr61 cysteine rich protein
61
1.44 ± 0.16 1.26 ± 0.17 2.69 ± 0.30 2.61 ± 0.14 M32490
97372_at Dazap1 DAZ associated
protein 1
-2.21 ± 0.10 -2.09± 0.08 -1.20 ± 0.10 -1.06± 0.11 AA880432
102896_at Dok1 downstream of
tyrosine kinase 1
3.28 ± 1.07 6.24 ± 0.31 3.79 ± 0.14 1.17 ± 0.17 U78818
97426_at Emp1 epithelial membrane
protein 1
1.18 ± 0.15 1.04 ± 0.08 4.98 ± 0.45 4.06 ± 0.14 X98471
97689_at F3 coagulation factor
III
-1.16 ± 0.11 1.42 ± 0.14 3.29 ± 0.17 2.14 ± 0.17 M26071
95637_at Flnb filamin, beta -1.53 ± 0.10 1.04 ± 0.12 2.11 ± 0.15 1.63 ± 0.13 AI838592
102196_at Gna11 guanine nucleotide
binding protein,
alpha 11
1.23 ± 0.14 2.15 ± 0.07 1.28 ± 0.11 -1.35± 0.10 U37413
95082_at Igfbp3 insulin-like growth
factor binding
protein 3
1.03 ± 0.14 -1.46± 0.08 2.41 ± 0.17 1.47 ± 0.28 AI842277
100566_at Igfbp5 insulin-like growth
factor binding
protein 5
1.65 ± 0.07 1.02 ± 0.06 -1.05 ± 0.10 2.06 ± 0.13 L12447




2.19 ± 0.06 -1.37± 0.06 -1.61 ± 0.14 -1.52± 0.12 L27220
100277_at Inhba inhibin beta-A -2.15 ± 0.09 -3.25± 0.06 -1.77 ± 0.12 -1.59± 0.10 X69619
160828_at Inhbb inhibin beta-B -1.58 ± 0.09 -2.41± 0.08 -1.14 ± 0.12 1.15 ± 0.18 X69620
104386_f_at Itgav integrin alpha V -1.88 ± 0.07 -2.69± 0.08 2.06 ± 0.13 2.23 ± 0.31 AI843901
93682_at Ldb2 LIM domain binding
2
2.84 ± 0.18 1.69 ± 0.09 -1.89 ± 0.10 -1.80± 0.10 U89489
103021_r_at Map3k1 mitogen activated
protein kinase kinase
kinase 1
-1.36 ± 0.19 -2.14± 0.11 -1.05 ± 0.18 1.39 ± 0.14 AI317205
94891_s_at Mea1 male enhanced
antigen 1
2.01 ± 0.15 2.63 ± 0.11 1.36 ± 0.10 -1.55± 0.15 M27938
96632_at Morf4l2 mortality factor 4
like 2
1.84 ± 0.07 2.40 ± 0.06 1.20 ± 0.13 -1.17± 0.12 AB025049
92717_at Neurod1 neurogenic
differentiation 1
1.31 ± 0.08 1.27 ± 0.10 -1.78 ± 0.11 -2.58± 0.11 U28068
160668_at Ogfr opioid growth factor
receptor






1.41 ± 0.13 2.41 ± 0.15 -1.03 ± 0.11 -1.84± 0.16 U57747
XIV
95368_at Plxna2 plexin A2 2.24 ± 0.10 2.07 ± 0.15 -1.28 ± 0.10 -1.19± 0.13 D86949
93390_g_at Prom1 prominin 1 1.00 ± 0.11 -1.54± 0.14 1.03 ± 0.12 2.13 ± 0.11 AF039663
97474_r_at Ptn pleiotrophin -1.04 ± 0.08 -3.79± 0.07 1.04 ± 0.10 1.46 ± 0.13 D90225






2.21 ± 0.18 1.93 ± 0.13 -1.09 ± 0.14 -1.12± 0.12 D85028








8.87 ± 0.47 3.89 ± 0.12 1.07 ± 0.20 -1.36± 0.17 AA266467





-4.00 ± 0.07 -2.12± 0.06 -1.66 ± 0.10 -1.82± 0.12 AF036585
97519_at Spp1 secreted
phosphoprotein 1
2.90 ± 0.07 1.84 ± 0.07 1.00 ± 0.10 1.60 ± 0.23 X13986
103832_at Tfip11 tuftelin interacting
protein 11
2.14 ± 0.20 2.81 ± 0.15 1.15 ± 0.13 -1.21± 0.12 AF097181
100953_at Timeless timeless homolog
(Drosophila)
-1.49 ± 0.07 -2.01± 0.07 -1.06 ± 0.10 1.23 ± 0.11 AB015598
161258_at Wt1 Wilms tumor
homolog
-3.34 ± 0.10 -3.99± 0.07 -1.23 ± 0.10 -1.20± 0.10 AV322247
Table 10.10.  Regulation of transcription
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
95479_at C1d nuclear DNA binding
protein
-1.83 ± 0.09 -2.84 ± 0.06 1.00 ± 0.12 -1.02 ± 0.13 X95591
92681_at Magel2 melanoma antigen,
family L, 2
3.33 ± 0.44 2.02 ± 0.20 1.85 ± 0.46 -1.79 ± 0.12 AJ243608
100554_at Pdlim1 PDZ and LIM domain 1
(elfin)
-1.44 ± 0.11 -2.21 ± 0.09 1.59 ± 0.11 1.72 ± 0.15 AF053367
92280_at Strm striamin -2.32 ± 0.13 -1.43 ± 0.09 1.71 ± 0.32 1.54 ± 0.22 AA867778
103762_at 2810405L04Rik RIKEN cDNA
2810405L04 gene
1.69 ± 0.08 2.69 ± 0.08 1.55 ± 0.23 -1.31 ± 0.18 AI853340
97438_r_at 4631416I11Rik RIKEN cDNA
4631416I11 gene
2.12 ± 0.30 1.20 ± 0.21 -1.85 ± 0.13 -1.33 ± 0.13 AW122483
97437_f_at 4631416I11Rik RIKEN cDNA
4631416I11 gene
2.86 ± 0.30 1.56 ± 0.15 -1.09 ± 0.15 -1.52 ± 0.11 AW122483
96196_i_at 5730589K01Rik RIKEN cDNA
5730589K01 gene
2.25 ± 0.12 2.85 ± 0.12 1.56 ± 0.13 -1.19 ± 0.11 AI851708
162010_r_at Atf2 activating transcription
factor 2
-1.02 ± 0.14 -2.51 ± 0.09 -1.24 ± 0.10 -1.14 ± 0.13 AV246802
95673_s_at Basp1 brain abundant,
membrane attached
signal protein 1
2.83 ± 0.08 2.64 ± 0.07 -1.03 ± 0.12 -1.24 ± 0.13 AW124113
XV
95674_r_at Basp1 brain abundant,
membrane attached
signal protein 1
3.25 ± 0.09 2.25 ± 0.06 -1.09 ± 0.16 -1.39 ± 0.16 AI851985
100544_at Brd7 bromodomain
containing 7












2.08 ± 0.18 2.41 ± 0.11 1.33 ± 0.15 -1.13 ± 0.12 AB012273




1.99 ± 0.17 2.03 ± 0.11 1.06 ± 0.11 -1.08 ± 0.14 AW122419




2.90 ± 0.07 3.30 ± 0.08 1.55 ± 0.18 -1.07 ± 0.12 U70736
160502_at Creg cellular repressor of
E1A-stimulated genes
3.72 ± 0.17 3.72 ± 0.33 3.45 ± 0.21 1.37 ± 0.15 AF084524
96793_at Dmap1 DNA methyltransferase
1-associated protein 1
2.17 ± 0.16 2.74 ± 0.08 1.32 ± 0.13 1.01 ± 0.17 AI607813
96297_at Ebna1bp2 EBNA1 binding protein
2
2.26 ± 0.13 2.51 ± 0.10 1.52 ± 0.10 1.00 ± 0.10 AI845934
160244_at Fem1a feminization 1 homolog
a (C. elegans)
1.65 ± 0.09 2.22 ± 0.13 1.25 ± 0.10 -1.09 ± 0.13 AI836048
96046_at Hdac1 histone deacetylase 1 1.89 ± 0.18 1.97 ± 0.07 1.19 ± 0.11 1.17 ± 0.13 X98207
97550_at Hdac7a histone deacetylase 7A -2.05 ± 0.06 -1.58 ± 0.08 -1.03 ± 0.10 -1.12 ± 0.11 AW047228
103765_at Hkr3 GLI-Kruppel family
member HKR3
1.84 ± 0.41 3.35 ± 0.32 1.70 ± 0.13 1.01 ± 0.11 AA718040
100007_at Irf2bp1 interferon regulatory
factor 2 binding protein
1
-2.53 ± 0.06 -1.67 ± 0.06 -1.25 ± 0.11 -1.16 ± 0.12 AI837573
160396_at Lass2 longevity assurance
homolog 2 (S.
cerevisiae)
1.47 ± 0.21 1.24 ± 0.15 2.27 ± 0.11 1.44 ± 0.12 AW121580
104590_at Mef2c myocyte enhancer
factor 2C
1.59 ± 0.07 1.36 ± 0.10 -1.94 ± 0.10 -2.19 ± 0.13 L13171




2.06 ± 0.08 1.15 ± 0.08 -1.45 ± 0.10 -1.19 ± 0.13 AW120605
96497_s_at Myt1l myelin transcription
factor 1-like
2.24 ± 0.12 2.07 ± 0.07 -1.47 ± 0.10 -1.56 ± 0.11 AI848062
100962_at Nab2 Ngfi-A binding protein
2
-1.42 ± 0.09 -1.28 ± 0.08 2.11 ± 0.13 1.44 ± 0.11 U47543
92562_at Nfe2l2 nuclear factor, erythroid
derived 2, like 2
1.07 ± 0.08 1.43 ± 0.08 2.99 ± 0.30 2.82 ± 0.15 U70475
99527_at Nfe2l3 nuclear factor, erythroid
derived 2, like 3
2.42 ± 0.58 2.47 ± 0.38 -4.39 ± 0.18 -1.21 ± 0.13 AB013852
XVI
102955_at Nfil3 nuclear factor,
interleukin 3, regulated
-1.02 ± 0.11 2.32 ± 0.14 1.05 ± 0.26 -1.83 ± 0.11 U83148
92747_at Nkx2-2 NK2 transcription
factor related, locus 2
(Drosophila)
-6.27 ± 0.12 -2.00 ± 0.16 1.14 ± 0.10 -1.03 ± 0.15 U31566
92956_at Notch3 Notch gene homolog 3
(Drosophila)
-1.48 ± 0.09 -2.07 ± 0.08 1.13 ± 0.15 1.10 ± 0.12 X74760
101665_at Nr5a1 nuclear receptor
subfamily 5, group A,
member 1
-2.03 ± 0.08 -2.21 ± 0.06 -1.35 ± 0.10 -1.16 ± 0.10 C85959
93740_at Nsep1 nuclease sensitive
element binding protein
1
3.42 ± 0.07 2.95 ± 0.09 1.01 ± 0.12 -1.15 ± 0.15 U33196
99158_at Ostf1 osteoclast stimulating
factor 1
-1.17 ± 0.16 -1.39 ± 0.09 2.71 ± 0.26 1.31 ± 0.13 U58888
102257_at Pknox1 Pbx/knotted 1
homeobox
1.99 ± 0.08 2.29 ± 0.08 -1.65 ± 0.16 -1.01 ± 0.20 AF061270
99015_at Pml promyelocytic leukemia -2.01 ± 0.07 -2.06 ± 0.06 -1.45 ± 0.10 1.05 ± 0.11 U33626
160146_r_at Polr2c polymerase (RNA) II
(DNA directed)
polypeptide C
2.47 ± 0.21 -1.15 ± 0.09 -1.23 ± 0.10 -1.26 ± 0.11 D83999
93325_at Polr2e polymerase (RNA) II
(DNA directed)
polypeptide E
2.03 ± 0.10 1.61 ± 0.07 1.33 ± 0.11 1.16 ± 0.13 AI845735
96306_at Polr2i polymerase (RNA) II
(DNA directed)
polypeptide I
1.76 ± 0.11 2.29 ± 0.09 1.08 ± 0.16 -1.97 ± 0.11 AI852210
95003_at Polr2k polymerase (RNA) II
(DNA directed)
polypeptide K
6.99 ± 0.18 4.09 ± 0.13 1.50 ± 0.20 1.15 ± 0.30 AA880275
102652_at Pou3f1 POU domain, class 3,
transcription factor 1
1.76 ± 0.17 -1.48 ± 0.13 -2.77 ± 0.11 1.03 ± 0.20 X56959
161347_r_at Rpo1-1 RNA polymerase 1-1 -2.40 ± 0.08 -5.28 ± 0.10 -1.27 ± 0.10 1.04 ± 0.10 AV148041
98085_f_at Rpo1-1 /// Rps28 RNA polymerase 1-1 ///
ribosomal protein S28
3.15 ± 0.11 2.86 ± 0.07 1.12 ± 0.14 -1.03 ± 0.19 U11248
98081_at Rpo1-3 RNA polymerase 1-3 1.96 ± 0.09 2.03 ± 0.12 1.11 ± 0.13 -1.19 ± 0.17 AI853173
102856_at Sox10 SRY-box containing
gene 10
-3.08 ± 0.08 -2.05 ± 0.08 -1.31 ± 0.11 1.08 ± 0.14 AF047389
101631_at Sox11 SRY-box containing
gene 11
2.53 ± 0.08 1.65 ± 0.17 -1.18 ± 0.10 -1.15 ± 0.13 AF009414
101684_r_at Srst simple repeat sequence-
containing transcript
3.59 ± 0.07 3.35 ± 0.19 -1.09 ± 0.11 -1.13 ± 0.10 X67863
103504_at Ssbp2 single-stranded DNA
binding protein 2
2.11 ± 0.08 1.87 ± 0.07 -1.23 ± 0.10 -1.25 ± 0.10 AI837107
100094_at Supt5h suppressor of Ty 5
homolog (S. cerevisiae)
1.92 ± 0.07 2.40 ± 0.07 1.27 ± 0.14 -1.04 ± 0.14 U88539




1.70 ± 0.33 3.21 ± 0.08 1.38 ± 0.13 1.09 ± 0.11 Y09972




1.49 ± 0.08 2.08 ± 0.10 1.11 ± 0.13 -1.21 ± 0.12 Y09973
XVII
93918_at Taf9 TAF9 RNA polymerase
II, TATA box binding
protein (TBP)-
associated factor
2.61 ± 0.07 2.53 ± 0.08 1.18 ± 0.12 -1.11 ± 0.13 AA673500
102700_at Tbr1 T-box brain gene 1 2.13 ± 0.10 1.44 ± 0.09 -1.09 ± 0.10 -1.19 ± 0.15 U49251
104622_at Tcea2 transcription elongation
factor A (SII), 2
1.45 ± 0.15 2.21 ± 0.28 1.16 ± 0.15 -1.12 ± 0.10 D86081
101008_at Tcerg1 transcription elongation
regulator 1 (CA150)
2.04 ± 0.16 1.89 ± 0.10 1.09 ± 0.13 -1.29 ± 0.10 AB023485
102354_at Tcf19 transcription factor 19 1.11 ± 0.14 1.05 ± 0.14 1.35 ± 0.14 2.34 ± 0.16 AI049398
100947_at Tcf20 transcription factor 20 3.65 ± 0.32 2.00 ± 0.28 -1.03 ± 0.11 -1.43 ± 0.19 AI847906
160363_at Tcfl1 transcription factor-like
1
1.95 ± 0.06 2.53 ± 0.09 -1.15 ± 0.10 -1.31 ± 0.11 D43643
100935_at Tcfl4 transcription factor-like
4
1.87 ± 0.15 2.31 ± 0.12 1.24 ± 0.10 -1.40 ± 0.13 U43548




1.51 ± 0.27 -1.09 ± 0.09 -2.14 ± 0.10 -1.42 ± 0.10 AF011543
93656_g_at Usf1 upstream transcription
factor 1
-1.64 ± 0.07 2.10 ± 0.09 1.14 ± 0.15 -1.27 ± 0.12 X95316
103013_at Usf2 upstream transcription
factor 2
-1.87 ± 0.08 -2.24 ± 0.07 -1.22 ± 0.11 -1.23 ± 0.11 X77602
92444_f_at Zfp1 zinc finger protein 1 2.46 ± 0.09 2.65 ± 0.11 -1.01 ± 0.10 -1.16 ± 0.11 X16493
102263_at Zfp143 zinc finger protein 143 2.55 ± 0.15 2.27 ± 0.15 1.15 ± 0.23 -1.21 ± 0.10 U29513
99502_at Zfp148 zinc finger protein 148 2.65 ± 0.14 1.49 ± 0.12 1.26 ± 0.13 1.00 ± 0.11 U80078
94937_at Zfp277 zinc finger protein 277 2.46 ± 0.13 2.40 ± 0.15 1.17 ± 0.14 1.25 ± 0.11 AW121594
98032_at Zfp35 zinc finger protein 35 2.01 ± 0.23 2.19 ± 0.11 1.09 ± 0.16 -1.30 ± 0.12 M36146
93350_f_at Zfp422 zinc finger protein 422 1.87 ± 0.16 2.95 ± 0.08 -1.28 ± 0.10 -1.06 ± 0.19 AW209414
102304_f_at Zfp61 zinc finger protein 61 2.71 ± 0.13 2.65 ± 0.17 1.02 ± 0.10 -1.27 ± 0.10 L28167
103841_at Zfp64 zinc finger protein 64 2.03 ± 0.11 2.82 ± 0.15 1.62 ± 0.21 -1.23 ± 0.11 U49046
95521_s_at Zfp68 zinc finger protein 68 1.85 ± 0.18 2.57 ± 0.15 -1.17 ± 0.10 -1.35 ± 0.13 AB024005
92934_at Zfp90 zinc finger protein 90 2.38 ± 0.10 2.08 ± 0.18 -1.08 ± 0.13 -1.62 ± 0.11 X79828
96707_at Zipro1 zinc finger proliferation
1
2.06 ± 0.07 2.50 ± 0.07 1.22 ± 0.24 -1.21 ± 0.14 D10630
Table 10.11.  Regulation of cell cycle
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
96220_at Lig3 ligase III, DNA, ATP-
dependent
2.34 ± 0.13 1.43 ± 0.08 1.18 ± 0.16 -1.02 ± 0.14 AW123157
95471_at Cdkn1c cyclin-dependent kinase
inhibitor 1C (P57)
2.36 ± 0.15 1.18 ± 0.12 1.22 ± 0.13 1.03 ± 0.11 U22399
92477_at Spin spindlin 1.11 ± 0.11 2.10 ± 0.13 -1.70 ± 0.10 -1.87 ± 0.19 AA681862
161931_r_at Mki67 antigen identified by
monoclonal antibody Ki
67
-4.08 ± 0.18 -1.83 ± 0.13 -1.29 ± 0.10 1.22 ± 0.13 AV309347
95610_at Cdc5l cell division cycle 5-
like (S. pombe)
2.10 ± 0.21 2.09 ± 0.13 1.02 ± 0.16 1.03 ± 0.11 AA636547
92423_at Pard6a par-6 (partitioning
defective 6,) homolog
alpha (C. elegans)
2.02 ± 0.08 2.14 ± 0.06 -1.08 ± 0.12 -1.25 ± 0.14 AF070970
XVIII
94954_at Anapc4 anaphase promoting
complex subunit 4
1.94 ± 0.07 2.08 ± 0.07 1.25 ± 0.14 -1.20 ± 0.11 AI846628
96236_at Cdc16 CDC16 cell division
cycle 16 homolog (S.
cerevisiae)
3.04 ± 0.23 2.92 ± 0.11 1.81 ± 0.21 -1.34 ± 0.18 AW122965
96319_at Cdc20 cell division cycle 20
homolog (S. cerevisiae)
1.90 ± 0.07 2.30 ± 0.07 1.50 ± 0.10 1.42 ± 0.11 AW061324
104090_at Cdc23 CDC23 (cell division
cycle 23, yeast,
homolog)
1.89 ± 0.08 2.68 ± 0.15 -1.11 ± 0.18 -1.29 ± 0.14 AA657164
97527_at Cks2 CDC28 protein kinase
regulatory subunit 2
2.33 ± 0.10 2.19 ± 0.07 1.25 ± 0.11 1.64 ± 0.10 AA681998
94232_at Ccnd1 cyclin D1 -2.21 ± 0.11 -2.31 ± 0.08 1.64 ± 0.10 1.28 ± 0.10 AI849928
102292_at Gadd45a growth arrest and DNA-
damage-inducible 45
alpha
2.49 ± 0.12 4.20 ± 0.16 4.73 ± 0.62 1.98 ± 0.26 U00937
94482_at Csnk2a2 casein kinase II, alpha
2, polypeptide
1.45 ± 0.21 2.04 ± 0.13 1.00 ± 0.11 -1.46 ± 0.13 AF012251
98067_at Cdkn1a cyclin-dependent kinase
inhibitor 1A (P21)
1.27 ± 0.09 1.25 ± 0.08 3.14 ± 0.33 1.19 ± 0.17 U09507
99135_at Cdc37 cell division cycle 37
homolog (S. cerevisiae)
1.42 ± 0.09 2.34 ± 0.06 1.08 ± 0.12 -1.06 ± 0.13 U43076
103520_at Vegfa vascular endothelial
growth factor A
2.88 ± 0.43 4.89 ± 0.21 -1.07 ± 0.22 -1.38 ± 0.14 M95200
102821_s_at Ran RAN, member RAS
oncogene family
2.09 ± 0.07 2.34 ± 0.08 1.40 ± 0.15 1.02 ± 0.17 L32752
101254_at Ran RAN, member RAS
oncogene family
2.25 ± 0.07 2.14 ± 0.06 1.33 ± 0.14 1.00 ± 0.16 L32751
101959_r_at Tfdp1 transcription factor Dp
1
2.01 ± 0.07 1.46 ± 0.06 1.14 ± 0.11 -1.06 ± 0.12 X72310
94264_at Raf1 v-raf-1 leukemia viral
oncogene 1
1.56 ± 0.07 2.22 ± 0.06 1.21 ± 0.19 -1.24 ± 0.15 AW122170
92502_at Plagl1 pleiomorphic adenoma
gene-like 1
-1.38 ± 0.12 -1.03 ± 0.07 2.04 ± 0.42 2.13 ± 0.20 X95504
93300_at Tgfb2 transforming growth
factor, beta 2
1.40 ± 0.18 -2.22 ± 0.08 1.14 ± 0.12 1.45 ± 0.16 X57413
99068_at Anapc1 anaphase promoting
complex subunit 1
1.89 ± 0.08 2.29 ± 0.08 1.39 ± 0.12 1.07 ± 0.10 X80169
160127_at Ccng1 cyclin G1 -1.01 ± 0.07 -1.34 ± 0.06 2.59 ± 0.15 1.97 ± 0.13 L49507
98478_at Ccng2 cyclin G2 2.24 ± 0.10 1.39 ± 0.07 -1.25 ± 0.10 -1.14 ± 0.12 U95826
100130_at Jun Jun oncogene 4.76 ± 0.45 8.30 ± 0.13 1.91 ± 0.42 -1.45 ± 0.14 X12761
97991_at Kras2 Kirsten rat sarcoma
oncogene 2, expressed
1.82 ± 0.13 2.06 ± 0.07 1.07 ± 0.14 -1.34 ± 0.10 X02452
96598_at D430039C20Rik RIKEN cDNA
D430039C20 gene
2.14 ± 0.27 1.75 ± 0.10 -1.20 ± 0.10 1.03 ± 0.10 AA122714
100559_at Dhx16 DEAH (Asp-Glu-Ala-
His) box polypeptide 16
2.03 ± 0.08 2.00 ± 0.09 1.39 ± 0.13 1.03 ± 0.16 AI853344
XIX
160650_at Polr3d polymerase (RNA) III
(DNA directed)
polypeptide D
2.79 ± 0.11 2.31 ± 0.14 1.00 ± 0.10 -1.05 ± 0.11 AI844711
94820_r_at Ccni cyclin I -1.33 ± 0.07 -2.73 ± 0.06 -1.38 ± 0.10 1.37 ± 0.13 AF005886
Table 10.12.  Transport
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
161029_at 6330416G13Rik RIKEN cDNA
6330416G13 gene
1.84 ± 0.25 2.37 ± 0.16 -1.07 ± 0.12 -1.44 ± 0.11 AI849583
93626_at Abcg2 ATP-binding cassette,
sub-family G (WHITE),
member 2
1.40 ± 0.20 -1.20 ± 0.13 2.79 ± 0.17 1.26 ± 0.16 AF103875
92288_at Ap1g1 adaptor protein complex
AP-1, gamma 1 subunit
2.53 ± 0.10 3.99 ± 0.22 -1.48 ± 0.16 -1.50 ± 0.30 X54424
100492_at Ap2a2 adaptor protein complex
AP-2, alpha 2 subunit
-3.73 ± 0.07 1.17 ± 0.08 -1.18 ± 0.11 -1.29 ± 0.11 AW122807
103878_at Ap3b1 adaptor-related protein
complex 3, beta 1
subunit
1.78 ± 0.07 2.08 ± 0.06 1.24 ± 0.15 1.00 ± 0.15 AF103809
102704_at Aqp4 aquaporin 4 -1.59 ± 0.08 -6.24 ± 0.09 -6.17 ± 0.10 1.22 ± 0.16 U88623
92428_at Asna1 arsA (bacterial) arsenite
transporter, ATP-
binding, homolog 1
1.55 ± 0.11 2.49 ± 0.09 -1.11 ± 0.17 -1.34 ± 0.16 AF039405
93797_g_at Atp1a1 ATPase, Na+/K+
transporting, alpha 1
polypeptide
-1.26 ± 0.10 2.16 ± 0.09 1.13 ± 0.18 1.46 ± 0.14 AW123952




(subunit 9), isoform 1
-3.88 ± 0.08 -2.23 ± 0.07 -1.69 ± 0.10 -1.34 ± 0.11 L19737
102854_s_at Atp7a ATPase, Cu++
transporting, alpha
polypeptide
3.21 ± 0.13 2.24 ± 0.16 1.23 ± 0.13 1.04 ± 0.12 U03434
102786_at Clcn3 chloride channel 3 1.51 ± 0.07 2.05 ± 0.09 1.16 ± 0.14 -1.28 ± 0.11 AI849432
94464_at Clcn3 chloride channel 3 2.01 ± 0.06 1.25 ± 0.07 1.20 ± 0.10 -1.22 ± 0.14 AF029347
94465_g_at Clcn3 chloride channel 3 2.23 ± 0.07 1.76 ± 0.07 1.14 ± 0.10 -1.26 ± 0.16 AF029347
95654_at Clic1 chloride intracellular
channel 1
1.45 ± 0.11 1.76 ± 0.09 3.64 ± 0.18 3.20 ± 0.45 AF109905
97248_at Dbi diazepam binding
inhibitor
-1.52 ± 0.06 -3.44 ± 0.06 -1.91 ± 0.09 1.19 ± 0.14 X61431
104469_at Gp38 glycoprotein 38 -1.70 ± 0.11 -2.19 ± 0.06 1.99 ± 0.13 2.67 ± 0.27 M73748
92946_f_at Gria2 glutamate receptor,
ionotropic, AMPA2
(alpha 2)
2.13 ± 0.07 1.18 ± 0.09 -1.15 ± 0.11 -1.18 ± 0.11 L32372
104684_at Grin1 glutamate receptor,
ionotropic, NMDA1
(zeta 1)
-2.44 ± 0.08 -1.47 ± 0.06 -1.32 ± 0.10 -1.11 ± 0.10 AI847120
104686_at Grin1 glutamate receptor,
ionotropic, NMDA1
(zeta 1)
-1.02 ± 0.13 2.30 ± 0.10 -1.68 ± 0.16 -1.73 ± 0.17 D10028
92392_at Kcna3 potassium voltage-gated
channel, shaker-related
subfamily, member 3
2.06 ± 0.16 1.22 ± 0.12 -1.16 ± 0.10 -1.14 ± 0.12 AI850484
XX
99450_at Kcnq2 potassium voltage-gated
channel, subfamily Q,
member 2
-2.33 ± 0.08 -1.90 ± 0.07 1.03 ± 0.15 -1.24 ± 0.10 AB000503




-1.45 ± 0.15 1.22 ± 0.16 2.37 ± 0.18 1.66 ± 0.17 AI642389
93993_at Lman2 lectin, mannose-binding
2




3.63 ± 0.15 2.19 ± 0.09 -1.18 ± 0.13 -1.91 ± 0.14 X61455
103953_at Sec22l1 SEC22 vesicle
trafficking protein-like 1
(S. cerevisiae)
2.36 ± 0.32 2.16 ± 0.07 1.76 ± 0.11 -1.04 ± 0.15 U91538
93711_at Sec23a SEC23A (S. cerevisiae) 1.55 ± 0.07 2.22 ± 0.06 -1.24 ± 0.10 -1.54 ± 0.15 D12713
161326_f_at Serpina6 serine (or cysteine)
proteinase inhibitor,
clade A, member 6
-2.25 ± 0.19 -1.67 ± 0.15 1.00 ± 0.11 1.10 ± 0.12 AV104178
92831_at Sfxn1 sideroflexin 1 2.50 ± 0.15 1.58 ± 0.08 1.04 ± 0.10 -1.08 ± 0.13 AI846308





1.15 ± 0.25 1.88 ± 0.17 -2.14 ± 0.15 -2.42 ± 0.15 D43797




1.40 ± 0.06 2.41 ± 0.10 -1.03 ± 0.26 -1.52 ± 0.10 U75215
98470_at Slc25a14 solute carrier family 25
(mitochondrial carrier,
brain), member 14
2.13 ± 0.13 2.79 ± 0.12 1.01 ± 0.16 -1.63 ± 0.15 AF076981




2.21 ± 0.07 1.96 ± 0.07 -1.05 ± 0.10 -1.19 ± 0.12 U27315




-1.64 ± 0.08 -2.59 ± 0.06 -1.06 ± 0.17 1.06 ± 0.13 AA062013
93804_at Slc2a3 solute carrier family 2
(facilitated glucose
transporter), member 3
1.72 ± 0.10 2.35 ± 0.13 -1.06 ± 0.12 -1.23 ± 0.10 AI854156
102683_at Slc30a3 solute carrier family 30
(zinc transporter),
member 3
-2.52 ± 0.08 -2.06 ± 0.07 -1.26 ± 0.11 -1.20 ± 0.10 U76009
101877_at Slc31a1 solute carrier family 31,
member 1
1.96 ± 0.18 2.24 ± 0.06 1.02 ± 0.11 -1.15 ± 0.11 AI854432
98457_at Slc4a4 solute carrier family 4
(anion exchanger),
member 4
-1.30 ± 0.13 -3.96 ± 0.11 -1.48 ± 0.13 1.46 ± 0.15 AF020195
XXI
161573_at Slc4a7 solute carrier family 4,
sodium bicarbonate
cotransporter, member 7
-3.75 ± 0.07 -2.01 ± 0.07 -1.12 ± 0.10 1.02 ± 0.16 AV278013
93471_at Slc4a7 solute carrier family 4,
sodium bicarbonate
cotransporter, member 7
-1.51 ± 0.07 -2.17 ± 0.07 1.03 ± 0.14 -1.08 ± 0.12 AI594427




-1.56 ± 0.12 -2.23 ± 0.08 -1.93 ± 0.13 1.25 ± 0.13 AV230927
96276_r_at Smbp SM-11044 binding
protein
-1.80 ± 0.07 -2.50 ± 0.06 -1.03 ± 0.21 1.13 ± 0.16 AI843327




2.51 ± 0.08 1.57 ± 0.11 1.13 ± 0.10 1.66 ± 0.14 AA032310
94550_at Snx1 sorting nexin 1 1.57 ± 0.15 2.03 ± 0.10 1.19 ± 0.10 1.05 ± 0.13 AW121324
102319_at Snx12 sorting nexin 12 1.55 ± 0.08 3.10 ± 0.13 1.31 ± 0.12 -1.22 ± 0.13 AF062484
104651_at Snx14 sorting nexin 14 2.03 ± 0.09 1.50 ± 0.10 1.31 ± 0.10 1.01 ± 0.11 AI839611
160635_at Stx18 syntaxin 18 1.73 ± 0.12 2.97 ± 0.09 1.39 ± 0.13 -1.10 ± 0.10 AI849070
100933_at Stx1a syntaxin 1A (brain) 1.35 ± 0.08 1.34 ± 0.08 -1.98 ± 0.10 -2.29 ± 0.13 D45208
96019_at Sypl synaptophysin-like
protein
2.22 ± 0.18 3.17 ± 0.22 1.51 ± 0.11 -1.01 ± 0.18 AI843476
98339_at Syt11 synaptotagmin 11 2.85 ± 0.07 3.38 ± 0.11 -1.59 ± 0.17 -1.61 ± 0.19 AB026808
160190_at Syt4 synaptotagmin 4 3.50 ± 0.20 1.10 ± 0.06 -1.45 ± 0.10 -1.40 ± 0.10 U10355
103035_at Tap1 transporter 1, ATP-
binding cassette, sub-
family B (MDR/TAP)
-1.48 ± 0.15 1.05 ± 0.11 2.11 ± 0.14 1.45 ± 0.17 U60020
99481_at Atp1a2 ATPase, Na+/K+
transporting, alpha 2
polypeptide
1.02 ± 0.08 -1.64 ± 0.07 -3.57 ± 0.09 -1.03 ± 0.26 AI839697
94739_at Trpc1 transient receptor
potential cation channel,
subfamily C, member 1
1.03 ± 0.10 2.35 ± 0.10 -1.47 ± 0.10 -1.37 ± 0.13 U73625
Table 10.13.  Electron transport
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
99009_at Nnt nicotinamide nucleotide
transhydrogenase
1.89 ± 0.08 1.00 ± 0.08 1.44 ± 0.17 2.31 ± 0.30 Z49204
99985_at Txnrd1 thioredoxin reductase 1 1.40 ± 0.06 2.37 ± 0.06 2.11 ± 0.11 1.13 ± 0.14 AB027565
160194_at Gcdh glutaryl-Coenzyme A
dehydrogenase
-2.80 ± 0.06 -1.35 ± 0.07 -1.30 ± 0.12 -1.03 ± 0.15 U18992
102000_f_at Uqcrc2 ubiquinol cytochrome c
reductase core protein 2
3.40 ± 0.10 2.28 ± 0.11 1.19 ± 0.10 -1.03 ± 0.12 AI842835
103922_f_at 1500005G05Rik RIKEN cDNA
1500005G05 gene
-1.38 ± 0.08 1.73 ± 0.10 4.87 ± 0.97 1.32 ± 0.34 AI839690
100550_f_at Cox6c cytochrome c oxidase,
subunit VIc
2.68 ± 0.07 1.40 ± 0.06 1.02 ± 0.10 -1.06 ± 0.12 AW060422
XXII
96112_at Etfa electron transferring
flavoprotein, alpha
polypeptide
2.30 ± 0.08 1.42 ± 0.07 1.26 ± 0.11 1.65 ± 0.12 AI851178
98918_at Txndc5 thioredoxin domain
containing 5
-3.23 ± 0.12 -1.25 ± 0.06 1.18 ± 0.15 1.10 ± 0.17 AI841920
94209_g_at Txndc7 thioredoxin domain
containing 7
2.11 ± 0.14 3.17 ± 0.17 1.04 ± 0.10 -1.26 ± 0.10 AW045202
94208_at Txndc7 thioredoxin domain
containing 7
2.83 ± 0.07 4.28 ± 0.11 -1.33 ± 0.15 -1.48 ± 0.18 AW045202
162469_r_at Cyc1 cytochrome c-1 -2.83 ± 0.07 -1.84 ± 0.07 -1.06 ± 0.15 -1.09 ± 0.14 AV069997
95072_at Cyc1 cytochrome c-1 2.41 ± 0.06 1.97 ± 0.09 1.15 ± 0.11 -1.20 ± 0.13 AW121892
96773_at Txndc4 thioredoxin domain
containing 4
(endoplasmic reticulum)
2.45 ± 0.11 3.46 ± 0.11 1.38 ± 0.11 1.28 ± 0.18 AW125408
Table 10.14.  Protein biosynthesis
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
100636_at Eif4ebp1 eukaryotic translation
initiation factor 4E
binding protein 1
3.25 ± 0.25 3.89 ± 0.31 3.17 ± 0.33 1.55 ± 0.21 U28656
101213_at Arbp acidic ribosomal
phosphoprotein P0
2.51 ± 0.07 2.46 ± 0.06 1.12 ± 0.11 -1.06 ± 0.15 X15267
104048_at Cars cysteinyl-tRNA
synthetase
2.11 ± 0.07 3.77 ± 0.11 1.23 ± 0.34 -1.32 ± 0.13 AI848732
94766_at Eef1a1 eukaryotic translation
elongation factor 1
alpha 1
2.43 ± 0.06 2.62 ± 0.07 1.06 ± 0.11 -1.14 ± 0.12 M17878





1.09 ± 0.07 2.04 ± 0.06 1.30 ± 0.10 1.16 ± 0.17 AI839632
94462_at Eif2b1 eukaryotic translation
initiation factor 2B,
subunit 1 (alpha)
1.68 ± 0.23 2.25 ± 0.06 1.57 ± 0.10 -1.15 ± 0.11 AW120719
94530_at Eif2b2 eukaryotic translation
initiation factor 2B,
subunit 2 beta
1.73 ± 0.07 2.77 ± 0.08 1.34 ± 0.21 -1.16 ± 0.13 AI840376
160554_at Eif3s6 eukaryotic translation
initiation factor 3,
subunit 6
2.13 ± 0.19 1.19 ± 0.06 1.06 ± 0.10 1.21 ± 0.14 AI839363
100557_g_at Eif4b eukaryotic translation
initiation factor 4B
2.01 ± 0.09 2.65 ± 0.06 -1.25 ± 0.10 1.32 ± 0.12 AW121930
98608_at Etf1 eukaryotic translation
termination factor 1
1.95 ± 0.09 2.13 ± 0.16 1.70 ± 0.14 -1.01 ± 0.14 AI845886
160451_at Etf1 eukaryotic translation
termination factor 1




1.42 ± 0.07 2.91 ± 0.08 1.16 ± 0.10 -1.37 ± 0.10 AI851129
161683_r_at Gtpbp1 GTP binding protein 1 -2.94 ± 0.07 -3.60 ± 0.06 -1.31 ± 0.09 -1.16 ± 0.10 AV239949
93752_at Iars isoleucine-tRNA
synthetase
2.12 ± 0.07 3.22 ± 0.07 1.17 ± 0.26 -1.32 ± 0.14 AI848393
XXIII
100136_at Lamp2 lysosomal membrane
glycoprotein 2
1.32 ± 0.12 1.24 ± 0.09 2.39 ± 0.12 2.48 ± 0.31 M32017
102019_at Mrpl13 mitochondrial
ribosomal protein L13
2.22 ± 0.07 2.07 ± 0.13 1.61 ± 0.10 1.15 ± 0.16 AA666635
99140_at Mrpl16 mitochondrial
ribosomal protein L16
2.31 ± 0.09 2.16 ± 0.19 1.63 ± 0.19 -1.31 ± 0.13 AW124920
98120_at Mrpl27 mitochondrial
ribosomal protein L27
1.97 ± 0.08 2.27 ± 0.07 1.56 ± 0.15 -1.05 ± 0.15 AI844807
102058_at Mrpl9 mitochondrial
ribosomal protein L9
2.03 ± 0.08 2.52 ± 0.15 1.24 ± 0.14 -1.08 ± 0.18 AI845667
97884_at Mrps11 mitochondrial
ribosomal protein S11




1.39 ± 0.07 2.10 ± 0.10 1.27 ± 0.10 -1.19 ± 0.12 AI846849
160423_at Mrps2 mitochondrial
ribosomal protein S2




2.95 ± 0.19 2.34 ± 0.12 1.11 ± 0.10 1.05 ± 0.17 AI875598
95070_at Nars asparaginyl-tRNA
synthetase
1.66 ± 0.07 2.35 ± 0.11 1.32 ± 0.19 -1.52 ± 0.12 AW125874
96693_at Rars arginyl-tRNA
synthetase
2.10 ± 0.10 3.57 ± 0.26 2.54 ± 0.37 -1.16 ± 0.16 AI849453
94767_at Rnu35b /// Rps11 RNA, U35b small
nucleolar /// ribosomal
protein S11
2.66 ± 0.07 2.27 ± 0.06 1.26 ± 0.11 -1.03 ± 0.17 U93864
100711_at Rpl10a ribosomal protein
L10A
1.98 ± 0.10 2.15 ± 0.06 1.20 ± 0.10 1.05 ± 0.15 U12403
102109_at Rpl13 ribosomal protein L13 2.24 ± 0.08 2.51 ± 0.07 1.30 ± 0.15 -1.01 ± 0.18 U28917
96290_f_at Rpl21 ribosomal protein L21 2.09 ± 0.06 1.74 ± 0.08 1.10 ± 0.10 -1.07 ± 0.13 U93863
92857_at Rpl22 ribosomal protein L22 1.74 ± 0.06 2.37 ± 0.07 1.14 ± 0.14 -1.32 ± 0.13 AI853960
100729_at Rpl26 ribosomal protein L26 2.42 ± 0.11 2.11 ± 0.06 1.27 ± 0.12 -1.03 ± 0.15 X80699
100734_at Rpl3 ribosomal protein L3 2.34 ± 0.08 2.32 ± 0.12 1.26 ± 0.12 -1.02 ± 0.16 Y00225
160081_at Rpl36a ribosomal protein L36a 2.03 ± 0.07 1.06 ± 0.12 -1.04 ± 0.10 1.14 ± 0.12 AW045418
92577_f_at Rpl37 ribosomal protein L37 2.06 ± 0.06 1.71 ± 0.06 1.21 ± 0.10 -1.11 ± 0.13 AW047116
101129_at Rpl5 ribosomal protein L5 2.03 ± 0.07 1.80 ± 0.06 1.27 ± 0.12 -1.03 ± 0.15 X83590
96962_at Rpl6 ribosomal protein L6 1.84 ± 0.07 1.96 ± 0.07 1.22 ± 0.13 -1.03 ± 0.16 X81987
97695_s_at Rpl7 ribosomal protein L7 2.12 ± 0.06 1.71 ± 0.06 1.15 ± 0.10 1.02 ± 0.12 M29015
98168_at Rpl7a ribosomal protein L7a 2.22 ± 0.06 2.23 ± 0.08 1.26 ± 0.13 1.00 ± 0.15 M14689
100694_at Rplp1 ribosomal protein,
large, P1
1.96 ± 0.06 2.56 ± 0.08 1.16 ± 0.13 -1.06 ± 0.15 U29402
160071_at Rpp30 ribonuclease P/MRP
30kDa subunit
(human)
1.90 ± 0.07 2.08 ± 0.10 1.04 ± 0.10 -1.41 ± 0.10 U95123
100686_at Rps2 ribosomal protein S2 2.11 ± 0.06 2.01 ± 0.08 1.17 ± 0.10 -1.11 ± 0.12 M20632
96300_f_at Rps27 ribosomal protein S27 2.29 ± 0.07 2.07 ± 0.10 1.27 ± 0.13 1.04 ± 0.17 AI854238
101137_at Rps3 ribosomal protein S3 2.03 ± 0.09 2.06 ± 0.06 1.28 ± 0.13 -1.10 ± 0.16 X76772
101664_at Rps3a ribosomal protein S3a 2.29 ± 0.08 2.39 ± 0.07 1.16 ± 0.11 -1.04 ± 0.15 Z83368
99336_at Rps5 ribosomal protein S5 1.98 ± 0.06 2.00 ± 0.06 1.28 ± 0.13 -1.02 ± 0.17 U78085
101577_at Rps6 ribosomal protein S6 2.03 ± 0.13 1.76 ± 0.06 1.25 ± 0.10 1.06 ± 0.13 Z54209
XXIV
101212_at Rps7 ribosomal protein S7 2.67 ± 0.07 2.45 ± 0.06 1.15 ± 0.12 -1.09 ± 0.17 AF043285
95054_at Tars threonyl-tRNA
synthetase
1.50 ± 0.15 2.50 ± 0.07 1.48 ± 0.22 -1.17 ± 0.13 AI849620
93564_at Yars tyrosyl-tRNA
synthetase
1.00 ± 0.08 2.05 ± 0.09 1.14 ± 0.25 -1.70 ± 0.13 AW122542
Table 10.15.  Protein transport
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
104297_at Ipo11 importin 11 1.20 ± 0.07 2.26 ± 0.07 1.29 ± 0.17 -1.13 ± 0.15 AW124742
95034_f_at Ipo4 importin 4 2.15 ± 0.10 1.71 ± 0.10 1.18 ± 0.10 -1.09 ± 0.13 AW212243
101104_at Dscr3 Down syndrome critical
region gene 3
1.65 ± 0.07 2.00 ± 0.13 1.13 ± 0.10 -1.09 ± 0.15 AB001990




-1.70 ± 0.09 1.85 ± 0.13 1.94 ± 0.20 1.29 ± 0.24 AF070975
94870_f_at Sara2 SAR1a gene homolog 2
(S. cerevisiae)
2.13 ± 0.12 2.16 ± 0.07 1.37 ± 0.11 -1.22 ± 0.17 AW124226
100074_at 2400003B06Rik RIKEN cDNA
2400003B06 gene
-6.99 ± 0.06 1.31 ± 0.20 1.59 ± 0.14 -1.34 ± 0.13 AW046723
160183_f_at 3930401E15Rik RIKEN cDNA
3930401E15 gene
2.83 ± 0.22 1.51 ± 0.07 1.19 ± 0.14 -1.16 ± 0.10 AI846109
92968_at Arf5 ADP-ribosylation factor
5
-2.76 ± 0.06 -1.66 ± 0.06 -1.05 ± 0.13 -1.36 ± 0.10 D87902
160868_at Rab3b RAB3B, member RAS
oncogene family
1.71 ± 0.24 1.92 ± 0.08 -1.89 ± 0.10 -2.30 ± 0.10 AI835990
101933_at Rab10 RAB10, member RAS
oncogene family
2.55 ± 0.13 1.42 ± 0.06 -1.39 ± 0.11 -1.49 ± 0.14 AF035646
97222_at Rab6 RAB6, member RAS
oncogene family
-1.97 ± 0.06 -2.09 ± 0.07 -1.20 ± 0.10 -1.14 ± 0.11 AI845921
98927_at Rab6 RAB6, member RAS
oncogene family
2.38 ± 0.11 1.10 ± 0.08 -1.14 ± 0.14 -1.44 ± 0.10 AI851048
160795_at Scamp1 secretory carrier
membrane protein 1
1.50 ± 0.10 2.23 ± 0.12 1.11 ± 0.16 -1.58 ± 0.11 AW123662
98106_at Timm44 translocator of inner
mitochondrial
membrane 44
1.87 ± 0.16 2.61 ± 0.08 1.14 ± 0.10 1.01 ± 0.12 U69898
104453_at 2310079P12Rik RIKEN cDNA
2310079P12 gene
2.78 ± 0.12 3.44 ± 0.06 1.89 ± 0.34 -1.02 ± 0.21 AW046336
95022_at Akap12 A kinase (PRKA)
anchor protein (gravin)
12
1.19 ± 0.09 -1.03 ± 0.08 3.13 ± 0.30 1.02 ± 0.10 AB020886
99156_at 2700099C19Rik RIKEN cDNA
2700099C19 gene




-2.09 ± 0.07 -1.94 ± 0.06 -1.02 ± 0.14 -1.04 ± 0.13 AB001927
101370_at Kpna1 karyopherin (importin)
alpha 1
2.02 ± 0.07 2.66 ± 0.14 1.14 ± 0.15 -1.37 ± 0.10 U20619
92790_at Kpna2 karyopherin (importin)
alpha 2
2.13 ± 0.16 1.39 ± 0.08 1.08 ± 0.10 1.44 ± 0.15 D55720
XXV
100710_at Vcp valosin containing
protein
1.76 ± 0.06 2.65 ± 0.08 2.10 ± 0.28 -1.02 ± 0.14 Z14044
Table 10.16.  Signal transduction
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
100439_i_at Ank1 ankyrin 1, erythroid -2.36 ± 0.10 -2.57 ± 0.06 -1.36 ± 0.11 -1.12 ± 0.11 U76758
100065_r_at Gja1 gap junction membrane
channel protein alpha 1
-1.68 ± 0.08 -2.55 ± 0.08 1.83 ± 0.19 1.96 ± 0.17 M63801
97195_at Gnai1 guanine nucleotide
binding protein, alpha
inhibiting 1
1.53 ± 0.13 2.49 ± 0.14 -1.76 ± 0.09 -1.96 ± 0.16 U38501
100386_at Gnaz guanine nucleotide
binding protein, alpha z
subunit
1.39 ± 0.11 1.99 ± 0.10 -1.67 ± 0.12 -2.10 ± 0.11 AF056973
160747_at Rgs3 regulator of G-protein
signaling 3
-2.16 ± 0.06 -1.35 ± 0.07 -1.35 ± 0.10 -1.02 ± 0.11 AI844739
92434_at Traip TRAF-interacting
protein
1.75 ± 0.13 2.66 ± 0.12 1.24 ± 0.10 -1.06 ± 0.12 U77844
97308_at 5730466P16Rik RIKEN cDNA
5730466P16 gene
1.75 ± 0.08 2.51 ± 0.09 1.16 ± 0.13 -1.21 ± 0.13 AI835409
99491_at Il10rb interleukin 10 receptor,
beta
-2.07 ± 0.16 -3.73 ± 0.07 -1.01 ± 0.11 1.25 ± 0.13 U53696
101096_s_at Hs1bp1 HS1 binding protein 2.20 ± 0.09 2.88 ± 0.06 1.42 ± 0.14 -1.07 ± 0.13 AF023482
102255_at Osmr oncostatin M receptor -1.83 ± 0.41 -1.59 ± 0.25 3.84 ± 0.17 2.70 ± 0.21 AB015978
92738_at Gdnf glial cell line derived
neurotrophic factor
-1.89 ± 0.09 -2.64 ± 0.07 -1.05 ± 0.10 -1.01 ± 0.12 D49921
104499_at Homer1 homer homolog 1
(Drosophila)
2.48 ± 0.22 1.89 ± 0.17 -1.08 ± 0.13 -2.12 ± 0.14 AB019479
102726_at Tac1 tachykinin 1 2.40 ± 0.23 2.00 ± 0.17 1.97 ± 0.19 -1.14 ± 0.13 D17584
103235_at Npy neuropeptide Y 1.09 ± 0.08 -1.19 ± 0.06 -3.07 ± 0.09 -3.12 ± 0.10 AI848386
102379_at Rassf1 Ras association
(RalGDS/AF-6) domain
family 1
1.47 ± 0.13 2.40 ± 0.11 -1.12 ± 0.10 -1.04 ± 0.13 AW049415
94290_at Akt1s1 AKT1 substrate 1
(proline-rich)
1.59 ± 0.08 2.78 ± 0.12 1.36 ± 0.11 -1.12 ± 0.12 AW124346
98434_at Arhgef7 Rho guanine nucleotide
exchange factor (GEF7)
1.93 ± 0.09 2.45 ± 0.08 1.10 ± 0.18 -1.20 ± 0.14 U96634




1.67 ± 0.15 2.25 ± 0.17 -2.29 ± 0.13 -1.96 ± 0.20 U50413
100057_at 2510027N19Rik RIKEN cDNA
2510027N19 gene
2.18 ± 0.13 2.60 ± 0.09 1.78 ± 0.16 1.08 ± 0.15 AI838320
98766_at Sh3bp5 SH3-domain binding
protein 5 (BTK-
associated)
1.53 ± 0.08 2.72 ± 0.19 -1.61 ± 0.10 -1.37 ± 0.11 AB016835
100024_at Shrm shroom -1.26 ± 0.07 -1.66 ± 0.07 2.17 ± 0.35 2.77 ± 0.18 AI641895
96572_at Azi2 5-azacytidine induced
gene 2
2.19 ± 0.19 2.03 ± 0.10 1.24 ± 0.27 -1.41 ± 0.12 AW047232
94006_at Azi2 5-azacytidine induced
gene 2
3.29 ± 0.28 2.49 ± 0.15 -1.19 ± 0.13 -1.21 ± 0.11 AB007141
XXVI
103328_at Tank TRAF family member-
associated Nf-kappa B
activator
2.65 ± 0.11 2.42 ± 0.10 1.66 ± 0.13 1.29 ± 0.14 U59864
103653_at Mras muscle and microspikes
RAS
1.93 ± 0.14 2.24 ± 0.11 -1.01 ± 0.10 -1.24 ± 0.10 AB004879
92376_at Rit1 Ras-like without CAAX
1
1.28 ± 0.07 1.70 ± 0.08 2.16 ± 0.34 -1.07 ± 0.11 U71205
103224_at Rab33a RAB33A, member of
RAS oncogene family
1.04 ± 0.06 -1.27 ± 0.07 -2.04 ± 0.09 -2.33 ± 0.11 D83277
101866_at Arfrp1 ADP-ribosylation factor
related protein 1
2.02 ± 0.15 2.91 ± 0.15 1.10 ± 0.15 -1.06 ± 0.13 AW060486
102083_at Rit2 Ras-like without CAAX
2
-2.65 ± 0.12 -1.22 ± 0.11 -1.09 ± 0.11 -1.22 ± 0.15 AF084463
93730_at Syn1 synapsin I 2.19 ± 0.07 2.18 ± 0.06 1.35 ± 0.11 1.06 ± 0.18 AF085809
Table 10.17.  Calcium binding
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
100569_at Anxa2 annexin A2 1.45 ± 0.09 1.80 ± 0.08 4.56 ± 0.25 2.84 ± 0.43 M14044
92539_at S100a10 S100 calcium binding protein
A10 (calpactin)
-1.80 ± 0.10 -1.23 ± 0.06 4.77 ± 0.55 2.54 ± 0.22 M16465
98600_at S100a11 S100 calcium binding protein
A11 (calizzarin)
-3.12 ± 0.08 -3.10 ± 0.06 5.31 ± 0.85 8.03 ± 0.50 U41341
100959_at S100a13 S100 calcium binding protein
A13
-3.02 ± 0.08 -3.37 ± 0.13 -1.23 ± 0.12 1.52 ± 0.11 X99921
100960_g_at S100a13 S100 calcium binding protein
A13
-1.44 ± 0.11 -2.27 ± 0.07 -1.08 ± 0.10 1.42 ± 0.10 X99921
162428_i_at S100a14 S100 calcium binding protein
A14
-3.78 ± 0.06 -3.92 ± 0.06 -1.46 ± 0.10 -1.28 ± 0.12 AV293396
94886_at Canx calnexin -3.08 ± 0.08 -3.06 ± 0.06 -1.14 ± 0.15 -1.16 ± 0.11 L18888
102197_at Nucb2 nucleobindin 2 2.32 ± 0.18 1.90 ± 0.15 -1.04 ± 0.11 -1.78 ± 0.11 AJ222586
Table 10.18.  DNA and RNA
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
161756_at 4833420N02Rik RIKEN cDNA 4833420N02
gene




2.02 ± 0.07 1.68 ± 0.07 1.25 ± 0.11 1.10 ± 0.13 AJ007780
95879_at Asf1a ASF1 anti-silencing function
1 homolog A (S. cerevisiae)
1.57 ± 0.09 -2.11 ± 0.08 1.03 ± 0.10 1.03 ± 0.12 C79052
96775_at Cbx1 chromobox homolog 1
(Drosophila HP1 beta)
4.97 ± 0.10 1.47 ± 0.13 -1.36 ± 0.14 1.16 ± 0.12 X56690
94506_at Cpsf5 cleavage and polyadenylation
specific factor 5
2.43 ± 0.13 1.79 ± 0.07 1.23 ± 0.11 1.14 ± 0.16 AI853113
XXVII
160751_i_at Crnkl1 Crn, crooked neck-like 1
(Drosophila)
2.62 ± 0.08 1.87 ± 0.12 -1.03 ± 0.11 -1.10 ± 0.14 AA216808
102853_at Cspg6 chondroitin sulfate
proteoglycan 6
2.02 ± 0.07 2.09 ± 0.13 -1.02 ± 0.12 -1.19 ± 0.10 Y15128
99544_at Dguok deoxyguanosine kinase 2.10 ± 0.07 2.44 ± 0.12 1.29 ± 0.16 -1.08 ± 0.17 AA980916
103891_i_at Ell2 elongation factor RNA
polymerase II 2
1.69 ± 0.14 1.72 ± 0.16 3.50 ± 0.41 1.49 ± 0.15 AI197161
103036_at G22p1 thyroid autoantigen 2.30 ± 0.15 1.78 ± 0.08 1.46 ± 0.11 1.47 ± 0.11 M38700
100371_at Hnrpa1 heterogeneous nuclear
ribonucleoprotein A1
1.51 ± 0.18 2.02 ± 0.11 -1.08 ± 0.13 -1.20 ± 0.13 U65316
97759_at Kcnma1 potassium large conductance
calcium-activated channel,
subfamily M, alpha member
1
-1.13 ± 0.07 -2.82 ± 0.06 -1.44 ± 0.10 -1.45 ± 0.11 U09383
97907_at Lsm7 LSM7 homolog, U6 small
nuclear RNA associated (S.
cerevisiae)
2.07 ± 0.09 1.73 ± 0.07 1.53 ± 0.11 -1.12 ± 0.17 AW049564
93356_at Mcm7 minichromosome
maintenance deficient 7 (S.
cerevisiae)
1.97 ± 0.09 2.59 ± 0.08 1.14 ± 0.10 1.22 ± 0.15 D26091
94376_s_at Mre11a meiotic recombination 11
homolog A (S. cerevisiae)
3.09 ± 0.21 3.00 ± 0.23 1.52 ± 0.13 -1.18 ± 0.11 U60318
102819_at Nap1l2 nucleosome assembly protein
1-like 2
2.20 ± 0.07 2.57 ± 0.11 1.24 ± 0.17 -1.33 ± 0.10 X92352
92893_at Nfia nuclear factor I/A 2.60 ± 0.13 1.14 ± 0.08 -1.15 ± 0.10 1.92 ± 0.17 D90173
101930_at Nfix nuclear factor I/X 2.32 ± 0.07 1.55 ± 0.08 -1.39 ± 0.11 1.00 ± 0.15 Y07688
93830_at Nono non-POU-domain-containing,
octamer binding protein
2.24 ± 0.07 1.82 ± 0.09 -1.06 ± 0.10 -1.14 ± 0.13 AI851199
93831_at Nono non-POU-domain-containing,
octamer binding protein
2.66 ± 0.10 2.71 ± 0.14 -1.10 ± 0.12 -1.05 ± 0.11 AI316087
95712_at Orc6l origin recognition complex,
subunit 6-like (S. cerevisiae)
2.02 ± 0.11 2.51 ± 0.09 1.16 ± 0.13 -1.07 ± 0.12 AW045261
104690_at Polm polymerase (DNA directed),
mu
-2.12 ± 0.10 -1.75 ± 0.06 -1.26 ± 0.10 -1.14 ± 0.10 AI462166
95549_at Prim2 DNA primase, p58 subunit 2.23 ± 0.22 1.59 ± 0.10 1.23 ± 0.12 1.15 ± 0.13 D13545
96103_f_at Rad23b RAD23b homolog (S.
cerevisiae)
1.87 ± 0.09 2.85 ± 0.18 1.77 ± 0.22 -1.24 ± 0.10 X92411
160466_at Rae1 RAE1 RNA export 1
homolog (S. pombe)
1.56 ± 0.07 2.30 ± 0.07 1.56 ± 0.13 -1.10 ± 0.14 AI048716
97254_at Rbm8 RNA binding motif protein 8 2.47 ± 0.10 2.57 ± 0.06 1.60 ± 0.12 -1.16 ± 0.13 AA690061
160192_at Rbmxrt RNA binding motif protein,
X chromosome retrogene
2.43 ± 0.07 2.10 ± 0.06 1.20 ± 0.14 -1.14 ± 0.13 AF031568
160072_at Rfc3 replication factor C (activator
1) 3
2.21 ± 0.12 2.11 ± 0.08 1.10 ± 0.10 1.08 ± 0.17 AV026570
103418_at Rfc4 replication factor C (activator
1) 4
3.54 ± 0.17 2.36 ± 0.10 1.34 ± 0.11 1.21 ± 0.26 AW122092
92196_f_at Sf3a2 splicing factor 3a, subunit 2 -2.77 ± 0.06 -1.44 ± 0.06 -1.08 ± 0.12 -1.11 ± 0.11 X83733
XXVIII
97808_at Sf3b1 splicing factor 3b, subunit 1 2.91 ± 0.07 2.16 ± 0.11 1.23 ± 0.11 -1.13 ± 0.10 AI844532




1.20 ± 0.16 2.03 ± 0.11 1.28 ± 0.18 -1.01 ± 0.12 AF042799
95791_s_at Sfrs2 splicing factor,
arginine/serine-rich 2 (SC-
35)
2.26 ± 0.07 2.13 ± 0.12 1.13 ± 0.12 -1.18 ± 0.10 U14648
160869_at Sirt3 sirtuin 3 (silent mating type
information regulation 2,
homolog) 3 (S. cerevisiae)
1.87 ± 0.22 2.31 ± 0.10 1.10 ± 0.10 -1.38 ± 0.10 AI849490
93701_at Smarca5 SWI/SNF related, matrix
associated, actin dependent
regulator of chromatin,
subfamily a, member 5
2.05 ± 0.28 2.22 ± 0.13 1.31 ± 0.12 1.22 ± 0.14 AA982124
102062_at Smarcc1 SWI/SNF related, matrix
associated, actin dependent
regulator of chromatin,
subfamily c, member 1
2.65 ± 0.11 1.31 ± 0.12 -1.04 ± 0.12 -1.23 ± 0.13 U85614
94034_at Smfn small fragment nuclease 1.56 ± 0.19 1.50 ± 0.11 2.00 ± 0.16 -1.03 ± 0.11 AI839882
103302_r_at Sox3 SRY-box containing gene 3 -3.45 ± 0.07 -2.25 ± 0.06 -1.12 ± 0.11 1.29 ± 0.11 AA866668
100957_at Ssbp1 single-stranded DNA binding
protein 1
1.83 ± 0.10 1.45 ± 0.07 2.01 ± 0.10 1.34 ± 0.13 AA881160
101356_at Tk2 thymidine kinase 2,
mitochondrial
1.63 ± 0.09 2.13 ± 0.09 -1.08 ± 0.11 -1.47 ± 0.10 AI843384
99578_at Top2a topoisomerase (DNA) II
alpha
2.15 ± 0.07 1.56 ± 0.08 1.01 ± 0.12 1.82 ± 0.10 U01915
Table 10.19.  Protein modification
Time points (h) GenbankProbe id Symbol Gene Title












2.15 ± 0.33 -1.48 ± 0.11 -1.23 ± 0.16 -1.17 ± 0.12 AI845633





2.29 ± 0.07 2.73 ± 0.06 1.05 ± 0.16 -1.24 ± 0.10 AW108492
161021_at Pak3 p21 (CDKN1A)-
activated kinase 3





1.22 ± 0.13 -5.24 ± 0.07 1.55 ± 0.14 -1.07 ± 0.25 AV319920
93311_at Clk3 CDC-like kinase 3 1.98 ± 0.07 2.25 ± 0.11 1.23 ± 0.16 -1.11 ± 0.12 AF033565
101937_s_a
t





1.01 ± 0.17 2.91 ± 0.24 -1.03 ± 0.10 -1.23 ± 0.12 U58497
XXIX








2.91 ± 0.28 1.55 ± 0.19 -1.02 ± 0.10 -1.23 ± 0.14 AF079535




2.11 ± 0.13 2.01 ± 0.19 1.00 ± 0.14 1.85 ± 0.13 AF002823
101834_at Mapk3 mitogen activated
protein kinase 3
1.97 ± 0.09 2.13 ± 0.27 -1.78 ± 0.12 1.04 ± 0.20 Z14249
98771_at Ephb2 Eph receptor B2 2.86 ± 0.08 2.67 ± 0.13 -2.00 ± 0.17 -1.42 ± 0.17 L25890
95298_at Epha3 Eph receptor A3 2.43 ± 0.15 2.23 ± 0.15 -1.43 ± 0.10 -1.31 ± 0.21 M68513
161119_at Epha5 Eph receptor A5 2.28 ± 0.15 1.60 ± 0.07 -1.23 ± 0.11 -1.23 ± 0.12 AI854630
98446_s_at Ephb4 Eph receptor B4 2.48 ± 0.09 3.16 ± 0.09 1.53 ± 0.11 -1.11 ± 0.12 U06834
161964_r_a
t
Prkcz protein kinase C,
zeta
-2.07 ± 0.12 -3.14 ± 0.08 -1.38 ± 0.12 -1.10 ± 0.12 AV367375
97925_at Csnk1e casein kinase 1,
epsilon
2.88 ± 0.09 2.56 ± 0.14 1.04 ± 0.28 -1.57 ± 0.18 AB028241
98087_at Tbk1 TANK-binding
kinase 1
1.93 ± 0.27 2.61 ± 0.10 1.54 ± 0.12 1.09 ± 0.13 AW048562
97393_at Vrk1 vaccinia related
kinase 1
2.28 ± 0.12 2.00 ± 0.20 1.31 ± 0.17 1.02 ± 0.13 AF080253
92659_at Rapgef4 Rap guanine
nucleotide exchange
factor (GEF) 4
1.61 ± 0.20 1.07 ± 0.19 -1.71 ± 0.11 -2.50 ± 0.13 AF115480
93285_at Dusp6 dual specificity
phosphatase 6
-2.06 ± 0.07 -1.83 ± 0.06 1.49 ± 0.10 -1.36 ± 0.11 AI845584
100908_at Ptpra protein tyrosine
phosphatase,
receptor type, A
1.44 ± 0.16 1.93 ± 0.06 -1.16 ± 0.10 -1.29 ± 0.14 M36033
160760_at Ptprk protein tyrosine
phosphatase,
receptor type, K
1.55 ± 0.07 1.23 ± 0.06 -2.20 ± 0.09 -1.44 ± 0.11 L10106
92303_at Ptprr protein tyrosine
phosphatase,
receptor type, R
2.58 ± 0.07 2.11 ± 0.07 -1.35 ± 0.10 -1.41 ± 0.10 D31898
104422_at Ptprn protein tyrosine
phosphatase,
receptor type, N
-1.22 ± 0.07 1.12 ± 0.07 2.90 ± 0.15 -1.05 ± 0.11 U11812
93219_at Acp1 acid phosphatase 1,
soluble
1.94 ± 0.12 3.74 ± 0.13 1.13 ± 0.19 -1.10 ± 0.12 Y17343





1.11 ± 0.15 2.08 ± 0.07 1.30 ± 0.11 1.13 ± 0.12 AI006319








1.42 ± 0.17 2.21 ± 0.08 -1.15 ± 0.10 -2.00 ± 0.11 AW120868
104238_at Art5 ADP-
ribosyltransferase 5







-2.72 ± 0.07 -3.21 ± 0.06 -1.02 ± 0.13 -1.03 ± 0.11 AV089873
100684_at Prkcsh protein kinase C
substrate 80K-H









-3.57 ± 0.07 -2.88 ± 0.07 -1.90 ± 0.13 -1.08 ± 0.15 AV161234
XXXI
Table 10.20.  Cytoskeleton
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
162379_r_at Vim vimentin -8.34 ± 0.07 -7.48 ± 0.08 -1.49 ± 0.10 -1.01 ± 0.12 AV245272
93100_at Acta2 actin, alpha 2, smooth
muscle, aorta
-2.11 ± 0.07 -4.06 ± 0.08 1.68 ± 0.37 3.89 ± 0.49 X13297
95705_s_at Actb actin, beta, cytoplasmic -10.94 ± 0.06 -6.82 ± 0.05 1.45 ± 0.22 -1.67 ± 0.26 J04181
96573_at Actg actin, gamma,
cytoplasmic
2.40 ± 0.06 2.17 ± 0.06 -1.10 ± 0.10 -1.13 ± 0.11 M21495
102108_f_at Myh9 myosin heavy chain IX 1.69 ± 0.31 1.30 ± 0.07 3.20 ± 0.24 1.82 ± 0.16 AI505453
100923_at Myo10 myosin X 1.31 ± 0.07 1.03 ± 0.08 1.48 ± 0.14 2.09 ± 0.13 AJ249706
96426_at Tmsb4x thymosin, beta 4, X
chromosome
2.12 ± 0.07 1.75 ± 0.06 -1.04 ± 0.11 -1.19 ± 0.12 U38967
93541_at Tagln transgelin -1.63 ± 0.09 -2.06 ± 0.07 2.53 ± 0.49 4.16 ± 0.53 Z68618
100398_at Kif3a kinesin family member
3A
2.05 ± 0.08 1.69 ± 0.11 1.13 ± 0.14 1.06 ± 0.13 D12645
161003_at Kif3b kinesin family member
3B
1.58 ± 0.09 2.19 ± 0.09 -3.12 ± 0.11 -1.51 ± 0.22 D26077
94835_f_at Tubb2 tubulin, beta 2 2.03 ± 0.06 2.31 ± 0.08 1.03 ± 0.10 -1.37 ± 0.11 M28739
94789_r_at Tubb5 tubulin, beta 5 2.20 ± 0.06 2.71 ± 0.07 1.03 ± 0.13 -1.28 ± 0.13 X04663
98759_f_at Tuba2 tubulin, alpha 2 2.16 ± 0.09 2.48 ± 0.06 1.08 ± 0.12 -1.19 ± 0.13 M28727
160462_f_at Tubb3 tubulin, beta 3 1.64 ± 0.07 2.04 ± 0.07 -1.03 ± 0.10 -1.29 ± 0.11 AW050256
101419_at Tubb4 tubulin, beta 4 -2.16 ± 0.06 -1.56 ± 0.06 -1.17 ± 0.12 -1.70 ± 0.10 M28730
99924_at Tubg1 tubulin, gamma 1 2.00 ± 0.12 2.48 ± 0.17 1.09 ± 0.11 -1.04 ± 0.14 AW121845
100342_i_at Tuba1 tubulin, alpha 1 2.54 ± 0.09 2.84 ± 0.08 1.03 ± 0.11 -1.21 ± 0.12 M28729
101543_f_at Tuba6 tubulin, alpha 6 2.41 ± 0.06 3.07 ± 0.06 1.06 ± 0.12 -1.19 ± 0.14 M13441
102742_g_at Mapt microtubule-associated
protein tau
3.07 ± 0.07 2.10 ± 0.06 -1.16 ± 0.12 -1.51 ± 0.11 M18775
99541_at Kif11 kinesin family member
11
2.01 ± 0.13 1.08 ± 0.07 -1.10 ± 0.11 1.41 ± 0.14 AJ223293
101929_at 6720463E02Rik RIKEN cDNA
6720463E02 gene
-2.25 ± 0.06 2.00 ± 0.06 1.28 ± 0.10 -1.50 ± 0.11 AI836322
97276_at Ckap1 cytoskeleton-associated
protein 1
1.98 ± 0.10 1.81 ± 0.13 1.27 ± 0.18 -1.36 ± 0.14 AI853425
160461_f_at 2310057H16Rik RIKEN cDNA
2310057H16 gene
-1.07 ± 0.12 1.43 ± 0.06 2.94 ± 0.26 2.18 ± 0.13 AW215736
97909_at Stmn1 stathmin 1 2.11 ± 0.08 2.21 ± 0.06 -1.15 ± 0.10 -1.29 ± 0.12 AI838080
Table 10.21.  Cell adhesion
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
104407_at Alcam activated leukocyte cell
adhesion molecule
2.94 ± 0.09 -1.22 ± 0.07 -1.25 ± 0.15 -1.18 ± 0.14 L25274
98140_at Cdh1 cadherin 1 -2.68 ± 0.07 -2.72 ± 0.09 -1.25 ± 0.10 -1.16 ± 0.13 X60961
104743_at Cdh13 cadherin 13 1.93 ± 0.18 1.29 ± 0.10 -1.74 ± 0.10 -2.45 ± 0.10 AB022100
95898_at Cdh4 cadherin 4 2.30 ± 0.08 1.55 ± 0.07 -1.12 ± 0.10 -1.03 ± 0.11 X69966
101701_at Cdh8 cadherin 8 1.98 ± 0.16 1.13 ± 0.09 -2.37 ± 0.10 -1.42 ± 0.14 X95600
XXXII
94305_at Col1a1 procollagen, type I, alpha 1 -1.71 ± 0.38 -8.55 ± 0.07 -1.14 ± 0.22 1.38 ± 0.22 U03419
161156_r_at Col1a2 procollagen, type I, alpha 2 -2.53 ± 0.11 -2.69 ± 0.06 -1.37 ± 0.11 -1.23 ± 0.11 AV230631
101093_at Col4a1 procollagen, type IV, alpha 1 -1.66 ± 0.07 -2.24 ± 0.07 1.18 ± 0.10 1.21 ± 0.16 M15832
92567_at Col5a2 procollagen, type V, alpha 2 1.02 ± 0.16 -1.40 ± 0.08 2.05 ± 0.33 2.12 ± 0.38 L02918
102070_at Col9a3 procollagen, type IX, alpha 3 -2.19 ± 0.08 -1.67 ± 0.07 1.04 ± 0.11 1.26 ± 0.13 AW212495
93529_at D8Wsu49e DNA segment, Chr 8, Wayne
State University 49, expressed
-1.57 ± 0.07 -2.08 ± 0.07 -1.44 ± 0.10 -1.19 ± 0.10 AW125219
160649_at Gp1bb glycoprotein Ib, beta
polypeptide
-1.09 ± 0.09 -1.04 ± 0.09 -2.14 ± 0.10 -1.84 ± 0.11 AB001419
95511_at Itga6 integrin alpha 6 1.63 ± 0.12 1.43 ± 0.11 2.19 ± 0.13 1.77 ± 0.15 X69902
92366_at Lama2 laminin, alpha 2 2.42 ± 0.13 1.62 ± 0.20 1.40 ± 0.12 -1.22 ± 0.15 U12147
99669_at Lgals1 lectin, galactose binding,
soluble 1
-1.06 ± 0.07 -1.03 ± 0.06 4.01 ± 0.36 5.89 ± 0.72 X15986
161708_f_at Mpdz multiple PDZ domain protein -1.01 ± 0.39 -3.97 ± 0.16 1.48 ± 0.14 1.29 ± 0.17 AV244715
96582_at Ncam2 neural cell adhesion molecule
2
2.05 ± 0.21 1.79 ± 0.11 -1.79 ± 0.10 -1.07 ± 0.18 AF001287
160469_at Thbs1 thrombospondin 1 -2.17 ± 0.07 -3.20 ± 0.06 2.16 ± 0.39 2.91 ± 0.31 M62470
92558_at Vcam1 vascular cell adhesion
molecule 1
1.04 ± 0.08 -1.25 ± 0.08 1.37 ± 0.11 1.97 ± 0.13 M84487
94963_at Vcl vinculin -1.10 ± 0.09 1.25 ± 0.11 2.07 ± 0.14 1.92 ± 0.26 AI462105
Table 10.22.  Energy
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
97525_at Gyk glycerol kinase 1.78 ± 0.19 2.49 ± 0.11 1.89 ± 0.22 1.01 ± 0.13 U48403
94367_at AA407809 expressed sequence
AA407809
1.59 ± 0.08 2.13 ± 0.07 1.09 ± 0.11 -1.21 ± 0.10 AI850362
102783_at 2310009E04Rik RIKEN cDNA
2310009E04 gene
-2.81 ± 0.10 -2.72 ± 0.10 -1.25 ± 0.12 1.05 ± 0.10 AI131744
93268_at Glo1 glyoxalase 1 -1.80 ± 0.06 -2.28 ± 0.06 1.09 ± 0.11 1.15 ± 0.11 AI852001
93007_at Npy1r neuropeptide Y receptor
Y1




-2.07 ± 0.08 -2.00 ± 0.06 1.05 ± 0.11 -1.13 ± 0.11 AA939571
98984_f_at Gpd2 glycerol phosphate
dehydrogenase 2,
mitochondrial
3.92 ± 0.22 2.12 ± 0.14 1.19 ± 0.12 -1.54 ± 0.10 D50430
160921_at Acas2l acetyl-Coenzyme A
synthetase 2 (AMP
forming)-like
-2.16 ± 0.07 -2.19 ± 0.06 -1.23 ± 0.10 1.61 ± 0.21 AW125884





2.50 ± 0.12 1.66 ± 0.10 1.01 ± 0.10 -1.07 ± 0.15 AI836694
100573_f_at Gpi1 glucose phosphate
isomerase 1
1.93 ± 0.07 2.49 ± 0.13 3.13 ± 0.16 1.28 ± 0.21 M14220
161889_f_at Aldo1 aldolase 1, A isoform -2.51 ± 0.06 -1.28 ± 0.06 1.71 ± 0.10 1.06 ± 0.17 AV102160
XXXIII
160546_at Aldo3 aldolase 3, C isoform 1.22 ± 0.06 -1.40 ± 0.07 -2.71 ± 0.10 1.25 ± 0.21 AW121134
162032_f_at Pkm2 pyruvate kinase, muscle -2.69 ± 0.07 -2.86 ± 0.07 1.15 ± 0.14 -1.02 ± 0.16 AV368209









2.25 ± 0.09 2.57 ± 0.06 -1.03 ± 0.14 -1.22 ± 0.13 AF107848
Table 10.23.  Other biological processes
Time points (h) GenbankProbe id Symbol Gene Title
4.5 7.5 24 48
98037_at 1110003H18Rik RIKEN cDNA 1110003H18
gene
2.13 ± 0.07 1.51 ± 0.06 1.34 ± 0.10 1.03 ± 0.15 AW122782
99658_f_at 1110025H10Rik RIKEN cDNA 1110025H10
gene
-1.46 ± 0.14 -2.99 ± 0.07 -1.08 ± 0.12 -1.14 ± 0.10 AW047907
160590_r_at 1810030M08Rik RIKEN cDNA 1810030M08
gene
1.64 ± 0.07 2.05 ± 0.08 1.02 ± 0.13 -1.11 ± 0.10 AI853323
160595_at 2310042P20Rik RIKEN cDNA 2310042P20
gene
2.08 ± 0.08 1.73 ± 0.21 1.10 ± 0.10 -1.34 ± 0.12 AI842450
96096_f_at 2610207I16Rik RIKEN cDNA 2610207I16
gene
1.11 ± 0.08 1.03 ± 0.08 1.27 ± 0.13 2.03 ± 0.23 AI648018
100032_at Aaas achalasia, adrenocortical
insufficiency, alacrimia
2.98 ± 0.14 1.42 ± 0.13 1.22 ± 0.10 1.17 ± 0.11 X60136
99559_at Aldh3a2 aldehyde dehydrogenase
family 3, subfamily A2
1.76 ± 0.07 2.30 ± 0.14 1.39 ± 0.19 -1.14 ± 0.16 U14390
161401_f_at Aldh3a2 aldehyde dehydrogenase
family 3, subfamily A2
2.17 ± 0.17 1.39 ± 0.14 1.24 ± 0.12 -1.10 ± 0.12 AV276715
101447_at Apc adenomatosis polyposis coli 1.77 ± 0.07 2.72 ± 0.08 -1.49 ± 0.10 -1.29 ± 0.11 M88127
95144_at Arpc1a actin related protein 2/3
complex, subunit 1A
1.73 ± 0.06 2.17 ± 0.06 1.06 ± 0.15 -1.16 ± 0.14 AB024984
95133_at Asns asparagine synthetase 1.74 ± 0.07 3.13 ± 0.13 1.11 ± 0.24 -1.50 ± 0.17 U38940
96951_at Atp6v1d ATPase, H+ transporting, V1
subunit D
2.14 ± 0.14 1.65 ± 0.08 1.17 ± 0.10 -1.09 ± 0.13 AI839795
100996_at AU041707 expressed sequence
AU041707
2.53 ± 0.32 2.70 ± 0.23 -1.53 ± 0.17 -1.42 ± 0.16 AF015811
95469_at Btd biotinidase -2.16 ± 0.09 -1.68 ± 0.09 -1.17 ± 0.10 -1.05 ± 0.10 AA734444
92642_at Car2 carbonic anhydrase 2 -1.12 ± 0.11 1.27 ± 0.10 2.42 ± 0.11 1.31 ± 0.16 M25944
94241_at Coasy Coenzyme A synthase 1.42 ± 0.09 2.02 ± 0.07 1.58 ± 0.19 -1.07 ± 0.13 AI837229
98535_at Comt catechol-O-methyltransferase 2.23 ± 0.11 1.39 ± 0.07 1.13 ± 0.11 -1.06 ± 0.12 AF076156
98505_i_at Cpox coproporphyrinogen oxidase 2.03 ± 0.12 2.51 ± 0.16 1.32 ± 0.17 -1.13 ± 0.12 D16333
103492_at Cpxm1 carboxypeptidase X 1 (M14
family)
1.16 ± 0.35 3.05 ± 0.22 3.44 ± 0.21 1.38 ± 0.18 AF077738
97724_at Cry2 cryptochrome 2 (photolyase-
like)
1.85 ± 0.26 3.47 ± 0.09 -1.75 ± 0.17 -1.29 ± 0.22 AB003433
XXXIV
95620_at Dhrs7 dehydrogenase/reductase
(SDR family) member 7
1.60 ± 0.09 2.16 ± 0.09 1.70 ± 0.10 1.52 ± 0.13 AW120882
103550_at Ednrb endothelin receptor type B 1.63 ± 0.09 -3.50 ± 0.07 -1.62 ± 0.10 1.98 ± 0.17 U32329
103342_at Eed embryonic ectoderm
development
2.05 ± 0.13 1.76 ± 0.08 1.41 ± 0.12 1.19 ± 0.14 U78103
98121_at Fnta farnesyltransferase, CAAX
box, alpha
1.60 ± 0.07 2.00 ± 0.06 1.20 ± 0.14 -1.03 ± 0.13 D49744
93750_at Gsn gelsolin -1.66 ± 0.12 1.05 ± 0.10 1.83 ± 0.27 2.21 ± 0.26 J04953
160101_at Hmox1 heme oxygenase (decycling)
1
1.11 ± 0.14 2.34 ± 0.11 5.39 ± 0.82 2.23 ± 0.49 X56824
162460_f_at Igbp1 immunoglobulin (CD79A)
binding protein 1
-1.08 ± 0.10 -2.40 ± 0.13 1.08 ± 0.13 1.42 ± 0.16 AV048486
101102_at Igbp1 immunoglobulin (CD79A)
binding protein 1
2.10 ± 0.08 2.55 ± 0.07 1.06 ± 0.12 1.57 ± 0.21 AJ223156
93795_at Itpa inosine triphosphatase
(nucleoside triphosphate
pyrophosphatase)
2.11 ± 0.10 1.63 ± 0.08 1.25 ± 0.13 -1.04 ± 0.12 AW124626
93374_at Jph3 junctophilin 3 -2.50 ± 0.08 -2.63 ± 0.06 -1.46 ± 0.12 -1.41 ± 0.11 AI836349
161796_r_at Kcnq1 potassium voltage-gated
channel, subfamily Q,
member 1
-2.37 ± 0.07 -4.41 ± 0.07 -1.56 ± 0.10 -1.19 ± 0.12 AV367240
103630_at Lars leucyl-tRNA synthetase 1.85 ± 0.06 2.97 ± 0.08 1.42 ± 0.29 -1.30 ± 0.14 AI844089
103377_at Lrp2 low density lipoprotein
receptor-related protein 2
-1.72 ± 0.14 -2.24 ± 0.11 2.00 ± 0.13 1.60 ± 0.43 AW259788
99632_at Mad2l1 MAD2 (mitotic arrest
deficient, homolog)-like 1
(yeast)
2.11 ± 0.09 1.35 ± 0.10 1.17 ± 0.10 1.31 ± 0.11 U83902
160637_at Mocs2 molybdenum cofactor
synthesis 2
2.18 ± 0.09 1.51 ± 0.07 1.33 ± 0.12 -1.04 ± 0.11 AW060325
96082_at Mrpl30 mitochondrial ribosomal
protein L30






1.95 ± 0.06 2.55 ± 0.07 -1.05 ± 0.24 -1.88 ± 0.15 J04627
160463_at Myd116 myeloid differentiation
primary response gene 116
1.93 ± 0.09 4.30 ± 0.09 2.71 ± 0.47 1.12 ± 0.15 X51829
161000_i_at Nusap1 nucleolar and spindle
associated protein 1
1.52 ± 0.16 -1.35 ± 0.08 -1.36 ± 0.12 1.82 ± 0.13 AA275196




1.42 ± 0.12 1.95 ± 0.09 2.04 ± 0.20 1.19 ± 0.11 U16162
98021_at Paf53 RNA polymerase I
associated factor
1.90 ± 0.12 2.36 ± 0.11 1.57 ± 0.14 -1.11 ± 0.11 D14336
XXXV
160788_at Pes1 pescadillo homolog 1,
containing BRCT domain
(zebrafish)
1.87 ± 0.07 2.73 ± 0.11 1.41 ± 0.12 -1.07 ± 0.14 AI846045
94491_at Pex13 peroxisomal biogenesis
factor 13
1.61 ± 0.11 2.54 ± 0.10 -1.09 ± 0.10 -1.23 ± 0.11 AW123194
95074_at Pex19 peroxisome biogenesis factor
19
-1.57 ± 0.10 -2.16 ± 0.07 -1.31 ± 0.10 -1.03 ± 0.14 AW125309
96295_at Psat1 phosphoserine
aminotransferase 1
1.63 ± 0.08 2.47 ± 0.08 1.30 ± 0.16 1.33 ± 0.15 AW122030
93542_at Pter phosphotriesterase related 1.33 ± 0.15 1.02 ± 0.12 1.56 ± 0.11 3.54 ± 0.51 U28016
160314_at Pyp pyrophosphatase 2.11 ± 0.07 2.33 ± 0.06 1.38 ± 0.15 -1.33 ± 0.14 AI839803
162317_r_at Rps12 ribosomal protein S12 -5.09 ± 0.18 1.30 ± 0.19 1.13 ± 0.22 -1.23 ± 0.16 AV064697
93899_at Rps6kb1 ribosomal protein S6 kinase,
polypeptide 1
1.93 ± 0.16 2.05 ± 0.11 -1.25 ± 0.13 -1.21 ± 0.11 AJ000654
100732_at Rps8 ribosomal protein S8 1.46 ± 0.06 1.97 ± 0.07 1.33 ± 0.12 -1.07 ± 0.14 X73829
102769_f_at Sc5d sterol-C5-desaturase (fungal
ERG3, delta-5-desaturase)
homolog (S. cerevisae)
1.87 ± 0.10 -1.14 ± 0.10 -2.09 ± 0.11 -2.05 ± 0.13 AB016248
95049_at Snrpd2 small nuclear
ribonucleoprotein D2
3.17 ± 0.12 2.52 ± 0.18 1.21 ± 0.12 -1.10 ± 0.19 AI837853
101061_at Ssr2 signal sequence receptor,
beta
1.92 ± 0.07 2.01 ± 0.10 1.45 ± 0.10 1.00 ± 0.14 AI845293
95436_at Sst somatostatin 1.35 ± 0.11 1.64 ± 0.08 -1.19 ± 0.19 -4.06 ± 0.10 X51468
94564_at Sult4a1 sulfotransferase family 4A,
member 1
1.40 ± 0.13 3.05 ± 0.07 -2.26 ± 0.16 -2.37 ± 0.19 AF059257
93413_at Terf2 telomeric repeat binding
factor 2
2.95 ± 0.17 1.97 ± 0.10 1.05 ± 0.16 -1.09 ± 0.18 AF003000
160533_r_at Tnp1 transition protein 1 2.19 ± 0.17 1.51 ± 0.14 -1.22 ± 0.12 -1.14 ± 0.12 X12521
94381_at Umpk uridine monophosphate
kinase
1.43 ± 0.08 2.15 ± 0.16 1.37 ± 0.13 -1.31 ± 0.10 L31783
99126_at Xist inactive X specific
transcripts
2.68 ± 0.07 -1.31 ± 0.11 1.39 ± 0.11 1.17 ± 0.22 L04961
101890_f_at Zrf2 zuotin related factor 2 2.23 ± 0.08 2.81 ± 0.13 1.57 ± 0.25 -1.16 ± 0.16 U53208
Table 10.24.  Unknown biological processes
Time points (h) GenbankProbe id Symbol Gene Title







































































































































































































































































































































































































































































































































































































































3.82 ± 0.25 1.91 ± 0.22 1.10 ± 0.17 1.79 ±0.13 AI846811
104486_at A2m alpha-2-
macroglobulin

























































1.10 ± 0.07 -2.20 ± 0.06 -3.50 ± 0.09 -2.90 ±0.10 M35797
104578_f_a
t






























2.65 ± 0.58 -1.94 ± 0.20 -1.63 ± 0.11 -1.25 ±0.14 AI852629
97369_g_at Akap1 A kinase (PRKA)
anchor protein 1
1.30 ± 0.16 2.20 ± 0.15 -1.31 ± 0.11 -1.26 ±0.10 U95145
95001_at Akap8 A kinase (PRKA)
anchor protein 8
-1.02 ± 0.09 2.10 ± 0.29 1.26 ± 0.14 -1.12 ±0.11 AB028920
101947_at Akap8l A kinase (PRKA)
anchor protein 8-
like
1.09 ± 0.11 2.69 ± 0.10 1.56 ± 0.21 1.13 ±0.13 AB028921
XLII
93464_at Akap9 A kinase (PRKA)
anchor protein
(yotiao) 9















1.32 ± 0.08 2.59 ± 0.19 1.48 ± 0.11 -1.06 ±0.18 AA615951
98477_s_at Ank3 ankyrin 3,
epithelial
2.03 ± 0.13 1.85 ± 0.13 -1.26 ± 0.10 -1.61 ±0.11 L40632
93627_at Ankrd28 ankyrin repeat
domain 28
2.05 ± 0.13 1.95 ± 0.14 1.50 ± 0.15 -1.16 ±0.13 AI852287
102815_at Anxa11 annexin A11 -6.37 ± 0.18 -6.68 ± 0.13 1.41 ± 0.16 1.85 ±0.11 U65986
101393_at Anxa3 annexin A3 -1.81 ± 0.18 -2.57 ± 0.24 12.33 ± 3.14 9.26 ±0.80 AJ001633
96529_at Ap1gbp1 AP1 gamma
subunit binding
protein 1
2.77 ± 0.22 1.93 ± 0.13 -1.29 ± 0.12 -1.10 ±0.13 AW122059
93794_at Appbp1 amyloid beta
precursor protein
binding protein 1
3.45 ± 0.16 1.85 ± 0.13 1.13 ± 0.13 -1.21 ±0.14 AI846393




-1.21 ± 0.07 -1.02 ± 0.07 -1.75 ± 0.10 -2.56 ±0.10 U73198
98490_at Arl10c ADP-ribosylation
factor-like 10C





2.46 ± 0.21 1.96 ± 0.14 1.53 ± 0.17 -1.07 ±0.13 AW049185
93288_at Arpc2 actin related
protein 2/3
complex, subunit 2
2.26 ± 0.10 1.86 ± 0.09 1.04 ± 0.10 -1.22 ±0.12 AI835883
97259_at Arpp19 cAMP-regulated
phosphoprotein 19

















1.92 ± 0.08 2.49 ± 0.20 -1.04 ± 0.19 -1.87 ±0.17 AI853875
93900_at Bat2 HLA-B associated
transcript 2














































1.68 ± 0.17 2.08 ± 0.11 1.25 ± 0.10 -1.24 ±0.13 AJ011145



























3.24 ± 0.31 1.82 ± 0.15 1.14 ± 0.15 -1.04 ±0.16 AW122781
98948_at C77032 EST C77032 2.18 ± 0.11 2.43 ± 0.11 2.04 ± 0.17 -1.01 ±0.11 AI785289
104157_at C78212 expressed
sequence C78212
2.21 ± 0.17 1.46 ± 0.17 1.19 ± 0.11 -1.33 ±0.14 AW125643
101596_at C78859 expressed
sequence C78859
1.27 ± 0.17 1.08 ± 0.16 1.88 ± 0.16 -1.37 ±0.14 C78859
94990_at C78915 expressed
sequence C78915
1.26 ± 0.08 2.11 ± 0.07 1.20 ± 0.10 -1.22 ±0.14 AI854725
93741_at C87860 expressed
sequence C87860
1.63 ± 0.09 2.15 ± 0.07 1.36 ± 0.14 -1.11 ±0.11 AA693066
104529_at Caml calcium
modulating ligand
2.41 ± 0.08 2.65 ± 0.10 1.27 ± 0.16 -1.40 ±0.11 U21960
97930_f_at Cd151 CD151 antigen 1.01 ± 0.07 1.43 ± 0.10 2.80 ± 0.14 1.84 ±0.31 AF033620
160493_at Cd63 Cd63 antigen -1.66 ± 0.07 -1.50 ± 0.06 2.33 ± 0.10 1.99 ±0.29 D16432
103016_s_a
t
Cd68 CD68 antigen -1.39 ± 0.11 1.01 ± 0.09 3.10 ± 0.23 2.79 ±0.51 X68273
94084_at Cdc26 cell division cycle
26





1.22 ± 0.09 1.34 ± 0.09 -1.44 ± 0.12 -2.15 ±0.11 AI847045
102804_at Ceacam2 CEA-related cell
adhesion molecule
2
-2.82 ± 0.07 -2.94 ± 0.06 -1.36 ± 0.10 -1.29 ±0.11 X67279
99486_at Cenpb centromere
autoantigen B





-1.51 ± 0.08 -3.15 ± 0.09 -1.38 ± 0.10 -1.22 ±0.12 AV335015
92841_f_at Chgb chromogranin B 2.24 ± 0.07 1.55 ± 0.08 -1.27 ± 0.10 -1.38 ±0.12 X51429





1.66 ± 0.07 3.00 ± 0.07 1.56 ± 0.20 -1.24 ±0.10 AW122453
XLIV
binding protein 1
94030_at Commd2 COMM domain
containing 2
2.42 ± 0.09 2.19 ± 0.09 1.27 ± 0.12 -1.23 ±0.14 AI853431
96881_at Commd6 COMM domain
containing 6





2.99 ± 0.12 2.17 ± 0.21 1.30 ± 0.12 1.02 ±0.11 AI851085





2.30 ± 0.07 2.46 ± 0.07 1.34 ± 0.13 -1.05 ±0.13 AF071314
101580_at Cox7b cytochrome c
oxidase subunit
VIIb
2.38 ± 0.08 1.16 ± 0.06 1.05 ± 0.10 1.00 ±0.12 AI851220
97352_f_at Coxvib2 cytochrome c
oxidase subunit
VIb, testes-specific
-1.93 ± 0.08 -3.61 ± 0.08 1.00 ± 0.27 2.66 ±0.11 AW123567




1.99 ± 0.11 1.98 ± 0.10 1.09 ± 0.17 -1.63 ±0.11 AF028242
161942_f_a
t
Cwf19l1 CWF19-like 1, cell
cycle control (S.
pombe)









































































11, KL Mohlke 35

















12, ERATO Doi 7,
expressed

























































































-1.15 ± 0.07 -1.23 ± 0.06 2.16 ± 0.19 1.20 ±0.24 AW125274
96125_at Daxx Fas death domain-
associated protein
2.09 ± 0.07 2.60 ± 0.08 -1.21 ± 0.20 -1.24 ±0.12 AF110520





2.36 ± 0.11 3.79 ± 0.19 1.11 ± 0.17 -1.03 ±0.19 AI849939
100037_at Ddx18 DEAD (Asp-Glu-
Ala-Asp) box
polypeptide 18
1.82 ± 0.23 2.98 ± 0.16 1.01 ± 0.12 -1.12 ±0.21 AW213225
160492_at Ddx18 DEAD (Asp-Glu-
Ala-Asp) box
polypeptide 18
2.11 ± 0.08 2.51 ± 0.12 1.56 ± 0.20 -1.01 ±0.11 AI648005
99096_at Ddx24 DEAD (Asp-Glu-
Ala-Asp) box
polypeptide 24







2.87 ± 0.20 1.18 ± 0.06 1.16 ± 0.15 -1.05 ±0.14 L25126
92226_at Ddx50 DEAD (Asp-Glu-
Ala-Asp) box
polypeptide 50





2.08 ± 0.09 2.05 ± 0.07 1.44 ± 0.11 -1.07 ±0.12 Y08460
160892_at Dlgh3 discs, large
homolog 3
(Drosophila)
1.14 ± 0.15 2.14 ± 0.16 -1.32 ± 0.11 -1.53 ±0.10 D87117
101975_at Dlk1 delta-like 1
homolog
(Drosophila)
-1.87 ± 0.10 -2.55 ± 0.06 -1.35 ± 0.12 1.27 ±0.11 Z12171




2.18 ± 0.10 1.98 ± 0.08 1.43 ± 0.15 -1.19 ±0.15 AW122732



















3.76 ± 0.11 1.78 ± 0.13 1.52 ± 0.14 -1.30 ±0.11 AA647048





2.11 ± 0.13 -1.03 ± 0.07 -1.30 ± 0.11 -1.27 ±0.12 U29088





2.16 ± 0.11 1.09 ± 0.09 -1.35 ± 0.11 -1.45 ±0.13 D31953
100051_at Epb7.2 erythrocyte protein
band 7.2
-1.98 ± 0.06 -2.35 ± 0.08 -1.24 ± 0.13 1.25 ±0.14 U17297
103263_at Epc1 enhancer of
polycomb homolog
1 (Drosophila)
1.89 ± 0.07 2.50 ± 0.07 -1.05 ± 0.14 -1.22 ±0.13 AF079765




1.78 ± 0.09 3.26 ± 0.38 1.02 ± 0.10 1.16 ±0.11 L21768
XLVII
103859_at Eral1 Era (G-protein)-
like 1 (E. coli)




1.64 ± 0.12 3.02 ± 0.07 1.51 ± 0.24 -1.12 ±0.18 AJ007909
96031_r_at Fbxl5 F-box and leucine-
rich repeat protein
5










1.22 ± 0.06 1.21 ± 0.06 -4.21 ± 0.10 -4.63 ±0.09 AW045533
96569_at Fignl1 fidgetin-like 1 -2.61 ± 0.07 -3.11 ± 0.06 -1.17 ± 0.10 1.13 ±0.11 AA266298
160648_at Fignl1 fidgetin-like 1 -2.00 ± 0.07 -2.25 ± 0.07 -1.04 ± 0.10 1.61 ±0.10 AI047076
93309_at Fin14 fibroblast growth
factor inducible 14
2.53 ± 0.07 2.01 ± 0.06 1.42 ± 0.17 -1.13 ±0.16 U42386
104600_at Fip1l1 FIP1 like 1 (S.
cerevisiae)
2.51 ± 0.12 2.68 ± 0.13 1.45 ± 0.11 1.28 ±0.11 AI841692
93443_at Fndc1 fibronectin type III
domain containing
1
-3.37 ± 0.11 -1.90 ± 0.09 -1.38 ± 0.10 1.08 ±0.16 AW212271
98817_at Fst follistatin 1.30 ± 0.10 -1.19 ± 0.06 -2.06 ± 0.11 -2.20 ±0.11 Z29532
95756_at Ftsj3 FtsJ homolog 3 (E.
coli)













1.66 ± 0.08 2.62 ± 0.06 1.71 ± 0.27 -1.18 ±0.12 AW123904
98531_g_at Gas5 growth arrest
specific 5
2.25 ± 0.07 3.20 ± 0.08 2.08 ± 0.20 1.30 ±0.14 AI849615
92783_at Gh growth hormone -1.67 ± 0.08 -2.37 ± 0.09 -1.07 ± 0.12 -1.17 ±0.10 X02891




1.18 ± 0.06 2.52 ± 0.09 1.73 ± 0.12 1.09 ±0.12 AI929971
96943_at Gps1 G protein pathway
suppressor 1
2.47 ± 0.06 2.40 ± 0.09 1.27 ± 0.11 -1.21 ±0.13 AW125234






-1.03 ± 0.09 2.13 ± 0.07 -1.28 ± 0.12 -1.35 ±0.17 AW227647
96085_at Gsta4 glutathione S-
transferase, alpha 4








1.89 ± 0.23 2.66 ± 0.10 1.39 ± 0.17 -1.22 ±0.15 AA030469





1.24 ± 0.07 2.80 ± 0.23 1.96 ± 0.25 -1.13 ±0.10 Y13832
XLVIII
mRNA





2.30 ± 0.07 2.29 ± 0.09 1.63 ± 0.11 -1.20 ±0.21 AJ132616
94805_f_at Hist1h2a
c










-2.45 ± 0.07 -1.72 ± 0.07 1.50 ± 0.20 -1.32 ±0.12 AA981581
98090_at Hrb2 HIV-1 Rev binding
protein 2
4.04 ± 0.21 3.24 ± 0.24 1.75 ± 0.11 -1.10 ±0.13 AW210014
99109_at Ier2 immediate early
response 2
1.77 ± 0.08 3.53 ± 0.07 1.72 ± 0.14 1.24 ±0.18 M59821
94384_at Ier3 immediate early
response 3








-3.88 ± 0.07 -3.28 ± 0.08 -1.36 ± 0.10 -1.12 ±0.10 M16724












-1.88 ± 0.06 -2.01 ± 0.08 1.17 ± 0.11 -1.09 ±0.12 AV312395




2.01 ± 0.14 -1.14 ± 0.06 -1.38 ± 0.09 -1.30 ±0.10 AI842065
102644_at Kdt1 kidney cell line
derived transcript 1




-1.32 ± 0.07 -1.08 ± 0.07 2.34 ± 0.22 1.80 ±0.38 AW123934
103523_at Leng8 leukocyte receptor
cluster (LRC)
member 8
-5.32 ± 0.11 -1.12 ± 0.13 1.43 ± 0.24 1.10 ±0.10 AI851703














-1.69 ± 0.12 -2.23 ± 0.06 -1.40 ± 0.10 1.00 ±0.11 AV257486




2.84 ± 0.35 1.22 ± 0.26 3.92 ± 0.30 2.37 ±0.22 AI891475
98440_at Ltb4dh leukotriene B4 12-
hydroxydehydroge
nase



















-2.19 ± 0.07 1.51 ± 0.07 -1.27 ± 0.10 -1.83 ±0.11 AI843448
104752_at Mmrp19 monocyte
macrophage 19




1.85 ± 0.23 1.12 ± 0.15 1.04 ± 0.17 2.06 ±0.13 D14849
96151_at Mocos molybdenum
cofactor sulfurase
2.25 ± 0.28 2.16 ± 0.29 3.26 ± 0.13 1.08 ±0.13 AA839813
97803_at Mpp1 membrane protein,
palmitoylated


























2.07 ± 0.09 1.67 ± 0.12 1.18 ± 0.10 -1.05 ±0.12 AA739263





-2.25 ± 0.10 -1.64 ± 0.06 -1.17 ± 0.10 -1.11 ±0.11 Z35294
103264_at Mtmr1 myotubularin
related protein 1










1.94 ± 0.09 2.73 ± 0.13 -1.20 ± 0.10 -1.20 ±0.12 AW122052
103791_at Narg1 NMDA receptor-
regulated gene 1
1.77 ± 0.19 1.99 ± 0.08 1.12 ± 0.12 1.02 ±0.11 AW048763
93246_at Narg1 NMDA receptor-
regulated gene 1
2.02 ± 0.12 1.10 ± 0.06 1.21 ± 0.18 -1.08 ±0.11 AW260482
160398_at Nol7 nucleolar protein 7 2.48 ± 0.10 1.34 ± 0.07 1.66 ± 0.12 1.22 ±0.12 AW124661
101634_at Npm1 nucleophosmin 1 2.49 ± 0.07 1.92 ± 0.07 1.17 ± 0.10 1.01 ±0.14 M33212
93673_at Nrtn neurturin -1.84 ± 0.08 -2.51 ± 0.09 -1.02 ± 0.11 -1.05 ±0.16 U78109




1.51 ± 0.19 2.85 ± 0.32 1.61 ± 0.17 -1.42 ±0.17 AA681274
101366_f_a
t
Nvl nuclear VCP-like 3.47 ± 0.26 2.60 ± 0.20 1.26 ± 0.11 -1.26 ±0.11 AA250299
93600_at Obrgrp leptin receptor
gene-related
protein
2.16 ± 0.12 1.47 ± 0.06 -1.25 ± 0.11 1.01 ±0.13 AJ011565
100626_at Odf2 outer dense fiber of
sperm tails 2
1.64 ± 0.19 3.04 ± 0.31 1.08 ± 0.10 -1.16 ±0.16 AF034105
92500_at Odz3 odd Oz/ten-m
homolog 3
(Drosophila)
2.01 ± 0.12 -1.26 ± 0.07 -1.47 ± 0.10 -1.13 ±0.12 AB025412
97581_at Odz4 odd Oz/ten-m
homolog 4
(Drosophila)
-1.85 ± 0.08 -2.41 ± 0.07 -1.32 ± 0.11 1.08 ±0.11 AF059485
99549_at Ogn osteoglycin 1.03 ± 0.31 -6.87 ± 0.19 1.62 ± 0.49 4.77 ±0.64 D31951
103388_at P42pop Myb protein
P42POP
-3.59 ± 0.06 -3.12 ± 0.07 -1.25 ± 0.13 -1.10 ±0.12 AW047050
100720_at Pabpc1 poly A binding
protein,
cytoplasmic 1
2.02 ± 0.12 2.02 ± 0.06 1.01 ± 0.11 1.01 ±0.16 X65553
94461_at Pbef1 pre-B-cell colony-
enhancing factor 1
2.32 ± 0.14 2.06 ± 0.12 -1.11 ± 0.12 -1.10 ±0.11 AI852144
160899_at Pcp4 Purkinje cell
protein 4









-4.91 ± 0.11 -3.78 ± 0.06 -1.42 ± 0.09 -1.11 ±0.10 AB001489
94445_at Pls3 plastin 3 (T-
isoform)




1.89 ± 0.23 3.27 ± 0.24 1.73 ± 0.29 -1.08 ±0.12 AI553452










1.52 ± 0.10 3.06 ± 0.09 1.11 ± 0.11 1.02 ±0.11 AF088911
93010_at Pqbp1 polyglutamine
binding protein 1
2.16 ± 0.18 2.37 ± 0.09 1.02 ± 0.10 -1.49 ±0.10 AJ250406
97496_f_at Prkcdbp protein kinase C,
delta binding
protein




1.37 ± 0.12 2.50 ± 0.10 1.59 ± 0.17 -1.09 ±0.10 AW060487
161006_at R75096 expressed
sequence R75096
-2.93 ± 0.10 -3.07 ± 0.07 -1.36 ± 0.10 -1.38 ±0.11 AI853978
101381_at Rabep1 rabaptin, RAB
GTPase binding
effector protein 1
1.97 ± 0.25 2.73 ± 0.08 1.06 ± 0.15 -1.47 ±0.10 D86066
LI
102724_at Rabep1 rabaptin, RAB
GTPase binding
effector protein 1





2.60 ± 0.09 3.77 ± 0.07 1.51 ± 0.26 -1.04 ±0.10 U12922
103840_at Rad17 RAD17 homolog
(S. pombe)
2.37 ± 0.15 1.68 ± 0.09 1.49 ± 0.10 -1.08 ±0.12 AJ011923
96154_at Renbp renin binding
protein
-2.12 ± 0.14 -1.31 ± 0.09 1.32 ± 0.14 1.28 ±0.12 AA600645
93020_at Rex3 reduced expression
3
2.21 ± 0.15 1.77 ± 0.06 1.12 ± 0.12 -1.56 ±0.10 AF051347
96653_at Rnaset2 ribonuclease T2 1.22 ± 0.07 -1.03 ± 0.07 2.15 ± 0.13 1.54 ±0.24 AI851762
98915_at Rnf149 ring finger protein
149
1.00 ± 0.11 1.48 ± 0.11 2.22 ± 0.23 1.05 ±0.11 AI849082
161814_f_a
t
Rnf19 ring finger protein
(C3HC4 type) 19
4.51 ± 0.12 2.67 ± 0.18 -1.03 ± 0.10 -1.48 ±0.10 AV355427
102131_f_a
t
Rnf20 ring finger protein
20
-3.05 ± 0.08 -2.93 ± 0.06 1.01 ± 0.13 1.08 ±0.13 AU014874
93518_at Rnps1 ribonucleic acid
binding protein S1
1.49 ± 0.07 2.04 ± 0.09 -1.01 ± 0.19 -1.35 ±0.10 X70067
97838_at Rnu22 RNA, U22 small
nucleolar









2.34 ± 0.06 2.85 ± 0.08 1.03 ± 0.12 -1.13 ±0.14 U93862
98564_f_at Rps26 ribosomal protein
S26
2.28 ± 0.07 2.09 ± 0.10 1.07 ± 0.10 -1.10 ±0.15 U67770





-1.97 ± 0.11 -2.17 ± 0.08 -1.59 ± 0.10 -1.04 ±0.10 C79529
95104_at Sdc2 syndecan 2 -2.08 ± 0.07 -2.34 ± 0.07 1.22 ± 0.11 1.33 ±0.12 U00674
95664_at Sec14l1 SEC14-like 1 (S.
cerevisiae)
2.21 ± 0.08 3.43 ± 0.09 -1.43 ± 0.11 -1.44 ±0.13 AW048159
103871_at Sec23ip Sec23 interacting
protein
2.02 ± 0.12 2.37 ± 0.16 1.36 ± 0.17 -1.04 ±0.13 AW123729
162420_r_a
t
Selk selenoprotein K -1.36 ± 0.07 -2.05 ± 0.07 1.29 ± 0.10 -1.34 ±0.12 AV290470







-1.34 ± 0.08 1.02 ± 0.06 2.29 ± 0.18 1.42 ±0.15 U25844




2.08 ± 0.07 1.84 ± 0.07 -1.55 ± 0.15 -1.22 ±0.15 AJ001700
101861_at Sgce sarcoglycan,
epsilon





2.43 ± 0.09 1.72 ± 0.11 -1.19 ± 0.11 1.01 ±0.12 AI848671
104216_at Shoc2 soc-2 (suppressor
of clear) homolog
(C. elegans)
1.63 ± 0.25 2.50 ± 0.18 -1.51 ± 0.10 -1.17 ±0.16 AF068921
LII





-2.48 ± 0.12 -2.94 ± 0.08 -1.25 ± 0.10 -1.36 ±0.10 U25739





-2.48 ± 0.07 -2.76 ± 0.08 -1.30 ± 0.13 -1.24 ±0.12 AW048729
98553_at Slmap sarcolemma
associated protein











1.85 ± 0.14 2.23 ± 0.09 1.03 ± 0.13 -1.17 ±0.13 X69942




2.16 ± 0.09 1.71 ± 0.11 -1.24 ± 0.10 1.14 ±0.12 AI838562
96712_at Smoc1 SPARC related
modular calcium
binding 1
-2.49 ± 0.07 -2.45 ± 0.07 1.01 ± 0.16 2.07 ±0.41 AI848508
93273_at Snca synuclein, alpha 1.50 ± 0.06 1.01 ± 0.06 -2.81 ± 0.10 -2.98 ±0.09 AF044672
100510_at Sncb synuclein, beta -2.38 ± 0.07 -2.75 ± 0.06 -1.46 ± 0.13 -1.37 ±0.10 AI839708
94313_at Snrp1c U1 small nuclear
ribonucleoprotein
1C
2.45 ± 0.07 2.04 ± 0.10 1.54 ± 0.12 1.01 ±0.12 X96767
100101_at Snrpa small nuclear
ribonucleoprotein
polypeptide A
1.73 ± 0.08 2.11 ± 0.07 1.28 ± 0.16 -1.15 ±0.11 L15447
93832_at Spag7 sperm associated
antigen 7
1.23 ± 0.07 2.04 ± 0.07 1.14 ± 0.11 -1.04 ±0.11 AI854541
97160_at Sparc secreted acidic
cysteine rich
glycoprotein
1.28 ± 0.07 -1.84 ± 0.10 3.00 ± 0.17 3.64 ±0.59 X04017
160319_at Sparcl1 SPARC-like 1
(mast9, hevin)
1.05 ± 0.07 -1.21 ± 0.06 -2.20 ± 0.10 -1.37 ±0.10 U66166
94387_at Spata5 spermatogenesis
associated 5
1.94 ± 0.11 2.87 ± 0.19 1.36 ± 0.26 -1.47 ±0.19 AF016544
98428_at Spg4 spastic paraplegia
4 homolog
(human)





-2.65 ± 0.07 -1.49 ± 0.06 -1.70 ± 0.10 -2.85 ±0.10 X92864
101995_at Sqstm1 sequestosome 1 3.11 ± 0.06 5.59 ± 0.09 3.58 ± 0.34 1.17 ±0.27 U40930
92579_at Ssb Sjogren syndrome
antigen B
2.21 ± 0.15 1.07 ± 0.07 1.05 ± 0.12 -1.06 ±0.10 L00993
96724_r_at Ssx2ip synovial sarcoma,
X breakpoint 2
interacting protein
2.55 ± 0.24 2.07 ± 0.07 -1.03 ± 0.10 1.07 ±0.11 AW122911
97310_at St13 suppression of
tumorigenicity 13
1.59 ± 0.09 2.54 ± 0.06 1.39 ± 0.14 1.14 ±0.10 AW124318
LIII




1.65 ± 0.41 2.41 ± 0.23 -1.05 ± 0.12 1.00 ±0.12 AB012611
93366_r_at Sugt1 SGT1, suppressor
of G2 allele of
SKP1 (S.
cerevisiae)
2.17 ± 0.11 1.64 ± 0.15 1.15 ± 0.12 1.05 ±0.11 AI838149
93365_s_at Sugt1 SGT1, suppressor
of G2 allele of
SKP1 (S.
cerevisiae)
2.96 ± 0.19 2.44 ± 0.19 1.20 ± 0.12 1.04 ±0.13 AI838149
94368_at Supv3l1 suppressor of var1,
3-like 1 (S.
cerevisiae)
2.43 ± 0.11 2.56 ± 0.19 1.58 ± 0.17 -1.02 ±0.12 AW049139
101031_at Surf1 surfeit gene 1 1.76 ± 0.10 2.28 ± 0.10 1.85 ± 0.25 -1.10 ±0.14 M14689
104283_at Tbc1d15 TBC1 domain
family, member 15









1.35 ± 0.08 1.51 ± 0.08 -1.40 ± 0.22 -2.31 ±0.10 X78989
99144_s_at Tgoln1 trans-golgi
network protein
1.74 ± 0.18 3.11 ± 0.10 1.25 ± 0.16 1.14 ±0.20 D50031
99057_at Thy1 thymus cell antigen
1, theta
-2.55 ± 0.07 -1.59 ± 0.06 1.50 ± 0.22 -1.29 ±0.11 M12379
160678_at Tm4sf12 transmembrane 4
superfamily
member 12
1.13 ± 0.11 -2.02 ± 0.08 1.05 ± 0.14 2.26 ±0.21 AA871166
95120_at Tm4sf13 transmembrane 4
superfamily
member 13
2.33 ± 0.08 1.19 ± 0.09 -1.28 ± 0.10 -1.33 ±0.11 AI837621
92437_at Tm7sf2 transmembrane 7
superfamily
member 2
-1.29 ± 0.11 -1.09 ± 0.07 -4.50 ± 0.10 -2.69 ±0.10 AW047445
95383_at Tm7sf2 transmembrane 7
superfamily
member 2








1.24 ± 0.08 -2.59 ± 0.07 -1.67 ± 0.11 -1.15 ±0.10 AI837838
100039_at Tmem4 transmembrane
protein 4
2.86 ± 0.24 2.93 ± 0.13 1.34 ± 0.10 1.25 ±0.17 AW125880
92942_at Trim21 tripartite motif
protein 21
-1.99 ± 0.09 -2.24 ± 0.07 -1.32 ± 0.12 1.18 ±0.17 AA138192
101372_at Trip13 thyroid hormone
receptor interactor
13
2.42 ± 0.29 1.99 ± 0.25 2.20 ± 0.35 -1.30 ±0.13 AI852645
96921_at Ttc1 tetratricopeptide
repeat domain 1












2.07 ± 0.08 1.97 ± 0.08 1.36 ± 0.24 -1.13 ±0.11 S69507
100717_at U90926 cDNA sequence
U90926
-2.99 ± 0.07 -3.01 ± 0.06 -1.38 ± 0.10 1.02 ±0.10 U90926
LIV
U90926
97285_f_at Ubxd1 UBX domain
containing 1
2.25 ± 0.22 2.23 ± 0.07 1.07 ± 0.11 -1.01 ±0.14 AW120609
100091_at Ugalt2 UDP-galactose
translocator 2




















2.31 ± 0.11 1.58 ± 0.07 1.07 ± 0.15 1.03 ±0.11 U92454
160130_at Wdr26 WD repeat domain
26
2.40 ± 0.09 1.86 ± 0.09 1.43 ± 0.12 -1.15 ±0.12 AA795284




± 0.04 1.37 ± 0.18 -1.98 ±0.77 AW214136
96018_r_at Zdhhc5 zinc finger, DHHC
domain containing
5
1.02 ± 0.09 -2.21 ± 0.06 -1.02 ± 0.10 -1.15 ±0.10 AI853561
104582_g_a
t
Zdhhc6 zinc finger, DHHC
domain containing
6
2.23 ± 0.09 2.32 ± 0.18 1.32 ± 0.10 1.01 ±0.12 AI845438
95533_at Zfp106 zinc finger protein
106
-1.11 ± 0.07 -2.61 ± 0.07 -1.82 ± 0.12 1.18 ±0.14 AW048037
99001_at Zfp292 zinc finger protein
292
2.40 ± 0.11 1.11 ± 0.11 -1.11 ± 0.13 -1.15 ±0.10 AF017806
100897_f_a
t
Zfp297 zinc finger protein
297
-2.37 ± 0.11 -1.31 ± 0.11 1.20 ± 0.16 1.11 ±0.17 AF100956
104437_at Zfp30 zinc finger protein
30
2.42 ± 0.16 1.51 ± 0.08 1.21 ± 0.14 -1.21 ±0.15 Z30174
93324_at Zfp36l1 zinc finger protein
36, C3H type-like
1
1.27 ± 0.11 -1.39 ± 0.07 1.28 ± 0.10 2.24 ±0.14 M58566
98277_at Zfpn1a4 zinc finger protein,
subfamily 1A, 4
(Eos)
-2.06 ± 0.09 -1.47 ± 0.08 -1.18 ± 0.10 -1.16 ±0.10 AB017615
103753_at Zzz3 zinc finger, ZZ
domain containing
3
3.06 ± 0.10 2.43 ± 0.18 1.29 ± 0.15 1.05 ±0.11 AI159572
101217_at --- -
11.95
± 0.15 -3.15 ± 0.11 -1.30 ± 0.10 1.06 ±0.12 D18865
161737_at --- -5.94 ± 0.08 -2.93 ± 0.17 1.13 ± 0.12 -1.05 ±0.13 AV312560
101863_at --- -5.45 ± 0.18 -1.42 ± 0.22 -1.18 ± 0.13 1.00 ±0.16 C78246





-3.83 ± 0.10 -2.60 ± 0.09 -1.48 ± 0.10 1.10 ±0.13 AI591977
102094_f_a
t
--- -2.78 ± 0.06 -2.83 ± 0.06 -1.10 ± 0.11 1.25 ±0.15 AI841270
161535_at --- -2.76 ± 0.07 -3.37 ± 0.06 -1.31 ± 0.11 -1.23 ±0.11 AV234882
161124_at --- -2.49 ± 0.07 -2.88 ± 0.07 -1.33 ± 0.10 -1.06 ±0.10 AV237354
161196_r_a
t
--- -2.42 ± 0.08 -2.50 ± 0.06 -1.35 ± 0.12 1.19 ±0.15 AV254135
102348_at --- -2.41 ± 0.07 -4.37 ± 0.06 1.66 ± 0.25 1.17 ±0.19 AI551087
101685_f_a
t
--- -2.32 ± 0.07 -2.60 ± 0.06 -1.34 ± 0.10 -1.36 ±0.12 AI463421
162311_f_a
t
--- -2.22 ± 0.07 -3.54 ± 0.08 -1.11 ± 0.10 -1.20 ±0.10 AV050648
LV
92778_i_at --- -2.09 ± 0.10 -1.91 ± 0.07 -1.16 ± 0.11 -1.04 ±0.10 Z22552
161615_f_a
t
--- -1.99 ± 0.07 -2.36 ± 0.08 -1.22 ± 0.10 -1.07 ±0.10 AV352346
162496_r_a
t
--- -1.87 ± 0.07 -2.31 ± 0.08 -1.74 ± 0.10 -1.07 ±0.12 AV153195
162292_r_a
t










-1.54 ± 0.09 -2.29 ± 0.13 1.42 ± 0.10 1.24 ±0.13 AA763213
102091_f_a
t
--- -1.25 ± 0.14 -2.35 ± 0.10 1.03 ± 0.10 -1.14 ±0.13 AA407599
161528_r_a
t
--- -1.14 ± 0.11 -3.51 ± 0.11 -1.99 ± 0.10 -1.06 ±0.14 AV227261
101216_at --- 1.15 ± 0.11 -2.21 ± 0.08 -1.09 ± 0.11 -1.63 ±0.13 R75193
























1.69 ± 0.10 2.11 ± 0.07 1.08 ± 0.16 -1.40 ±0.14 AA790056










2.19 ± 0.11 1.27 ± 0.08 -1.05 ± 0.10 -1.02 ±0.10 AI037032
96579_at Transcribed
sequences





2.35 ± 0.10 2.65 ± 0.12 -1.06 ± 0.11 -1.24 ±0.14 AI852553
101732_at --- 2.36 ± 0.20 2.10 ± 0.14 -1.13 ± 0.11 -1.12 ±0.11 M12039
LVI


















2.58 ± 0.09 1.97 ± 0.09 -1.03 ± 0.10 -1.40 ±0.10 AW121616
100379_f_a
t
--- 2.80 ± 0.11 1.75 ± 0.11 1.91 ± 0.14 -1.12 ±0.10 AI837905
96316_at  Transcribed
sequences
3.01 ± 0.23 1.82 ± 0.15 -1.08 ± 0.12 1.21 ±0.15 AI839289
